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Abstract  
 
Malaria transmission blocking vaccines (TBV) have been prioritized as an intervention 
to facilitate malaria elimination, but tools are required to support roll-out and 
evaluation. This thesis presents research that aids development of pre-fertilization 
TBV candidate 10C (amino acids 159-428 of Pfs48/45). 
Gametocytes must be detected to identify the infectious reservoir and support 
mosquito infectivity studies. I proposed filter papers as a novel, cost effective, 
practical approach for collection and detection of mRNA in low density gametocytes. 
Comparing 3 filter papers, 2 RNA extraction methods and 2 molecular detection 
techniques, I concluded Whatman 903 and Whatman 3MM filter papers, combined 
with guanidine based nucleic acid extraction and detection using QT-NASBA, were 
operationally most appealing and most sensitive.  
To identify natural recognition to 10C and 230CMB (a vaccine candidate including 
amino acids 444-730 of Pfs230), cross sectional surveys were performed sampling 
school children (n=510) in 3 countries. I demonstrated naturally exposed individuals 
had antibodies against 10C and 230CMB which displayed age dependent acquisition 
(p<0.03). Supportive datasets demonstrated 10C and 230CMB antibodies are 
significantly associated with >90% transmission reducing activity (TRA) (p<0.003).   
To assess the TRA of 10C-immunized rats against genetically diverse parasites, I 
sampled venous blood from naturally infected participants in Burkina Faso (n=53), 
and performed direct membrane feeding assay combined with serum replacement 
using European control serum spiked with IgG from 10C vaccinated rats.  I 
demonstrated 10C vaccine induced IgG significantly reduced transmission in 4/5 
participants who were infectious and infected >2 mosquitoes. This resulted in 80.9-
100% reduction in oocyst prevalence (p<0.042), and 85.2-100% reduction in oocyst 
density (p<0.023).  
My research identified an attractive combination of tools for detecting low density 
gametocytes to facilitate sampling in remote field settings.  I advanced progress of 
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10C vaccine candidate by indicating antibodies are acquired following natural malaria 
exposure and are associated with functional TRA. 
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Chapter 1: General introduction 
 
1.1 Parasite biology 
 
1.11 Malaria pathology and parasite life cycle 
 
Malaria continues to be a serious global health problem with approximately half the 
world population at risk (World Health Organization 2011).  In 2010, there were an 
estimated 225 million clinical malaria episodes, not accounting for multiple episodes 
in the same individual, resulting in around 660,000 deaths and a financial cost of 
approximately 12 billion USD (World Health Organization 2011).  Distributed across 
106 countries worldwide, malaria is mostly found in tropical climates with favourable 
conditions that support the life cycle of both the insect vector responsible for 
transmission, and the Plasmodium parasites  (Karl, David et al. 2008; Hay, Okiro et al. 
2010; World Health Organization 2010; World Health Organization 2011). In 2010,  
approximately 91% of all malaria related deaths occurred within the Africa continent, 
with the majority of the disease burden located in Sub-Saharan Africa where 
fatalities are predominantly among pregnant women and children under 5 years of 
age (Hay, Okiro et al. 2010; World Health Organization 2011). Often, malaria endemic 
regions are in developing countries which struggle to finance the healthcare 
infrastructure required to effectively control such a pathogenic and infectious 
disease (Williams, Hering et al. 2013). The healthcare cost to these countries severely 
undermines economic stability, thereby hindering further development (Doolan, 
Dobano et al. 2009).   
Malaria is a vector borne protozoan parasitic disease with 6 main species capable of 
infecting humans, Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, 
Plasmodium ovale curtisi, Plasmodium ovale wallikeri and  Plasmodium knowlesi 
(Sutherland, Tanomsing et al. 2010; Lau, Fong et al. 2011; Lee, Divis et al. 2011). P. 
ovale was recently recognized as having two distinct sub-species that may exhibit 
varying symptom severity (Sutherland, Tanomsing et al. 2010). P. knowlesi was more 
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recently identified as an important human pathogen, but long tailed macaques are 
the natural reservoir (Singh, Kim Sung et al. 2004). Plasmodia are protozoa belonging 
to the family Apicomplexa and have morphologically distinct species which differ in 
disease severity (CDC 2010). While P. vivax is more widely distributed, P. falciparum 
is responsible for the most morbidity and over 90% of malaria related deaths, and is 
the species this thesis focuses on (Bousema and Drakeley 2011; WHO 2013).  
The symptoms caused by P. falciparum are the consequence of the asexual 
proliferation cycle which occurs within the hu an host’s erythrocytes (Wipasa, Elliott 
et al. 2002). Symptoms appear approximately 7-28 days post sporozoite inoculation 
and typically begin with fever, chills, headache, vomiting and general malaise (CDC 
2010). If not treated within 24 hours, parasites can rapidly proliferate and disease 
can quickly progress to complicated infection resulting in severe anaemia, renal 
failure, cerebral malaria, acute respiratory distress, coma, and death (Beeson and 
Brown 2002; CDC 2010). Complicated infection can manifest as a result of delayed 
drug treatment (or due to treatment failure), but is also co  on in ‘at risk’ groups 
who have limited immunity such as children under the age of 5, 
immunocompromised individuals, or pregnant women who are at risk of developing 
placental malaria (Meerman, Ord et al. 2005). Plasmodia have a complex life cycle 
within the human host, and insect vector responsible for disease transmission (Figure 
1.0.).  
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Figure 1.0. The life cycle of Plasmodium species. (Figure taken directly from the 
referenced source (CDC 2012)) 
 
The asexual cycle takes place within the human host and generates parasites with a 
haploid genome, whereas the sexual reproduction cycle, which occurs in the insect 
vector, results in parasites with a diploid genome (Gonzales, Patel et al. 2008). 
Malaria is transmitted when an infected female Anopheline mosquito takes a blood 
meal from a human. When feeding, a parasitized mosquito will inject up to several 
hundreds of sporozoites from its salivary glands (which harbour the infectious 
parasites) into the human dermis where they may reside for up to 6 hours (CDC 
2012). After this period, the sporozoites migrate and enter the blood stream or 
lymph system (Amino, Thiberge et al. 2006; Yamauchi, Coppi et al. 2007; Doolan, 
Dobano et al. 2009). Pre-erythrocytic parasite stages, sporozoites and liver stage 
parasites express surface antigens including circumsporozoite protein (CSP), 
thrombospondin-related adhesion protein (TRAP), liver stage antigen 1 and 3 (LSA1, 
 30 
 
LSA3) and exported protein 1 (EXP1) (Winzeler 2006; Kafsack, Rovira-Graells et al. 
2014).  
Once inside a human host, sporozoites migrate to hepatocytes, where they may 
traverse several cells before finally infecting one to undertake the exo-erythrocytic 
cycle (CDC 2010; Offeddu, Thathy et al. 2012). Inside hepatocytes, over 
approximately 1 week, sporozoites develop into mature schizonts, which harbour 
merozoites. The schizonts burst to release up to 30,000 merozoites which enter the 
blood stream where they invade erythrocytes, the site of the asexual proliferation 
cycle (CDC 2012). During the asexual cycle, the parasite expresses antigens such as 
apical membrane antigen -1 (AMA-1), Plasmodium falciparum erythrocyte 
membrane protein-1 (PfEMP-1), merozoite surface protein-1-5 (MSP-1-5), ring-
infected erythrocyte surface antigen precursor (RESA) and glutamate rich protein 
(GLURP) (Wipasa, Elliott et al. 2002; Hill 2011).  
Within the erythrocytes, merozoites enter a cycle beginning with maturation into 
trophozoites, which then develop over days to form into schizonts (CDC 2010). 
Mature schizonts erupt to produce more merozoites, ensuring the continuation of 
the asexual cycle in the human host. A small proportion of newly released 
merozoites leave the asexual cycle to develop into male and female gametocytes; a 
process which may be regulated by DNA-binding protein PfAP2-G  (Kafsack, Rovira-
Graells et al. 2014).  Gametocytes are the sexual stage of the parasite that are not 
associated with clinical symptoms but are solely responsible for transmission to the 
insect vector (Bousema and Drakeley 2011). Gametocytes are produced 
approximately 7-15 days following the first asexual reproduction cycle, and appear in 
five morphologically different developmental stages (Talman, Domarle et al. 2004; 
Drakeley, Sutherland et al. 2006).  Developing inside the erythrocyte, gametocytes 
gradually increase in size until occupying the entire cell (Baker 2010). Due to the 
presence of a microtubular cytoskeleton and double membrane, gametocyte 
infected erythrocytes can be identified by their distinctive curved shape (Meszoely, 
Erbe et al. 1987). Early stage gametocytes (I-IV) are not found in human peripheral 
blood, but instead sequester within cells in the bone marrow, and possibly the spleen 
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(Sinden and Smalley 1979; Bousema and Drakeley 2011; Peatey, Watson et al. 2013). 
Sequestration is thought to be a tactic that enables gametocyte maturation to occur 
undisturbed in regions with low blood flow where they will not be targeted and 
cleared by host immunity (Wang, Mwakalinga et al. 2010; Bousema and Drakeley 
2011; Farfour, Charlotte et al. 2012; Peatey, Watson et al. 2013; Aguilar, Magallon-
Tejada et al. 2014).  From stage V onwards,  gametocyte sex can be determined and 
females identified by a smaller nucleus and more concentrated pigment and, 
depending on the staining procedure, a different coloured cytoplasm (Bousema and 
Drakeley 2011). During the first 6 days of their development, gametocytes appear to 
be metabolically inactive, with nucleic acid synthesis restricted to just ribonucleic 
acid (RNA) synthesis. Here, mRNA is synthesized for proteins such as P25 and P28 
that will be translated once inside the mosquito midgut (Baker 2010; Bousema and 
Drakeley 2011).  
Following maturation, stage V gametocytes emerge from sequestration and can be 
found in sub dermal capillaries, the optimal site for ingestion by a female mosquito 
when it takes a blood meal (Lensen, Bril et al. 1999; Bousema and Drakeley 2011).  
Once released into the blood stream, a lag period of several days must pass until 
gametocytes become infectious to mosquitoes (Bousema, Okell et al. 2010; Bousema 
and Drakeley 2011). When released into the blood stream, gametocytes circulate for 
an average of 4-6 days (Bousema, Okell et al. 2010). 
Mosquitoes can become infected if they passively ingest infectious mature 
gametocytes when taking a blood meal (CDC 2012).  Once inside the mosquito, 
gametocytes become spherical gametes, and discard the membrane of the 
erythrocyte they developed in (Bousema and Drakeley 2011). Male gametes then 
undergo 3 rounds of deoxyribonucleic acid (DNA) replication to produce up to 8 male 
microgametes, whereas females produce 1 macrogamete (Paul, Brey et al. 2002; Aly, 
Vaughan et al. 2009). Gametocyte activation to become gametes is thought to be 
stimulated by the different environment in the mosquito, specifically, a lower 
temperature, the presence of xanthurenic acid or a more alkaline surrounding 
(Bousema and Drakeley 2011; Guttery, Holder et al. 2012). The sexual replication 
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cycle begins with gametes proceeding to the mosquito midgut where they fuse to 
generate a diploid zygote, which undergoes meiosis to form a motile ookinete, which 
then penetrates the midgut wall (CDC 2010). Inside the midgut wall, ookinetes 
develop into oocysts which enlarge until they eventually rupture to release 
sporozoites which  migrate to mosquito salivary glands, ready to be inoculated into 
another human host during the next blood meal (CDC 2010).    
Plasmodium produces an array of antigens to ensure development and survival in the 
mosquito midgut. Within these, known gametocyte antigens can be split into pre and 
post fertilization antigens, depending on whether they are present before or after 
fertilization of female macrogametes by exflagellated male microgametes in the 
mosquito midgut (Bousema and Drakeley 2011). Pre-fertilization antigens include 
Pfs48/45 and Pfs230 and post fertilization antigens include Pfs25 and Pfs28, which 
are discussed in more detail in section 1.55.(Drakeley, Sutherland et al. 2006; CDC 
2010).  
 
1.2 Malaria epidemiology 
 
1.21 Malaria transmission and the human infectious reservoir 
 
While asexual parasites are responsible for the symptoms associated with malaria, 
gametocytes are responsible for transmission. Infectious gametocyte carriers form 
the infectious reservoir that maintains and seeds transmission (Bousema and 
Drakeley 2011). While gametocytes do not cause symptoms, gametocyte carriers can 
be both symptomatic or asymptomatic malaria-infected individuals, the symptoms 
being attributed to concurrent asexual parasite carriage (Bousema and Drakeley 
2011). Gametocytes were once thought to be uncommon in malaria infections, but 
the development of sensitive molecular detection methods revealed they are 
present in most infections, but often circulating at low (submicroscopic) densities, 
where they escape detection by microscopy, the routine method for asexual parasite 
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detection (Carter 1980; Ouedraogo, Bousema et al. 2009; Ouedraogo, Bousema et al. 
2010). Gametocytes only comprise a small proportion of all parasites that are 
present in infections with approximately 1 produced for every 156 asexual parasites 
(Eichner, Diebner et al. 2001; Bousema and Drakeley 2011). To some extent, 
gametocyte carriage mirrors asexual parasite dynamics. For example, high density 
gametocyte prevalence (detectable by microscopy) mimics patterns of asexual 
parasite prevalence, peaking during the high transmission season and following 
waves of asexual parasites (Boudin, Lyannaz et al. 1991). In contrast, submicroscopic 
gametocytes are often circulating at low levels for a much longer duration 
(Shekalaghe, Bousema et al. 2007). 
Submicroscopic gametocyte carriers may still have a significant impact on 
transmission with extremely low densities of 0.1-10/µL capable of infecting 
mosquitoes (Carter 1980; Pradel 2007; Schneider, Bousema et al. 2007; Ouedraogo, 
Bousema et al. 2009). It is not currently well understood who within the population is 
the most important contributor to the human infectious reservoir. While all 
gametocyte positive individuals should be considered capable of transmission, and 
submicroscopic infections certainly play a role, higher density infections (those 
microscopically detected) are more likely to infect mosquitoes and could therefore 
comprise a larger proportion of the human infectious reservoir (Ouedraogo, 
Bousema et al. 2009). 
Gametocyte presence is influenced by malaria transmission intensity, season, age, 
duration and type of symptoms, anti-malarial drugs and other host and external 
influences (Jones, McElroy et al. 1997; Hogh, Gamage-Mendis et al. 1998; Price, 
Nosten et al. 1999; Robert, Awono-Ambene et al. 2000; Sokhna, Trape et al. 2001; 
Targett, Drakeley et al. 2001; Tjitra, Suprianto et al. 2002; Bousema and Drakeley 
2011). Malaria infections are complex but can be broadly categorized according to 
symptoms, symptomatic or asymptomatic, and their parasite densities, referred to as 
detected by microscopy, or too low to be detected by microscopy (submicroscopic) 
(Lin, Saunders et al. 2014). The consensus opinion is that gametocytes are more likely 
to be seen in symptomatic infection where rounds of asexual proliferation, typical of 
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symptomatic disease, are followed by an increase in gametocyte prevalence and 
density (Drakeley, Akim et al. 2000; Bousema, Gouagna et al. 2004; Dunyo, Milligan 
et al. 2006; McKenzie, Jeffery et al. 2007; Ouedraogo, Schneider et al. 2007). 
However, research conducted in The Gambia and Nigeria found there to be a positive 
association between gametocyte carriage and a lack of fever (von Seidlein, Drakeley 
et al. 2001; Sowunmi, Fateye et al. 2004; Bousema and Drakeley 2011).  
Studies have also shown that recrudescent infections can result in higher gametocyte 
prevalence (Price, Nosten et al. 1999; Robert, Awono-Ambene et al. 2000; Sokhna, 
Trape et al. 2001; Sowunmi, Fateye et al. 2004). Similarly, haemoglobinopathies may 
impact on gametocyte carriage with genetic differences in the B-globin of 
haemoglobin resulting in HbAS, HbAC, HbCC genotypes which are associated with 
increased gametocytaemia (Robert, Tchuinkam et al. 1996; Gouagna, Bancone et al. 
2010; Bousema and Drakeley 2011). Differences in gametocyte densities have also 
been observed between ethnic tribes in Burkina Faso, with individuals belonging to 
the Fulani tribe generally carrying lower densities than individuals in the sympatric 
Mossi tribe, a phenomenon thought to be attributed to a stronger immunoglobulin G 
(IgG) response (Paganotti, Palladino et al. 2006; Bousema and Drakeley 2011; Tiono, 
Sirima et al. 2013).   
Gametocytes are a product of asexual stage parasites. Following exposure to 
parasites, individuals acquire asexual stage immunity which can reduce asexual 
parasite density and therefore also affect gametocyte presence (Bousema, Gouagna 
et al. 2004). Figure 1.1. presents the prevalence of microscopically detectable 
gametocytes by age group in different regions of endemicity. In high endemic 
settings, younger children have yet to acquire asexual parasite immunity and 
therefore have higher asexual parasite densities, which results in the generation of 
more gametocytes (Molineaux and Gramiccia 1980; Drakeley, Bousema et al. 2006; 
Bousema and Drakeley 2011). For this reason, children under the age of 10 tend to 
harbour more microscopically detectable gametocyte infections and have been 
suggested to form the main human infectious reservoir (Boudin, Lyannaz et al. 1991; 
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Githeko, Brandling-Bennett et al. 1992; Toure, Doumbo et al. 1998; Drakeley, Akim et 
al. 2000; Mabunda, Casimiro et al. 2008; Ouedraogo, Bousema et al. 2010).  
Since immunity to the asexual parasite stages is acquired with cumulative exposure 
which is inherently linked with age, this results in an age dependent decrease of 
gametocyte prevalence (Drakeley, Sutherland et al. 2006). It has been suggested this 
reduction in gametocyte carriage with age could also be attributed to sexual stage 
immunity that is associated with clearance of gametocytes from the blood stream 
although this requires confirmation, and identification of the responsible gametocyte 
antigens (Bousema, Gouagna et al. 2004; Saeed, Roeffen et al. 2008). 
 
 
Figure 1.1. Gametocyte prevalence by age group in populations sampled from different 
endemic settings in Burkina Faso, Tanzania and The Gambia. Gametocyte prevalence 
was determined by microscopy. Figure taken directly from the referenced 
publication. (Bousema and Drakeley 2011).  
 
 In low transmission or low seasonal transmission regions asexual stage immunity 
may wane between seasons and the result is no distinct relationship between age 
and gametocyte carriage, and similar proportions of each age group are 
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gametocytaemic (Figure 1.1.) (Bousema and Drakeley 2011). In areas with marked 
seasonality, gametocyte prevalence during the dry season may be low, and chronic 
low density parasite carriage may be responsible for maintaining the infectious 
reservoir to the following season (Babiker, Abdel-Muhsin et al. 1998; Abdel-Wahab, 
Abdel-Muhsin et al. 2002; Nassir, Abdel-Muhsin et al. 2005; Bousema and Drakeley 
2011).  
 
1.22 The flexibility of gametocyte production 
 
Despite the low prevalence of gametocytes in the dry season, within these sparse 
infections the proportion of all parasites that are gametocytes may be relatively high 
(Bousema and Drakeley 2011). This suggests a relative shift to gametocyte 
production, which may be a strategy to ensure transmission still occurs during the 
dry season (Boudin, Lyannaz et al. 1991; Drakeley, Sutherland et al. 2006; Mair, 
Lasonder et al. 2010). 
While the highest gametocyte densities are found in younger age groups, the 
proportion of total parasites that are gametocytes is lowest within this age group, 
with approximately only 2% of their total parasite load being gametocytes 
(Ouedraogo, Bousema et al. 2010). In contrast, adults have lower total parasite 
numbers, but a higher proportion of both microscopic and submicroscopic 
gametocytes amounting to 15% of their overall parasite burden (Drakeley, 
Sutherland et al. 2006; Ouedraogo, Bousema et al. 2010; Bousema and Drakeley 
2011). This complex dynamic (Figure 1.2.) may be considered a strategy to ensure 
transmission is ongoing even when parasite densities are low (Roper, Elhassan et al. 
1996). However, the data revealing this pattern was derived from a high transmission 
setting and this finding requires confirmation in other levels of endemicity and 
preferably should be supported by detection of asexual parasites that are committed 
to the gametocyte pathway (Bousema and Drakeley 2011). 
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Figure 1.2. The relationship between age and gametocyte carriage in Burkina Faso 
(Ouedraogo, Bousema et al. 2010). Gametocyte prevalence was determined by 
microscopy, Figure taken directly from the referenced publication. 
 
1.23 Who is infectious to mosquitoes? 
 
The human infectious reservoir (the proportion of the human population that is 
capable of infecting mosquitoes) is determined by gametocyte carriage, infectivity, 
mosquito biting patterns and the relative contribution of different age groups to the 
total human population (Bousema and Drakeley 2011). Generally, there is an 
increasing relationship between gametocyte density and prevalence of infection in 
mosquitoes; however, submicroscopic gametocyte densities, including those 
undetectable using molecular methods, have been demonstrated to result in 
infection, both in the field, and under laboratory conditions (Jeffery and Eyles 1955; 
Bonnet, Gouagna et al. 2000; Schneider, Bousema et al. 2007). A study performing 
membrane feeding assays in Kenya demonstrated 4.1% of mosquitoes were infected 
by submicroscopic infection compared to 8.3% infected by microscopically detected 
gametocytes (Schneider, Bousema et al. 2007). The authors suggested because 
submicroscopic carriers are more prevalent, their contribution to the infectious 
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reservoir is in fact comparable to that of microscopically detectable parasites 
(Schneider, Bousema et al. 2007).  
Body size, human behaviour and foot odour are among the variables indicated to 
influence mosquito biting behaviour (Bousema and Drakeley 2011; Omolo, Njiru et 
al. 2013).  Despite having lower gametocyte densities, since adults have more body 
mass this increases the likelihood of mosquito contact and therefore feeding, so their 
influence on transmission must not be underestimated (Drakeley, Sutherland et al. 
2006; Bousema, Drakeley et al. 2007; Ouedraogo, Bousema et al. 2010). 
Furthermore, as adults in high endemic settings are likely to be asymptomatic 
carriers, they may not seek treatment and will continue to be potential transmitters 
of parasites (Ganguly, Saha et al. 2013). Consequently, as asymptomatic infections 
are often long lasting, this increases the likelihood of gametocyte presence and 
increases the likelihood of human-mosquito contact (Bousema and Drakeley 2011). 
Human behavioural patterns also influence who is likely to be bitten. For example, 
studies have revealed if households have a bed net, it will not necessarily be used for 
children; since they are likely to be sleeping at dusk when mosquitoes start feeding, 
this makes them especially vulnerable to being bitten (Korenromp, Miller et al. 
2003). In a similar vein, adults are likely to be awake (at least for part of the mosquito 
feeding time) and therefore also unprotected by a bed net (Korenromp, Miller et al. 
2003).  
Attempts have been made to identify which age groups are most infectious to 
mosquitoes. With this knowledge, targeted control interventions could be adopted 
(WHO 2012; Sturrock, Hsiang et al. 2013). Studies looking at populations in Burkina 
Faso, The Gambia and Tanzania suggested different groups were contributing most 
to the infectious reservoir. The study in Burkina Faso concluded all age groups 
contributed equally, whereas data from The Gambia suggested those over the age of 
20 were most infectious, and the Tanzanian research concluded 1-4 year olds and 
those over the age of 20 were most infectious (Boudin, Olivier et al. 1993; Drakeley, 
Akim et al. 2000).  Since these studies were performed, the advent of sensitive 
molecular gametocyte detection methods has enabled investigation of the impact of 
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submicroscopic carriers, by age, to gain a more complete understanding of 
infectiousness.  
 
1.3 Natural infections and acquisition of immunity 
 
1.31 Acquired immunity against asexual stages of malaria 
 
As touched on briefly, antibodies may develop and immunity gained against asexual 
parasite stages following natural infection. The concept of naturally acquired 
immunity (NAI) was first introduced by Robert Koch in 1900 when he examined 
prevalence and density of parasites in blood films from regions of high and low 
malaria endemicity, and deduced that immunity against malaria was acquired 
following uninterrupted and heavy exposure to parasites (Koch 1900; Koch 1900; 
Koch 1900; Koch 1900; Doolan, Dobano et al. 2009). By 1920, it had been recognized 
that NAI was gained in relation to the intensity of the exposure, lost when exposure 
is removed, and was specific to the species and parasite stage (Sergente 1910; 
Schuffner 1919).  
Since immunity is acquired following exposure, which accumulates over time, the 
outcome is an age dependent antibody acquisition pattern, which results in an age 
dependent decrease in vulnerability to severe disease (Doolan, Dobano et al. 2009). 
As malaria exposure varies with season, and transmission intensity, both of these 
impact on the dynamics of antibody acquisition (Drakeley, Corran et al. 2005; Doolan, 
Dobano et al. 2009). Age dependent immunity develops throughout life, first 
manifesting as clinical immunity, which decreases parasite pathogenicity and 
associated symptoms, then eventually leading to anti-parasitic immunity, where 
asexual parasites are actively controlled (Baird 1995; Good 2001; Doolan, Dobano et 
al. 2009). The relationship between antibodies and derived protection is complex and 
the presence of antibodies or a high antibody titre does not necessarily equate to 
protection, or a high level of protection, respectively (Struik and Riley 2004).  
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1.32 Immunity in high transmission regions 
 
Immunity is acquired in different stages. Newborn babies are generally protected for 
approximately their first 6 months by passively acquired maternally derived IgG, 
obtained in the final trimester of pregnancy (Riley, Wagner et al. 2000). During the 
first 18 weeks post birth, this immunity protects from high parasitaemia with 
infections appearing as asymptomatic, and generally resolving quickly (Franks, Koram 
et al. 2001; Doolan, Dobano et al. 2009). After 18 weeks, maternal antibodies begin 
to wane and there is a significant increase in risk of severe infection as active 
immunity has yet to develop (Wagner, Koram et al. 1998; Riley, Wagner et al. 2000).  
This leaves young children extremely vulnerable to severe disease and death and this 
age group carries the highest parasitaemias, but is also susceptible to symptomatic 
infection from very low densities (McGuinness, Koram et al. 1998).  However, after 
surviving infections, infants acquire their own immunity that becomes more 
protective following subsequent exposures (Doolan, Dobano et al. 2009). 
Anti disease immunity develops next  which protects against clinical disease, 
reducing the extent of morbidity (Marsh and Kinyanjui 2006). The functionality and 
memory of immunity seems variable, with no clear association between the number 
or duration of parasite exposures and the level of protection induced; in some 
individuals a single malaria infection is sufficient to protect against death and clinical 
disease, whereas for others, multiple infections will only induce limited protection 
(Struik and Riley 2004). Generally, in a high transmission setting, the risk of severe 
malaria is highest in the first years of life, which reduces the risk of clinical disease at 
approximately 2-5 years of age (Doolan, Dobano et al. 2009). 
In older children and adults, anti-parasite immunity develops which controls parasite 
densities and protects from severe disease (Baird, Owusu Agyei et al. 2002). While 
mild clinical infections may still be common, infections are often asymptomatic 
(Doolan, Dobano et al. 2009). This is thought to be due to lower parasite density, 
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although recent evidence challenges an exact relationship between parasite density 
and severity of symptoms (Goncalves, Huang et al. 2014). As immunity builds, 
parasite densities in subsequent infections become progressively lower and lower 
(Langhorne, Ndungu et al. 2008).  
Recent studies have reiterated that while high levels of clinical immunity to blood 
stage parasites is common among adults in high endemic settings, there is no 
evidence of naturally acquired sterile immunity, even though it can be 
experimentally induced in human and mouse models (Nussenzweig, Vanderberg et 
al. 1967; Hoffman, Goh et al. 2002; Roestenberg, McCall et al. 2009; Tran, Li et al. 
2013). While possible that partial immunity is acquired against sporozoites or liver 
stage parasites, the theory that sterile immunity is not gained is supported by the 
repeated re-infections commonly seen (when using molecular methods to determine 
parasite prevalence) in high endemic settings among all age groups (Tran, Li et al. 
2013).  Though there is speculation about the role of genetic polymorphisms or low 
density sporozoite inoculation in preventing the natural development of sterile 
immunity, it largely remains a mystery why such immunity can be induced 
experimentally, and not through natural infection (Barry, Schultz et al. 2009; 
Offeddu, Thathy et al. 2012). It is certainly of interest to vaccine developers to gain 
an understanding of the underlying mechanisms leading to sterile immunity (Tran, Li 
et al. 2013). 
 
1.33 Immunity in low transmission regions 
 
In regions with low or unstable transmission of malaria, the entomological 
inoculation rate (EIR) is often between 1-5 per year, which slows the acquisition of 
protective immunity ((WHO) 2010). Consequently, acute clinical cases are prevalent 
in all age groups, including older children and adults (Carneiro, Roca-Feltrer et al. 
2010; Griffin, Ferguson et al. 2014). Furthermore, the risk of cases progressing to 
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severe malaria (if untreated) is high, and the populations living in these settings are 
at risk from epidemics((WHO) 2010).  
While it is expected that individuals in low transmission settings would not benefit 
from the same degree of immunity experienced in high transmission areas, and that 
asymptomatic infections including those harbouring submicroscopic parasites would 
be less common, recent studies challenge these ideas (Okell, Ghani et al. 2009; Okell, 
Bousema et al. 2012). A study by Baliraine et al, discovered a high prevalence of 
asymptomatic infections, including those detected by microscopy in a region of hypo-
endemicity in Kenya (Baliraine, Afrane et al. 2009). Similarly, findings from Okell and 
colleagues showed submicroscopic parasite carriage is not only more common 
among adults in low transmission settings but accountable for 20-50% of mosquito 
infections (Okell, Bousema et al. 2012). The authors hypothesized that low density 
asymptomatic carriage was due to older and monoclonal infection; they suggested 
when individuals become infected with a second clone, this results in a higher 
parasite density and clinical disease (Okell, Bousema et al. 2012). Leading from this 
they speculated that super infections, typical of high endemic areas, are the cause of 
higher parasite densities, and that acquired immunity may only have partial cross 
protection against different clones (Okell, Bousema et al. 2012).  
 
1.34 Serological markers of exposure 
 
Along with protecting from the clinical consequences of malaria infection, antibodies 
are also valuable markers of malaria exposure. While malaria transmission can be 
measured using parasite prevalence data, EIR or clinical data, these indicators can be 
subject to seasonal and geographical variation (Cook 2010; Cook, Reid et al. 2010).  
Monitoring of serological responses is cheaper, simpler to sample (since filter papers 
samples can be used), and is more stable due to antibody longevity (Cook, Reid et al. 
2010). Asexual serological markers such as AMA-1, GLURP and MSP-1 are all 
routinely measured for this purpose using enzyme linked immunosorbent assay 
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(ELISA) (Corran, Cook et al. 2008; Drakeley and Cook 2009; Cook, Reid et al. 2010; 
Proietti, Pettinato et al. 2011; Stone, Bousema et al. 2012; Proietti, Verra et al. 2013).  
The rate of antibody acquisition (seroconversion) to these asexual stage antigens can 
be modelled to demonstrate the force of infection as indicator of transmission 
intensity (Drakeley, Corran et al. 2005). In high transmission regions seroconversion 
occurs faster, and consequently younger age groups are more likely to be antibody 
positive, whereas in low transmission regions, the rate of antibody acquisition is 
slower, and the age of seroconversion may therefore be older (Drakeley, Corran et al. 
2005).  These differences across transmission settings also reflect the time between 
infections, which is longer in low transmission settings (therefore removing the 
stimulus for boosting), whereas individuals in high transmission regions may suffer 
from chronic low parasite density carriage which acts to maintain their antibody 
levels (Drakeley, Corran et al. 2005). The rate of seroconversion varies by plasmodial 
antigen and it has been hypothesized that individuals seroconvert against AMA-1 
after just one or two infections and that antibodies may circulate for a longer time 
(compared to those derived against other antigens) in absence of boosting (Drakeley, 
Corran et al. 2005). MSP-1 and GLURP antibody responses are generally lower than 
that for AMA-1 (Drakeley, Corran et al. 2005; Stone, Bousema et al. 2012). Since 
antibody levels decline in absence of parasite exposure, antibody prevalence and 
density can be used  as a proxy to measure the impact of parasite reducing 
interventions (Cook, Reid et al. 2010). In this thesis serological markers of malaria 
exposure are measured to provide information about parasite exposure.  
 
1.35 Evidence for naturally acquired sexual stage immunity from the field 
 
Most gametocytes are not ingested by mosquitoes, but are instead removed by the 
human immune system which breaks down infected erythrocytes to expose 
gametocytes (and their surface proteins) which can result in the production of anti-
gametocyte immune responses (Bousema and Drakeley 2011). Anti-gametocyte 
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immunity has been suggested to function in several ways, by clearing gametocytes 
from the site of sequestration, or from blood circulation or by blocking transmission 
to the mosquito (Bousema and Drakeley 2011).  
Immunity hypothesized to clear gametocytes circulating within the human host can 
be split into gametocyte specific or non specific. It has been suggested gametocyte 
specific antibodies recognize molecules on the gametocyte infected erythrocyte, and 
serum reacting to this (demonstrated using immunofluorescence) has been linked 
with reduced gametocyte prevalence (Saeed, Roeffen et al. 2008; Sutherland 2009; 
Bousema and Drakeley 2011). Overall there is limited evidence for this theory. For 
non specific immunity, it has been suggested that immunity derived against 
molecules presented on the surface of the infected erythrocytes or trophozoites, 
such as PfEMP-1, could cross react with young gametocytes which may have identical 
adhesion molecules (Day, Hayward et al. 1998; Cham, Turner et al. 2009; Bousema 
and Drakeley 2011). This has been suggested to affect gametocyte maturation during 
sequestration (Day, Hayward et al. 1998; Cham, Turner et al. 2009; Bousema and 
Drakeley 2011). Once more, there is limited evidence to validate this hypothesis.  
Whilst innate and cellular immune responses do play a role in immunity that effects  
the parasite’s sexual sta e (such as release of tumour necrosis factor (TNF)-alpha, 
which may reduce gametocyte infectiousness) antibody responses play the largest 
protective role (Naotunne, Karunaweera et al. 1991; Karunaweera, Carter et al. 1992; 
Bousema, Drakeley et al. 2006; Bousema and Drakeley 2011). As antibodies are 
produced against many of the surface sexual stage antigens, they have a larger 
impact, compared to cell-mediated immune responses (Bousema and Drakeley 
2011).  
Individuals in endemic settings may have antibodies against gametocyte proteins and 
for a subset of this population, these antibodies have been demonstrated to have 
functional transmission reducing activity (TRA) (Carter, Graves et al. 1989; Drakeley, 
Mulder et al. 1998; Healer, McGuinness et al. 1999; Struik and Riley 2004; Bousema 
and Drakeley 2011). This has been evidenced by a reduced oocyst density in the 
mosquito, which is demonstrated using membrane feeding assays, discussed further 
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in section 1.47.(Bousema and Drakeley 2011). This observation of naturally acquired 
TRA initiated interest in using gametocyte antigens as vaccine candidates that aim to 
reduce the parasite reservoir in the mosquito vector (Sauerwein 2007).  
Pfs48/45 and Pfs230 are 2 gametocyte proteins that transmission blocking immunity 
develops against (Bousema, Roeffen et al. 2010). Pfs48/45 is concerned with 
gametocyte attachment during fertilization, and Pfs230 has a suggested role in 
arrangement of exflagellation centres, (function is further discussed in section 1.55.) 
(Vermeulen, Ponnudurai et al. 1985; Kocken, Jansen et al. 1993; Williamson, Criscio 
et al. 1993; van Dijk, Janse et al. 2001; Eksi, Czesny et al. 2006; van Schaijk, van Dijk 
et al. 2006; Bousema and Drakeley 2011).  Membrane feeding assays, specifically the 
standard membrane feeding assay (SMFA) and direct membrane feeding assay 
(DMFA) have confirmed the TRA of  high levels of antibodies against Pfs230 and 
Pfs48/45 in endemic sera from Africa and Australasia (Graves, Carter et al. 1988; 
Roeffen, Mulder et al. 1996; Healer, McGuinness et al. 1999; Mulder, Lensen et al. 
1999; Drakeley, Eling et al. 2004; Bousema, Roeffen et al. 2006; Drakeley, Bousema 
et al. 2006; van der Kolk, de Vlas et al. 2006; Bousema, Drakeley et al. 2007; 
Bousema, Roeffen et al. 2010; Bousema and Drakeley 2011).   
These results are promising, but not all studies found a relationship between 
antibody presence and TRA, with some indicating individuals with no antibodies 
against Pfs48/45 or Pfs230 still demonstrated TRA (Graves, Carter et al. 1988; 
Premawansa, Gamage-Mendis et al. 1994; Drakeley, Bousema et al. 2006; Bousema, 
Drakeley et al. 2007; Bousema, Roeffen et al. 2010). Results from  a study performed 
in a low transmission region  in Sri Lanka indicated there was no relationship 
between TRA and Pfs48/45 or Pfs230 antibodies (Premawansa, Gamage-Mendis et 
al. 1994). This suggests transmission reducing (TR) functionality of these antibodies 
may be dependent on repeated exposure, typical of higher endemicity, or 
alternatively, TRA is caused by antibodies derived against other antigens not 
measured in the study (Premawansa, Gamage-Mendis et al. 1994; Bousema and 
Drakeley 2011).  
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The degree of transmission reduction also varies. A study in Tanzania showed gradual 
deterioration of TRA (at the >50% level) with age which was hypothesized to be 
attributed to lower gametocyte densities (and therefore lower antibody levels), or 
possibly reduced antibody avidity (Drakeley, Bousema et al. 2006). The same study 
found superior transmission blockers, i.e. individuals with >90% transmission 
reduction, were associated with higher antibody titre, and these individuals were 
from each age category (Drakeley, Bousema et al. 2006). For this reason, it was 
suggested  that submicroscopic gametocyte densities may be sufficient to elicit 
functional TRA at the >90% level (Drakeley, Bousema et al. 2006). While high 
antibody titres may be more effective at transmission reduction, low antibody levels 
may actually enhance transmission, which has been reported for P.vivax 
(Ponnudurai, Van Gemert et al. 1987; Peiris, Premawansa et al. 1988; Naotunne, 
Rathnayake et al. 1990; Gamage-Mendis, Rajakaruna et al. 1992; Healer, McGuinness 
et al. 1999; van der Kolk, de Vlas et al. 2006; Bousema and Drakeley 2011).  
 
1.36 Evidence for age dependent acquisition of Pfs48/45 and Pfs230 antibodies 
 
The rate and pattern of naturally acquired antibodies to Pfs48/45 and Pfs230 with 
age is not clear.  It has been suggested sexual stage antibodies (derived against 
Pfs48/45 and Pfs230) develop quickly, are reliant on recent rather than cumulative 
exposure, and are short lived (Riley, Bennett et al. 1994; Drakeley, Eling et al. 2004; 
Drakeley, Bousema et al. 2006; Bousema, Roeffen et al. 2010; Bousema and Drakeley 
2011). Since gametocyte exposure is highest in children, the majority of studies have 
reported that Pfs48/45 and Pfs230 antibodies are more commonly found in children, 
and decrease with age, as gametocyte load and therefore stimulus for antibody 
production also decreases (Bousema, Sutherland et al. 2011). Continuing with this 
idea, it has therefore also been suggested that Pfs48/45 and Pfs230 antibodies will 
be less prevalent in the older age groups in high transmission areas (Bousema, 
Drakeley et al. 2007). 
 47 
 
However, this age dependent decrease is not always evident, with studies both 
supporting and contradicting this theory. For Pfs230, evidence from a study in The 
Gambia showed no relationship with age and antibody prevalence or titre (Riley, 
Bennett et al. 1994). Alternatively, a study in Papua New Guinea found an increase of 
antibody prevalence and density for Pfs48/45 and Pfs230 with age (Graves, 
Doubrovsky et al. 1991), whereas evidence from Tanzania showed an age dependent 
decrease (Drakeley, Sutherland et al. 2006; Bousema, Drakeley et al. 2007; Bousema 
and Drakeley 2011). The dynamics of sexual stage exposure and antibody prevalence, 
titre and functionality still remain unclear and need further investigation, especially 
in the context of transmission blocking vaccine (TBV) candidate development, to 
ensure host immune-responsiveness is not a limitation.  
 
1.4 Measuring the human infectious reservoir 
 
1.41 Gametocyte detection 
 
Detection of malaria infection routinely relies on the use of microscopy or rapid 
diagnostic tests (RDTs), depending on available resources (Bell 2002). Both assays are 
sufficiently sensitive to detect asexual parasite densities that are clinically relevant in 
the majority of malaria endemic settings (WHO 2009). Whilst it is sufficient to detect 
asexual parasites for the sake of routine clinical care, there are circumstances where 
it is required to specifically detect gametocytes. Gametocyte detection is especially 
valuable in epidemiological studies to understand transmission intensity and detect 
the human infectious reservoir, for infectivity studies to understand gametocyte 
prevalence and densities  relevant for mosquito infection, and for malaria control 
purposes, such as determining efficacy of transmission blocking interventions or 
gametocidal drugs (Bousema, Drakeley et al. 2006; Schneider, Bousema et al. 2007; 
Wampfler, Mwingira et al. 2013).  
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1.42 Rapid diagnostic test (RDT) and microscopy based gametocyte detection 
 
Microscopy and RDTs have limited sensitivity to detect all malaria infections since up 
to 80% of infections may be present at submicroscopic parasite densities (Okell, 
Bousema et al. 2012). Moreover, RDTs are not parasite stage-specific so have no role 
in specifically detecting gametocytes (Moody 2002). While microscopy can detect as 
few as 16 gametocytes/ µL (Churcher, Bousema et al. 2013; Karl, Laman et al. 2014), 
often densities in the range of 20-50/ µL are not seen (when screening 100 views) 
(Dowling and Shute 1966; Moody 2002; Karl, Davis et al. 2009; Bousema and 
Drakeley 2011). This is insufficient for accurate measurement since gametocytes 
often circulate at much lower densities (Ouedraogo, Bousema et al. 2009), and 
evidence has indicated microscopy negative blood samples are capable of infecting 
mosquitoes, which spurred the development of more sensitive detection tools 
(Muirhead-Thomson 1954; Jeffery and Eyles 1955; Muirhead-Thomson 1998; 
Bousema and Drakeley 2011).   
The sensitivity of gametocyte detection can be improved in several ways, by reading 
more microscopy fields, by increasing the blood volume screened using 
concentration methods, or by using molecular detection techniques (Bousema and 
Drakeley 2011).  In one study, increasing the number of fields that were viewed from 
100 to 1000  (on a thick blood film) reportedly increased gametocyte prevalence by 
300%  (Colbourne 1956). An alternative approach is an enhanced microscopy 
method, magnetic deposition microscopy (MDM) which concentrates asexual stage 
parasites due to the magnetic properties of their hemozoin crystals (Karl, David et al. 
2008).  Whilst hemozoin crystals are not gametocyte specific, this method enables 
specific reading of parasite infected blood, which is more time efficient; a study 
assessing symptomatic individuals reported an increased gametocyte prevalence of 
7.3% to 45% when using MDM compared to reading a normal blood smear (Drakeley, 
Sutherland et al. 2006; Karl, David et al. 2008; Bousema and Drakeley 2011).  
Another technique is the quantitative buffy coat (QBC) method which separates and 
concentrates parasites from platelets, monocytes, granulocytes and lymphocyctes in 
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a whole blood sample (Spielman, Perrone et al. 1988; Bousema and Drakeley 2011). 
The blood is drawn in an acridine orange capillary tube which is then centrifuged to 
separate the parasite infected erythrocytes from other blood cell components (Pinto, 
Rodrigues et al. 2001). When illuminated under ultra violet (UV) light, acridine 
orange stained parasites fluoresce, thereby enabling rapid and specific parasite 
counting under the microscope (Pinto, Rodrigues et al. 2001). A transmission study 
conducted in Cameroon by Mulder et al. reported an increased gametocyte estimate 
from 4.6% (determined by conventional microscopy) to 19.1% when using QBC 
(Mulder, van der et al. 1998; Bousema and Drakeley 2011). Even with the enhanced 
sensitivity offered by these adapted methods, microscopy remains labour intensive, 
requires skilled technicians (and repeated quality checks to ensure skills are 
maintained) (Fernando, Karunaweera et al. 2004), is insufficient for low gametocyte 
densities (Bousema and Drakeley 2011), and not appropriate for remote field 
settings.  
 
1.43 Molecular detection of gametocytes 
 
Individuals with microscopy negative gametocytes have been reported to be 
infectious to mosquitoes (Boudin, Lyannaz et al. 1991; Bousema, Dinglasan et al. 
2012), indicating the need for improved detection methods. To enable sensitive 
detection of submicroscopic gametocytes, molecular techniques targeting 
gametocyte specific mRNA transcripts have been developed (Bousema and Drakeley 
2011). Whilst DNA is present in both asexual and sexual stage parasites, RNA 
transcription of specific genes is up-regulated in just gametocytes, thereby providing 
a gametocyte specific target  (Talman, Domarle et al. 2004; Karl, David et al. 2008). 
The mRNA of approximately 300 genes is exclusively produced in gametocytes, 
providing the opportunity for detection, quantification or genotyping, depending on 
the gene assessed (Silvestrini, Bozdech et al. 2005; Young, Fivelman et al. 2005; 
Bousema and Drakeley 2011). Since many Plasmodium genes have no introns, DNA 
and RNA appears identical, and methods seeking to specifically detect gametocytes 
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must remove genomic DNA by digest prior to RNA detection or use alternative 
approaches to avoid the amplification of double stranded DNA (Babiker and 
Schneider 2008). 
Pfs25mRNA is abundantly expressed in mature gametocytes, zygotes and ookinetes 
(Jones, Chichester et al. 2013). This transcript has so far been the most commonly 
used target for detection of mature gametocytes (Wampfler, Mwingira et al. 2013).  
Although translationally suppressed until after fertilization in the mosquito, 
Pfs25mRNA transcripts can be detected in stage V gametocytes circulating in the 
human host (Bousema and Drakeley 2011). Currently, three molecular methods: 
reverse transcriptase polymerase chain reaction (RT-PCR), reverse transcription loop 
mediated isothermal amplification (RT-LAMP) and quantitative nucleic acid sequence 
based amplification  (QT-NASBA) have been adapted for gametocyte detection 
targeting Pfs25mRNA (Trager and Jensen 1976; Ponnudurai, Meuwissen et al. 1982; 
Boom, Sol et al. 1990; Babiker, Abdel-Wahab et al. 1999; Schneider, Schoone et al. 
2004; Bousema, Schneider et al. 2006; Mens, Schoone et al. 2006; Mens, Sawa et al. 
2008; Bousema and Drakeley 2011).  Reportedly, QT-NASBA detects gametocyte 
densities as low as 0.02-0.1 gametocytes/µL, while both RT-PCR and RT-LAMP have 
detection thresholds of approximately 1-2 gametocytes/µL (Babiker, Abdel-Wahab et 
al. 1999; Notomi, Okayama et al. 2000; Schneider, Schoone et al. 2004; Mlambo, 
Vasquez et al. 2008). As well as varying sensitivity, these techniques differ in terms of 
assay cost, ease of use, time to result, equipment needed and if read-out is 
qualitative or quantitative.  The use of molecular techniques has vastly improved the 
accuracy of estimations of the human infectious reservoir, with studies consistently 
showing a 3-10 fold increase in gametocyte prevalence when using molecular tools, 
compared to microscopy (Ali, Mackinnon et al. 2006; Bousema, Schneider et al. 2006; 
Schneider, Bousema et al. 2006; Shekalaghe, Drakeley et al. 2007; Mens, Sawa et al. 
2008; Bousema and Drakeley 2011).  
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1.44 Reverse transcription polymerase chain reaction (RT-PCR) 
 
RT PCR is a qualitative PCR method informing only of presence or absence of 
gametocytes (Mlambo, Vasquez et al. 2008). Due to the lack of introns in 
Pfs25mRNA, parasite RNA and DNA is identical in coding sequence, therefore 
residual DNA from asexual stage parasites will also produce positive results (Babiker 
and Schneider 2008; Joice, Narasimhan et al. 2013). To avoid this, test samples must 
be subjected to a DNA digestion step prior to use. Amplification occurs as follows; 
starting with an RNA sample, cDNA copies are generated using reverse transcriptase, 
then nested PCR is performed from the cDNA template (Babiker and Schneider 
2008). To confirm specificity of positive samples (i.e. to ensure asexual DNA has been 
digested), DNA controls (where the reverse transcriptase is heat inactivated, and 
substituted for a DNA polymerase) must be conducted for every positive sample 
(Babiker and Schneider 2008). While RT-PCR is convenient as it can be performed on 
a conventional thermocycler, and the methodology is straight forward to conduct 
and interpret, reagent cost is increased since 2 reactions must be included for each 
positive result. Additionally, it has been speculated the DNA digest may degrade a 
fraction of the RNA copies and result in reduced sensitivity. A quantitative version of 
RT- PCR (qRT-PCR) has more recently been developed which uses a titration curve of 
cultured gametocytes to enable quantification. The reported sensitivity is 1 copy 
number /µL (Wampfler, Mwingira et al. 2013).  
 
1.45 Quantitative nucleic acid sequence based amplification (QT-NASBA) 
 
QT-NASBA  is a quantitative molecular detection method that amplifies RNA under 
the action of three enzymes, AMV-RT (avian myeloblastosis virus reverse 
transcriptase), RNase H and T7 RNA polymerase, and two target specific primers 
(Schneider, Schoone et al. 2004). Amplification occurs as follows, a primer containing 
a T7 promoter hybridizes to single stranded RNA in the sample. AMV-RT then 
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extends the sequence and RNA is hydrolyzed from the cDNA:RNA complex by RNAse 
H, leaving the cDNA from which double stranded DNA is amplified with the second 
primer (Schneider, Schoone et al. 2004). The newly generated double stranded DNA 
contains a T7 promoter which allows continual generation of new RNA under the 
action of T7 RNA polymerase. When primers have been exhausted, amplification 
occurs solely due to transcription.  Here, fluorescent dye binds to the new DNA and 
electrochemiluminescence (ECL) is measured as the output. As there is a linear 
relationship between the newly transcribed material and the number of gametocytes 
in the reaction, sample quantification is possible (Schneider, Schoone et al. 2004; 
Schneider, Wolters et al. 2005).  
QT- NASBA is advantageous since RNA is amplified isothermally at 41°C, a 
thermocycler is theoretically not required and because the reaction temperature is 
too low to denature DNA this ensures primers only anneal to single stranded RNA 
therefore resulting in RNA specific amplification (Schneider, Schoone et al. 2004; 
Babiker and Schneider 2008). QT-NASBA is rapid with an incubation time of 90 
minutes, compared to hours of thermocycling needed for conventional PCR, and has 
a higher level of sensitivity as previously mentioned. Whilst the initial investment in 
quantitative equipment is high, the reduction in person hours to result means it is 
more cost effective and less labour intensive (Schneider, Schoone et al. 2004; 
Schneider, Wolters et al. 2005).  
 
1.46 Reverse transcription loop mediated isothermal amplification (RT-LAMP) 
 
RT-LAMP is an alternative isothermal amplification method which has also been 
optimized for gametocyte detection targeting Pfs25mRNA (Buates, Bantuchai et al. 
2010). The methodology functions as follows, under the action of AMV and Bst 
enzymes, 8 target regions are amplified using 6 primer sets . RNA is firstly reverse 
transcribed to cDNA which contains complementary sequences at both ends that self 
anneal. Auto-cycling strand displacement takes place which results in a hairpin 
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looped product from which new DNA is generated (Notomi, Okayama et al. 2000). A 
fluorophore calcein is included in the reaction which is initially quenched by 
manganese; when the reaction starts, pyrophosphate is generated as a by-product 
and it binds to the calcein displacing it from the manganese which allows it to 
fluoresce (Tomita, Mori et al. 2008). Along with fluorescence, a positive result also 
manifests as visible turbidity in the reaction mixture and this can be measured either 
by using a turbidimeter or by visualizing fluorescence using a UV light source (Tomita, 
Mori et al. 2008). RT-LAMP is advantageous as it occurs within a closed tube system, 
which reduces contamination risk (Chang, Chen et al. 2012), and it also does not 
require a thermocycler which makes it more potentially more amenable for use in 
the field. Whilst it has been suggested to be more sensitive than RT-PCR, it is 
currently unknown how it performs compared to QT-NASBA.  
 
1.47 Membrane feeding assays 
 
While gametocyte presence is suggestive of transmission potential, mosquito feeding 
assays are the only assays that can provide direct evidence of infectiousness to 
mosquitoes (Lin, Saunders et al. 2014). There are 3 main mosquito feeding assays 
that will be discussed, which are used for 2 purposes in this thesis, to determine the 
human infectious reservoir and to quantify the impact of naturally acquired sexual 
stage antibodies on transmission efficiency (Bousema and Drakeley 2011).  
Gaining an understanding of who forms the infectious reservoir could be used to 
target interventions towards infectious hotspots, for a more specific approach to 
malaria control (Bonnet, Gouagna et al. 2003; Ouédraogo, Sattabongkot et al. 2013; 
Sturrock, Hsiang et al. 2013). Two methods are used to determine the human 
infectious reservoir by assessing the infectiousness of gametocytes to mosquitoes, 
direct skin feeding  and membrane feeding using whole blood samples (Muirhead-
Thomson 1957; Ponnudurai, Lensen et al. 1989; Bousema and Drakeley 2011) (see 
Figure 1.3.). 
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Figure 1.3. Membrane feeding assays for assessing malaria transmission to mosquitoes  
(Bousema and Drakeley 2011). Methodologies for skin feeding, direct membrane 
feeding assay (DMFA) and standard membrane feeding assay (SMFA) are indicated. 
Figure taken directly from the referenced publication. 
 
For direct skin feeding, colony reared uninfected mosquitoes are fed directly on 
infected individuals, in an endemic setting (Bousema and Drakeley 2011). While this 
is most representative of a natural infection, it raises ethical concerns about 
transmission of other mosquito borne pathogens (particularly when feeding 
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mosquitoes on children) (Bousema, Dinglasan et al. 2012). This method is currently 
only accepted and used in a limited number of countries (Bousema and Drakeley 
2011). DMFA using a whole blood sample offers an alternative method to circumvent 
ethical concerns. DMFA is performed in the field where mosquito colonies derived 
from local mosquitoes are offered whole blood from naturally infected gametocyte 
carriers through a membrane covered water jacketed feeder (Bousema and Drakeley 
2011). To emulate natural infection as much as possible, blood is drawn from the 
participant and fed to mosquitoes immediately (Bousema and Drakeley 2011).  
To determine the TRA of naturally acquired sexual stage antibodies, two methods 
can be used, the DMFA or the SMFA (Figure 1.3.). DMFA is performed in combination 
with serum replacement to determine the TRA of naturally occurring antibodies 
(André Lin Ouédraogo, Jetsumon Sattabongkot et al. 2013). To investigate this, whole 
blood samples are drawn from participants, the volume is split in half and both 
aliquots centrifuged. While one volume is resuspended in autologous plasma then 
offered to mosquitoes, the autologous plasma is removed from the second aliquot 
and replaced with naive plasma from an unexposed individual, before being fed to 
mosquitoes (Tchuinkam, Mulder et al. 1993; Bousema, Roeffen et al. 2006; Bousema 
and Drakeley 2011; Bousema, Sutherland et al. 2011).  These paired conditions allow 
comparison of infectiousness to mosquitoes and calculation of transmission 
reduction, which may be attributed to the presence of sexual stage antibodies 
(André Lin Ouédraogo, Jetsumon Sattabongkot et al. 2013). This is discussed in more 
detail in Chapter 6.0.  
SMFA is usually performed in a non endemic country and uses uninfected laboratory 
reared mosquitoes that are offered blood meals of cultured gametocytes combined 
with uninfected blood and either autologous endemic sera or control unexposed 
(naive) serum, which once more enables comparative assessment of TRA of 
antibodies in endemic serum (Bousema and Drakeley 2011). After the feeding 
process, methodologies for DMFA and SMFA are the same. Approximately 1 week 
after feeding, (when oocysts have had sufficient time to develop), mosquito midguts 
are dissected and if infection is successful, oocysts are visible (Ponnudurai, Van 
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Gemert et al. 1987; Lensen, van Druten et al. 1996; Mulder, Lensen et al. 1999).  
Oocyst prevalence or density can be compared as an outcome measure between 
control and endemic serum fed mosquitoes (Bousema and Drakeley 2011). Higher 
oocyst prevalence and/or density would be expected in mosquito midguts offered 
naive serum, compared to autologous serum, if the autologous serum contained 
transmission blocking antibodies that could control or reduce oocyst development 
(Diallo, Toure et al. 2008).  
While these methods have improved our understanding of the infectious reservoir 
and the TRA of naturally acquired antibody responses, there are advantages and 
disadvantages (Ponnudurai, Lensen et al. 1989; Bonnet, Gouagna et al. 2000; 
Sattabongkot, Maneechai et al. 2003; Bousema, Sutherland et al. 2011). Generally, 
infection prevalence for skin feeding is higher than that for DMFA. For example, a 
study from Burkina Faso resulted in 78.6% of infected mosquitoes using skin feeding, 
compared to 41.4% using DMFA (Bousema, Dinglasan et al. 2012; Gouagna, Yao et al. 
2013). Similarly, a study in Mali suggested infectivity was three fold higher for 
mosquitoes fed on skin feeding compared to mosquitoes fed using DMFA (Diallo, 
Toure et al. 2008). Despite this, results are strongly related and DMFA provides a 
more ethical measure to determine infectiousness (Diallo, Toure et al. 2008). 
Compared to SMFA, DMFA is advantageous since it is more representative of natural 
infection, uses local mosquitoes and more genetically diverse endemic gametocytes 
occurring at natural densities, however, it is more difficult to standardize (Mulder, 
Lensen et al. 1999; Drakeley, Eling et al. 2004; Bousema and Drakeley 2011). Since 
large gametocyte cultures can be grown, SMFA has the advantage of exploring a 
greater number of test conditions at the same time while allowing more control to 
be exerted over variables such as gametocyte density, for this reason it is the current 
gold standard technique for determining TRA (van der Kolk, De Vlas et al. 2004; 
Bousema and Drakeley 2011). Studies performed in The Gambia and Cameroon have 
indicated there is an overall relationship between infectiousness determined using 
DMFA and SMFA, but differences do exist (Mulder, Lensen et al. 1999; Drakeley, Eling 
et al. 2004).  
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While these methods are labour intensive and there is notable inter lab protocol 
variation which complicates comparability, they are extremely valuable for 
understanding transmission and efforts are continuing to develop protocols that 
represent natural infection as accurately as possible (Roeffen, Mulder et al. 1996).  
 
1.5 Future interventions for malaria elimination 
 
 
1.51 Recent successes and the move to elimination 
 
Malaria has been successfully reduced or eliminated from some endemic areas 
where intense control programme(s) have been well managed and maintained (Barat 
2006). These successful control efforts are thought to be greatly facilitated by a 
combination of good infrastructure, political stability, effective tools, good technical 
support and the financial means to roll out the interventions (Barat 2006). In these 
regions scaling up existing control measures, mostly involving vector control such as 
the roll out of ITNs and IRS, was found to be effective (Targett and Greenwood 2008).  
Parasite prevalence has also been reduced through use of improved diagnostics 
(namely RDTs) and use of artemisinin combination therapy (ACTs) which also benefits 
from gametocidal activity (Sutherland, Ord et al. 2005; Kleinschmidt, Schwabe et al. 
2009). As a result of wide-scale implementation of vector control and improved 
diagnosis and treatment, a number of low transmission countries have successfully 
reduced malaria related deaths and disease including South Africa, The Gambia, 
Zanzibar and Kenya, among others (Barat 2006).  In South Africa, following a 
household spraying campaign and use of artemether-lumefantrine (AL) the number 
of cases over three years decreased by 99% (Duffy and Mutabingwa 2005). Similarly, 
parasite prevalence dropped from 35-40% prevalence to 2% in Zanzibar over a period 
of 15 years (Bhattarai, Ali et al. 2007). This has been suggested to be due to a high 
level of coverage of preventative measures with 96% of surveyed individuals having 
 58 
 
at least one preventative method used in their house (Anon 2009). The Gambia 
achieved success in reducing their parasite prevalence by 50-85% across 4 sites over 
a period of 4 years by rolling out of chemoprophylaxis and insecticide treated bed 
nets (Ceesay, Casals-Pascual et al. 2008).  Similarly, the same interventions were 
used in Kenya between from 1999-2007,  where a decline of 28-63% was found in 
paediatric malaria cases (Okiro, Hay et al. 2007).  
Stimulated by these successes, 32 out of the 99 countries with endemic malaria were 
preparing an elimination strategy in 2010 (Feachem, Phillips et al. 2010). Moving 
from malaria control to elimination requires a change in tactics from focusing on 
prompt diagnosis and treatment of symptomatic infection, to treating all infections 
(Mendis, Rietveld et al. 2009). Elimination is most realistic when transmission 
intensity is already low and it has been suggested there will need to be a shift from 
targeting specific groups like young children or pregnant women, to adopting a 
community based approach to treat every infection, including those that are 
asymptomatic (Targett and Greenwood 2008). With this objective in mind, the high 
prevalence of low density parasitaemias and asymptomatic infections complicates 
efforts, since detection of these infections requires a different set of more sensitive 
tools (Okell, Bousema et al. 2012). In line with this, mathematical modelling has 
suggested that malaria elimination is unlikely to be achieved in the majority of 
African settings by further scaling-up of currently available tools (Griffin, 
Hollingsworth et al. 2010).  
Despite the promising advances in malaria control so far, a combination of drug and 
insecticide resistance, the emergence of counterfeit drugs, and an anticipated 
reduction in funding due to the economic crises all threaten to jeopardize the 
progress made, and reiterates the need for new approaches to malaria control 
(World Health Organization 2011). The current theory is that eradication of malaria is 
not possible with the tools that are currently available (malERA 2011), and an 
emphasis has been placed on developing gametocidal or transmission blocking tools 
(Nunes, Woods et al. 2014). Whilst chloroquine, quinine and ACTs can be effective 
against young gametocytes, and useful for reducing gametocyte carriage, they are 
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not completely effective against mature gametocytes and therefore do not prevent 
transmission shortly after treatment (Adjalley, Johnston et al. 2011). In addition to 
transmission-blocking drugs, malaria vaccines that interrupt malaria transmission are 
also high on the priority list for malaria elimination (Alonso, Brown et al. 2011).  
 
1.52 Vaccines 
 
Throughout the duration of the Plasmodium life cycle, the parasite undergoes 
numerous morphological changes, producing antigenically distinct stages (Ferreira, 
da Silva Nunes et al. 2004). Antigens presented on the parasite cell surface are 
exposed to a host’s blood system presenting an opportunity for vaccination 
strategies. Clyde and colleagues had the first described success in vaccine 
development when they inoculated volunteers with irradiated sporozoites, using 
mosquitoes, which upon challenge effectively prevented blood stage infection 
(Nussenzweig, Vanderberg et al. 1967; Clyde, Most et al. 1973).  In addition to ‘whole 
parasite approaches’ to vaccination  there has  een considera le invest ent in 
vaccine development focused on specific antigens targets from the different parasite 
life stages (see Figure 1.4.). 
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Figure 1.4. Approaches to malaria vaccines  based on different stages of the parasite 
life cycle (MVI.PATH 2011). Figure taken directly from the referenced source. 
 
1.53 Pre-erythrocytic vaccines 
 
Pre-erythrocytic vaccines are regarded as highly appealing as, if fully effective,  they 
would prevent invasion by evoking immunity against sporozoites and liver stage 
parasites before they entered the blood stream (Targett, Moorthy et al. 2013). As 
they would prevent infection, clinical malaria and subsequent transmission potential 
(Hill 2011), a successful pre-erythrocytic vaccine has the greatest appeal. If fully 
effective, this would also qualify as a vaccine that interrupts malaria transmission 
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(VIMT) (MalERA 2011). The most advanced vaccine to date is recombinant pre-
erythrocytic vaccine candidate RTS,S /AS01 which is comprised of the 19 NANP 
epitope repeats of CSP fused with hepatitis B surface antigen (Agnandji, Lell et al. 
2012). CSP is a promising vaccine candidate as it covers the entire surface of the 
sporozoite and is essential for several important functions including salivary gland 
infection, and the targeting and invading of hepatocytes (Aly, Vaughan et al. 2009).  
Development of RTS,S /AS01 began in 1987 and phase III trials are still ongoing, but 
initial results indicate the vaccine confers approximately 32.1% protection against 
severe malaria and clinical episodes in children and infants, which dropped to 16.8% 
protection after 4 years (The RTS 2011; Offeddu, Thathy et al. 2012; Olotu, Fegan et 
al. 2013). While an important achievement resulting from decades of research, due 
to the relatively low protection induced, it is unlikely to lead to the eradication of 
malaria, but will provide another useful control or tool for decreasing malaria 
incidence (Targett, Moorthy et al. 2013). Alternate pre-erythrocytic candidates 
include thrombospondin-related anonymous protein (TRAP) and LSA-1, which were 
being developed in combination with 3 other antigens as a multistage DNA vaccine; 
the initial results indicated limited efficacy (Wang, Richie et al. 2005), but both 
antigens continue to be utilized in  several vaccine candidates and feature highly in 
the WHO Rainbow Table of candidates undergoing clinical projects, including 1 that 
combines RTS,S and TRAP (Schwartz, Brown et al. 2012; (WHO) 2013).  
 
1.54 Blood stage vaccines 
 
Vaccines targeting the asexual stage do not aim to prevent infection, but instead 
have the objective of preventing or lessening the symptoms associated with malaria 
by reducing the asexual proliferation cycle (Hill 2011).  Blood stage targets are mostly 
molecules found on the surface of the merozoite that are believed to be involved in 
invasion of the erythrocytes (Hu, Chen et al. 2008; Targett and Greenwood 2008). 
These antigens include AMA-1, erythrocyte binding antigen (EBA-175), MSP-1,2, 3, 
erythrocyte membrane protein (PfEMP-DBL3),  and synthetic peptide 166 (SP166) 
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(Patarroyo, Amador et al. 1988). AMA-1 and MSP-1, 83kDa and ~200kDa respectively, 
are two of the leading asexual stage candidates with antibodies found in naturally 
exposed populations that are linked with clinical immunity (Hu, Chen et al. 2008). 
Currently, a chimeric vaccine comprised of sequences from both antigens is under 
development and has so far proven to be safe,  immunogenic and induces inhibitory 
antibodies in monkeys and rabbits (Hu, Chen et al. 2008). The polymorphic nature of 
these antigens can be problematic, for example AMA-1 has more than 300 unique 
haplotypes and there is concern that vaccine induced immunity may not protect 
against all strains of parasites (Takala, Coulibaly et al. 2009).   
GLURP is a 220-kDa protein present on pre-erythrocytic and erythrocytic parasites 
that has 3 main regions, the N terminal non repetitive region called R0, R2 which is 
the C-terminal repetitive region, and R1 which is the central repeated region 
(Babiker, Ranford-Cartwright et al. 1999; Agyeman-Budu, Brown et al. 2013). 
Antibodies in naturally exposed populations have been found against R0 and R2, but 
not R1 which therefore has not been of interest as a vaccine candidate (Theisen, 
Dodoo et al. 2001). Candidates named GMZ1 and GMZ2 have both been developed 
using GLURP,  although GMZ1 (Imoukhuede, Ventura et al. 2010), was dropped in 
favour of developing candidate GMZ2 , a recombinant fusion of two antigens, R0 of 
GLURP and a conserved section of the C terminus of MSP-3 (Wampfler, Mwingira et 
al. 2013). This candidate is currently undergoing phase I trials in Germany and Gabon, 
and so far seems to be immunogenic and safe (Mouchet 1994; Roberts, Manguin et 
al. 2000; Baumann, Magris et al. 2012; Agyeman-Budu, Brown et al. 2013).   
While asexual vaccines ideally would provide protection against disease, it is 
accepted they may only result in a reduction in parasite density, rather than a 
reduction in parasite prevalence, which was the outcome for a vaccine comprised of 
MSP-1 and  MSP-2 (Genton, Betuela et al. 2002; Targett and Greenwood 2008).  
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1.55 Transmission blocking vaccines 
 
Since malaria eradication has been a long term goal for many funding bodies, the 
funds available for developing sexual stage vaccines is expected to increase 
(Schwartz, Brown et al. 2012). Although efficacious pre-erythrocytic vaccines may 
also prevent transmission by preventing or reducing malaria infection rates, the term 
malaria transmission blocking vaccine (MTBV) is traditionally used for vaccines that 
specifically target sexual stage malaria proteins. Different from the other two classes 
of malaria vaccines, MTBV do not provide direct protection to the vaccinated 
individual, but instead work on a population level, which is somewhat different to 
many conventional vaccines (Sauerwein 2007).  
Transmission blocking vaccinated individuals will generate an antibody response that 
acts inside the mosquito after antibodies are passively ingested when the mosquito 
takes a blood meal. Inside the mosquito, antibodies may prevent midgut invasion, 
the development of the zygote or further sporogonic development, thereby 
preventing generation of sporozoites and blocking onwards transmission (Carter 
2001; van Dijk, Janse et al. 2001; Baton and Ranford-Cartwright 2005; Sauerwein 
2007). Parasite densities are at their lowest in the mosquito (Figure 1.5.) which 
makes it an appealing stage to introduce control since lower densities could be easier 
to overcome (Sinden 2010). 
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Figure 1.5. Approximate parasite load at each stage of the parasite life cycle (Sinden 
2010).  Figure taken directly from the referenced publication. 
 
The concept of sexual stage vaccines was first developed approximately 35 years ago 
where transmission blocking antigens on gametes and ookinetes were identified by 
use of surface labelling experiments and monoclonal antibodies (Rener, Graves et al. 
1983; Carter, Miller et al. 1984).  Early transmission blocking successes were 
achieved by immunizing chickens with formalin treated erythrocytes infected with P. 
gallinaceum (Carter and Chen 1976; Gwadz 1976).  This was later replicated 
immunizing mice with formalin fixed P. yoelii gametes and rhesus monkeys with 
P.knowlesi gametes (Gwadz, Carter et al. 1979; Mendis and Targett 1979).  
Since then, transmission blocking vaccines have predominantly focused on individual 
antigen targets which are sexual stage proteins that can be divided into pre and post-
fertilization candidates according to when they are expressed (Bousema and 
Drakeley 2011). Pre-fertilization proteins are expressed before fertilization, on stage 
V gametocytes in the human host, whereas post fertilization proteins are expressed 
after ookinete development in the mosquito midgut (Carter 2001; Targett and 
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Greenwood 2008; Bousema, Sutherland et al. 2011). Pre-fertilization candidates 
include Pfs48/45, Pfs230, HAP2 and Pfs47 (Bousema and Drakeley 2011). HAP2 is 
required for the fusion of gamete membranes and knock-out parasites are incapable 
of gamete fusion and therefore fertilization (Blagborough and Sinden 2009). 
Development of this candidate has not advanced as far as others, but recently, it has 
been confirmed for the first time that antibodies against HAP2 are capable of 
transmission blocking activity (Miura, Takashima et al. 2013). 
Pfs48/45, Pfs47 and Pfs230 all play a role in fertilization and belong to the 6-Cys 
protein group which is defined by six conserved cysteine residues (Outchkourov, 
Vermunt et al. 2007; Outchkourov, Roeffen et al. 2008; Bousema and Drakeley 2011). 
While functions remain unclear for some proteins, as many members of this group 
have glycophosphatidylinositol (GPI) anchors (except Pfs230), it has been suggested 
they are located on the parasite surface and therefore exposed to host immunity, 
which has sparked interest in the potential for natural antibody boosting of these 
vaccine candidates (van Schaijk, van Dijk et al. 2006). Pfs47 is a female fertility 
protein (Bousema and Drakeley 2011), located on the surface of macrogametes (van 
Schaijk, van Dijk et al. 2006). Knock-out experiments indicated pfs47 deletion does 
not impact on fertility, but does reduce oocyst survival (van Schaijk, van Dijk et al. 
2006; Molina-Cruz, Garver et al. 2013).  
Pfs48/45 is located on the surface membrane of gametocytes (male and female), 
gametes (macrogametes only) and zygotes, where it plays a role in male fertility, 
specifically, in the attachment of microgametes (males) to macrogametes (females) 
during fertilization (van Dijk, van Schaijk et al. 2010; Bousema and Drakeley 2011). 
Experiments using knock-out parasites indicated male gametes cannot attach to and 
fertilize the females (which remain fertile) (van Dijk, Janse et al. 2001; van Dijk, van 
Schaijk et al. 2010). Antibodies derived against both Pfs48/45 and Pfs230 are thought 
to block transmission by inhibiting zygote formation, resulting in reduced oocyst 
formation (Vermeulen, Ponnudurai et al. 1985; Carter, Graves et al. 1990; Roeffen, 
Geeraedts et al. 1995; Williamson, Keister et al. 1995; Roeffen, Mulder et al. 1996; 
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Healer, McGuinness et al. 1997; Outchkourov, Roeffen et al. 2008; van Dijk, van 
Schaijk et al. 2010).   
 Pfs48/45 has 5 B cell epitopes, and antibodies against epitopes 1 and 5 have been 
demonstrated to be most effective at blocking transmission, but antibodies produced 
against epitopes 2b and 3 can block transmission in combination (Targett 1988; 
Carter, Graves et al. 1990; Targett, Harte et al. 1990; Roeffen, Mulder et al. 1996; 
Roeffen, Teelen et al. 2001; Outchkourov, Vermunt et al. 2007; Outchkourov, 
Roeffen et al. 2008). Pfs48/45 is being developed as a vaccine candidate by several 
groups, and has been shown to induce strong humoral antibody titres capable of 
inducing transmission blocking in 90% of mice and rats (Outchkourov, Roeffen et al. 
2008; Bousema and Drakeley 2011; Theisen, Roeffen et al. 2014). Due to the large 
number of cysteine residues, development has been hindered as it is difficult to 
produce a properly folded product capable of inducing high levels of transmission 
blocking immunity (Outchkourov, Roeffen et al. 2008). The overexpression vector 
used impacts on correct folding and attempts have been made to express part of 
Pfs48/45 in Escherichia coli, which resulted in a yield of just 10-20% of correctly 
folded protein (Outchkourov, Vermunt et al. 2007). Another approach has been to 
use Lactococcus lactis where successful folding is dependent on the fermentation 
conditions, rather than co expression with bacterial folding catalysts (Theisen, 
Roeffen et al. 2014).  
Pfs230 has a similar role to Pfs48/45 and is also concerned with gamete recognition 
and fertilization (van Dijk, van Schaijk et al. 2010). Knock-out parasites have been 
indicated to be unable to interact with red blood cells or form exflagellation centres, 
resulting in reduced oocyst production (Eksi, Czesny et al. 2006; Bousema and 
Drakeley 2011). Pfs230 has 5 epitopes and has proven to be complicated to produce 
as a vaccine due to its 363kDa size and 70 cysteine residues (Farrance, Rhee et al. 
2011). Whilst full length Pfs230 is too large to produce by expression vectors, amino 
acids 444-730 in the N terminal region have been successfully overexpressed in 
Agrobacterium tumefaciens using a plant based system (Farrance, Rhee et al. 2011). 
Serum from rabbits vaccinated against this section has been shown to result in 
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approximately 99% reduction in oocyst prevalence (in the presence of complement) 
compared to control serum using SMFA (Farrance, Rhee et al. 2011).  Another 
research group expressed the C fragment of Pfs230 in E.coli which demonstrated a 
reduction in oocyst prevalence of 70-90% (Williamson, Keister et al. 1995).  
Whilst antibodies derived against Pfs48/45 are capable of transmission blocking on 
their own, transmission reducing immunity derived against Pfs230 is complement 
mediated (Read, Lensen et al. 1994; Roeffen, Geeraedts et al. 1995; Bousema and 
Drakeley 2011). It has been suggested pre-fertilization antigens Pfs48/45 and Pfs230 
may have the advantage of boosting vaccine induced immunity, during natural 
infection (Bousema and Drakeley 2011; Bousema, Sutherland et al. 2011). Although, 
this natural exposure may act as a double-edged sword by forming a stimulus for 
antigenic variation and, in the case of vaccination, escape mutants (Nunes, Woods et 
al. 2014). 
Pfs25 and Pfs28 are post fertilization candidates expressed on the surface of 
gametes, zygotes and ookinetes (Sharma 2008). Studies exploring homologues in P. 
berghei suggest their function is concerned with ookinete survival, traversal of the 
ookinete into the midgut epithelium and oocyst production (Tomas, Margos et al. 
2001; Baton and Ranford-Cartwright 2005; Bousema and Drakeley 2011). Post 
fertilization proteins are only exposed within the mosquito and since they are not 
exposed to human immunity there is no human selection pressure, and antibodies 
against Pfs25 and Pfs28 are not found in the serum of people living in endemic areas 
(van Dijk, Janse et al. 2001). While advantageous since a lack of selection pressure 
may mean less genetic polymorphism (Bousema and Drakeley 2011), as there is no 
possibility of natural immune boosting, vaccines directed against these targets will 
need to induce a long lasting effective antibody response. 
Due to the high number of cysteine residues and specific tertiary structure, Pfs25 has 
also been complicated to produce in the correct conformation (Kaslow, Quakyi et al. 
1988). Groups have also struggled to produce immunogenic and safe candidates, and 
adverse side effects were encountered with Pfs25 combined with emulsion 
Montanide ISA 51 (Wu, Ellis et al. 2008; Bousema and Drakeley 2011). Other groups 
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have suffered problems with insufficient immunogenicity (Vogel 2010), and have 
produced Pfs25 as a chemically conjugated nanoparticle in an attempt to improve 
this, which so far looks promising (Shimp, Rowe et al. 2013). More recent 
advancements have been achieved by expressing Pfs25 in a plant based system fused 
to Alfalfa mosaic virus coat protein which produces as a virus like particle (VLP) 
(Jones, Chichester et al. 2013). The highly immunogenic nature of VLPs makes this 
technique appealing and early results are encouraging with complete transmission 
blocking achieved in mice (following 1 or 2 vaccinations)  which remains even 
following a period of 6 months (Jones, Chichester et al. 2013). Other researchers 
expressed codon harmonized Pfs25 in E. coli and recently published results stating 
vaccine induced antibodies in mice gave 100% transmission blocking (Kumar, Angov 
et al. 2014).  
 
1.56 The rationale for deployment of transmission blocking vaccines 
 
TBV generally function as a community control method and current thinking suggests 
their specific use would be guided by transmission intensity (Sauerwein 2007). In 
regions of high or moderate transmission intensity, TBV (when available) could have 
more impact combined with an asexual stage vaccine with the overall aim of 
contributing towards a reduction in morbidity, mortality, and transmission (Smith, 
Chitnis et al. 2011). In regions of seasonal transmission, the vaccine could be used to 
protect against epidemics, or reduce the survival of drug or vaccine resistant 
parasites (Sauerwein 2007; Bousema and Drakeley 2011). It is currently thought TBV 
would most likely be used in regions of low transmission where the vaccine could 
even be used alone, or in combination with other control methods to move towards 
elimination of the infectious reservoir to stop malaria transmission (Carter, Mendis et 
al. 2000; Sauerwein 2007; Bousema and Drakeley 2011).  An alternative approach 
would be to use TBV as a quarantine tool to prevent reintroduction of malaria from 
potentially infectious migrants into regions that have eliminated, but could support 
malaria reintroduction (Sauerwein 2007). 
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In order to impact on transmission reduction, a high level of vaccine coverage would 
be needed and it has been suggested that 80% population coverage could result in 
an overall 3.5 fold reduction in transmission (Saul 2007). Natural boosting of a 
vaccine induced immune response would be potentially advantageous (Carter, 
Mendis et al. 2000; Chowdhury, Angov et al. 2009). Not only would this boost the 
antibody titre of poor responders but could eliminate or reduce the need for follow 
up booster vaccinations which would make roll out of the vaccine logistically easier.  
The research performed in this PhD helps to support development of a TBV, by 
investigating the natural recognition, diversity and functionality of a candidate 
named 10C, which contains the 10 C terminal cysteine residues of Pfs48/45.  
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Chapter 2: Aims of the thesis 
 
1. To compare methodologies for collection and detection of low densities of P. 
falciparum gametocytes from filter papers, and conclude on the optimal combination 
(Chapter 4). 
2. To determine the sensitivity and specificity of different diagnostic methods to 
identify individuals who are infectious to mosquitoes during the dry season in 
Burkina Faso (Chapter 6). 
3. To identify if there are naturally acquired antibody responses to two leading 
transmission blocking vaccine candidates, 10C (Pfs48/45) and 230CMB (Pfs230), in 
school aged children in 3 different endemic settings in Africa (Chapter 5). 
4. To identify genetic polymorphisms in pfs48/45 (containing vaccine candidate 10C) 
in 3 endemic settings in Africa (Chapter 5). 
5. To assess the ability of R0-10C (Pfs48/45) vaccine induced IgG in rats to reduce 
transmission of P. falciparum gametocytes from naturally infected gametocyte 
carriers in Burkina Faso (Chapter 6).  
6. To determine the association between naturally acquired antibody responses to 
10C (Pfs48/45) and 230CMB (Pfs230) and naturally acquired transmission reducing 
immune responses (Chapters 5 and 6) 
Detailed chapter specific objectives are embedded within each chapter, in sections 
4.2., 5.2., and 6.2. While research performed in this thesis investigated antibody 
responses (and their functionality) to 230CMB antigen, 10C was the primary focus 
since this was the vaccine candidate produced by collaborators.  
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Chapter 3: Materials and methods 
 
3.1 Serological methods 
 
 3.11 Antigens selected for antibody measurement using enzyme linked 
immunosorbent assay (ELISA) 
 
Antibodies that develop against asexual antigens are commonly used as a proxy to 
indicate malaria exposure. Because of the longevity of antibody responses, they 
provide markers of exposure that are suitable indicators of stable transmission 
intensity (Cook, Reid et al. 2010). In this thesis, P. falciparum antigens were used to 
measure antibodies produced against asexual antigens AMA-1, MSP-119 and GLURP 
(protein functions are covered in section 1.54.), along with recombinant transmission 
blocking vaccine candidates maltose binding protein (MBP)-10C (Pfs48/45), R0-10C  
(Pfs48/45) and 230CMB (Pfs230) (provided by Fraunhofer Center for Molecular 
Biotechnology).  
The AMA-1 antigen used in these experiments encompassed amino acids 22-545 
from the 3D7 strain, which is a conserved portion with a high level of cross reactivity 
with other strains (Hodder, Crewther et al. 2001). MSP-1 19 is a 19kDa sub fragment 
derived from the C-terminal domain of MSP-1-42. While largely conserved, 4 main 
polymorphic amino acids have been previously described (Miller, Roberts et al. 1993; 
Kang and Long 1995; Hui and Hashimoto 2007). The antigen used in this study 
represented amino acids 1631-1726 from the K1/Wellcome allele of MSP-1 19 which 
is a commonly found allele across Africa (Drakeley, Corran et al. 2005). GLURP is 
predominantly found on mature schizont infected erythrocytes, but is also expressed 
in liver stage parasites (Pratt-Riccio, Bianco et al. 2011). Studies investigating 
geographically diverse samples have revealed low levels of polymorphisms (Theisen, 
Soe et al. 1998). For this thesis unless otherwise stated, antibodies were quantified 
against GLURP-R2.   
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Pfs48/45 is a gametocyte surface protein, which was discussed in section 1.55. Both 
MBP-10C and R0-10C are transmission blocking vaccine candidates produced by 
collaborators (at Radboud University Medical Centre, Nijmegen, The Netherlands and 
Gennova Biopharmaceuticals, Ltd. Pune, India). MBP-10C consists of amino acids 
159-428 found in the 10 C-terminal cysteine residues of Pfs48/45. This includes 
epitopes 1, 2b and 3, (Figure 3.0.). 10C was fused to MBP which was expressed in E. 
coli as described elsewhere (Outchkourov, Roeffen et al. 2008). A factor Xa cleavage 
site is situated between MBP and 10C. 
 
 
Figure 3.0. The structure of Pfs48/45 protein and the location of 10C vaccine candidate 
(Outchkourov, Roeffen et al. 2008).  Figure adapted from the referenced publication. 
 
R0-10C is a chimeric blood/liver stage and transmission blocking vaccine candidate 
that is comprised of an asexual stage antigen and a sexual stage antigen. The 10C 
terminal cysteine residues of Pfs48/45 were fused to R0, the N-terminal non 
repetitive region (residues 24-489) of asexual stage antigen GLURP, Figure 3.1. (Will 
Roeffen, personal communication). A FXa site was positioned between R0 and 10C to 
enable cleavage of 10C for specific sexual stage antibody detection, and a HIS-tag 
was included at the C terminal end. 
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Figure 3.1. Schematic representation of the components of R0-10C vaccine (provided 
by Will Roeffen, Radboud UMC, Nijmegen, The Netherlands).  
 
Antibodies were measured against another TBV candidate termed 230CMB which 
corresponds to amino acids 444-730 from the C domain of Pfs230 (Figure 3.2.), 
(Farrance, Rhee et al. 2011). This candidate was produced by Fraunhofer CMB, but 
antibodies were quantified against it since it occupies a similar functional niche to 
our vaccine candidate. The main focus of this thesis was development of our 
candidate, MBP-10C which was later replaced with R0-10C.  
 
 
Figure 3.2. Structure of Pfs230. (a) Cysteine motifs in Pfs230, and location of 230CMB 
vaccine candidate. (b) Representation of the amino acids included in vaccine 
candidate 230CMB (Farrance, Rhee et al. 2011). The numbers refer to the amino acid 
locations. CM= cysteine motifs. Figure taken directly from the referenced 
publication. 
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3.12 ELISA to detect asexual antibodies 
 
Total IgG binding to AMA-1, MSP-1 19 and GLURP R2 antigens was quantified using 
the same ELISA protocol which was performed as follows. Fifty µL of antigen per well 
was coated onto high binding Immulon 4 microtitre 96 well plates (VWR, 
Bedfordshire, UK) diluted in coating buffer (15mM Na2CO3, 35mM NaHCO3, pH 9.5) 
to an end concentration of 1.25µg/mL for AMA-1 and 0.5µg/mL for MSP-1 19 and 
GLURP. Plates were incubated overnight at 4°C, then the following day they were 
washed 3 times with phosphate buffered saline (PBS) 0.05% v/v Tween 20 wash 
buffer. Plates were then blocked with 150µL per well of  1%  w/v milk powder 
(Marvel, Lincolnshire, UK) in PBS Tween 20 (0.05% v/v ) for 3 hours at room 
temperature. Plates were washed 3 times as before, then test samples added to the 
plate in duplicate, diluting samples in blocking buffer (1%  w/v milk powder (Marvel, 
Lincolnshire, UK) in PBS Tween 20 (0.05% v/v) to the following serum dilutions, 
1/2000 for AMA-1 and 1/1000 for MSP-1 19 and  GLURP. A positive control standard 
curve was generated from hyper immune serum to enable quantification of the 
antibody titre, and standardization of optical densities (ODs) to correct for plate to 
plate variation. A 7 point standard curve was titrated in 4 fold dilutions starting at 
1/50 for GLURP and MSP-1 19 and 1/100 for AMA-1, then added to the plate in 
duplicate. Two blank wells were left per plate, where no sample was added, to allow 
correction for reagent background reactivity. Plates were incubated overnight once 
more, then washed 5 times in PBS Tween 20 (0.05% v/v) wash solution. Next, 50µL of 
horseradish peroxidase (HRP) conjugated rabbit anti-human IgG –HRP (Dako, 
Cambridgeshire, UK) diluted 1/5000 in PBS Tween 20 (0.05% v/v) was added per well, 
which  was incubated at room temperature for 3 hours, then plates were washed 5 
more times as before. One hundred µL of SigmaFast O-phenylene diamine (OPD), 
 75 
 
(Sigma-Aldrich, Dorset, UK) substrate was added per well and left to develop in the 
dark for 14 minutes for AMA-1 and 15 minutes for GLURP and MSP-119. Reactions 
were stopped with 25µL of 2M H2SO4 per well, then ODs determined using an ELISA 
microplate reader (DynexTechnologies, Virginia, USA) at 492nm.  
 
3.13 ELISA to detect sexual stage antibodies 
 
Antibodies against recombinant sexual stage antigens 10C and 230CMB were 
quantified using a different protocol to keep results comparable with a collaborating 
laboratory. This was done as follows, 96 well Maxisorp Nunc plates (Nunc, 
Stockholm, Sweden) were coated overnight at 4°C with 100µL per well of 0.1µg/mL 
of 10C or 230CMB diluted in PBS (Gibco, Life Technologies, Bleiswijk, The 
Netherlands). The following day, plates were blocked for 30 minutes using 150µL of 
5% w/v milk powder (Marvel, Lincolnshire, UK) in PBS. Plates were then washed 3 
times with PBS, and 100µL of test serum was diluted to 1/500 in PBS (with 1% w/v 
milk powder and 0.05% v/v Tween 20), which was incubated for 4 hours at room 
temperature. As before, samples were tested in duplicate, and hyper immune serum 
was used as a positive control which was titrated from 1/200 in doubling dilutions 7 
times to produce a standard curve. Plates were washed 3 times, then incubated with 
100µL per well of human-IgG-HRP (Pierce Biotechnology, Illinois, USA) diluted to 
1/40,000 in PBS (with 0.05% v/v Tween 20), for 2 hours at room temperature. Plates 
were washed 4 times, then 100µL of tetramethylbenzidine substrate (TMB) solution 
was added per well and incubated for 20 minutes to allow development of the 
substrate. Reactions were stopped using 50µL per well of 0.2M H2SO4 and ODs were 
measured at 450nm (BioRad iMark Microplate Reader, Hertfordshire, UK).  
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3.14 Analyzing ELISA results 
 
Different positive controls were used for the asexual and sexual stage ELISA. For the 
asexual stage ELISA, serum taken from 3 hyper-immune adults who lived in a 
hyperendemic region in Tanzania was used. For the sexual stage ELISA, serum was 
used from an expatriate with high levels of antibodies against native sexual stage 
proteins, and functional transmission reducing activity (van der Kolk, De Vlas et al. 
2004; Saeed, Roeffen et al. 2008). Antibodies in European naive control serum was 
quantified to enable identification of non specific ELISA assay reactivity.  Serum from 
European volunteers (recruited from the London School of Hygiene and Tropical 
Medicine (LSHTM)), who had not travelled to a malaria endemic region was used for 
this negative control population.  
Results were analyzed using a macro enabled Excel spreadsheet (Microsoft, 
Washington, USA) that had been optimized to average, correct and normalize OD 
values, then convert them to titre. All test samples were assayed in duplicate, and 
repeated if duplicates differed by 50% or more. OD values from good pairs were 
averaged and the blank well OD was subtracted, to correct for background noise 
from assay reagents. The standard curve was plotted and a line of best fit was fitted 
to the curve. ODs were normalized against the fitted value corresponding to the mid-
point dilution on the standard curve. Normalization aims to correct for plate to plate 
variation, which could occur due to substrate development times varying slightly 
from assaying plates in high throughput.   
To determine antibody prevalence in test samples, positive and negative samples 
were firstly identified using the mixture model which was supplied as algorithms 
written by Jamie Griffin (Imperial College London), in STATA (Statacorp, Texas, USA) 
(Corran, Cook et al. 2008). The mixture model splits the normalized OD values into 
two Gaussian distributions, a narrow curve (typically) for the sero-negatives 
representing the lower ODs and a broader one for the sero-positives representing 
the higher ODs,  using maximum likelihood methods. The mean OD of the sero-
negative population plus 3 standard deviations was used to define the cut off of 
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positive and negative test samples (Corran, Cook et al. 2008; Bousema, Roeffen et al. 
2010).  
To calculate antibody density (titre), a titration curve was fitted to the control serum 
data by least squares minimisation using a three parameter sigmoid model and a 
‘solver add in’ in a macro enabled Excel spreadsheet (Microsoft, Washington, USA), 
using an arbitrary value of 1000 units/mL of antibody in the control sample. Using 
the standard curve, averaged ODs were converted to units/mL and antibody titre was 
calculated using the following equation: 
Titre= dilution/[maximum OD/(OD test serum-minimum OD)-1]  
(Drakeley, Corran et al. 2005; Proietti, Verra et al. 2013).  
 
3.2 Molecular parasite detection  
 
3.21 Nested PCR for parasite detection 
 
Parasite prevalence was determined using nested PCR (nPCR) developed by Snounou 
et al., which detects DNA copies of 18S rRNA (Snounou, Viriyakosol et al. 1993). This 
was performed as follows. Reactions were assembled in 0.2mL PCR tubes (BioRad, 
Veenendaal, The Netherlands) as outlined in Table 3.0. using the following genus 
specific primers for the primary PCR reaction: forward primer 5'-
TTAAAATTGTTGCAGTTAAAACG-3' and reverse primer: 5'-CYTGTTGTTGCCTTAAACTTC-
3', and adding the italicized reagents indicated in the table to the reaction tubes.  
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Table 3.0.  Reagents and volumes for nest 1 nPCR reaction for qualitative detection 
of all parasite stages. 
reagent  Final Concentration volume per reaction 
(µL) 
Nuclease free H2O - 8.4 
10 X NH4 buffer 1X 2.0 
50 mM MgCl2 2 mM 0.8 
10 mM dNTPs  
(2.5 mM each) 
 
(200 µM each) 
1.6 
primer mix 1 (2.5 µM each 
primer) 
250 nM (each primer) 2.0 
Bioline Taq polymerase 1.0 unit 0.2 
   
 mastermix total  15.0 
 template(added separately)  5.0 
 
The following thermocycling conditions were used for amplification: 95°C for 5 
minutes, (58°C for 2 minutes, 68°C for 2 minutes and 94°for 1 minute) for 25 cycles, 
then 58°C for 2 minutes, 68°C for 5 minutes, then held at 4°C until use (Snounou, 
Viriyakosol et al. 1993).   
Nested PCR (referred to as nest 2) was performed in 0.2mL PCR tubes using the 
following P. falciparum specific primers, forward primer 5’–
TTAAACTGGTTTGGGAAAACCAAATATATT–3’ and reverse pri er 5’–
ACACAATAGACTCAATCATGACTACCCGTC–3’  Reactions were otherwise assembled as 
outlined in Table 3.1., (adding the italicized reagents to the reaction tubes) and using 
the same thermocycling conditions as previous, but performing 30 cycles, instead of 
25.  
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Table 3.1. Reagents and volumes for nest 2 nPCR reaction for qualitative detection 
of all parasite stages. 
reagent  Final Concentration volume per reaction (µL) 
Nuclease free H2O - 12.4 
10 X NH4 buffer 1X 2.0 
50 mM MgCl2 2 mM 0.8 
10 mM dNTPs (2.5 mM each 
dNTP (each) 
(200 µM each) 1.6 
primer mix 2 (2.5 µM each 
primer) 
250 nM (each primer) 2.0 
Bioline Taq 1.0 unit 0.2 
   
 mastermix total  19.0 
 nest 1 product (added 
separately) 
 1.0 
 
To visualize amplified product, a 2.0% TBE (Tris Borate) agarose gel was prepared as 
follows. Two g of agarose (Sigma-Aldrich, Dorset, UK) was mixed with 100mls of 1x 
TBE (BioRad, Hertfordshire, UK). This was heated by microwave until dissolved, then 
when cool, 5µL of ethidium bromide (Sigma-Aldrich, Dorset, UK) was added. The 
mixture was gently swirled to combine, then poured into a gel cast (BioRad, 
Hertfordshire, UK) with combs and allowed to set. Five µL of the nest 2 PCR product 
was mixed with 3µL of loading dye (Thermo Fisher Scientific, Hertfordshire, UK), then 
added to the gel. Five µL of Hyperladder I (Bioline, London, UK) was included to allow 
estimation of the product size. PCR products were resolved by electrophoresis (60 
minutes, 80 volts) and visualized using a transilluminator (BioRad, Hertfordshire, UK). 
Positive results were identified as a band of 205 base pairs in size. 
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3.3 Chapter specific methodologies   
 
3.31 Preparation of work space and equipment for RNA extraction and molecular 
detection  
See section 4.41. 
3.32 Collection of cultured gametocytes on filter paper 
See section 4.42.  
3.33 RNA extraction from filter papers 
See sections 4.43 for excision of filter paper blood spots, 4.44 for guanidine based 
RNA extraction and section 4.45 for RNA extraction using the Qiagen mRNA kit. 
3.34 DNA digest performed on extracted nucleic acid 
See sections 4.51 and 4.54.  
3.35 Gametocyte detection using RT-LAMP 
See sections 4.52 and 4.56. 
3.36 Gametocyte detection using QT-NASBA 
See section 4.61. 
3.37 Gametocyte detection using RT-PCR 
See section 4.64. 
3.38 MSP-2 genotyping of natural parasite infections 
See section 5.71. 
3.39 DNA extraction from filter papers 
See section 5.73. 
3.40 Sequencing pfs48/45 in endemic parasites 
See sections 5.74-5.81. 
3.41 Purification and validation of functionality of IgG from R0-10C vaccinated rats  
See sections 6.31-6.35. 
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3.42 Field sampling for collection of endemic parasites for membrane feeding 
assays in Burkina Faso 
See sections 6.41-6.46.  
3.43 Mosquito husbandry, direct membrane feeding assay (DMFA) (with serum 
replacement), and oocyst counting  
See sections 6.48-6.51. 
3.44 QT-NASBA for detection of 18S rRNA 
See section 6.52. 
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Chapter 4: Collection and detection of low density gametocytes 
 
4.1 Introduction to publication 
 
4.11 The importance and operational challenges of detecting low gametocyte 
densities 
 
The infectious reservoir consists of all individuals in a population with infectious 
gametocytes in their peripheral blood. The presence of gametocytes thereby serves 
as a valuable indicator of malaria transmission potential (Bousema and Drakeley 
2011). To fully understand local transmission dynamics, a detailed understanding of 
who within the population is carrying gametocytes is essential. As described in 
section 1.2., gametocytes often circulate at low densities below the detection of 
microscopy (Ouedraogo, Bousema et al. 2009). Decreasing malaria prevalence with 
accompanying lower parasite densities in many regions in Africa reinforces the 
urgency for improved techniques able to consistently detect sub-microscopic 
gametocyte densities (Okell, Bousema et al. 2012; Baidjoe, Stone et al. 2013). 
 
4.12 Challenges with sampling gametocytes 
 
While molecular detection of 18S rRNA enables identification of infection, detection 
of Pfs25mRNA  allows the specific identification of  submicroscopic gametocytes 
(Schneider, Schoone et al. 2004). Detecting mRNA is a challenge, due to its labile 
nature it can rapidly degrade outside of cells. Consequently, samples need to be 
handled and stored carefully to maintain mRNA integrity and facilitate accurate 
detection (Kast, Berens-Riha et al. 2013). Historically, RNA sampling has been 
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performed by diluting whole blood in RNA preserving buffer which inactivates 
RNases and permeates cells and tissues to protect and stabilize intercellular RNA 
(Kast, Berens-Riha et al. 2013). While useful, RNA diluted in buffer still needs to be 
stored at -80°C until use. This is unproblematic for well equipped labs, but less 
attractive for resource poor environments where accessibility to freezers and 
continuous power supply can be a constraint.  
To circumvent this problem, finger prick sampling and filter paper sample collection 
provides the most operationally attractive combination of methods that enable large 
scale sampling with minimal discomfort (Toledo, Januario et al. 2005; Kast, Berens-
Riha et al. 2013). For this purpose, small blood volume finger prick samples can be 
directly transferred to filter papers which are then no longer categorized as 
hazardous, and can be sent between laboratories without specialist shipping (Pritsch, 
Wieser et al. 2012). Furthermore, they can be shipped at room temperature which 
avoids the need for a cold chain, contributing to a cheaper cost. While the use of 
filter papers does not mean results can be obtained in the field, unless equipment is 
available, they do provide an inexpensive tool for collection and transport of samples 
to an equipped laboratory and thereby facilitate the incorporation of molecular 
gametocyte detection in epidemiological surveys of malaria endemic regions (Pritsch, 
Wieser et al. 2012). 
Whilst filter papers are generally a user friendly collection method, due to the 
susceptibility of RNA to degradation it is expected that correct filter paper drying and 
storage will significantly impact on detection success. Currently, there are no clear 
guidelines for filter paper handling, or indicators of RNA integrity when sampling is 
performed on the different filter paper types. For antibody collection, a study 
demonstrated filter paper and glass fibre papers offered similar stability, but both 
resulted in antibody decay (compared to paired serum samples), when incubated at 
room temperature with ambient humidity for more than a week (Corran, Cook et al. 
2008). This study emphasized the importance of storing blood spots with desiccant 
and in frozen conditions (Corran, Cook et al. 2008). However, for collection of DNA, 
storage temperature appears less relevant, whereas desiccating is essential  and 
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allows storage of nucleic acid on filter papers for several years (Hwang, Jaroensuk et 
al. 2012).  
 
4.13 Different filter paper types for sample collection 
 
A range of filter papers are commercially available, some of which have been tailored 
for specific purposes. The widespread use of filter papers was initiated in the 1960s 
with the Guthrie card which was produced by Robert Guthrie for the collection of 
neonatal blood to diagnose phenylketonuria (PKU). Since then, their use has 
expanded to diagnostics, drug resistance screening, evaluating drug 
pharmacokinetics, and disease surveillance (Stevens, Pass et al. 1992; Toledo, 
Januario et al. 2005; Steegen, Luchters et al. 2007; Ashley, Stepniewska et al. 2010; 
Cook, Reid et al. 2010). Filter paper material spans from the commonly used cellulose 
paper, to glass, quartz, nylon and polyvinyl chloride (PVC). Cellulose papers are either 
plain or treated with chemicals, with the plain papers more commonly used for 
serological and nucleic acid collection (Baidjoe, Stone et al. 2013). As well as 
treatment with chemicals, filter papers vary in thickness and pore size. While 
untreated cellulose papers can be adapted for collection of a range of samples, 
including antibody and nucleic acid collection, the treated cellulose papers are only 
appropriate for nucleic acid collection due to impregnation with lysis buffers and/or 
nucleic acid stabilizing reagents.    
 
4.14 Previous research investigating gametocyte collection on filter papers 
 
A previous study evaluated the 903 filter paper (Schleicher and Schuell, New 
Hampshire, USA) and the FT2 filter paper (GE Healthcare, Buckinghamshire, UK) as 
tools for collection and storage of gametocytes which were then detected using RT-
PCR (Mlambo, Vasquez et al. 2008). Filter papers were incubated at 25°C or at 37°C 
(with or without pre treatment with RNAlater (Qiagen, Surrey, UK). Non-filter paper 
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controls of whole blood diluted in RNAlater were included as controls and were 
stored at -80°C, or 37°C overnight followed by -80°C. RNA from gametocytes stored 
on the 903 paper was successfully extracted and detected from all incubation 
conditions, whereas those stored on the FT2 paper were not well detected (Mlambo, 
Vasquez et al. 2008).  
While a useful starting point, the study did not examine low densities of gametocytes 
that comprise the bulk of the infectious reservoir in many endemic settings and may 
pose additional challenges for successful gametocyte detection. Furthermore, it was 
not clear if the same results could be found with a larger range of incubation 
conditions, or when using the commonly available Whatman 3MM paper for 
sampling, or QT-NASBA as the detection method. In this chapter, I therefore 
performed a more rigorous study, testing the detectability of gametocytes at 
densities of 0.1-10 gametocytes/L, which are commonly observed in the field 
(Drakeley, Sutherland et al. 2006).  
 
4.15 RNA extraction from samples collected on filter paper  
  
RNA extraction methodologies commonly follow the same set of steps. The 
guanidine based extraction method extracts total nucleic acid. The process begins by 
adding buffer to the filter paper in a microcentrifuge tube which is then shaken. The 
buffer contains chaotropic agent, guanidine thiocyanate (GuSCN) which lyses red 
blood cells to release the nucleic acid, and exposes DNases and RNases which are 
concurrently inactivated (Boom, Sol et al. 1990). In the next step, supernatant is 
mixed with silica which binds to the nucleic acids due to the high concentration of 
GuSCN. A series of wash steps with ethanol and acetone follow to remove PCR 
inhibitors and contaminants and reduce the concentration of chaotropic GuSCN in 
preparation for nucleic acid elution. The silica is then dried and nucleic acid is eluted 
into nuclease free buffer, ready for use. As there is genomic DNA present in 
extracted material, it must be digested prior to performing detection with techniques 
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that could result in DNA amplification, such as RT-PCR (Boom, Sol et al. 1990; 
Casanova 2007). The Qiagen RNeasy kit (Qiagen, Surrey, UK) has the same principle 
but uses silica embedded centrifugable columns for purification. Although more 
costly, it has the benefit of being a more convenient method using spin columns with 
pre-prepared reagents.  
 
4.2 Study design and objective  
 
This chapter was devised to identify the optimal filter paper sampling method, RNA 
extraction technique and nucleic amplification method for detection of low density 
gametocytes. While this was performed in this chapter in a standardized laboratory 
setting, this information was needed for field sample collection carried out in 
subsequent chapters in this thesis. 
Three filter papers were evaluated for preservation of low density gametocytes, 
when stored under a range of temperature conditions for up to 3 months. The 903 
Protein Saver Card (GE Healthcare, Buckinghamshire, UK) was selected due to 
previous validation for gametocyte collection and the FTA Classic Card chosen since 
Whatman recommend this card specifically for RNA sampling. The Whatman 3MM 
filter paper was evaluated under a subset of conditions. Despite its extensive use for 
antibody and DNA collection, at the time of devising this study it had not been 
validated for RNA collection, and was included as a secondary objective. Three 
gametocyte densities (10, 1.0 and 0.1/µL) spanning the previously reported 
microscopic detection threshold were selected to test the sensitivity of different 
approaches (Karl, Davis et al. 2009; Bousema and Drakeley 2011).   
Two RNA extraction methods, guanidine based extraction (Boom, Sol et al. 1990) and 
the Qiagen RNeasy kit (Qiagen, Surrey, UK) were compared. Guanidine based RNA 
extraction was chosen due to its previous successful combination with molecular 
detection technique QT-NASBA, and potential for scaling up to high throughout 
which is useful in large epidemiological studies (Schneider, Schoone et al. 2004; 
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Schneider, Wolters et al. 2005). Qiagen extraction was chosen due to previous 
validation with the 903 Protein Saver Card and because it is one of the more widely 
used commercial extraction kits (Mlambo, Vasquez et al. 2008).  
The outcome measure for this study was successful gametocyte detection by QT-
NASBA, RT-PCR (and RT-LAMP was initially intended to be included). QT-NASBA was 
included due to the reported high level of sensitivity for low density detection and 
extensive previous use in field studies, including detection from filter paper  
(Schneider, Schoone et al. 2004).  RT-PCR was assessed since it has previously been 
validated for detection of gametocytes from filter paper (Mlambo, Vasquez et al. 
2008).  While just one study had been published using RT-LAMP, and this was 
performed from whole blood samples, RT-LAMP was included due to its portability 
and use of a heat block, rather than thermocycler, which increases its appeal for field 
use (Buates, Bantuchai et al. 2010).  
Specific objectives 
1.  Test the ability of filter papers to preserve mRNA when stored under a range of 
incubation conditions, compared to whole blood diluted in RNA stabilizing buffer and 
stored at -80°C.  
2. Identify the RNA extraction method that is operationally most attractive and 
results in the highest or equivalent sensitivity of gametocyte detection.  
3. Identify the molecular detection method that results in the highest sensitivity of 
gametocyte detection. 
4. Conclude on the optimal combination of filter paper, RNA extraction and 
molecular detection method for identification of low density gametocytes from filter 
papers. 
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4.3 Publication: Filter paper collection of Plasmodium falciparum mRNA for 
detecting low-density gametocytes 
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Abstract 
Background  
Accurate sampling of sub-microscopic gametocytes is necessary for epidemiological 
studies to identify the infectious reservoir of Plasmodium falciparum. Detection of 
gametocyte mRNA achieves sensitive detection, but requires careful handling of 
samples. Filter papers can be used for collecting RNA samples, but rigorous testing of 
their capacity to withstand adverse storage conditions has not been fully explored. 
 
Methods  
Three  a etocyte dilutions: 10/µ   1 0/µ  and 0 1/µ  were spotted onto hat an™ 
903 Protein Saver Cards, FTA Classic Cards and 3MM filter papers that were stored 
under frozen, cold chain or tropical conditions for up to 13 weeks. RNA was 
extracted, then detected by quantitative nucleic acid sequence-based amplification 
(QT-NASBA) and reverse-transcriptase PCR (RT-PCR).  
 
Results 
Successful gametocyte detection was more frequently observed from the Whatman 
903 Protein Saver Card compared to the Whatman FTA Classic Card, by both 
techniques (p<0.001). When papers were stored at higher temperatures, a loss in 
sensitivity was experienced for the FTA Classic Card but not the 903 Protein Saver 
Card, or Whatman 3MM filter paper. The sensitivity of gametocyte detection 
decreased when papers were stored at high humidity.  
 
Conclusions 
This study indicates the Whatman 903 Protein Saver Card is better for Pfs25 mRNA 
sampling compared to the Whatman FTA Classic Card, and that the Whatman 3MM 
filter paper may prove to be a satisfactory cheaper option for Pfs25 mRNA sampling. 
When appropriately dried, filter papers provide a useful approach to Pfs25 mRNA 
sampling, especially in settings where storage in RNA-protecting buffer is not 
possible.   
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Keywords: Reverse-transcription polymerase chain reaction (RT-PCR), Quantitative 
nucleic acid sequence-based amplification (QT-NASBA), Sub-microscopic, 
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paper. 
 
Background 
 
The recent decline in the burden of malaria has placed malaria elimination and 
eradication back on the agenda of the international research community and health 
policy makers (World Health 2007; O'Meara, Mangeni et al. 2010; MalERA 2011; 
malERA 2011). As a consequence, vaccines and anti-malarial drugs that specifically 
target the transmission stages of malaria parasites, gametocytes, are a high priority 
(MalERA 2011; malERA 2011). These interventions aim to reduce the infectious 
reservoir of malaria: the number of individuals capable of infecting mosquitoes. 
Infectiousness of humans to mosquitoes depends on the presence of mature 
gametocytes in the peripheral blood, and sensitive detection of gametocytes is 
therefore paramount. In the last decade, it has become evident that detection of 
gametocytes by microscopy is insufficiently sensitive to assess potential infectivity. 
Gametocyte densities below the microscopic threshold for gametocyte detection (~ 5 
gametocytes/µL) frequently result in mosquito infection (Carter 1980; Pradel 2007; 
Schneider, Bousema et al. 2007; Ouedraogo, Bousema et al. 2009).   
Molecular detection of low levels of gametocyte specific mRNA enables identification 
of submicroscopic gametocyte carriers, and has revealed gametocyte prevalence to 
be four to ten times higher than estimated by microscopy (Abdel-Wahab, Abdel-
Muhsin et al. 2002; Sutherland, Alloueche et al. 2002; Nassir, Abdel-Muhsin et al. 
2005; Bousema, Schneider et al. 2006; Drakeley, Sutherland et al. 2006; Paganotti, 
Palladino et al. 2006; Ouedraogo, Schneider et al. 2007; Sauerwein 2007; Schneider, 
Bousema et al. 2007; Shekalaghe, Drakeley et al. 2007; Karl, David et al. 2008; 
Nwakanma, Kheir et al. 2008). 
However, whilst mRNA-based gametocyte detection has aided epidemiological 
research concerned with low density Plasmodium falciparum gametocytes, the labile 
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nature of RNA and the ubiquitous presence of RNAses pose challenges to sampling 
under field conditions, where high heat and humidity may lead to mRNA degradation 
(Bauer, Polzin et al. 2003). Optimal handling of RNA samples, e.g., stabilizing in 
buffer, shipping on dry ice, and storing at -80°C, allows maintenance of integrity of 
nucleic acids but restricts sampling to well-equipped laboratories. To facilitate RNA 
sampling and storage in settings with limited resources a filter paper-based approach 
has been proposed (Mlambo, Vasquez et al. 2008). Filter papers have been routinely 
used for reliable collection and storage of whole blood samples for both antibody 
and DNA recovery (Corran, Cook et al. 2008; Taylor, Martin et al. 2011). The value of 
filter-paper matrices for malaria mRNA collection remains to be confirmed, in 
particular for detecting low-density infections under field conditions. In this study, 
the suitability of three different filter papers that are recommended for DNA or RNA 
storage has been determined for the mRNA-based detection of low-density 
gametocyte concentrations. Samples were stored on two filter papers under 
different conditions, ranging from those available in well-equipped laboratories to 
humid and hot tropical conditions, whereas the third paper was included in a smaller 
subset of conditions. Two commonly used RNA extraction protocols were compared 
and gametocytes were detected by both reverse-transcriptase PCR (RT-PCR) and 
quantitative nucleic acid sequence based amplification (QT-NASBA).  
 
Methods 
 
Figure 4.0 depicts an overview of the methodology.  
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Figure 4.0. Overview of experimental procedure. 
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counting chambers by two independent microscopists and diluted to densities of 10, 
1.0 and 0.1 gametocytes per µL in parasite negative European whole blood. These 
concentrations were chosen because they span the microscopic threshold for 
gametocyte detection (Bousema and Drakeley 2011) but may still be detectable by 
molecular methods (Babiker, Schneider et al. 2008).  Large blood spots of 50µL of the 
different dilutions were aliquoted in five replicates per filter paper, incubation 
condition and time point, and allowed to dry overnight before being sealed into 
plastic bags with a silica desiccant sachet. To evaluate the impact of sub-optimal 
drying on mRNA recovery, after aliquoting the sample some papers were 
immediately sealed into bags without air drying overnight, and were stored without 
desiccant in containers with ~80% relative humidity. Two sets of papers were 
handled this way and are referred to as the conditions ‘with hu idity’ in Figure 4.0.  
Three filter paper types were evaluated: the Whatman 903 Protein Saver Card, 
Whatman FTA Classic Card and the Whatman 3MM filter paper (GE Healthcare Ltd., 
New Jersey, USA). The FTA Classic Card was included as it is impregnated with 
chemicals that lyse cells, denature proteins and protect nucleic acids from nucleases, 
oxidative and UV damage. The 903 Protein Saver Card, has no stabilizing properties 
but has previously been shown to be suitable for RNA collection (Mens, Schoone et 
al. 2006; Mlambo, Vasquez et al. 2008). The 3MM plain filter paper has no nucleic 
acid stabilizing properties, was not expected to perform well and was therefore 
evaluated under a smaller subset of conditions (Whatman 2009). 
Storage conditions were considered to replicate likely conditions that may be 
encountered at field sites for sampling and during transportation back to the 
laboratory. Frozen and cold chain incubation temperatures were: -80°C, -20°C and 
4°C. To represent laboratories without access to any cold storage, ambient/room 
temperature (an average of 22°C, but with a range from 20-24°C) and hot tropical 
temperatures (35°C, in an incubator) conditions were included. To mimic sampling 
under humid conditions, papers were also stored at 22°C and at 35°C in a wet box 
with a hygrometer, reaching ~ 80% relative humidity. Filter papers were incubated 
for one week under a ‘transportation/shippin ’ te perature  then oved to a 
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second ‘stora e’ te perature  where replicates were kept for an additional four 
weeks or twelve weeks before RNA extraction.  
As non- filter paper controls, 50µL aliquots of the three gametocyte densities and 
parasite negative diluent blood were stored in RNA stabilizing guanidine 
isothiocyanate buffer (Boom, Sol et al. 1990), at -80°C. A total of twenty replicates of 
gametocyte negative human blood was blotted onto 903 Protein Saver Cards; twenty 
onto the FTA Classic Card and ten onto the 3MM papers. These negative controls 
were stored at -20°C or 35°C with silica gel desiccant before extraction and analysis.  
 
RNA extraction 
 
To determine optimum extraction methods, a small-scale comparison extracting total 
RNA with the RNeasy Mini Blood kit (QIAGEN Ltd, Crawley, UK) and a guanidine 
based extraction protocol (Boom, Sol et al. 1990; Mlambo, Vasquez et al. 2008) was 
conducted. Replicates  of all three gametocyte densities were spotted onto the 903 
Protein Saver Card (n=21) and the FTA Classic Card (n=21) which were air dried 
overnight then stored at -80°C or -20°C for twenty-four hours. RNA was extracted by 
both methods and sensitivity was determined by QT-NASBA, and measured in terms 
of the number of positive results. RNeasy extraction from filter papers was 
performed as described elsewhere, following an initial homogenization step where 
entire 50µL blood spots were excised from filter papers then rocked horizontally in 
individual microcentrifuge tubes at 150 rpm for one hour with 500µL of RNeasy Lysis 
 uffer (Q   EN  td  Crawley  U ) plus β-mercaptoethanol (0.14M final 
concentration). Following this, samples were centrifuged through QIAshredder 
columns (QIAGEN Ltd, Crawley, UK) as described elsewhere (Mlambo, Vasquez et al. 
2008). 
For guanidine-based extraction, filter papers were similarly homogenized in 700µL of 
guanidine isothiocyanate L6 buffer (8.3M GuSCN, 82mM Tris-HCL pH 6.4, 36mMM 
EDTA pH 8 and 2% v/v Triton-X-100) and rocked for 1.5 hours at 150 rpm. After this, 
the supernatant was kept and an additional 700µL of guanidine isothiocyanate L6 
buffer was added to the filter paper that was rocked for thirty more minutes at 150 
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rpm. Then the supernatants were pooled and RNA extraction performed as described 
(Boom, Sol et al. 1990). Non filter paper controls were gametocyte concentrations of 
10, 1.0 and 0.1 gametocytes per µL in parasite negative European whole blood that 
was stored immediately in L6 buffer, and were extracted according to protocol from 
this media (Boom, Sol et al. 1990).  
 
Gametocyte detection 
 
Gametocyte specific Pfs25 mRNA transcripts were detected in extracted material 
using quantitative nucleic acid sequence based amplification (QT-NASBA) and reverse 
transcription polymerase chain reaction (RT-PCR). QT-NASBA was conducted as 
previously described using the NucliSENS Easy Q Basic Kit, Version 2 (BioMérieux 
Benelux B.V, Boxtel, The Netherlands), see Table S1 in the additional files for primers 
and molecular beacon (Schneider, Schoone et al. 2004). Prior to RT-PCR, potentially 
contaminating DNA was digested with DNA-freeTM (Applied Biosystems, Warrington, 
U )  Twenty µ  reactions were conducted accordin  to the anufacturer’s protocol 
with the following amendments: RNA sample was added to 2µL of rDNase I, 2µL of 
10X DNase I buffer, and inactivated with 4µL of DNase inactivation reagent. Nested 
RT-PCR was conducted using a previously published protocol with novel primers, 
described in Table S1 in the additional files and amended cycling conditions 
(Mlambo, Vasquez et al. 2008; Stresman, Kamanga et al. 2010).  Reactions were set 
up using lyophilized Illustra Ready to Go RT-PCR beads (Illustra, GE Healthcare UK 
Ltd, Buckinghamshire, UK) and PCR cycling was conducted as described below. To 
generate cDNA, reactions were held at 42°C for 30 minutes, followed by 95°C for five 
minutes. Primary PCR conditions were 94°C for two minutes, then 45 cycles of: 94°C 
for thirty seconds, 52°C for one minute and 68°C for 2.5 minutes. Nested PCR was 
performed using 2µL of primary PCR product and the same conditions as before, but 
with thirty cycles instead. The PCR product was analysed on a 1.5% agarose gel and 
produced a band of ~124 base pairs.  
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Data analysis  
 
Statistical comparisons of the filter paper types and detection methods were 
performed using statistical software STATA Version 11 (Statacorp, Texas, USA). 
Co parisons of filter paper or extraction perfor ance were done  y  earson’s 2 or 
trend test. Where appropriate, multivariate logistic regression models were used to 
allow for the effect of gametocyte concentrations when comparing the effect of 
storage temperature by filter paper type and to allow for the effects of gametocyte 
concentrations and storage temperature when comparing the performance of filter 
papers. GraphPadPrism Version 5 (GraphPad Software Inc., La Jolla, USA) was used 
for graphical presentation. 
  
Results  
 
Selection of an RNA extraction method 
 
In a pilot experiment RNA extraction from bloodspots on desiccated 903 Protein 
Saver Cards stored at -80°C or -20°C was found to be similar using guanidine-based 
extraction (18/21 successful amplifications) or RNeasy based extraction (19/21 
successful amplifications), with no significant difference found between the two 
(p=0.635), Table 4.0.  
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Table 4.0. RNeasy Mini Blood kit (QIAGEN Ltd, Crawley, UK) and Boom RNA 
extraction technique comparison, determined by QT-NASBA.  
  -80oC -20oC -80oC -20oC 
 903 Protein Saver FTA TM Classic Card 
extraction 
type 
10 1 0.1 10 1 0.1 10 1 0.1 10 1 0.1 
Boom  (5/5) (5/5) (4/5) (2/2) (1/2) (1/2) (5/5) (5/5) (1/5) (2/2) (2/2) (2/2) 
RNeasy (5/5) (5/5) (4/5) (2/2) (2/2) (1/2) (5/5) (3/5) (1/5) (2/2) (1/2) (0/2) 
 
RNA extraction from the FTA Classic Card was less efficient by RNeasy (12/21 
successful amplifications) compared to guanidine-based extraction (17/21 successful 
amplifications), although this difference was not significant (p=0.095), Table 4.0. 
Therefore, all subsequent experiments were continued with guanidine-based 
extraction, which is less laborious and less expensive.  
 
Positive and negative controls 
 
For non-filter paper controls when gametocyte dilutions were stored at -80°C in 
protective guanidine buffer, all of the samples with 10 gametocytes /µL or 1 
gametocyte /µL were detected by QT-NASBA, but six out of eight were detected for 
both dilutions by RT-PCR. For the 0.1 gametocytes/µL samples five of eight were 
successfully detected by QT-NASBA, and three of eight for RT-PCR (Table 4.1.). None 
of the negative European donor blood showed RNA amplification by either QT-
NASBA or RT-PCR (0/23). 
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Table 4.1. Detection comparison for QT-NASBA and RT-PCR for whole blood stored 
directly in guanidine RNA preservation buffer at -80°C.  
  Gametocyte density/µL 
  10 1 0.1 negative  
QT NASBA 100 (8/8) 100 (8/8) 62.5 (5/8) 0 (0/4) 
RT-PCR 75 (6/8) 75 (6/8) 37.5 (3/8) 0 (0/4) 
 
 
Storage duration  
 
There was no evidence for a difference in the proportion of successful amplifications 
between samples stored in their second condition for 4 weeks compared to those 
stored for 12 weeks by either QT-NASBA (regression analysis adjusting for 
gametocyte concentration and storage condition, p=0.89) or RT-PCR (regression 
analysis adjusting for gametocyte concentration and storage condition, p=0.49) 
(Tables S2 and S3 in the additional files). Therefore, data from the two time-points 
was combined for the comparison of storage conditions for subsequent analysis.  
 
Detection of gametocytes from filter papers  
 
Detection of gametocytes from filter papers stored at -80°C or -20°C 
 
All gametocyte concentrations that were blotted onto the 903 Protein Saver Cards 
and stored with desiccant at -80°C were successfully detected by QT-NASBA and RT-
PCR (Figure 4.1. (a), Tables S2 and S3 in additional files). All gametocyte 
concentrations that were blotted onto the FTA Classic Cards and stored with 
desiccant at -80°C were successfully detected by QT-NASBA but not by RT-PCR 
(Figure 4.1. (b), p=0.007). 
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Figure 4.1. Effect of frozen storage on gametocyte mRNA preserved on filter papers. 
Percentage of mRNA amplification in 10, 1.0 and 0.1 gametocyte/µl dilutions, 
determined by QT-NASBA (open bars) and RT-PCR (hatched bars), when stored on 
filter paper. (a) shows the Whatman 903 Protein Saver filter paper, (b) the Whatman 
FTA Classic Card, and (c) sample stored in guanidine isothiocyanate buffer, when 
stored under frozen temperatures for up to thirteen weeks. Raw data are shown in 
Tables S2 and S3, additional files. 
 
 
Detection of gametocytes from filter papers stored at increasing temperatures  
 
The proportion of cards that gave successful amplification for all gametocyte 
dilutions was unaffected by increasing storage temperature if using the 903 Protein 
Saver Card (Figures 4.2. and 4.3., Tables S2 and S3 in the additional files; (test for 
trend adjusting for gametocyte concentration, p=0.18).  
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Figure 4.2. Effect of cold chain storage on gametocyte mRNA preserved on filter papers. Percentage of mRNA amplification in 10, 1.0 and 0.1 
gametocyte/µl dilutions, determined by QT-NASBA (open bars) and RT-PCR (hatched bars), when stored on (a) the Whatman 903 Protein Saver filter 
paper and (b) the Whatman FTA Classic Card, under cold chain conditions with variable humidity for up to thirteen weeks. 
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In contrast, there was evident loss in sensitivity when samples on FTA Classic Cards 
were stored at a higher temperature. Successful detection by QT-NASBA of 
gametocytes blotted on FTA Classic Cards was achieved for 100% (9/9), 63.2% (12/19), 
53.3% (16/30) and 31.6% (6/19) of the samples that were continuously stored with 
desiccant at -80°C, -20°C, 22°C and 35°C, respectively (test for trend, p=0.002). 
Similarly, successful detection by RT-PCR of gametocytes blotted on FTA Classic Cards 
was achieved for 46.7% (7/15), 50.0% (5/10), 27.8% (5/18) and 10.5% (2/19) of the 
samples that were continuously stored with desiccant at -80°C, -20°C, 22°C and 35°C, 
respectively (test for trend adjusting for gametocyte concentration, p=0.02).  
The use of RT-PCR for gametocyte detection led to similar conclusions about the effect 
of increasing storage temperature on the detectability of gametocytes from 903 
Protein Saver Cards (test for trend adjusting for gametocyte concentration, p=0.83) or 
FTA Classic Cards (test for trend adjusting for gametocyte concentration, p=0.01). 
 
Detection of gametocytes from filter papers stored at changing temperatures  
 
Compared to 903 Protein Saver Cards that were continuously stored at -20°C, the 
chance of detecting gametocytes by QT-NASBA from 903 Protein Saver Cards that 
were first stored at higher temperatures (4°C, 22°C or 35°C) was not reduced (test for 
trend, p=0.41). In contrast, FTA Classic Cards that were first stored at higher 
temperatures (4°C, 22°C or 35°C) were less frequently successfully amplified by QT-
NASBA (test for trend adjusting for gametocyte concentration, p=0.09). The use of RT-
PCR for gametocyte detection resulted in similar conclusions about changing storage 
temperature and a loss in the detectability of gametocytes from 903 Protein Saver 
Cards (test for trend adjusting for gametocyte concentration, p=1.00) and FTA Classic 
Cards (test for trend adjusting for gametocyte concentration, p=0.09). 
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Detection of gametocytes from filter papers stored under humid conditions  
 
A subset of filter papers were examined in humid and dry conditions; these samples 
were stored at 22°C for one week and subsequently shifted to -20°C (Figure 4.2.) or 
were stored at 35°C for an additional 12 weeks  (Figure 4.3.).  
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Figure 4.3. Effect of tropical condition storage on gametocyte mRNA preserved on filter papers. Percentage of mRNA amplification in 10, 1.0 and 0.1 
gametocyte/µl dilutions, determined by QT-NASBA (open bars) and RT-PCR (hatched bars), when stored on (a) the Whatman 903 Protein Saver filter 
paper and (b) the Whatman FTA Classic Card, under tropical conditions with variable humidity for up to thirteen weeks.  
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For the first condition, 22°C for one week followed by -20°C for the next 12 weeks, 
there was no reduction in the proportion of successfully amplified samples from 903 
Protein Saver Card by QT-NASBA (regression analysis adjusting for gametocyte 
concentration, p=0.87). However, there was a clear reduction in the proportion of 
successfully amplified samples from FTA Classic Cards by QT-NASBA (regression 
analysis adjusting for gametocyte concentration, p=0.049). Comparisons between 
humid and dry conditions for these storage temperatures gave similar results when RT-
PCR was used for gametocyte detection from 903 Protein Saver Cards (regression 
analysis adjusting for gametocyte concentration, p=1.00) or FTA Classic Cards 
(regression analysis adjusting for gametocyte concentration, p=0.009). 
When stored at 35°C, there was a clear reduction in the proportion of successfully 
amplified samples from 903 Protein Saver Card by QT-NASBA (regression analysis 
adjusting for gametocyte concentration, p<0.001). For FTA Classic Cards, too few 
samples gave successful amplification for statistical analysis; none of the samples 
stored under wet conditions at 35°C were successfully detected. Comparisons between 
humid and dry conditions for these storage temperatures gave similar results when RT-
PCR was used for gametocyte detection. 
 
Detection of gametocytes from Whatman 3MM filter papers  
 
Whatman 3MM papers were not expected to be a suitable media for mRNA storage, so 
were incubated under fewer conditions (Figure 4.4., Tables S2 and S3 additional files). 
These samples were tested under three conditions: at -20°C for thirteen weeks, at 22°C 
for thirteen weeks and at 35°C for one week followed by -20°C storage for the next 
twelve weeks.  
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Figure 4.4. Performance of Whatman 3MM as a storage media for gametocyte mRNA. 
Percentage of mRNA amplification in 10, 1.0 and 0.1 gametocyte/µl dilutions, 
determined by QT-NASBA (open bars) and RT-PCR (hatched bars), when stored on the 
Whatman 3MM filter paper, incubated under different conditions for up to thirteen 
weeks.  
 
 
When continuously stored at -20°C, there was no difference between the proportion 
of successfully detected samples for all gametocyte dilutions by QT-NASBA between 
3MM and 903 Protein Saver Cards (regression analysis adjusting for gametocyte 
concentration=0.34) or FTA Classic Cards (regression analysis adjusting for gametocyte 
concentration, p=0.10). When stored continuously at 22°C, 3MM filter papers 
performed as well as 903 Protein Saver Cards (regression analysis adjusting for 
gametocyte concentration, p=0.95) but better than FTA Classic Cards (regression 
analysis adjusting for gametocyte concentration,p=0.01). When stored at 35°C for one 
week followed by -20°C for the next twelve weeks, 3MM filter papers performed as 
well as 903 Protein Saver Cards (regression analysis adjusting for gametocyte 
concentration, p=0.75) but better than FTA Classic Cards (regression analysis adjusting 
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for gametocyte concentration, p=0.01). When RT-PCR was used, similar results were 
obtained.   
 
Discussion 
 
This study was designed to investigate optimal collection and storage conditions to 
enable reliable detection of P. falciparum gametocyte densities found in natural 
infections. Filter papers were found to be a suitable media for Pfs25 mRNA detection 
from low gametocyte concentrations after storage for up to thirteen weeks. 
Furthermore, it was found that gametocyte Pfs25 mRNA stored on 903 Protein Saver 
Cards is remarkably stable at temperatures higher than -80°C.  
Unlike the general detection of malaria parasites, which is based on amplification of 
Plasmodium nuclear or mitochondrial DNA, the specific detection of gametocytes 
depends on mRNA. Reliable sampling for gametocytes currently depends on RNA 
extraction in the field (Sutherland, Alloueche et al. 2002; Schneider, Bousema et al. 
2007) or storage of samples in stabilizing buffer at -80°C in order to protect the 
integrity of mRNA, which is much more labile than DNA. The main aims of this study 
were to determine which filter papers were most suitable for storage of gametocyte 
mRNA in dried whole blood samples, and to explore flexibility of storage conditions 
and whether less stringent conditions are permissible without affecting estimates of 
gametocyte prevalence. This study builds upon similar research evaluating RNA 
detection from filter paper (Mlambo, Vasquez et al. 2008) but provides more rigorous 
testing with a larger number of replicates in diverse incubation conditions including 
both high and low humidity, which is of particular relevance for sampling in the tropics. 
QT-NASBA reliably detected gametocyte densities of ten or one gametocyte/µL when 
immediately stored in RNA-stabilizing buffer at -80°C and was found to be more 
sensitive than RT-PCR for detecting low gametocyte concentrations. The higher 
sensitivity of QT-NASBA is unlikely to be explained by amplification of ssDNA (Pritsch, 
Wieser et al. 2012); but we do consider it plausible that the DNAse digestion step may 
have negatively influenced the sensitivity of RT-PCR. It is also important to note that 
we compared QT-NASBA with RT-PCR as it was previously used for Pfs25 mRNA 
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detection (Mlambo, Vasquez et al. 2008; Stresman, Kamanga et al. 2010); more 
sensitive quantitative RT-PCR assays may become available that make this assay 
comparable in sensitivity to QT-NASBA. Under optimal conditions, storage in RNA-
stabilizing buffer at -80°C, it was observed that not all samples with 0.1 gametocyte/µL 
were detected by QT-NASBA. This may reflect variability in extraction efficiency or RNA 
amplification (Churcher et al in preparation) or an inevitable consequence of very low 
pathogen concentrations and sample volumes (an average of five gametocytes per 
50µL blood sample blotted on the paper). The use of an extraction control could 
address uncertainties on extraction efficiency between samples but was not used in 
this study or in other studies using Pfs25 mRNA RT-PCR or NASBA (Schneider, Schoone 
et al. 2004; Schneider, Wolters et al. 2005; Mens, Schoone et al. 2006; Schneider, 
Bousema et al. 2006; Mens, Spieker et al. 2007; Ouedraogo, Schneider et al. 2007; 
Schneider, Bousema et al. 2007; Mens, Sawa et al. 2008; Ouedraogo, Bousema et al. 
2009).  
Detection of gametocytes from filter papers stored at -80°C succeeded with a similar, 
but slightly higher frequency compared to detection of gametocytes from samples 
stored directly in RNA stabilizing buffer. The unexpected improved detection from 
filter paper samples has been previously acknowledged in similar studies (Pritsch, 
Wieser et al. 2012) where it has been suggested the drying step enhances blood cell 
lysis, leading to a higher probability of detection. It is currently unclear whether this 
apparent superiority of filter papers over RNA stabilizing buffer is specific to Pfs25 
mRNA and if other gametocyte mRNA targets are less well stored or recovered using 
filter papers.  
The successful detection of gametocytes from filter papers stored at -80°C formed a 
useful starting point for analyses that aimed to determine the suitability of filter 
papers for storage under less favourable conditions.  No evidence was found that 
increasing storage temperature resulted in a lower success rates for gametocyte 
detection from 903 Protein Saver Cards. Contrary to this, gametocyte detection from 
the FTA Classic Cards was most efficient when stored at -80°C, lower when stored at -
20°C or 22°C and lowest when stored at 35°C. FTA Classic Cards were also more 
susceptible to changes in storage temperature with short-term storage at 
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temperatures higher than -20°C resulting in a loss in detectability of gametocytes from 
these cards. Qualitative gametocyte detection from 903 Protein Saver Cards was not 
affected by different storage temperatures.  
 
Incomplete drying of filter papers resulted in a loss in efficiency of gametocyte 
detection. This effect was most apparent at the highest temperature tested (35°C) and 
FTA Classic Cards appeared most susceptible to this detrimental effect of moisture on 
gametocyte detection. This loss in sensitivity could be a result of RNA degradation 
and/or incomplete sample elution from insufficiently dried filter papers. It has 
previously been acknowledged that insufficient drying impacts on the sample elution 
which is likely to contribute to the loss in detection seen here. On visual inspection 
following blood spot elution, filter papers stored under humid conditions remained 
red, suggesting incomplete recovery of the blood-product (Mei, Alexander et al. 2001). 
Exposure to heat and moisture has been suggested to cause damage or denaturation 
of RNA not only by the formation of nicks in the nucleic acid strands, or by strand 
hydrolysis, but also by amplifying degradation caused by UV light exposure(Rogers and 
Burgoyne 2000; Moscoso, Raybon et al. 2005; Kansagara AG 2008). Removing moisture 
by overnight drying and inclusion of desiccant not only prevents physical destruction of 
the paper, but will also slow RNA degradation.  
 
The general-purpose 3MM paper permitted detectable RNA recovery as often as the 
903 Protein Saver Card and more often than the FTA Classic Card under all conditions. 
As this filter paper has no specific sample preservation properties and is generally used 
for DNA and serological sample collection, it was not expected to perform as well as it 
did. Previous success has been reported for viral RNA storage on the 3MM filter paper, 
with transcripts being detected after twelve weeks of storage at 32°C, without a loss in 
sensitivity (Michaud, Gil et al. 2007). Studies conducting RT-PCR from measles virus 
RNA stored on the 3MM filter paper have shown successful amplification following 
twenty-five weeks of storage at room temperature, but a loss in sensitivity with 
increasing temperature, and detection for just one week post storage for papers 
incubated at 37°C in humid conditions, due to fungal growth (De Swart, Nur et al. 
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2001). These results are promising, and use of 3MM is particularly appealing due to its 
low cost and common use as a substrate for DNA collection (Corran, Cook et al. 2008; 
Cook, Reid et al. 2010). A recent publication provided evidence that this paper is 
indeed suitable for Pfs25 mRNA storage (Pritsch, Wieser et al. 2012). When this 
publication was in preparation, Pritsch et al published similar research showing the 
suitability of 3MM for Pfs25 mRNA storage for low density gametocytes (Pritsch, 
Wieser et al. 2012). Results are in broad agreement: 3MM paper is suitable for Pfs25 
mRNA storage, higher storage temperatures may lead to a lower sensitivity of 
gametocyte detection, and filter paper Pfs25 mRNA collection may lead to higher RNA 
yield than RNA extraction from whole blood samples. The manuscript by Pritsch 
provides additional details on the stability and quantification of Pfs25 mRNA; the 
current manuscript has limitations in the sense that RNA yield from filter papers was 
not determined. The analyses were restricted to gametocyte prevalence and some 
RNA degradation may therefore have remained undetected. However, the current 
manuscript extends previous reports on the use of filter paper for RNA storage by the 
concurrent examination of the sensitivity of RT-PCR, by showing a side-by-side 
comparison of three filter papers and by examining the effects of a large range of 
storage conditions including a combination of high temperature and high humidity, 
which is particularly relevant for field sample collection.  
 
In addition to Pfs25 mRNA stability and recovery, the cost and operational ease are 
important considerations when choosing a methodology. The filter papers used in this 
study differ substantially in cost from USD $2 for 100 papers for the 3MM, $133 for 
100 903 Protein Saver Cards, to approximately $400 for 100 of the FTA classic cards, in 
2011. Whilst the extraction methods performed equally well in the small comparison 
conducted, the guanidine-based extraction is more affordable at $1.2 per reaction and 
is more amenable to large-scale extraction. The Qiagen protocol, complete with 
Qiashredder homogenization and DNA digest, is more expensive at $4.5 per extraction. 
The individual expense of molecular detection is $7 per reaction for QT-NASBA, but 
amounts to ~$14 for RT-PCR as it requires a DNA digest and a DNA control per sample, 
to exclude the possibility of DNA contamination. The combination of 903 Protein Saver 
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Cards (which allows a minimum of five spots per card), guanidine extraction and QT-
NASBA detection gives a total cost of $8.5per sample. The cheapest combination of 
methods is the 3MM paper, guanidine-based extraction and QT-NASBA for detection, 
which would amount to approximately $8.22 per sample. 
 
Conclusions 
 
In summary, these findings indicate that filter paper cards can be used for collection 
and storage of Psf25 mRNA for detecting low gametocyte concentrations. The 903 
Protein Saver Card and 3MM filter papers are both recommended as they appear 
particularly promising in this respect and appear to be robust storage media under 
temperatures higher than those conventionally used for RNA storage. Thorough drying 
of papers was more important for successful gametocyte detection than the 
temperature under which samples were stored.  
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4.4 Linking methods and results:  
 
The publication discusses the main findings of this chapter. This section details 
optimization of protocols, including RT-LAMP (which had initially been intended to be 
included in the comparative study) and additional work that supports the results in the 
publication. To improve the clarity, the methods and results follow each other in some 
instances  and headin s are la elled with either ‘ ethods’ or ‘results’.  
This section begins with general methods detailing preparation of this study, then it is 
split into the following overall headings: 
 Gametocyte detection using reverse transcriptase loop mediated isothermal 
amplification (RT-LAMP) from RNA treated with a DNA digest. 
 Molecular detection using quantitative nucleic acid sequence based 
amplification (QT-NASBA) and reverse transcription polymerase chain reaction 
(RT-PCR). 
 Detection of Pfs25mRNA from filter paper blood spots collected in an endemic 
setting. 
An extended discussion follows at the end.   
 
4.41 Methods: Preparation of work space and equipment for RNA extraction and 
molecular detection 
 
There were 2 designated cabinets used for:  
1) Excision of blood spots and nucleic acid extraction. 
2) Preparation of molecular detection reaction mastermixes.  
Before use, all bench space and cabinets were sterilized as described next. Bench 
surfaces, pipettes and lab equipment (pipette tip boxes, tube racks etc) were sterilized 
 116 
 
thoroughly using 100% ethanol followed by RNase Zap (Sigma-Aldrich Ltd, Dorset, UK). 
Specific pipettes and filter tips were designated for RNA extraction protocols, with a 
separate set used for molecular protocols. All microcentrifuge tubes used were 
nuclease free (Life Technologies, Lincolnshire, UK). Cabinets were sterilized as follows, 
UV light exposure for 30 minutes in a closed hood with a UV light and timer, followed 
by cleaning with 100% ethanol, then cleaning with RNase Zap. For molecular protocols, 
addition of test sample nucleic acid (or amplified product for a nest 2 reaction) was 
performed in a separate clean area, and was added with a specific pipette. 
 
4.42 Methods: Collection of cultured gametocytes on filter paper  
 
To provide low density gametocytes for spotting onto filter papers for the comparative 
study, 3D7 gametocytes were cultured and supplied as a kind gift from Marga van der 
Vegte-Bolmer (Radboud UMC, Nijmegen, The Netherlands). Gametocytes were diluted 
in malaria negative European Blood provided from individuals with no travel history to 
a malaria endemic country (supplied by Radboud UMC, Hospital Blood Bank, Nijmegen, 
The Netherlands) to 10, 1.0 and 0.1 gametocytes/µL. Fifty µL of gametocyte spiked 
blood was spotted five times onto each filter paper per incubation condition. The 903 
Protein Saver Card has 5 stamped circles printed on it to aid with sample collection. 
Since the FTA card had 4 large circles, the 5th blood spot was spotted in the centre of 
the others. The 3MM paper is provided on a continuous roll with a fixed width of 0.78 
inches. Sections were cut that were 5 inches in length, which were stapled into 
cardboard covers, then the 5 samples were spotted evenly spaced onto the paper. 
Since the 3MM paper is thin, sample was pipetted slowly to allow absorption and 
avoid sample run off. Table 4.2. indicates the total number of sample replicates stored 
per gametocyte density, incubation condition and filter paper type.  
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Table 4.2. The number of filter paper replicates incubated for each filter paper type, 
gametocyte density and incubation condition. RT = room temperature, AD= filter 
papers were air dried overnight before storage (average temperature: 22°C, relative 
humidity ~40%), NT=condition not tested, WK=week. Filter papers were stored at the 
temperature indicated for ‘te p wk 1’ for the first week  then were moved to the 
temperature indicated in ‘temp wk 2’, where they remained until extraction after 1 or 
3 months (half the number of filter paper replicates indicated in this table were 
extracted at each time point). 
Filter paper: 
  
  
  
Whatman 903 
Protein Saver 
Card 
Whatman FTA 
Classic Card 
Whatman 3MM 
Incubation condition gametocyte density/µL 
drying silica 
gel 
temp 
wk 1 
temp 
wk 2 
10 1 0.1 0 10 1 0.1 0 10 1 0.1 0 
AD Yes  -80 °C -80 °C 5 5 5 NT 5 5 5 NT NT NT NT NT 
AD Yes -20 °C -20 °C 10 10 10 10 10 10 10 10 10 10 10 10 
AD Yes 35 °C 35 °C 10 10 10 10 10 10 10 10 NT NT NT NT 
AD Yes 35 °C -20 °C 10 10 10 NT 10 10 10 NT 10 10 10 NT 
AD Yes RT RT 10 10 10 NT 10 10 10 NT 10 10 10 NT 
AD Yes RT -20 °C 10 10 10 NT 10 10 10 NT NT NT NT NT 
AD Yes 4 °C -20 °C 10 10 10 NT 10 10 10 NT NT NT NT NT 
wet No 35 °C 35 °C 10 10 10 NT 10 10 10 NT NT NT NT NT 
wet No RT -20 °C 10 10 10 NT 10 10 10 NT NT NT NT NT 
 
Twenty additional replicate blood spots per filter paper and gametocyte dilution were 
prepared to enable protocol optimization before extraction of test papers. Following 
sample aliquoting, filter papers were air dried overnight at ambient temperature then 
sealed into individual air tight plastic bags with a 0.5g sachet of colour changing 
desiccant (GeeJay, Bedfordshire, UK), before incubated under test conditions. Filter 
papers evaluated in humid conditions were sealed into plastic bags immediately 
following sample aliquoting and were incubated without silica gel desiccant.  
Incubation conditions were chosen that span temperatures typical for the field, a well 
equipped laboratory, or transportation between the 2. A selection of conditions had 
incubation at one temperature for the first week, followed by movement to a second 
temperature for the rest of the duration, which was devised to mimic storage during 
transport of filter papers from the field back to the laboratory. Specifically, standard 
storage temperatures were included such as 4°C (fridge temperature), -20°C and -80°C 
 118 
 
(freezer temperatures) along with room temperature storage (~22°C) and storage at a 
tropical temperature, 35°C. Due to high humidity commonly experienced in the 
tropics, paired incubation conditions with and without humidity were included for two 
temperatures: room temperature for the first week, followed by -20°C for the second 
week, and for papers incubated at 35°C throughout. A benchtop incubator was used 
for 35°C incubation, and humidity maintained by incubating filter papers (sealed in 
plastic bags) inside Tupperware   plastic boxes with a small pad of water soaked tissue 
that was changed every day 2/3 days (as needed) to maintain an average relative 
humidity of 82% (range 44-98%). Humidity was monitored daily with a hygrometer 
(Screwfix, Somerset, UK). Half the filter papers (5/10) were stored for 1 month and the 
other half were stored for 3 months to assess if longer term storage led to a 
measurable loss in mRNA detection. Following incubation, filter papers stored for 1 
month were kept at -80°C until 3 month filter papers had finished incubating, then 
RNA extraction and mRNA detection was performed.   
 
4.43 Methods: Excision of filter paper blood spots  
 
In preparation for extraction, entire 50µL blood spots were excised from filter papers 
in a laminar flow cabinet that had been sterilized as outlined previously. All equipment 
used for excision, including microcentrifuge tube racks, scissors and tweezers, were 
sterilized in the same manner. To excise the blood spots, scissors were flame sterilized 
using a Bunsen burner, allowed to cool, then blood spots were cut allowing a ~2mm 
margin to avoid contact of the scissors with the sample. Using sterilize tweezers, the 
blood spot was removed into a microcentrifuge tube ready for extraction.  
 
4.44 Methods: Guanidine based RNA extraction 
 
To compare guanidine based extraction and Qiagen RNA extraction methods, 
gametocytes (10, 1.0 and 0.1/ µL) were spotted onto Whatman 903 Protein Saver 
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(n=42, total) and FTA Classic Card filter papers (n=42), which were stored at -20°C or -
80°C overnight before extraction. Half were extracted using guanidine based extraction 
and the other half were extracted using Qiagen extraction, as outlined in the 
publication.  
Guanidine based extraction was performed as follows from excised blood spots, 700µL 
of L6 lysis buffer (8.3M GuSCN, 82mM Tris-HCl (hydrochloric acid) [pH 6.4], 36 mM 
ethylenediaminetetraacetic acid (EDTA) and 2% v/v Triton X-100), see appendix 1 for 
preparation, was added per microcentrifuge tube which was horizontally shaken at 
150 rpm for 1.5 hours. Supernatant was removed to a new microcentrifuge tube and 
another 700µL added to the filter paper which was shaken as before for 30 more 
minutes. The supernatant was removed to the same microcentrifuge tube as previous, 
and 30µL of silica suspension was added (see appendix 1 for preparation) and mixed 
thoroughly by vortex. Tubes were shaken horizontally for 10 minutes at 150 rpm as 
before, vortexed for 5 seconds, then centrifuged for 15 seconds at 12,000g. 
Supernatant was removed, then 1mL of L2 wash buffer (5.25 M GuSCN, 50 mM Tris  
HCl [pH 6.4],) see appendix 1 for preparation, was added and microcentrifuge tubes 
were vortexed to resuspend the pellet. Tubes were centrifuged at 12,000g and 
supernatant was removed by aspiration. This was repeated once more with 1mL of L2 
buffer, twice more with 1mL of 70% ethanol, then once with 1mL of acetone. Following 
this, microcentrifuge tubes were incubated in a hot block at 56°C for 10 minutes with 
the lids off to dry the pellets. Next 50µL of RNase free water (Ambion, Renfrewshire, 
UK) was added to the pellet which was vortexed thoroughly to mix. Samples were 
incubated at 56°C with the lids on for 10 minutes, then centrifuged for 2 minutes at 
12,000g. The top 35µL of supernatant containing the eluted nucleic acid was 
transferred to a new microcentrifuge tube and stored at -80°C until use.  
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4.45 Methods: RNA extraction using Qiagen RNA mini kit 
 
To complete the RNA extraction comparison, the second half of the filter papers 
(discussed in 4.44) were extracted using the Animal Cells protocol (RNA Mini Kit, 
Qiagen, Surrey, UK) as follows. Entire 50µL blood spots were aseptically excised (as 
described before) into 1.5mL microcentrifuge tubes containing 500µL of RTL buffer 
(Qiagen) plus β-mercaptoethanol (0.14 M end concentration). This was horizontally 
shaken at 150 rpm for 1 hour on a rotary shaker. Then, the filter paper and buffer were 
transferred to a QiaShredder Column (Qiagen, Surrey, UK) inside a collection tube, and 
centrifuged for 2 minutes at 14,000 rpm. Supernatant was removed to a new 
microcentrifuge tube, then 500µL of 70% ethanol was added and this was mixed by 
pipetting. Half this volume was added to a spin column in a collection tube which was 
centrifuged for 2 minutes at 13,000 rpm, then flow through was discarded and the 
procedure repeated with the remaining volume. The column was washed with 700µL 
of RW1 buffer (Qiagen) which was centrifuged for 2 minutes at 13,000 rpm. The flow 
through was discarded and another wash performed with 500µL of RPE buffer (Qiagen) 
that had been pre-diluted with 4 volumes of 100% ethanol. This was centrifuged for 2 
minutes at 13,000 rpm, the flow through discarded again, then the wash step repeated 
and spin columns transferred to fresh collection tubes and centrifuged for 1 minute at 
13,000 rpm to dry the column membrane. Columns were moved to new 
microcentrifuge tubes and 50µL of RNase free water (Ambion, Renfrewshire, UK) was 
added directly to the membrane, then columns were centrifuged at 10,000 rpm for 1 
minute to elute the RNA. Samples were stored at -80C until use.  
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4.5 Linking methods and results: Gametocyte detection using reverse 
transcriptase loop mediated isothermal amplification (RT-LAMP) from RNA 
treated with a DNA digest 
 
4.51 Methods: DNA digestion of the extracted nucleic acid using DNase I (RNase-free) 
 
Guanidine based extraction extracts total nucleic acid. To eliminate DNA that may 
amplify during the RT-PCR reaction, a DNA digest had to be performed. Similarly, while 
the Qiagen kit should result in extraction of RNA, the manufacturers recommend 
following with a DNA digest, if performing an amplification technique that is sensitive 
to small amounts of DNA.  
Initially, DNA was digested using DNase I (RNase-free) (Ambion, Renfrewshire, UK). 
Digest reactions were set up according to the supplied protocol as follows. In a 
microcentrifuge tube, the following were combined, 5µL of 10x DNase I buffer, 1µL (2 
units) of DNase I, 9µL of RNase free water (Ambion, Renfrewshire, UK) and 10µL of 
25mM of EDTA. Twenty five µL of the previously extracted nucleic acid was added and 
reactions incubated at 37C for 30 minutes on a thermocycler (C1000 Thermal Cycler, 
BioRad, Hertfordshire, UK), followed by 75C for 5 minutes to inactivate the enzyme. 
RNA was stored at -80°C until use.  
 
4.52 Methods: Reverse transcription loop mediated isothermal amplification (RT-
LAMP) performed on DNase I (RNase-free) treated RNA 
 
Using the RNA that had been treated with the DNase I (RNase-free) digest, gametocyte 
detection with RT-LAMP was performed using the protocol published by Buates and 
colleagues and the RT-LAMP Loopamp kit, produced by Eiken (Tokyo, Japan) (Buates, 
Bantuchai et al. 2010).  
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First, a primer mix was prepared as follows, 40pmol of FIP and BIP was combined with 
20pmol of LOOP-F and LOOP-B and 5pmol of F3 and B3 (see Table 4.3. for primer 
sequences).  
Table 4.3. Primer sequences for detection of Pfs25mRNA using RT-LAMP. 
Primer name Sequence (5’ to 3’ orientation) 
F3 TTTTAATTCAGATGAGTGGTCAT 
B3 CTTACATTCATTTGGTATACAAACA 
FIP  GTCTTTTCGTCACATTTCAGAACTTATGTAAATGTGAAAATGATTTGGTG 
BIP  ACCATGTGGAGATTTTTCCAAATGTCAAGATTACATTTACAAGCGTATG 
LOOP-F CTTCACATGTTTCTTCATTTACTAA 
LOOP-B ATTAAAATAGATGGAAATCC 
 
Maintaining reagents on ice, the mastermix was prepared as outlined in Table 4.4. and 
italicized reagents were added to the reaction tubes.  
European malaria negative blood was used as a negative control and a high density 
cultured sample (1000 gametocytes/µL (g/µL)) was used as a positive control. Both 
were included with each assay. Positive control sample was provided by Marga van der 
Vegte-Bolmer, and the negative control blood came from Radboud Hospital Blood 
Bank (Radboud UMC, Nijmegen, The Netherlands). 
 Table 4.4. RT-LAMP mastermix reagents and volumes using Loopamp RNA 
amplification kit (Eiken, Tokyo, Japan) 
reagent Volume for 1 reaction (µL) 
2 x reaction mix  12.5 
primer mix  1.3 
Enzyme mix  1.0 
Water  7.2 
calcein  1.0 
 
Mastermix total 23.0 
Template RNA (added separately) 2.0 
 
Amplification reactions were performed in a thermocycler (C1000 Thermal Cycler, 
BioRad, Hertfordshire, UK), using the following conditions: 65C for 90 minutes, 
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followed by 80C for 5 minutes. Positive samples were determined by fluorescence 
when using a hand held UV lamp (Mini Fluorescent UV Lamp, Fujitsu, London, UK) and 
as turbidity when detected by eye. Results were read by 3 lab personnel and test 
samples were compared to controls, to aid with interpretation of results (Buates, 
Bantuchai et al. 2010).  
 
4.53 Results: Gametocyte detection using reverse transcription loop mediated 
isothermal amplification (RT-LAMP) performed on DNase I (RNase free) treated 
nucleic acid 
 
To assess if the protocol was optimized, the following samples were amplified by RT-
LAMP:  the positive control sample (1000g/µL) (already extracted), 4 positive samples 
extracted using Qiagen, 4 x positive samples extracted using guanidine based 
extraction, and 2 negative control samples (all of which were treated with the DNAse I 
digest). The 4 positive samples were 2 x 100 g/µL and 2x 10g/µL. One sample of each 
density (and the negative controls) had been spotted onto both the Whatman 903 
Protein Saver Card and the FTA Classic Card. All 11 samples produced positive results 
(determined by fluorescence/eye, data not shown) including the negative control 
blood, which was from individuals with no travel history to a malaria endemic country. 
The false positive results were thought to be attributed to the presence of EDTA which 
was added to the digest reaction to prevent RNA from undergoing scission during heat 
inactivation of the enzyme. EDTA has been recognized as resulting in false positive 
results, when using detection by fluorescence (Francois, Tangomo et al. 2011). Figure 
4.5.demonstrates the suspected reason for these false positive results. In the  reaction, 
the fluorophore calcein is initially quenched by Mn2+, since EDTA is a chelator of 2+ 
ions, it is likely EDTA chelated Mn2+ from the calcein which resulted in fluorescence 
and a false positive result, for all reactions (Ambion 2007; Francois, Tangomo et al. 
2011).  
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Figure 4.5. Principle of the LAMP reaction using calcein as a fluorophore (Tomita, Mori et 
al. 2008). Figure taken directly from the referenced publication. 
 
To avoid using EDTA in the DNA digest reaction, the DNA Free Kit (Ambion) was used 
instead. 
 
4.54 Methods: DNA digestion of the extracted nucleic acid using the DNA Free Kit  
 
A second DNA digest was tried using the DNA Free kit (Ambion, Renfrewshire, UK), as 
follows. Sixteen µL of extracted nucleic acid was mixed with 2µL of 10x DNase I buffer 
and 2µL of rDNase I in a microcentrifuge tube. This was gently mixed by pipetting, and 
then was incubated at 37°C for 30 minutes on a thermocycler (C1000 Thermal Cycler, 
BioRad, Hertfordshire, UK). Four µL of DNase inactivation reagent was then added to 
the reaction, which was incubated at room temperature for 2 minutes, during which it 
was mixed 3 times by pipetting to disperse the reagent. Tubes were then centrifuged 
at 10,000g for 1.5 minutes and ~18µL of supernatant was removed to a new 
microcentrifuge tube, which was stored at -80°C until use. 
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4.55 Results: Gametocyte detection using reverse transcription loop mediated 
isothermal amplification (RT-LAMP) performed on nucleic acid treated with the DNA 
Free Kit  
 
RT-LAMP was attempted once more (as before) using the same extracted nucleic acid 
for the test samples, but performing the new DNA Free digest on the extracted 
samples first. For guanidine based extraction, digest reaction volume was halved since 
there was less extracted material remaining. Results were determined by 
fluorescence/ turbidity as before. Positive and negative results were difficult to 
distinguish. This resulted in 5/11 positive for reader 1, 8/11 for reader 2 and 7/11 for 
reader 3, with poor inter reader agreement including for positive and negative 
controls.  
 
4.56 Methods: Reverse transcription loop mediated isothermal amplification (RT-
LAMP) using hydroxy naphthol blue to indicate positive results 
 
To try to improve the sensitivity of RT-LAMP with the aim of achieving better 
discrimination of positive and negative results (and therefore improving inter reader 
agreement), the fluorophore calcein was replaced with hydroxy naphthol blue (HNB), a 
metal indicator that changes from purple to blue if by-product magnesium 
pyrophosphate is produced and the pH changes (Goto, Honda et al. 2009; Wastling, 
Picozzi et al. 2010).  Reactions were assembled as before (in Table 4.4.) substituting 
calcein with 0.15µL of HNB per reaction and adjusting the final volume of water to 
8.05µL. Along with a colour change from purple to blue, positive results also cause a 
change in turbidity which can be measured on an ELISA microplate reader at an 
absorbance of 650nm (Goto, Honda et al. 2009). To distinguish positive and negative 
results using the microplate reader, the OD value of the negative controls plus 2 
standard deviations was used as a cut off value. To determine if filter paper sampling 
was interfering with reagents in the RT-LAMP reaction, whole blood samples (10, 1.0 
 126 
 
and 0.1 gametocytes/ µL) preserved in L6 buffer were extracted and gametocytes 
detected by RT-LAMP.  
 
4.57 Results: Performance of RT-LAMP 
 
Despite varying the DNA digest protocol and positive result indicator, it remained 
difficult to identify positive results with 3 readers having poor agreement. There was 
no improvement when fluorophore calcein was replaced with HNB, and use of the 
microplate reader did not result in positive samples. There was also no improvement 
when using gametocytes preserved in L6 buffer as the starting material. Rather than 
investing in a technique that was not performing well in controlled conditions in my 
hands, and therefore likely to be problematic in less well equipped field conditions, 
further work using RT-LAMP was suspended and RT-LAMP was not included for 
comparison in the publication. 
 
4.6 Linking methods and results: Molecular detection using quantitative 
nucleic acid sequence based amplification (QT-NASBA) and reverse 
transcription polymerase chain reaction (RT-PCR) 
 
4.61 Methods: Quantitative nucleic acid sequence based amplification (QT-NASBA) 
 
QT-NASBA reactions were prepared in an RNA cabinet that had been decontaminated 
as previously outlined. A cultured gametocyte sample (3D7) was used to generate a 
trend line which was titrated 10 fold from  106, 105, 104, 103, 102  to 10 
gametocytes/mL, to serve as an internal control to identify positive results, enable 
calculation of gametocyte load and indicate efficiency of amplification. Pfs25mRNA 
was amplified using the NucliSens EasyQ Basic Kit 2 (BioMérieux, Benelux B.V, Boxtel, 
The Netherlands) which was kept at 4°C until use. The enzyme and mastermix 
preparations are provided as lyophilized pellets and once reconstituted the volume is 
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enough for 16 reactions, consequently, all experiments were assembled in multiples of 
16. For each experiment, 3 water controls were included along with the 6 trend line 
samples.  The mastermix was prepared as follows. The enzyme pellet comprised of 
AMV-RT, RNase H and T7 RNA polymerase in bovine serum albumin (BSA), was 
reconstituted in 42µL of NASBA enzyme diluent which was left to dissolve at room 
temperature without mixing.  Next, 53.3µL of NASBA buffer was added to the 
mastermix pellet and then vortexed. The remaining reagents, outlined in Table 4.5., 
were added to this tube which was mixed by vortex.  
Table 4.5. QT-NASBA mastermix reagents and volumes 
Reagent Volume for 16 reactions (µL) 
Mastermix pellet (Reconstituted first in 53.3µL of H2O) 53 
Molecular Beacon (Texas Red Pfs25 beacon (20µM) 2.4 
NASBA water (BioMérieux) 7.0 
Pfs25 primer (forward) (10µM)  3.3 
Pfs25 primer (reverse) (10µM) 3.3 
KCl (640mM) 10.7 
 
Mastermix total 5.0 
Enzyme (added separately) 2.5  
Template nucleic acid (added separately) 2.5  
 
The primer and molecular beacon sequences are indicated in Table 4.6.  
Table 4.6. QT-NASBA primer and molecular beacon sequences 
Primer name Sequence (5’ to 3’ orientation) 
Pfs25 forward GACTGTAAATAAACCATGTGGAGA 
Pfs25 Reverse T7-CATTTACCGTTACCACAAGTTA 
Molecular beacon 
Texas Red Pfs25 
beacon 
TexasRed-CGATCGCCCGTTTCATACGCTTGTAA-CGATCG-
DABSYL 
 
Five µL of reaction mastermix was aliquoted into 0.2mL Low Profile PCR Tube Strips 
(BioRad, Veenendaal, The Netherlands) then tubes were centrifuged at 10,000 rpm for 
10 seconds. Then the italicised reagents (Table 4.5.) were added separately as follows. 
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2.5µL of template nucleic acid, water control or positive control trend line was added 
per tube which was centrifuged as before. Tubes were inserted into the Nuclisens 
EasyQ heat block (BioMérieux, Benelux B.V, Boxtel, The Netherlands) without the lids 
on, then held at 65°C for 2 minutes, followed by 41°C for 2 minutes. Next, the enzyme 
aliquot was centrifuged, then 2.5µL of enzyme added into the tube lids (Optical Flat 8-
cap strips, BioRad, Veenendaal, The Netherlands) which were securely added to the 
tubes, then centrifuged once more. This ensures reactions begin at the same time to 
improve comparability of results. Samples were amplified for 90 minutes at 41°C in a 
BioRad CFX96 Real Time System (BioRad, Veenendaal, The Netherlands).  
Results were analyzed using BioRad CFX Manager (BioRad, Veenendaal, The 
Netherlands) which provides a time to positivity value (TTP) referring to the cycle 
number when sample amplification crosses the background noise threshold. A positive 
sample is identified when the TTP value exceeds the mean fluorescence of the 3 
negative water controls +20 standard deviations (Schneider, Wolters et al. 2005).  TTP 
can be converted to log parasitaemia from the equation off the slope of the trend line 
values, using regression. Higher gametocyte density samples produce a lower (faster) 
TTP due to the larger quantity of mRNA which amplifies more quickly. Low density 
samples take longer to amplify and cross the threshold, and often have larger TTP 
values.  
 
4.62 Results: Comparison of RNA extraction methods assessed using QT-NASBA 
 
Gametocyte detection was performed using QT-NASBA on RNA extracted with Qiagen 
or guanidine based extraction from extra replicate Whatman 903 Protein Saver and 
FTA Classic Card filter papers which had been stored at -20°C or -80°C (which is 
covered in the attached publication). The objective was to conclude on an optimal 
extraction method (determined by higher detection using QT-NASBA), prior to 
extraction of the test papers. There was no statistically significant difference between 
the 2 extraction methods, but since guanidine based extraction was more cost 
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effective and amenable to high throughput, it was used to extract all filter papers 
outlined in the attached publication. 
 
4.63 Results: Performance of QT-NASBA 
 
Variation had been observed in the quantitative results, when comparing the RNA 
extraction techniques. Further extractions were performed to explore the variation 
seen, using low density replicate samples detected by QT-NASBA. For this purpose 5 
replicate blood spots of 0.1 gametocytes/µL were spotted onto both the 903 Protein 
Saver Card, and the FTA Classic Card, which were stored at -80°C overnight, then 
guanidine based extraction was performed followed by detection using QT-NASBA. The 
data in Table 4.7. demonstrates the variation between TTP for filter paper replicates 
with results ranging from a rapid TTP of 33.22 to negative, for the Whatman 903 
Protein Saver Card and 38.24 to negative for the FTA Classic Card within the same 
replicate group.  
 
Table 4.7. Time to positivity (TTP) values for amplification of Pfs25 mRNA using QT-
NASBA detecting 0.1 gametocyte/µL spotted onto Whatman 903 Protein Saver Card 
and FTA Classic Card. Nucleic acid was extracted using guanidine based extraction. 
 Filter paper type  
 RNA extraction method: Whatman 903 
Protein Saver Card 
FTA Classic Card 
Guanidine extraction 47.64 56.8 
  34.97 negative 
  negative negative 
  33.8 negative 
  33.22 38.24 
Number positive 4/5 2/5 
 
To attempt to gain an understanding of the variation seen with these extractions, TTP 
values for the same trend line samples included across 17 QT-NASBA experiments from 
this study were compared, as shown in Figure 4.6. The more concentrated gametocyte 
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densities, 106 and 105 were detected 100% (17/17), which decreased to 94.1% (16/17) 
for 104 and 103 , and furthermore, 76.5% for 102 (13/17), and 58.8% for 101 (10/17). 
 
 
 
Figure 4.6. Time to positivity (TTP) values for titrated gametocyte trend line samples 
performed across multiple experiments. Trend line samples were titrated from 106-101 
gametocytes/mL. Time is expressed as minutes. This data was sourced from 17 QT-
NASBA experiments performed for the publication within this chapter, samples were 
extracted using guanidine based extraction. Mean TTP values are shown (indicated by 
the central dots) with bars indicating the 95% confidence interval.   
 
The confidence intervals indicate high variation in detection time for the lower 
gametocyte densities. This is likely to reflect normal stochastic variation seen when 
detecting very low density material. Therefore, not all replicates with low density 
gametocytes would be expected to be positive. Additionally, the use of small volumes 
of extracted nucleic acid (2.5µL) further amplifies the random element of a QT-NASBA 
reaction actually containing gametocytes, and producing a positive result.  Due to this 
wide variation observed at low gametocyte densities, it was decided to display 
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qualitative results (gametocyte prevalence) instead of quantitative results (gametocyte 
density) for the publication in this chapter.  
Performance of QT-NASBA for detection of low density gametocytes spotted onto filter 
papers stored under different temperature conditions is discussed in the attached 
publication. For detection using QT-NASBA, RNA was not treated with a DNA digest. 
 
4.64 Methods: Reverse transcription polymerase chain reaction (RT-PCR) 
 
RT-PCR was conducted from RNA (extracted using guanidine based extraction) that 
had been treated with the DNA digest (DNA Free). RT-PCR was performed using Illustra 
Ready to go RT-PCR beads (GE Healthcare, Buckinghamshire, UK) and primers designed 
by Professor Colin Sutherland. Asexual controls were performed for each sample to 
ensure contaminating DNA was not response for amplification. Reactions were set up 
as follows. Reaction tubes containing mastermix beads were maintained on ice while 
the following was added per reaction, 2.5µL of primer 2F (10µM- 
TAATGCGAAAGTTACCGTGG), 2.5µL of primer 1R (10µM- TCCATCAACAGCTTTACAGG) 
and 37.5µL of nuclease free water. This was incubated for 5 minutes at room 
temperature to allow the lyophilized bead to dissolve. At this point, the asexual control 
reactions (only) were incubated at 95°C for 10 minutes to inactivate the reverse 
transcriptase, then aliquots were cooled on ice and the protocol was continued. For all 
samples, 7.5µL of RNA template was added, then reactions were inserted into the 
thermocycler (C1000, Thermal Cycler, BioRad, Hertfordshire, UK), and the following 
was performed to synthesise cDNA from the RNA: 42°C for 30 minutes, then 95°C for 5 
minutes to inactivate the enzyme. Without removing reactions from the thermocycler, 
the primary PCR reaction was performed using the following conditions: 94°C for 2 
minutes, then 45 cycles of (94°C for 30 seconds, 52°C for 1 minute, then 68°C for 2.5 
minutes). The nested PCR reaction was assembled as shown in Table 4.8. using the 
following primers, 6F (AACCATGTGGAGATTTTTCC) and 7R (ACATTCTTACATTCATTTGG). 
The italicized reagents were added to the reaction tubes, then the following 
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amplification conditions were performed: 94°C for 2 minutes, then 30 cycles of (94°C 
for 30 seconds, 52°C for 1 minute and 68°C for 2.5 minutes).  
Table 4.8. Pfs25mRNA RT-PCR mastermix reagents and volumes. 
Reagent Volume for 1 reaction (µL) 
Nuclease free water (Ambion) 8.5 
GoTaq Greenmastermix (Promega) 12.5 
6F primer (10µM) 1.0 
7R primer (10µM) 1.0 
 
Mastermix total 23.0 
Primary PCR product (added separately) 2.0 
 
Positive reactions produced a product of ~125 base pairs in size which was visualized 
on a 2% TBE gel (Figure 4.7.) using Hyper ladder I 100 base pair molecular ladder 
(Bioline, London, UK) as a size marker. In the instance of a positive result for the DNA 
control, the DNA digest was repeated increasing the volume of rDNase I to 4µL to 
eliminate all remaining contaminant DNA. 
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Figure 4.7. RT-PCR positive and negative control results using novel primers. Lane 1: 5µL 
of Molecular ladder Hyperladder I (100 base pairs (b.p.), Bioline, Lane 2: 2µL of 
amplified positive control (~125 base pairs), lane 3:  2µL of amplified negative control. 
Visualized on a 2% TBE gel.  
 
 
4.65 Results: Performance of RT-PCR    
 
Performance of RT-PCR for detection of low density gametocytes spotted onto filter 
papers stored under different temperature conditions is discussed in the attached 
publication. 
 
4.66 Results: Comparative sensitivity of RT-PCR and QT-NASBA 
 
This study was devised to compare extraction and detection of gametocytes from filter 
papers stored under a temperature range rather than conclude on a limit of detection 
for the molecular detection methods, hence why lower gametocyte densities were not 
included. However, to give an indication of the relative sensitivity of the methods, 
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detection was compared for samples on Whatman 903 Protein Saver Cards and FTA 
Classic cards stored at -20°C or -80°C, for 3 months which were extracted by guanidine 
based extraction, Table 4.9.  
Table 4.9. Comparison of detection of low density gametocyte samples stored frozen 
on filter papers using RT-PCR and QT-NASBA. Nucleic acid was extracted from 50µL 
blood spots using guanidine based extraction. Eight replicate samples were stored on 
Whatman 903 Protein Saver and 8 on the FTA Classic Card per gametocyte density 
(data are consolidated). Half the filter papers were stored at -80°C and the other half 
at -20°C. n/N of detected replicates is shown in the table with percent detection in 
brackets, and the corresponding p-value comparing detection with RT-PCR and QT-
NASBA. 
 Gametocytes/µL 
 
 10  1.0  0.1 
QT-NASBA 16/16 (100%) 12/16 (75.0%) 12/16 (75.0%) 
RT-PCR 15/16 (93.8%) 4/16 (25.0%) 9/16 (56.3) 
p-value 0.310 0.005 0.264 
 
While QT-NASBA does not consistently show a statistically significant higher level of 
detection compared to RT-PCR, when comparing combined gametocyte density results 
QT-NASBA is significantly more sensitive when considering both the results in this table 
(p=0.007) and for the experiment outlined in the publication (p=0.042). Possibly, the 
lower sensitivity for RT-PCR could be partly attributed to loss of RNA during the DNA 
digestion step. 
 
4.7 Linking methods and results: Detection of Pfs25mRNA from filter paper 
blood spots collected in an endemic setting 
 
4.71 Methods: Detection of Pfs25mRNA from filter paper blood spots collected on 
Whatman 3MM in an endemic setting  
 
To extend the research shown in the publication using cultured gametocytes handled 
in a laboratory environment, to field isolates collected in an endemic setting, RNA was 
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extracted from 48 Whatman 3MM filter paper blood spots collected in Kanungu, by 
staff from Mulago Hospital, Kampala, Uganda. Whole blood was dabbed from finger 
prick onto filter papers which were air dried overnight. Filter papers were then stored 
in individual sealable plastic bags along with desiccant and were kept at room 
temperature for several months before being transferred to -20°C. Nucleic acid was 
then extracted as before using guanidine based extraction followed by Pfs25mRNA 
detection using QT-NASBA. 
 
4.72 Results: Detection of Pfs25mRNA from field collected samples stored on 
Whatman 3MM filter paper 
 
Pfs25mRNA was successfully detected in nucleic acid extracted from blood spots 
stored on Whatman 3MM collected in an endemic setting. While accurate parasite 
counts and demographic information are currently not available for these samples, 
33.3% (16/48) of individuals were positive for gametocytes, indicating it seems 
possible to detect field collected gametocytes from the Whatman 3MM filter paper. 
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4.8 Extended discussion 
 
As discussed in the publication, this chapter aimed to identify the optimal combination 
of methods for collecting, extracting and detecting low density gametocytes. The range 
of gametocyte densities and incubation conditions selected in this study demonstrated 
decay of mRNA and subsequent loss of detection sensitivity in suboptimal sampling 
and storage conditions, which enabled discrimination of better performing filter 
papers, the 903 Protein Saver and the Whatman 3MM, the most user friendly  
extraction RNA method, guanidine-based extraction, and the more sensitive detection 
method, QT-NASBA.  
 
4.81 The suitability of filter papers for RNA storage and extraction 
 
The most surprising findings from this chapter was the poor detection of gametocytes 
from the FTA classic card and the good detection from the Whatman 3MM. The FTA 
classic card preserved RNA best when stored at -80°C, then detection sensitivity 
decreased with warmer incubation temperatures. Incomplete filter paper drying also 
impacted most on detection from the FTA classic card, with no RNA detected from any 
filter papers stored wet. These results question the applicability of use of the FTA card 
in the tropics where exposure to high temperature and moisture is expected.  
This study importantly revealed that Whatman 3MM filter paper is suitable for RNA 
collection. These results are new and promising since this filter paper is commonly 
used in epidemiological studies for DNA and antibody collection. The duration of filter 
paper storage was fairly short (3 months, plus 1 week) but it now seems plausible that 
gametocytes could be detected from retrospectively collected filter papers.  However, 
since little is known about long term degradation of mRNA from historically collected 
filter papers, this idea must be approached with caution, since it could be difficult to 
interpret if negative results were truly negative or the result of degraded undetectable 
mRNA. A safe approach to testing this could be to evaluate batches of samples that 
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have been collected and stored under the same conditions for the same amount of 
time.  
Furthermore, in this chapter I provided evidence that detection from Whatman 3MM 
extends from laboratory prepared samples by indicating gametocytes can also be 
detected from blood samples collected on Whatman 3MM in an endemic setting. 
Gametocyte detection from Whatman 3MM was unexpected as this filter paper is 
made from standard cellulose, is not endorsed for RNA collection and is the cheapest 
of the 3 evaluated papers at $2 for 100 papers. Using the Whatman 3MM, collection of 
gametocytes is now more affordable compared to the filter papers specifically 
marketed, or previously used for RNA collection, such as the FTA Classic Card ($400 for 
100), or the 903 Protein Saver Card ($133 for 100).  
 
4.82 My findings in context of recent research 
 
At the time of submitting this manuscript, another study was published that also 
demonstrated RNA could be preserved and detected from Whatman 3MM filter paper. 
My study supports their findings but builds upon it by providing a more comprehensive 
comparison of several filter papers and using a wider range of incubation conditions, 
while comparing 2 molecular detection techniques.  
In contrast to the Whatman 3MM and 903 Protein Saver Cards, the FTA Classic Card is 
specifically marketed for nucleic acid collection. According to Whatman, the filter 
paper contains reagents that stabilize nucleic acids and protect them from damage by 
oxidation, enzymatic activity and UV light (Whatman 2013). In my study, detection of 
sample eluted from the FTA Classic Card was found to be less sensitive, compared to 
the other filter papers.  In contrast, the study by Pritsch et al, found no difference for 
detection from the FTA Classic Card, compared to the 903 Protein Saver Card and the 
3MM, but papers were stored for just 1 day at room temperature (Pritsch, Wieser et 
al. 2012). Another study published more recently by Wampfler et al  found poor 
detection from the FTA Classic Card,  which is in line with my findings, and the authors 
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judged the elution step to be the major stumbling block for RNA retrieval from this 
paper Felger, personal communication, (Wampfler, Mwingira et al. 2013).  
It was assumed using filter paper samples instead of whole blood would result in a 
trade off with reduced sample detection for a more user friendly collection method. In 
this study, there was similar or better detection from filter paper collected RNA 
compared to whole blood in L6 RNA stabilizing buffer. This was unexpected as it is 
assumed some RNA would be lost during sample elution.  While previous studies have 
shown RNA can degrade over a period of 2 weeks when stored at -20°C in L6 lysis 
buffer, it should be more stable when stored at -80°C (Damen, Sillekens et al. 1998; 
Schneider 2006). Interestingly, Pritsch et al. had the same finding that samples were 
better detected from filter papers compared to whole blood. In their study, they 
suggested this could be due to the presence of single stranded DNA, not RNA. To test 
this, they divided samples into two groups and subjected them to either a DNAse or 
RNase digest. Samples digested with RNAse all produced negative results, whereas 
those digested with DNAse remained positive, confirming it was RNA that was 
detected. Similarly, interaction between fresh blood and extraction kit reagents were 
ruled out, since the same detection sensitivity was obtained for filter paper and 
gametocyte spiked medium (Pritsch, Wieser et al. 2012). The higher detection seen 
from filter papers has been suggested to be the result of improved red blood cell lysis, 
which may occur during sample drying (Pritsch, Wieser et al. 2012).  
 
4.83 Potential contributors to good and poor gametocyte detection from filter paper 
 
While all 3 filter papers are made of cellulose, the key differences are filter paper 
thickness and whether the paper has undergone pre-treatment with nucleic acid 
preserving chemicals. Detection was best from the Whatman 3MM or the 903 Protein 
Saver Card, and worst from the FTA Classic Card. The Whatman 3MM is thinnest at 
335µM, the FTA card is between 480-580µM and the 903 Protein Saver is thickest at 
520µM (Personal communication, Whatman representative).  It seems logical the 
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thickness of the card is not negatively impacting sample elution as detection is 
comparable for the 3MM and the 903 Protein Saver Card. Therefore it seems plausible 
that the remaining difference, impregnation of the FTA card with RNA stabilizing 
buffers is contributing to poor extraction and/or detection. According to Whatman, the 
FTA Card has been treated with sodium dodecyl sulphate (SDS) detergent, a buffering 
agent, a metal ion chelator and a compound that neutralizes free-radicals (Whatman 
2013). Following sample drying the nucleic acids are supposedly immobilized within 
the fibres of the card (Personal communication, Whatman representative). Possibly, 
the GuSCN based lysis buffer is not sufficient to mobilize nucleic acids out of the paper 
matrix, which could be resulting in incomplete elution. Whilst Whatman do provide a 
specific purification reagent buffer for the FTA Card, it was not used due to the 
significant cost which prevented it being useful for large epidemiological surveys. This 
reagent has been tested in other studies where its use was discontinued due to 
unsatisfactory RNA yield, and high cost (Wampfler, Mwingira et al. 2013).  
The 3MM paper is primarily used for blotting and chromatography and is designed to 
have rapid wicking (Whatman 2013). As a consequence, this paper is thinnest which is 
evident from the wider diameter a 50µL sample produces, compared to the other 
papers. Possibly, the good detection from this paper could be partly attributed to the 
larger surface area a sample occupies which is resulting in better contact with elution 
buffer, and therefore more complete elution and better downstream detection.   
Filter papers that were not properly dried were very difficult to detect mRNA from. 
The loss in detection could be attributed to mRNA degradation or incomplete sample 
elution.  As addressed in the publication, exposure to heat and moisture may cause 
damage by allowing nicks to form in the RNA strand (Dobbs, Madigan et al. 2002; 
Moscoso, Raybon et al. 2005). Successful elution can be confirmed by visual inspection 
of the filter paper, which should be white following this step.  Many of the FTA cards 
evaluated under wet conditions remained red following elution, which implies at 
minimum, there is still haemoglobin bound to the filter paper matrix, and possibly also 
mRNA.  
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4.84 The RNA extraction methods 
 
Two RNA extraction methods were initially compared with the objective of identifying 
one as being more sensitive, cost effective and amenable to high throughput testing. 
While it could be assumed samples processed with the Qiagen kit might result in 
better detection as reagents are supplied, therefore reducing operator error, it is 
possible use of columns can result in reduced yield. It has previously been indicated 
that small RNA fragments may remain in the spin column matrix following extraction. 
Use of larger weight carrier RNA has been suggested as a solution that improves 
binding of the target RNA, while protecting it from degradation, therefore resulting in 
improved yield (Qiagen 2010). While carrier RNA was not used in this study, it may 
have improved the Qiagen extraction protocol, although since Pfs25 is larger in size 
(654 nucleotides) this target may not suffer this problem. Detection from guanidine 
and Qiagen extracted gametocytes were found to be comparable, but guanidine based 
extraction was used for the study due to cheaper cost.  
 
4.85 Gametocyte molecular detection methods 
 
RT-LAMP was initially included as a 3rd molecular detection method for comparison. 
Whilst unknown at the time, the problems experienced in this study with EDTA causing 
false positive results, can be avoided by using heparin as an anticoagulant in the blood 
collection tubes (Francois, Tangomo et al. 2011). However, this would have deemed 
the material less suitable for RT-PCR (unless treated with heparinise), since heparin 
interferes with reverse transcriptase (Bai, Fischer et al. 2000). While poor inter reader 
agreement lead to discontinued use of RT-LAMP, results were determined by eye, and 
microplate reader (which has not been extensively validated as a method).  Possibly if 
a turbidimeter had been available this technique may have been adequate.  
QT-NASBA has clear advantages over RT-PCR (other than being more sensitive, 
overall), such as fewer steps and no need for the DNA digest, during both of which RNA 
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may be lost. Due to the necessity to include a DNA digest and non- reverse 
transcriptase control to confirm specificity of positive results, RT-PCR is not only twice 
as expensive (using the Ready to Go kit) but takes approximately 1 day to process 48 
samples, compared to 2.5 hours for QT-NASBA.  
Despite these disadvantages, the sensitivity of RT-PCR was improved using new 
primers, which often detected 0.1 gametocytes/µL, compared to the detection limit of 
1-2 gametocytes/µL for the previously published primers (Mlambo, Vasquez et al. 
2008). Although the cost of the QT-NASBA Real Time equipment is high, which does 
restrict use to more affluent laboratories, it was found to be both faster and cheaper 
per sample. Despite the high level of sensitivity of molecular techniques, studies have 
still reported infected mosquitoes from gametocyte negative (by microscopy and QT-
NASBA) samples, but this is likely to be the result of RNA degradation in samples, or 
just very low gametocyte densities (Schneider, Bousema et al. 2006). It is important to 
note, the sensitivity of molecular detection is limited by the volume of blood that is 
processed and by increasing this volume, the sensitivity may also increase.  
 
4.86 QT-NASBA gametocyte detection versus quantification  
 
In this study, gametocyte prevalence was used as the QT-NASBA outcome to compare 
molecular detection methods, rather than gametocyte density.  While I felt confident 
about the accuracy of gametocyte detection, there was variation in quantitative 
readings between sample replicates of the same density. The use of QT-NASBA as a 
qualitative method was questioned by a peer reviewer but it was considered justified 
for our purposes. Firstly, the majority of epidemiological surveys focus on the 
prevalence of gametocyte infections, not the densities (which fluctuate daily) and filter 
paper collection is the most convenient sampling medium for large surveys in remote 
settings. While it is important for some studies to have accurate gametocyte density 
counts, such as clinical trials looking at effects of gametocydical drugs, these studies 
are more likely to have the facilities for storing RNA in stabilizing buffer at -80°C and 
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would therefore not rely on filter papers for sample collection. Secondly, from this 
study, and since confirmed by others, it came to light there are concerns with reliable 
quantification of mRNA using TTP values generated by QT-NASBA and a high degree of 
variation has been seen at low gametocyte concentrations (Churcher, Bousema et al. 
2013; Dinko 2013).  It is important to note NASBA was originally developed as a 
qualitative method that has since been adapted to quantitative measuring and still 
needs some refining (Compton 1991). Furthermore, since Pfs25mRNA is thought to be 
a female specific marker or at minimum more abundantly expressed in female 
gametocytes, this also contributes to the uncertainty around these density 
estimations, and what precisely is being measured, and how representative it is of 
total gametocyte load (Schneider, Bousema et al. 2006).  
Previous studies have reported uncertainty around gametocyte density estimates 
when using QT-NASBA and it has been highlighted that confidence intervals and 
standard errors are rarely revealed (Churcher, Bousema et al. 2013). I have shown the 
confidence intervals for trend line values, which have the largest number of replicates 
at the same density, to demonstrate variation.  It has been speculated this intra assay 
measurement error could be attributed to varying enzyme efficiency, or inaccuracies 
from pipetting small volumes. But the most likely reason can be explained by the 
‘ onte Carlo effect’  which su  ests that the presence or absence of template in a low 
density sample is random (Wampfler, Mwingira et al. 2013). In this experiment, the 
gametocyte densities used are very low, and it is likely the variation simply reflects 
that there may or may not be a gametocyte in the reaction. Furthermore, small 
volumes of template are used for molecular detection, which further decreases the 
likelihood of there being a gametocyte in the reaction to detect.  Due to these 
concerns, gametocyte prevalence was presented, rather than gametocyte density as 
this was the most robust version of the results. 
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4.87 Future perspectives  
 
While performed under controlled conditions, this study was devised, to answer 
specific sampling questions to plan for gametocyte collection in the field. The 
incubation time of up to 3 months was selected for logistical reasons but may not 
necessarily represent the longest time filter papers would be left before being 
processed. Detection was compared from papers incubated for 1 week and 1 or 3 
months and no statistically significant difference was found between the 2 time points. 
Whilst useful in the scope of shorter epidemiological studies, this time frame is too 
short for surveys that may wish to bank filter paper samples for years before 
processing them. While a study by Wampfler et al. incubated filter papers for up to 2 
years, they firstly excised blood spots and diluted them in Trizol, therefore good 
detection could be attributed to stabilization of the buffer and not the filter paper, so 
this study also does not answer questions about long term storage using just filter 
papers.  
To build upon research in this chapter, it would be valuable to repeat the study, 
focusing on the Whatman 3MM paper using longer incubation periods. It would be 
useful to look at the effect of freeze thawing the papers which would likely occur if for 
example, if papers are stored at -20°C in the field, shipped at room temperature, 
frozen on arrival, then finally thawed before processing, as the effect of condensation 
is likely to contribute to mRNA degradation.   
 
4.88 Conclusions 
 
This study indicates filter papers are appropriate tools for detection of low density 
gametocytes, which importantly highlights that routinely, possibly retrospectively 
collected filter papers can be used for gametocyte detection. In my hands the FTA 
classic Card performed poorly, unless stored under optimal conditions, but the 903 
Protein Saver Card was found to be appropriate for use. Detection from the Whatman 
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3MM performed equally well compared to the 903 Protein Saver Card, but needs to be 
evaluated under the full range of conditions. Whilst the Qiagen Kit and guanidine 
based extraction were comparable in terms of detection, the guanidine extraction 
method is cheaper and more amenable to high throughput. With the new primers, RT-
PCR was more sensitive than the previously reported primers (Mlambo, Vasquez et al. 
2008), but QT-NASBA was more sensitive overall. The cheaper cost per reaction and 
faster turn-around time made QT-NASBA more amenable to high throughput.  
What is evident from this study is that careful handling of filter papers is imperative to 
successful sample elution, extraction and detection. Filter papers must be handled 
with gloves at all times. Thorough drying of filter papers in the most sterile 
environment possible and storing them in sealable plastic bags with desiccant is 
recommended for all filter papers. When implementing filter paper sampling for RNA 
in the field, it is important to ensure health care workers have been properly trained in 
correct collection, drying and storage of papers prior to beginning a study.  
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Chapter 5: Assessing naturally acquired antibody responses to 10C and 
230CMB transmission blocking vaccine candidates in endemic settings 
 
5.1 Introduction to the manuscript 
 
Previous studies assessing recognition of native sexual stage proteins, Pfs48/45 and 
Pfs230 have confirmed antibody presence in malaria exposed populations in endemic 
settings, but provided conflicting evidence regarding patterns of antibody acquisition 
following exposure to gametocytes, as discussed in section 1.36. (Bousema, Roeffen et 
al. 2006). Gaining an understanding of how these antibodies are acquired, and their 
functionality may provide insight into how a TBV based on the same antigens may 
function in an endemic setting. Cumulative antibody exposure (over time) would be 
reflected by an increase in antibody prevalence with age (Bousema, Roeffen et al. 
2010). In contrast, a short lived antibody response would be reflected by no obvious 
age pattern, or an age dependent decrease in antibody response that is associated 
with immune control of asexual, and therefore sexual stage parasites densities, 
resulting in lower antigen exposure (Drakeley, Bousema et al. 2006). While an age 
dependent antibody pattern remains uncertain, previous studies indicated antibodies 
to native proteins Pfs48/45 and Pfs230 are acquired following exposure and are 
associated with functional transmission reducing activity that results in a reduction of 
oocyst prevalence or density in mosquitoes (Bousema, Roeffen et al. 2006). This 
information is highly relevant with regard to vaccines targeting pre-fertilization 
antigens (expressed on gametocytes) that may benefit from boosting of immunity 
following natural exposure (Chowdhury, Angov et al. 2009).  
While antibody prevalence has been explored for native proteins, the laboriousness of 
the production of native antigen for these assays has hindered large-scale 
epidemiological surveys. This chapter focuses on the assessing the recognition and 
functionality of two new recombinant transmission blocking vaccines that are under 
development and were briefly described in section 3.11. Both Pfs48/45 and Pfs230 are 
well established vaccine candidates due to their essential role in parasite fertilization. 
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However the development of recombinant antigens has been complicated by the large 
number of disulphide bonds in both proteins (van Dijk, Janse et al. 2001; Eksi, Czesny 
et al. 2006). Since the majority of sexual stage B cell epitopes depend on tertiary 
structures, correct protein folding is critical to the induction of functional antibodies 
(Theisen, Roeffen et al. 2014).  
 
5.12 The recombinant vaccine candidates 
 
MBP-10C was the primary vaccine candidate produced under the REDMAL 
collaborative project that this thesis supports. The C-terminal 10C fragment was 
selected as the subunit for this vaccine candidate since it induced the highest titres of 
functional transmission blocking antibodies and was the most stable product when 
stored following production (Outchkourov, Roeffen et al. 2008). MBP-10C was over 
expressed in E. coli along with 4 folding catalysts (chaperone proteins) which ensured 
that folding occurred within the periplasmic space which has the optimal redox 
environment for correct formation of disulphide bonds (Outchkourov, Roeffen et al. 
2008). Due to complications with this candidate, which are discussed in this chapter, 
MBP-10C was replaced with polyvalent candidate R0-10C (see Figure 3.1. for candidate 
schematic) (Theisen, Roeffen et al. 2014).  
R0-10C vaccine candidate contains an asexual and transmission blocking component 
and therefore may have the benefit of inducing immunity that both protects the 
vaccinated individual and provides community level protection (Theisen, Roeffen et al. 
2014). Furthermore, the transmission blocking component may help protect the 
asexual component by reducing the likelihood of vaccine escape mutants (Theisen, 
Roeffen et al. 2014). In addition to altering the fusion partner, R0-10C was produced in 
Lactococcus lactis, which was selected due to previous successful use for good 
manufacturing practice (GMP) production of GMZ2 and LSA3 among other antigens 
(Esen, Kremsner et al. 2009). Since L. lactis has no chaperones, correct protein folding 
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is entirely dependent on the fermentation process. To enable quantification of 10C 
antibodies in this chapter, R0 was cleaved first. 
The second candidate 230CMB, introduced in section 3.11., was produced by 
Fraunhofer, USA (Farrance, Rhee et al. 2011).  Functionality was demonstrated in 
vaccinated rabbits which produced high titres of antibodies that resulted in >99% 
reduction in oocyst density in the presence of complement (Farrance, Rhee et al. 
2011). While 10C was the focus of the REDMAL project and this thesis, since Pfs48/45 
and Pfs230 occupy similar functional niches and 230CMB recombinant antigen was 
kindly supplied, natural antibody responses were explored for both. 
 
5.13 Genetic polymorphisms 
 
Since 10C and 230CMB are exposed to host immunity during clearance of infected 
erythrocytes, they may also be subject to selection pressure and therefore be 
antigenically diverse (Takala and Plowe 2009). Vaccines are often produced using just 
one allele variant, therefore it is extremely important to assess genetic polymorphisms 
of the target antigen in the population prior to selecting an allele/alleles for vaccine 
development (Barry, Schultz et al. 2009; Takala and Plowe 2009). Previously, genetic 
polymorphisms have led to vaccine failure, for example the strain of MSP-2 used in the 
Combination B malaria vaccine only protected against that strain and enabled escape 
of other variants which ultimately led to vaccine failure (Klenerman and Zinkernagel 
1998; Genton, Al-Yaman et al. 2003; Dutta, Lee et al. 2007). While it has been 
suggested sexual stage antigens (especially post fertilization targets, such as Pfs25) are 
not as immunogenic or polymorphic as asexual stage antigens (such as AMA-1, or MSP-
1 and 2), polymorphisms have still been identified in 23 out of 449 amino acids in 
Pfs48/45 (Escalante, Grebert et al. 2002; Struik and Riley 2004; Takala and Plowe 
2009). The implications of these polymorphisms are unknown but previous studies 
assessing transmission reducing immunity in The Gambia and Cameroon speculated 
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immunity of variable function could be due to sequence polymorphisms in pfs48/45 
(Drakeley, Mulder et al. 1998).  
 
5.2 Objectives 
 
This chapter has five main objectives.  
1. Optimize and validate an ELISA assay to enable quantification of antibody 
responses against 10C and 230CMB recombinant antigens. 
 
2. Assess if there are naturally acquired antibodies to 10C and 230CMB vaccine 
candidates in school aged children in 3 malaria endemic settings in Africa.  
 
3. Determine whether the acquisition of antibody responses to 10C and 230CMB 
is dependent on age, season, transmission intensity and concurrent parasite 
carriage in 3 malaria endemic settings in Africa.  
 
4. Explore the relationship between transmission reducing activity and 10C and 
230CMB antibody prevalence and density, using supportive datasets with 
mosquito membrane feeding data. 
 
5. Assess the presence (or absence) of polymorphisms in the pfs48/45 gene, with 
special consideration to the 10C (subunit of Pfs48/45) vaccine region, in 
samples from 3 malaria endemic settings. 
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5.3 Manuscript: Naturally acquired antibody responses to recombinant 
Pfs230 and Pfs48/45 transmission blocking vaccine candidates 
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Abstract.    
 
Pfs48/45 and Pfs230 are P. falciparum sexual stage proteins and promising malaria 
transmission-blocking vaccine candidates. These proteins are expressed by 
gametocytes while in the human bloodstream and, consequently, antibody responses 
may be naturally acquired and target antigens may be under selective pressure. This 
has consequences for the future evaluation of vaccine immunogenicity and efficacy in 
populations naturally exposed to malaria. We determined naturally acquired antibody 
responses to the recombinant proteins Pfs48/45 -10C and Pfs230-230CMB in children 
from three malaria endemic settings in Ghana, Tanzania and Burkina Faso. We also 
examined genetic polymorphisms in the P. falciparum gene pfs48/45. Antibody 
prevalence was 1.1-18.2% for 10C and 6.7-18.9% for 230CMB. Antibody responses 
were markedly lower for these sexual stage antigens compared to responses against 
asexual stage malaria antigens. In Burkina Faso we observed evidence of an age-
dependent acquisition pattern for both 10C (p<0.001) and 230CMB (p=0.031). 
Membrane feeding assays confirmed transmission reducing activity of antibodies for 
both 10C (p=0.017) and 230CMB (p=0.049). 17 single nucleotide polymorphisms were 
found in pfs48/45 (from 126 samples), with 5 non-synonymous SNPs in the Pfs48/45 
10C region. We conclude there are naturally acquired antibody responses to both 
vaccine candidates which have functional relevance by reducing the transmissibility of 
infected individuals. We identified genetic polymorphisms, in pfs48/45 which exhibited 
geographical specificity.  
Keywords:  
Plasmodium falciparum, gametocyte, gamete, transmission, immunity, polymorphism 
Abbreviations: 
SNP (single nucleotide polymorphism), MTBV (Malaria transmission blocking vaccines), 
TRA (transmission reducing activity), RDT (rapid diagnostic test), GLURP (glutamate rich 
protein), SMFA (standard membrane feeding assay), MSP-2 (merozoite surface 
protein-2), MOI (multiplicity of infection). 
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INTRODUCTION 
 
The recent decline in the burden of malaria, particularly in sub-Saharan Africa has re-
emphasized elimination as an attainable goal for many malaria endemic countries 
(Ceesay, Casals-Pascual et al. 2008; Barnes, Chanda et al. 2009; World Health 
Organization 2012). Novel malaria control strategies that specifically aim to reduce 
malaria transmission may be required to move from malaria control to elimination 
(Okell, Griffin et al. 2011). Malaria transmission blocking vaccines (MTBV) are high on 
the priority list for malaria elimination and eradication strategies (Sauerwein 2007; 
Targett and Greenwood 2008; Griffin, Hollingsworth et al. 2010). The transmission of 
malaria from man to mosquito depends on the presence of mature sexual stage 
parasites, gametocytes, in the human peripheral blood.  Once ingested by blood 
feeding mosquitoes, male and female gametocytes activate to become gametes that 
fuse to form zygotes that penetrate the mosquito midgut wall as ookinetes to form 
oocysts. These oocysts enlarge over time to release sporozoites that migrate to the 
mosquito salivary glands and render the mosquito infectious to human beings upon 
their next feeding. MTBV aim to elicit antibodies that are passively ingested when a 
mosquito takes a blood meal which reduce or arrest parasite development, thereby 
blocking transmission to the next host (Kaslow 1993). Transmission-blocking antigens 
can be categorized as those that play a role before zygote formation (pre-fertilization) 
and those that affect the subsequent development of mosquito stages (post-
fertilization). Pre-fertilization proteins Pfs48/45 and Pfs230 are both found on the 
surface of gametocytes and become exposed in humans (Vermeulen, Ponnudurai et al. 
1985; Kaslow 1993). This exposure allows the acquisition of immune response during 
natural malaria infections. Antibody responses to both proteins have been detected in 
naturally exposed populations and have been associated with functional transmission 
reducing activity (TRA) (Bousema, Roeffen et al. 2006; Drakeley, Bousema et al. 2006; 
Bousema, Roeffen et al. 2010). Immune recognition may also result in selective 
pressure that gives rise to genetic polymorphisms associated with reduced 
susceptibility of parasites to natural or vaccine-induced immune responses. For 
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pfs48/45, 5 main non synonymous genetic polymorphisms have been described 
previously with clear geographical clustering (Conway, Machado et al. 2001). Both the 
presence of naturally acquired antibody responses and genetic polymorphisms in 
vaccine protein regions are of great importance for the planning and evaluation of 
vaccine trials in naturally exposed populations.  
Here we determine for the first time, naturally acquired antibody responses to MTBV 
candidates Pfs48/45-10C and Pfs230-230CMB, assess their functionality and describe 
genetic polymorphisms in local isolates of pfs48/45.  
 
MATERIALS AND METHODS 
 
Study areas and populations 
 
Three study sites were selected to reflect different levels of transmission intensity: a 
site of hyper endemicity in Ouahigouya, Burkina Faso, meso endemicity in 
Bondo,Tanzania and hypo endemicity in Asutsuare in Ghana. One hundred and eight 
children were randomly sampled from 1 school in Ghana, which was 200 children  
sampled in total across 2 schools in Burkina Faso and 202 children sampled in total 
across 2 schools in Tanzania using strategies described by Brooker et al (Brooker, 
Kolaczinski et al. 2009). Two cross sectional surveys were conducted during the peak 
transmission season and at the end of the dry season in 2011 and 2012 at each study 
site (Brooker, Kolaczinski et al. 2009). Ethical permission was granted from LSHTM 
(approval number 5946) and from local and national ethics committees in Burkina 
Faso  Tanzania and  hana  ritten consent was  ained fro  participant’s  uardians 
prior to sampling. At each survey, finger prick samples of approximately 300µL were 
taken in BD microtainers (Becton Dickinson, Oxford, UK) for microscopy, plasma 
collection and filter paper storage (Whatman 3MM, Maidstone, UK). Plasma was 
diluted to 1/20 in 0.05% sodium azide in phosphate buffered saline (PBS), which was 
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stored at -20°C until use. Blood spot filter papers were air dried overnight, then sealed 
into individual plastic bags with silica desiccant, and stored at -20°C until use. Parasite 
detection was done by microscopy and Rapid Diagnostic Test (RDT, Premier Medical 
First Response, India). Clinical decision making was based on the RDT result and all RDT 
positive individuals with reported fever in the past 24-48 hours were treated for 
malaria according to national guidelines.  Parasite counts were obtained by microscopy 
and slides were read by two independent microscopists, both examining 100 fields. 
Parasite densities were determined after reading against 1000 leukocytes. 
Questionnaires were administered to participants to gain details about malaria 
symptoms, bed net use and socio economic status.  
 
Antigens  
 
Pfs48/45-10C was obtained from the chimeric R0-10C vaccine protein produced at the 
cGMP-facility of Gennova, India, using the standard proposed medium composition as 
described by Theisen et al. (Theisen, Roeffen et al. 2014). The R0-10C vaccine protein 
includes 10 cysteine residues spanning epitopes I-III from the C terminal domain of 
Pfs48/45, fused to GLURP-R0. R0 was firstly cleaved from Pfs48/45-10C and successful 
removal of GLURP-R0 was confirmed by testing plasma samples from GLURP-
vaccinated volunteers (Hermsen, Verhage et al. 2007) (see supporting information). 
Pfs230-230CMB was obtained as a transmission blocking candidate that was 
developed by Fraunhofer USA Center for Molecular Biotechnology. The recombinant 
protein encompasses a conserved region including the pro-domain and part of the first 
cysteine residue of Pfs230, corresponding to amino acids 444-730 (Farrance, Rhee et 
al. 2011). Additional asexual stage antigens were included to contrast sexual stage 
antibody responses to asexual stage antibody responses. These recombinant asexual 
proteins were, apical membrane antigen (AMA-1 3D7, Biomedical Primate Research 
Centre, Rijswijk, the Netherlands), merozoite surface protein 119 (MSP-119 Wellcome 
allele, provided by Patrick Corran, London School of Hygiene & Tropical Medicine with 
 157 
 
permission of Tony Holder) and R2 region of GLURP, provided by Michael Theisen, 
Statens Serum Institut, Copenhagen. 
 
Enzyme linked immunosorbent assays  
 
10C and 230CMB antibodies were quantified as follows;  96 well Maxisorp NUNC plates 
(Nalge Nunc International Corp., Naperville, IL, USA) were coated overnight at 4°C with 
100µl per well of 0.1µg/ml of antigen diluted in PBS. Plates were blocked for 30 
minutes with 150µl of 5% non-fat skimmed milk (Marvel, Premier International Foods 
Ltd., Spalding, UK) in PBS. Following this, plates were washed 3 times with PBS, and 
100µl of test serum was diluted to 1/500 in PBS (with 1% milk and 0.05% Tween 20), 
and incubated on the plates for 4 hours at room temperature. Plates were then 
washed 3 times as before and incubated with 100µl per well of human-IgG-HRP (Pierce 
Biotechnology Inc., Rockford, IL, USA) diluted to 1/40,000 in PBS with 0.05%  Tween 
20, for 2 hours at room temperature. Next plates were washed 4 times, then 100µl of 
tetramethylbenzidine substrate (TMB) solution was added per well and incubated for 
20 minutes. Reactions were stopped using 50µl per well of 0.2M sulphuric acid and 
optical densities were measured at 450nm (Bio-Rad iMark Microplate Reader, 
Hertfordshire, UK). Serum from an expatriate with established high levels of sexual 
stage immune responses and functional transmission reducing activity (TRA) was used 
as a positive control (Saeed, Roeffen et al. 2008) and titrated from 1/200 in doubling 
dilutions 7 times to produce a standard curve. Antibody responses were quantified 
against asexual antigens MSP-119, AMA-1 and, GLURP as described elsewhere (Proietti, 
Verra et al. 2013). For all assays, averaged sample ODs were normalized (using the 
midpoint dilution as reference), against a titration curve fitted to the positive control 
sample by least squares minimisation using a three variable sigmoid model and 
assigning an arbitrary value of 1000u/mL to calculate titre (Drakeley, Corran et al. 
2005; Proietti, Verra et al. 2013). The mixture model was used to distinguish positive 
and negative samples by fitting test sample ODs to two Gaussian distributions using 
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maximum likelihood methods in STATA (Version 11, Statacorp, Texas, USA). The mean 
OD of the seronegative (the test samples with low ODs) population plus 3 standard 
deviations was used as the cut off value. This resulted in a cut off OD value above 
which a sample was considered antibody positive of; 0.17 for AMA-1, 0.23 for MSP-119, 
0.2 for GLURP, 0.35 for 10C and 0.44 for 230CMB (Corran, Cook et al. 2008; Bousema, 
Roeffen et al. 2010). 
 
Analysis of functional transmission-blocking immunity 
 
While it was not possible to perform membrane feeding assays in this study where 
small-volume finger prick blood samples were obtained, we performed 10C and 
230CMB ELISA on a sample set (n=58) with a known functional transmission-blocking 
phenotype in the standard membrane feeding assay (SMFA) (Bousema, Roeffen et al. 
2010). The methodology for SMFA is described in detail elsewhere (Bousema, Roeffen 
et al. 2010). Briefly, 3-5 day old Anopheles stephensi mosquitoes were offered a blood 
meal containing NF54 P. falciparum gametocytes with purified control serum or test 
sample at a final dilution of 1:3 in the feeder. Twenty blood-fed, surviving mosquitoes 
were dissected 7 days later and oocyst counts were made. Transmission reducing 
activity (TRA) was determined as the percentage reduction in arithmetic mean oocyst 
number in test samples as compared to paired controls. The test samples were taken 
from gametocyte positive individuals recruited from a health centre in a region of hypo 
endemicity in Lower Moshi, Tanzania (Bousema, Roeffen et al. 2010) of whom 32.8% 
blocked transmission of NF54 parasites by >50% and 15.5% by >90%.  
 
Sequencing of the pfs48/45 gene 
 
Samples were selected at random for sequencing of the pfs48/45 gene. In Burkina Faso 
and Tanzania, this selection was made from microscopy-positive parasite carriers. In 
 159 
 
Ghana, where microscopy data was not available at the time of sequencing, we 
selected samples regardless of asexual parasite presence but first confirmed parasite 
prevalence by nested PCR, which was performed according to standard methods 
(Baidjoe, Stone et al. 2013). In total we obtained 126 readable sequences for samples 
from Burkina Faso (n=39), Ghana (n=39) and Tanzania (n=48). Sequencing was 
performed as described elsewhere (Anthony, Polley et al. 2007). Briefly, DNA was 
extracted from filter paper blood spots using the QIAamp DNA Micro Kit (QiagenTM 
Hilden   er any) and the dried  lood spot protocol accordin  to anufacturer’s 
instructions. pfs48/45 was sequenced between nucleotides 44 and 1303  in 2 segments 
(Anthony, Polley et al. 2007). Firstly nested PCR was performed, then the secondary 
PCR product was purified using the QIAquick PCR purification kit (QiagenTM  Hilden, 
Germany), and sequencing PCR was performed using the BigDye V3.1 sequencing kit 
(Applied Biosystems, San Francisco, CA, USA). Products were ethanol precipitated then 
sequenced on an ABI3730 sequencer (Applied Biosystems, San Francisco, CA, USA), 
and chromatograms analyzed using CLC Sequence Viewer 6 (Cambridge, MA, USA). To 
gauge the number of clones per sample, MSP-2 genotyping of asexual parasites was 
performed using capillary electrophoresis as described elsewhere (Liljander, Wiklund 
et al. 2009; Schoepflin, Valsangiacomo et al. 2009). GeneMapper version 4.0 (Applied 
Biosystems, Paisley, UK) and FSTAT version 293 (Jérôme Goudet, Lausanne, 
Switzerland) software was used to analyze results and calculate the expected 
heterozygosity.  
 
Statistical analysis 
 
All statistical analyses were performed using STATA Version 11 (Statacorp, Texas, USA) 
and graphical presentation of data was done using GraphPadPrism Version 5 
(GraphPad Software Inc., La Jolla, USA). Study participants were categorized into 3 age 
categories; 3-8, 9-11 and >11 to determine age dependent antibody acquisition 
patterns   earson’s Chi Square and Spear an’s Rank were used to deter ine the 
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association between categorical and continuous variables; odds ratio’s with 95% 
confidence intervals (95% CI) and correlation coefficients were used to quantify effect 
sizes. Generalized estimating equations (GEE) were used to determine associations 
between antibody prevalence and age, season, site and parasite status, adjusting for 
multiple observations per individual.  
 
RESULTS 
 
A total of 208 samples were collected from Ghana (108 individuals), 521 from Tanzania 
(202 individuals) and 389 from Burkina Faso (200 individuals), from participants 
sampled during the peak transmission season and at the end of the dry season for 
Tanzania and Ghana, and during the peak transmission season and in the middle of the 
dry season for Burkina Faso (Table 5.0.). 
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Table 5.0. Characteristics of survey participants. IQR, interquartile range based on 25th and 75th percentiles, GM, geometric mean, CI, 
95% confidence interval. n=number positive, N=total number in category. This table contains data for participants where we know their 
age (38 people are missing from this table). 
  Burkina Faso Tanzania Ghana 
Age group <8.0 9-11 >11 <8.0 9-11 >11 <8.0 9-11 >11 
Number 195 163 22 40 175 305 55 58 67 
Age, median (IQR) 7 (6-8) 10(9-11) 12 (12-13) 8 (7-8) 10 (10-11) 14(12-15) 7 (6-8) 10 (9-10) 12 (13-14) 
Gender, % female 
(n/N) 
47.2  
(92/195) 
53.7 
(87/162) 
33.3  
(7/21) 
75.7 
(28/37) 
58.9 
(103/175) 
47.5 
(145/305) 
45.5  
(25/55) 
37.9  
(22/58) 
34.9 
(22/63) 
Asexual prevalence, 
% (n/N)   
38.0 
(74/195) 
40.7 
(66/162) 
38.1  
(8/21) 
22.5 
 (9/40) 
11.4  
(20/175) 
11.5 
(35/304) 
3.6  
(2/55) 
10.3  
(6/58) 
4.5  
(3/66) 
Asexual density,  
GM (IQR) 
970 
(245-2796) 
462 
(120-1196) 
818 
(397-2304) 
1204 
(1120-2707) 
501 
(128-1960) 
384 
(112-996) 
119 
(32-440) 
321 
(128-480) 
142 
(64-400) 
Gametocyte 
prevalence, % (n/N) 
9.7  
(19/195) 
10.5 
(17/162) 
9.5  
(2/21) 
2.5  
(1/40) 
2.3  
(4/175) 
1.3  
(4/305) 
0 
(0/55) 
0 
(0/58) 
0 
(0/67) 
Gametocyte density, 
GM (IQR) 
18.3  
(8-38) 
15.9  
(8-20) 
11.0 
 (8-15) 
8.0  
(8.0-8.0) 
16.0 
(8-40) 
33.8 
(24-56) 
n/a n/a n/a 
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The majority of children were sampled in both surveys, with 5.5-7.9% of children 
sampled just once.  Overall asexual parasite prevalence by microscopy was 39.2% 
(148/378) in Burkina Faso, 12.3% (64/519) in Tanzania and 6.1% (11/180) in Ghana; 
gametocyte prevalence was 10.1% (38/378) in Burkina Faso, 1.7% (9/520) in Tanzania 
and 0% (0/180) for Ghana. The prevalence of both asexual parasites (OR= 1.01, 95% CI 
0.94-1.09; p=0.70) and gametocytes (OR= 1.00, 95% CI, 0.88-1.15; p=0.94) did not vary 
significantly with age in this school-age population, after adjusting for season and 
study setting. Asexual parasite density in parasite positive individuals declined with 
increasin  a e (β=-0.079, se=0.022; p<0.001); and gametocyte density in gametocyte 
carriers was not associated with a e (β=-0.013, se=0.022; p=0.55), after adjusting for 
season and study setting. Asexual parasite prevalence was significantly higher in the 
transmission season compared to the dry season (OR= 2.00, 95% CI 1.50-2.68; 
p<0.001), but this seasonality was not observed for patent gametocyte prevalence 
(OR= 1.18, 95% CI 0.65 - 2.14 p=0.59), after adjusting for age and study setting.  
The complexity of infection was determined by MSP2 genotyping for a subset of the 
samples that were sequenced for pfs48/45, Ghana (n=27), Tanzania (n= 37), and 
Burkina Faso (n=34).  Multiplicity of infection (MOI) followed the same between-
country pattern as parasite prevalence: Ghana had the lowest MOI, with an average of 
1.96, followed by Tanzania with 3.35, and Burkina Faso with 3.88 (Table 5.1.).  
Table 5.1. Multiplicity of infection (MOI) and pfs48/45 sequencing results by study 
location. *A sub population of the sequenced samples were assessed to determine 
multiplicity of infection.  
 
 Burkina Faso Tanzania Ghana 
Number of analyzed samples (MOI) 34* 37* 27* 
Average number of clones 3.88  3.35  1.96  
% single clone infections 17.6  10.8  44.0 
Allelic richness 46.9 38.8 14.0 
Expected heterozygosity 0.973 0.970 0.903 
Number of analyzed samples (sequencing) 39 48 39 
Number of pfs48/45 haplotypes 15 21 11 
pfs48/45 haplotypes,% 3D7  17.9 50.0 69.2 
pfs48/45 haplotypes, % mixed clone 56.4 43.8 15.4 
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Allelic richness, a measure of genetic diversity, was lowest in Ghana (14.0), followed by 
Tanzania (38.8) and Burkina Faso (46.9). The heterozygosity index showed a similar 
pattern with 0.903 for Ghana, 0.970 for Tanzania and 0.973 for Burkina Faso (Table 
5.1.).  
 
Antibody responses in relation to age, parasite carriage and study setting 
 
Antibody profiles for asexual stage antigens AMA-1, MSP-119 and GLURP, and 
transmission blocking vaccine candidates 10C and 230CMB are shown in Table 5.2.  
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   Burkina 
Faso 
  Tanzania   Ghana  
Age group 
 
<8.0 9-11 >11 <8.0 9-11 >11 <8.0 9-11 >11 
AMA-1, prevalence 
(n/N) 
 
61.5 
(118/192) 
67.7 
(107/158) 
90.9 
(20/22) 
92.1 
(35/38) 
79.8 
(126/158) 
79.9 
(226/283) 
14.3 
(7/49) 
24.6 
(14/57) 
44.3 
(27/61) 
Titre, GM (95% CI) 909 
(728-1136) 
1129 
(896-1422) 
2364 
(1198-4667) 
1194 
(822-1738) 
827 
(678-1008) 
1080 
(928-1259) 
854 
(290-2520) 
700 
(395-1240) 
517 
(346-773) 
MSP-1, prevalence 
(n/N) 
24.2 
(47/194) 
 
26.5 
(43/162) 
15 
(3/20) 
32.5 
(13/40) 
40.8 
(71/174) 
44.6 
(136/305) 
18.9 
(10/53) 
0 
(0/58) 
19.7 
(13/66) 
Titre, GM (95% CI) 1179 
(844-1646) 
931 
(648-1338) 
548 
(187-1610) 
1106 
(656-1867) 
1300 
(1029-
1643) 
1085 
(926-1271) 
594 
(389-905) 
0 
(0-0) 
1240 
(821-1874) 
GLURP, prevalence 
(n/N) 
 
32.4 
(56/173) 
61.9 
(91/147) 
63.2 
(12/19) 
77.5 
(31/40) 
60.1 
(104/173) 
66.8 
(197/295) 
7.6 
(4/53) 
12.3 
(7/57) 
24.2 
(16/66) 
Titre, GM (95% CI) 968 
(728-1288) 
1433 
(1126-
1824) 
1317 
(528-3285) 
871 
(605-1255) 
879 
(739-1045) 
1195 
(1028-
1389) 
1116 
(156-7990) 
841 
(489-1446) 
539 
(382-761) 
10C, prevalence 
(n/N) 
8.33 
(16/192) 
28.1 
(45/160) 
31.8 
(7/22) 
18.8 
(6/32) 
11.8 
(17/144) 
 
16.5 
(43/261) 
 
1.82 
(1/55) 
 
0 
(0/57) 
 
1.5 
(1/66) 
 
Titre, GM (95% CI) 81 
(60-110) 
80 
(70-91) 
70 
(49-99) 
77 
(45-131) 
107 
(75-151) 
86 
(71-104) 
50 0 53 
230CMB, 
prevalence (n/N) 
6.8 
(13/192) 
16.8 
(27/161) 
22.7 
(5/22) 
12.5 
(4/32) 
13.2 
(19/144) 
22.9 
(60/262) 
5.5 
(3/55) 
1.8 
(1/57) 
12.1 
(8/66) 
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Table 5.2. Antibody prevalence and density for asexual stage and sexual stage antigens. Titres refer to antibody positive individuals 
only. GM, geometric mean, CI, 95% confidence interval. 
 Burkina Faso Tanzania Ghana 
Age group 
 
<8.0 9-11 >11 <8.0 9-11 >11 <8.0 9-11 >11 
230CMB Titre, GM 
(CI) 
384 
(204-722) 
265 
(235-299) 
598 
(139-2574) 
273 
(78-957) 
299 
(202-442) 
307 
(256-367) 
623 
(192-2021) 
202 284 
(190-426) 
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Combining all age categories, the proportion of people antibody positive for any 
asexual antigen was 77.1% (300/389) for Burkina Faso, 85.0% (443/521) for Tanzania 
and 31.1% (64/206) for Ghana (Figure 5.0).  
 
 
 
Figure 5.0. Antibody prevalence for asexual antigens in relation to age group and country 
of origin. Individuals counted as asexual positive have antibodies to any or multiple of 
the following antigens; AMA-1, MSP-119 or GLURP. The bars show the antibody 
prevalence in the age groups, shaded by country; white for Ghana, light grey for 
Tanzania and dark grey, Burkina Faso. The error bars indicate the 95% confidence 
interval, and the asterisks indicates a statistically significant positive increasing trend at 
the following levels: 0.05 – 0.01 (*), 0.01- 0.001 (**), and <0.001 (***). Results did not 
change significance boundary when using age as either a categorical or continuous 
variable. 
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Figure 5.1. Antibody prevalence for sexual stage antigens in relation to age group and 
country of origin. (a) Responses to 10C, (b) Responses to 230CMB. The bars show the 
antibody prevalence in the age groups, shaded by country; white for Ghana, light grey 
for Tanzania and dark grey, Burkina Faso. The error bars indicate the 95% confidence 
interval, and the asterisks indicates a statistically significant positive increasing trend at 
the following levels: 0.05 – 0.01 (*), 0.01- 0.001 (**), and <0.001 (***). Results did not 
change significance boundary when using age as either a categorical or continuous 
variable. An interaction between parasite prevalence and age was assessed for antibody prevalence 
trends depicted in this graph. An association was only found in Burkina Faso. 
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The overall proportion positive for 10C antibodies was considerably lower with 18.0% 
(69/383) antibody prevalence in Burkina Faso, 15.1% (66/438) in Tanzania and 1.9% 
(4/206) in Ghana; and antibody titre followed the same pattern (Table 5.2., Figure 5.1 
(a)). 230CMB antibody prevalence was 12.2% (47/384) in Burkina Faso, 18.9% (83/439) 
in Tanzania and 6.3% (13/205) in Ghana (5.1.(b)). The prevalence and density of 
antibodies against all antigens were all correlated (p<0.001 for all comparisons; Table 
5.3.).  
Table 5.3. Associations between antibody titres for the different antigens. The 
spearman correlation coefficient is presented with the related p-value. 
 AMA-1 MSP-1 GLURP 10C 230CMB 
AMA-1      
MSP-1 r=0.39, 
p<0.001 
    
GLURP r=0.55, 
p<0.001 
r=0.64, 
p<0.001 
   
10C r=0.38, 
p<0.001 
r=0.30, 
p<0.001 
r=0.44, 
p<0.001 
  
230CMB r=0.32, 
p<0.001 
r=0.33, 
p<0.001 
r=0.42, 
p<0.001 
r=0.53, 
p<0.001 
 
 
 
Overall, the prevalence of antibody responses to any of the asexual stage antigens 
increased significantly with age in years (OR= 1.12, 95% CI, 1.05 -1.21; p=0.001), after 
adjusting for concurrent parasite carriage, season and study setting. When this age-
dependency of asexual antibody prevalence trend was examined per study setting, 
there was a significant positive association in Burkina Faso (p=0.022) and Ghana 
(p=0.012) but not Tanzania (p=0.41). Antibody prevalence to 10C increased with age 
(Figure 5.1. (a)), but this trend was only statistically significant in Burkina Faso (OR= 
1.39, 95% CI 1.18- 1.65; p<0.001). Similarly, antibody responses to 230CMB increased 
with age, but only in Burkina Faso (OR= 1.21, 95% CI 1.02 -1.44; p=0.031) and Tanzania 
(OR= 1.22, 95% CI, 1.07 -1.38, p=0.003), with no clear pattern for Ghana (p=0.32). The 
concurrent presence of asexual parasites was significantly associated with the 
prevalence of antibodies against any asexual stage antigen (OR 3.55, 95% CI 2.32-5.42, 
p<0.001) and against the individual asexual antigens; AMA-1, MSP-119 and GLURP 
(p<0.012) and antibody titre for AMA-1 (p<0.001), GLURP (p<0.001) but not MSP-119 
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(p=0.64). The concurrent presence of asexual parasites was also associated with a 
higher prevalence of antibodies against 10C (OR 2.01, 95% CI 1.30-3.11, p=0.002) and 
230CMB (OR 1.65, 95% CI 1.06-2.57; p=0.027) and a higher antibody titre for 10C (log10 
titre: β=0 35  se=0 081  p<0 001) and 230C   (lo 10 titre: β=0 37  se=0 076  p<0 001)  
after adjustment for age, season and study setting. There was no association between 
microscopically detectable gametocytes and antibody prevalence for 10C (p=0.456) or 
230CMB (p=0.281). 
 
Functional transmission reducing activity 
 
A total of 58 samples with SMFA results from a previous study were successfully tested 
for 10C and 230C   anti odies  of which 19/58 reduced trans ission  y ≥50% and 
9/58 reduced transmission by ≥90%   oth 10C and 230C   anti ody prevalence was 
significantly associated with TRA at both the 50% and 90% levels (Table 5.4.).  
 
Table 5.4. Relationship between sexual stage antibody responses and functional 
transmission reducing activity (TRA). Transmission reducing activity was categorized 
at >50% and >90%. Odds ratios are presented with 95% confidence intervals, and the 
associated p-values.  
Antibody 
prevalence 
TRA >50% TRA >90% 
OR (95% CI) p-value OR (95% CI) p-value 
10C  
 
5.54 (1.21-25.43) 0.028 7.04(1.41-35.13) 0.017 
230CMB  8.48(1.91-37.64) 0.005 4.69(1.00-21.85) 0.049 
 
pfs48/45 sequencing 
 
We sequenced pfs48/45 in a subset of samples from Tanzania (n=48), Ghana (n=39) 
and Burkina Faso (n=39). All variation discussed here is compared to the 3D7 reference 
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sequence (PlasmoDB 2012).  17 single nucleotide polymorphisms (SNPs) were found, 
10 of which were synonymous and 7 non-synonymous. 12 of the SNPs (5 of the non-
synonymous SNPs) are within the vaccine candidate region (Table 5.5.).  Two new non 
synonymous substitutions were found at nucleotide locations 396 (amino acid position 
132) and 468 (amino acid position 156), that appeared once in both Ghana and 
Tanzania, and are outside of the 10C recombinant protein region. For Ghana, the 
majority of samples (69.2%) were identical to 3D7 for pfs48/45; for Tanzania and 
Burkina Faso this proportion was 50.0% and 17.9%, respectively (Table 5.1.). Ghana 
had the lowest number of haplotypes (n=11), (defined as a specific collective of SNPs), 
Burkina Faso had 15 and Tanzania, 21, resulting in 44 unique haplotypes overall. Ghana 
also had the lowest number of infections with mixed pfs48/45 haplotypes (15.4%), 
followed by Tanzania (43.8%) and Burkina Faso (56.4%).  Five SNPs were found most 
frequently in terms of appearing in different haplotypes and also appearing in the 
largest numbers of samples. These are located at nucleotide positions 757, 762, 911, 
940 and 965 and are all non synonymous amino acid changes (Table 5.5.).
 171 
 
Table 5.5. Single nucleotide polymorphisms (SNPs) in pfs48/45 per study location. The shading defines the SNPs found within the 
different epitope regions 
location and type of nucleotide change SNP frequency by country 
Pfs48/45 
epitope 
location  
nucleotide location 
(corresponding amino 
acid if changed) 
amino acid 
change 
 
Ghana  
 
Burkina Faso  
 
Tanzania 
 
Total 
epitope V  328   1 0 0 1 
  336  0 1 0 1 
 396 (132) I=T 1 0 0 1 
  419  0 0 1 1 
  468 (156) F=V 0 0 1 1 
epitope II & III  492   1 0 0 1 
  502  0 0 1 1 
 556  1 0 1 2 
  753  1 0 0 1 
  757 (253) K=E 2 5 13 20 
  762 (254) N=K 9 12 21 42 
 epitope I 911 (304) V=D 7 3 8 18 
  940 (314) L=I 2 29 6 37 
 965 (322) S=N 7 4 6 17 
  989  1 0 0 1 
  1023  2 0 1 3 
 1047  0 0 1 1 
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DISCUSSION 
 
The present study is the first to determine natural recognition of MTBV candidates 
Pfs48/45-10C and Pfs230-230CMB in three malaria endemic settings and extends our 
appreciation of genetic polymorphisms in pfs48/45. These observations need to be 
taken into consideration in the planning of vaccine trials that have to allow for the 
presence of protein recognition prior to vaccination and potential immune boosting 
following natural antigen exposure. 
Pre-fertilization and post-fertilization antigens for MBTV differ not only in their 
mechanisms of action but also in their potential for immune-boosting following 
natural infections. Whilst the possible immune boosting of Pfs230 and Pfs48/45 
antibodies has been commonly mentioned (Bousema and Drakeley 2011), it is only 
with the availability of recombinant proteins that the extent of natural immune 
recognition can be fully explored. The availability of recombinant proteins also allows 
addressing immuno-epidemiological questions about the rate of antibody acquisition 
and its relationship with age and transmission intensity (Kaslow 1997). All studies up 
to date have relied on assays using natural antigen from cultured gametocyte 
extract, limiting throughput and sensitivity because of high background reactivity 
(Roeffen, Mulder et al. 1996; Bousema, Drakeley et al. 2006; Bousema, Roeffen et al. 
2006; Drakeley, Bousema et al. 2006; Bousema, Drakeley et al. 2007; Bousema, 
Roeffen et al. 2010; Ouedraogo, Roeffen et al. 2011). We examined antibody 
responses to P. falciparum transmission blocking vaccine candidates and asexual 
stage vaccine candidates in three endemic settings in Africa. Multiplicity of infection 
(MOI), allelic richness, asexual parasite prevalence and serological markers of malaria 
exposure were used to characterize sites in Ghana, Tanzania and Burkina Faso (Arnot 
1998; Babiker, Ranford-Cartwright et al. 1999; Schoepflin, Valsangiacomo et al. 2009; 
Agyeman-Budu, Brown et al. 2013). All indices used, indicate low transmission 
intensity in our site in Ghana and intense transmission intensity in our site in Burkina 
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Faso. Tanzania was selected as a site of meso endemicity. A reduction in malaria 
burden of 65.4% was reported between 2003-2008, which was attributed to 
declining numbers of mosquitoes (Mmbando, Vestergaard et al. 2010; Ishengoma, 
Francis et al. 2011; Meyrowitsch, Pedersen et al. 2011). However, in our survey 
higher antibody prevalence combined with higher parasite prevalence within our 
youngest age group suggests transmission may once more be on the rise. 
Naturally acquired antibody responses recognizing transmission blocking vaccine 
candidates 10C and 230CMB broadly followed the pattern of asexual stage antibody 
responses with lowest antibody responses in Ghana, the area of low transmission 
intensity. 10C and 230CMB antibody responses were also associated with concurrent 
asexual parasite prevalence, indicative of higher malaria exposure (Bousema, Kreuels 
et al. 2011), and a general trend of higher antibody prevalence in older children. The 
interaction between parasite prevalence and age in Burkina Faso suggests there is 
higher probability of being 10C or 230CMB antibody positive when both the parasite 
is present and when children are older.  
The age-dependency of sexual stage malaria immunity has not been firmly 
established (Drakeley, Bousema et al. 2006; Bousema, Roeffen et al. 2010; 
Ouedraogo, Roeffen et al. 2011) and, although more detailed studies across a larger 
age-range are needed, our findings indicate that the recombinant vaccine proteins 
are suitable tools for such studies. Importantly, we observed a highly significant 
association between naturally acquired antibody responses recognizing 10C and 
230CMB and functional TRA, as was previously reported for the native proteins 
Pfs48/45 and Pfs230 (Graves, Carter et al. 1988; Bouharoun-Tayoun, Oeuvray et al. 
1995; Healer, McGuinness et al. 1999; Drakeley, Eling et al. 2004; Bousema, Roeffen 
et al. 2006; Drakeley, Bousema et al. 2006; Bousema, Roeffen et al. 2010). While TRA 
in the supportive dataset was significantly associated with antibodies against 10C 
and 230CMB, there may be antibodies to other candidate transmission-blocking 
antigens that we have not ruled out as contributors. In general, our assays fall short 
of providing definitive evidence for the transmission-blocking activity of naturally 
acquired 230CMB and 10C antibodies. Whilst, antibodies generated by immunization 
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of rodents with 230CMB or 10C and monoclonal antibodies against Pfs230 and 
Pfs48/45 are causally associated with transmission blocking activity, our 
epidemiological findings do not provide the same level of evidence (Roeffen, Beckers 
et al. 1995; Chowdhury, Angov et al. 2009; Farrance, Rhee et al. 2011; Theisen, 
Roeffen et al. 2014). To formally conclude that naturally acquired 10C and 230CMB 
antibodies in humans are responsible for the observed transmission-blocking activity, 
future studies may affinity purify antibodies against these two antigens and test 
these purified antibodies using SMFA. 
Taken together, our findings of natural recognition of 10C and 230CMB antibody 
responses and their association with commonly used proxy-markers of malaria 
exposure (age, concurrent parasite prevalence, serological markers of cumulative 
exposure to asexual stage antigens) suggest that natural parasite exposure may 
boost vaccine induced immunity (Farrance, Rhee et al. 2011; Theisen, Roeffen et al. 
2014), and that field trials with these vaccine candidates have to take into account 
naturally acquired immune responses to the vaccine proteins. 
For the 10C vaccine candidate, we provided relevant information on genetic variation 
in the pfs48/45 gene in our three field sites. We identified 5 previously documented 
non-synonymous substitutions (Conway, Machado et al. 2001) and discovered 2 new 
non-synonymous substitutions that were both detected once and are present 
outside the part of the pfs48/45 gene that forms the basis of the 10C vaccine. The 
genetic sequence of 10C in the R0-10C vaccine was based on cultured isolate 
3D7/NF54. In a recent study, R0-10C induced immunity showed statistically 
significant TRA (>90%) against cultured isolates 3D7/NF54, and NF135 which have 
polymorphisms in amino acids 254, 304 and 322 (Theisen, Roeffen et al. 2014), 
indicating that these polymorphisms do not necessarily translate in lower vaccine 
efficacy. While a substantial proportion of field isolates were different from 
3D7/NF54 (30.8% in Ghana, 50.0% in Tanzania and 82% in Burkina Faso), it is 
currently unknown whether this has consequences for 10C vaccine efficacy. 
Polymorphisms on positions 757 and 940 may be of particular interest in this respect, 
since these were commonly detected in field isolates but not in NF135, a cultured 
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strain for which efficient transmission blocking activity of anti-10C antibodies was 
confirmed (Theisen, Roeffen et al. 2014). Previous research highlighted that the 5 
non synonymous substitutions resulted in 9 haplotypes that showed geographical 
clustering across Africa, Asia and South America (Conway, Machado et al. 2001; 
Escalante, Grebert et al. 2002; Anthony, Polley et al. 2007). These findings are in line 
with our study which found these substitutions to be common, but resulted in a 
larger number of haplotypes, with many being mixed infections. While we only 
analysed samples from African settings, we also found clear geographical clustering 
of haplotypes. A high number of mixed clone infections were seen in our samples. As 
it was not possible to determine which SNPs belonged to different clones, mixed 
sequencing results were designated new haplotype identities. It is possible that 
dominant clones may shroud lower density clones resulting in an underestimation in 
the MOI and pfs48/45 sequencing data (Agyeman-Budu, Brown et al. 2013). Genetic 
polymorphisms in vaccine candidates can threaten success by enabling immune 
escape mutants (Cooreman, Leroux-Roels et al. 2001). The majority of non 
synonymous substitutions found in these samples, and in previous studies are within 
the vaccine candidate region. It is currently unclear, but of utmost importance, to 
determine if vaccine induced immunity is likely to be efficacious against strains with 
a different genetic composition on the functional epitopes.  
In summary, we have found that antibodies against two new recombinant vaccine 
candidates are naturally acquired, found in serum from 3 endemic regions across 
both East and West Africa, and show age dependency in Burkina Faso. The functional 
importance of these antibodies has been confirmed using samples with SMFA data 
which showed a significant correlation between antibody prevalence and TRA. Our 
samples show genetic variation within the vaccine candidate that exhibit 
geographical clustering, the relevance of which is currently not known. 
 
 
 
 176 
 
 ACKNOWLEDGMENTS 
 
We are grateful to the volunteers for their participation in the study, and to the 
teams from Centre National de Recherche et de Formation sur le Paludisme (CNRFP), 
Burkina Faso, Noguchi Memorial Institute for Medical Research, Ghana and 
Kilimanjaro Clinical Research Institute, Tanzania, for fieldwork and microscope slide 
reading.  
We would like to thank Dr. Jessica Chichester at Fraunhofer USA Center for 
Molecular Biotechnology for sharing their recombinant 230 CMB protein. 
This work was completed as part of the REDMAL project and was funded by the 
European FP7 project (#242079).  
 
Conflict of interest 
 
We declare there are no competing interests.  
 
 Supplementary methods and results  
 
A factor Xa site was included between R0 and 10C to enable cleavage and allow 
quantification of sexual stage antibodies. To cleave R0, the following mastermix was 
prepared; 200µL of 100% properly folded R0-10C (300µg) was incubated with 20µl of 
100mM of CaCl2, 20µl of 1% DOC in Tris-buffer and 4µl of undiluted Factor Xa 
Protease (New England BioLabs Inc, Leiden, The Netherlands) overnight at room 
temperature.   
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To confirm complete cleavage, product was visualized using sodium dodecyl sulphate 
(SDS) polyacrylamide gel electrophoresis and a 4-12% NuPAGE (R) gel (Invitrogen Life 
Technologies, Bleiswijk, The Netherlands). 15µl of cleaved product was incubated 
with 15µl of Tris-Glycine SDS, for 20 minutes at 80°C, then 15µl of product was 
visualized on the gel (Figure 5.2.).  
Protein reactivity against epitope 45.2b of Pfs48/45, was confirmed using Western 
Blotting. Protein bands were transferred from a second SDS gel to Hybond-C-extra 
paper (Amersham), which was blocked with 5% milk in PBS for 30 minutes on a 
shaking incubator. The gel was incubated in 1.5µg/ml of HRP-mAb85RF45.2b 
(epitope 45.2b of Pfs48/45) in PBS with 0.05% Tween 20 for 2 hours on a shaking 
incubator. The gel was then incubated with peroxidise substrate Kit Vector SG 
(SK4700, Vector Laboratories), which enabled identification of protein bands that 
reacted against epitope 45.2b.  
 
 
Figure 5.2. Sodium dodecylsulphate (SDS) polyacrylamide gel electrophoresis (a) and,  
Western blotting analysis of cut and uncleaved protein (b). Lanes 1 and 4 contain 
molecular weight markers (SeeBlue Pre-stained standard (Invitrogen LC5625) lanes 2 
and 5 have 100% uncleaved protein and the cleaved product is in lanes 3 and 6. 
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Figure 5.2. shows the product of the cleavage reaction (a), and the reactivity of the 
products to epitope 2b (b) in a Western blot. Uncleaved R0-10C is 89.8kDa in size, 
which following cleavage divides into R0, 58.3kDa in size, and 10C-6His which is 
31.5kDa. Figure 5.2 (b) shows there is reactivity against epitope 2b Pfs48/45 to two 
bands in the cleaved product, which are at the correct size for cleaved 10C and a 
minor band for uncleaved protein, which confirms that there is some uncleaved R0-
10C in the ‘cleaved’ product   
Reactivity of 10C was checked with a two site ELISA using anti-Pfs48.45 mAbs 
recognizing epitopes 1 and 2B, which was otherwise performed as before. Samples 
were assayed from known gametocyte carriers who had antibodies against Pfs48/45 
and had been shown to demonstrate transmission reducing activity using membrane 
feeding assays. To confirm specificity, a control sample was used from an individual 
who had been vaccinated with GLURP. High reactivity against gametocyte positive 
individuals and low reactivity against the GLURP vaccinated individual indicated the 
cleaved product was just 10C.  
10C was then purified by gel filtration on a Sephacryl S-200 column (GE Healthcare, 
The Netherlands) size exclusion column to remove the uncleaved protein. 150µL of 
10C was mixed with 1000µL of buffer (EDTA 250mM, Tris 1M pH 8.8, NaCl 100mM, 
0.8% sodium deoxycholate in ddH20), then loaded onto the column and run for 3 
hours to enable separation. Fractions corresponding to 10C were pooled and 
concentrated according to their expected molecular weight using VivaSpin columns 
(GE Healthcare, The Netherlands) which were centrifuged at 4000 rpm for 25 
minutes. Following this, supernatant was checked on SDS and Western blot once 
more, concentration estimated using Nanodrop and BCA and reactivity confirmed 
once more using ELISA. Product was concluded to be free of R0.  
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5.4 Linking methods and results: MBP-10C 
 
The linking information in this chapter is comprised of protocol optimization and 
building upon results covered in the manuscript through use of supportive sample 
sets. To improve clarity, this section has been split into sections addressing: 
 MBP-10C, R0-10C and the cross sectional survey sample sets.  
 10C and 230CMB antibody responses and their relationship with TRA (using 
supportive sample sets). 
 Genetic analysis of the cross sectional survey samples.  
MBP-10C was the primary version of the vaccine candidate (different to the one 
discussed in the attached manuscript). The first section below outlines development 
using this candidate, prior to its replacement. Within each section the methods are 
followed by the results, to improve the clarity. A final extended discussed follows at 
the end.  
 
5.41 Methods: MBP-10C ELISA assay 
 
An ELISA assay was optimized to enable quantification of MBP-10C antibodies. Total 
IgG was measured against recombinant MBP-10C (which was produced and supplied 
by W.Roeffen (Radboud UMC)), using ELISA as follows. Nunc plates (Nunc, 
Stockholm, Sweden) were coated with 100µL per well of 2µg/mL of MBP-10C diluted 
in PBS (Invitrogen, Life Technologies, Bleiswijk, The Netherlands), then incubated 
overnight at 4°C. Plates were washed 3 times with PBS then blocked with 150µL per 
well of PBS with 5% w/v milk powder (Sigma-Aldrich, Zwijndrecht, The Netherlands), 
for 15 minutes at room temperature. Plates were washed 3 more times with PBS, 
then incubated at room temperature for 3 hours with 100µL of test serum, diluted 
1/200 in PBS (with 0.05% v/v Tween 20 (Sigma-Aldrich) and 1% w/v milk powder). 
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Plates were washed 3 times, then incubated for 2 hours with 100µL per well of anti-
human-IgG-HRP (Dako, Cambridgeshire, UK) diluted 1/50,000 in PBS Tween 20 
(0.05% v/v). Plates were washed 4 times then incubated with 100µL of TMB (Sigma-
Aldrich, Zwijndrecht, The Netherlands) for 20 minutes at room temperature. The 
reaction was stopped with 50µL per well of 0.2M H2SO4 (Sigma-Aldrich, Zwijndrecht, 
The Netherlands) and OD was read at 450nm, using an iMark Microplate reader 
(BioRad, Veenendaal, The Netherlands). Samples were tested in duplicate and two 
blank wells were included per plate to adjust for background reactivity of reagents.  
To identify reactivity to the fusion protein MBP, IgG was measured using ELISA as 
outlined previously, but plates were coated with MBP at a concentration of 1µg/mL. 
Results were analyzed as discussed in the general methods in section 3.14.  
 
5.42 Methods:  Samples used for validation of MBP-10C ELISA  
 
Serum samples from previous studies performed in The Gambia (n=200) and 
Tanzania (n=360) were used to validate the ELISA assay. Tanzanian samples were 
collected from the Tanzanian Plantation Company in 2003-2004 from a village of low 
endemicity in Lower Moshi, with an estimated EIR of 3.4 per year (Bousema, Roeffen 
et al. 2010). This sample set was used for validation since antibody responses against 
native proteins Pfs48/45 and Pfs230 had previously been measured and it was 
hypothesized antibody responses against recombinant antigens would be 
comparable (Oesterholt, Bousema et al. 2006; Bousema, Roeffen et al. 2010). The 
Gambian samples were collected in 1990-1991 from the North bank of the Farafenni 
river, in a region of intense seasonal transmission where there was an asexual 
parasite prevalence of 5% during the dry season, and 35% during the wet season, 
which was determined by microscopy (Drakeley, Secka et al. 1999; Drakeley, Akim et 
al. 2000; Lulat 2003).  MBP-10C antibodies were also quantified in the European 
negative controls (n=23), (which were discussed in section 3.14.).   
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5.43 Results:  MBP-10C antibodies quantified in samples from malaria exposed 
individuals from the Tanzania Plantation Company (Lower Moshi, Tanzania) and 
The Gambia 
 
Results for the Tanzanian sample set are discussed first. In the graph below (Figure 
5.3.), all data are from the previous study, excluding MBP-10C and GLURP antibodies 
which were quantified in this chapter. MBP-10C antibody positivity was 2.5% for <5 
years, 11.3 % for 5-14 years and 8.7% for >15 years (Figure 5.3.). Antibody prevalence 
for native (Pfs48/45) and recombinant (MBP-10C) protein was not expected to be 
identical, but these patterns appeared similar enough for confidence to be gained in 
antibody measurement using MBP-10C. 
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Figure 5.3. Tanzania Plantation Company: Proportion of individuals antibody positive 
for MBP-10C, Pfs48/45, Pfs230, GLURP, AMA-1 and MSP-1 19 by age group. Error bars 
indicate the 95% confidence interval. Age groups are represented by different bar 
shading. NB: This data has been re-drawn with permission, excluding results for MBP-
10C and GLURP, which were determined in this chapter and plotted here to allow 
comparison with previous data (Bousema, Roeffen et al. 2010). 
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To further increase confidence in results, the ELISA assay was validated against a 
larger set of samples from The Gambia (n=178). MBP-10C antibody prevalence 
overall was 42.1% in these samples which is higher than commonly reported for 
sexual stage antigens (typically 10-40%) (Bousema, Roeffen et al. 2006).  
 
5.44 Results: MBP-10C antibody quantification in malaria unexposed European 
controls using ELISA 
 
Following unexpectedly high MBP-10C antibody prevalence in The Gambian dataset, 
MBP-10C antibodies were measured in malaria unexposed European individuals 
(n=23) to assess if there was non-specific reactivity. Negative controls typically 
produce low OD values not much higher than that obtained for a blank well, which 
on average is 0.02. In an ELISA assay where there is little non-specific response, 
negative controls would be expected to have an OD within the range of 
approximately 0.02-0.2. Figure 5.4. indicates the normalized ODs for European 
negative control samples which ranged from 0.13-0.85. This is high and indicates 
antibodies that bind to MBP-10C may not all be specific to 10C.  
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Figure 5.4. MBP-10C antibody responses measured in European negative controls. 
Antibody responses are expressed as normalized OD, and were measured in 23 
European negative controls. 
 
 
5.45 Results: Assessing reactivity to maltose binding protein (MBP) in malaria 
exposed and unexposed populations 
 
It was suspected some of the measured antibodies were specific to MBP, not 10C. To 
confirm this, IgG was measured as before coating plates with MBP. Figure 5.5. 
demonstrates there is a positive correlation (R2=0.561) between sample ODs for 
MBP-10C and MBP coated plates, suggesting reactivity is partly antibodies that bind 
to MBP.    
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Figure 5.5. The relationship between MBP-10C and MBP antibody responses measured 
in European negative controls. Antibody responses are expressed as normalized OD 
and were measured in 22 European negative control samples. The relationship was 
assessed using regression, R2=0.561. 
 
MBP antibodies were then measured in endemic serum. Figure 5.6. (a). indicates 
there is a also a relationship between MBP-10C and MBP antibody responses in 
serum from Tanzania and The Gambia, suggesting these populations also react 
against fusion protein MBP. To attempt to isolate 10C antibody responses, OD values 
for MBP were subtracted from ODs to MBP-10C, (referred to as 10C adjusted ODs). 
Figure 5.6. (b) demonstrates there was no discernible pattern between the adjusted 
results (10C) and MBP-10C ODs. For example, some samples with high MBP-10C ODs 
had zero or negative 10C-specific reactivity after subtraction of MBP. While MBP-10C 
had initially showed promising reactivity with antibodies in the Tanzanian sera 
samples, responses were found to be strongly related to MBP (Figure 5.6.(b)). 
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Figure 5.6. The relationship between MBP-10C and MBP antibody responses in 
endemic and European control serum. (a) The relationship between antibody 
responses measured against MBP-10C and MBP. (b) The relationship between 
adjusted OD responses for 10C and MBP-10C. Dots represent European negative 
controls, squares represent serum from The Gambia and triangles represent 
Tanzanian serum.  
 
While the presence of a factor Xa cleavage site between MBP and 10C would have 
enabled cleavage to assess reactivity to 10C, problems with production of MBP-10C 
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as a vaccine candidate, which are described next, simultaneously occurred and led to 
a revised vaccine candidate being used. 
The REDMAL project vaccine development objectives were to produce  >95% 
properly folded clinical grade material, a yield of 10mg/L, protein stability for at least 
9 months, and induction of high titres of functional transmission blocking antibodies 
in rodents (REDMAL 2011). MBP-10C overexpression was performed by Will Roeffen 
at Gennova Biopharmaceuticals, Pune, India. The majority of MBP-10C that was 
overexpressed was multimeric protein which induced high titres of antibodies, with 
no transmission reducing activity, whereas monomeric protein induced functional TR 
antibodies (Will Roeffen, personal communication). While variations of the 
fermentation protocol were attempted to try to increase the proportion that was 
monomeric, protein yields remained too low and all experiments with MBP-10C were 
discontinued and the revised candidate, R0-10C was developed instead.   
 
5.5 Linking methods and results: 10C ELISA and cross sectional surveys 
 
To allow assessment of antibodies specific to 10C, R0 was cleaved, then 10C was 
purified by Will Roeffen. 
 
5.51 Methods: Optimization of 10C ELISA 
 
To determine optimal ELISA reagent dilutions a checkerboard titration was 
performed, titrating coating antigen (purified 10C) and conjugate down and across 
the plate respectively. Antigen was titrated from 4µg/mL to 0.03µg/mL and the 
conjugate from 1/10,000-1/320,000. The objective was to select concentrations that 
achieved low reactivity for a Radboud Hospital blood bank negative control sample 
that previously produced higher reactivity in malaria ELISA assays (Will Roeffen, 
personal communication), and high reactivity for the positive control sample. ELISA 
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was otherwise performed as outlined in 3.13. , but samples were diluted to 1/200 in 
PBS and added to half the plate each. Optimal concentrations were determined to be 
1.0µg/mL of 10C coating antigen and 1/80,000 dilution for the conjugate (see Table 
5.6.).  These concentrations were optimized against 10C but were also found to be 
suitable for 230CMB (data not shown). 
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Table 5.6. Titration of 10C coating antigen and conjugate using ELISA.  Optical densities (ODs) are shown for a positive and negative control sample. 
Optimal concentrations were 1µg/mL of coating antigen and 1/80,000 conjugate dilution (highlighted in boxes). Rational for selection is explained in 
the text. 
 Positive control 1/200 dilution blood bank negative 5 (high responder) 1/200 dilution   
 Conjugate dilution 
10C 
Conc. 
(µg/ml) 1/10,000  1/20,000  1/40,000  1/80,000  1/160,000  1/320,000  1/10,000  1/20,000  1/40,000  1/80,000  1/160,000  1/320,000  
4 3.50  3.50  3.50  3.50  2.03 1.04 1.99 0.87 0.45 0.22  0.10  0.09  
2 3.50 3.50  3.50  2.59 1.70 0.81  1.29 0.60 0.34  0.17  0.09  0.07  
1 3.50 3.50  3.50 2.68  1.33 0.70  1.10  0.50  0.28  0.16  0.09  0.05  
0.5  3.50  3.50  3.50  2.11 1.15 0.55 0.99  0.53  0.27  0.14  0.08  0.05 
0.25  3.50  3.50  2.71 1.58 0.79 0.38  0.81 0.46  0.31  0.13 0.07 0.04  
0.125  3.50  3.50  1.87 0.98  0.48  0.25 0.80  0.43  0.32 0.11  0.06  0.04 
0.063  3.50  2.33  1.14 0.58  0.27  0.15  0.80  0.42  0.25 0.09  0.05 0.04  
0.030 2.62 1.74  0.71  0.32  0.19 0.09  0.78  0.39  0.18  0.09 0.05 0.03 
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Following this, a larger batch of antigen was produced and purified by Will Roeffen, 
to provide sufficient material for evaluating all sample sets assessed in this thesis. 
Due to slight variation in antigen production between batches, a new coating 
concentration of 0.1µg/mL, a conjugate dilution of 1/40,000, and test sample dilution 
of 1/500, were used for both 10C and 230CMB ELISA. These were determined in the 
same manner as previously described. The final ELISA protocol is in section 3.13.  
 
5.52 Methods: GLURP controls 
 
A concern with serological assessment using R0-10C vaccine candidate was that 
incomplete cleavage of R0 would result in measurement of asexual stage antibodies 
in addition to 10C responses. Since GLURP-R0 is widely found in naturally exposed 
individuals, R0 reactivity has the potential to mask 10C reactivity (Dodoo, Aikins et al. 
2008; Pratt-Riccio, Bianco et al. 2011). To ensure R0 had been cleaved from 10C, 
serum from individuals who had been vaccinated with AMA-1 or GLURP (and 
produced high antibody titres), was included on ELISA plates coated with 10C or 
230CMB antigens, Table 5.7. (Hermsen, Verhage et al. 2007; Esen, Kremsner et al. 
2009; Mordmuller, Szywon et al. 2010).  
Table 5.7. indicates OD values for GLURP are low and comparable to asexual antigen 
AMA-1, which demonstrates there is not additional reactivity to GLURP. Since OD 
values measured on 10C plates are comparable to 230CMB responses, which did not 
have a GLURP fusion partner, this further validates removal of R0 from 10C.  
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Table 5.7. Reactivity of GLURP and AMA-1 positive serum to 10C and 230CMB 
antigens using ELISA. Reactivity is expressed as normalized optical density (OD). 
Control serum normalized OD response 
  10C 230CMB 
GLURP 0.10 0.11 
AMA-1 0.15 0.20 
 
5.53 Methods: The cross sectional survey field sites, and my role in the surveys 
 
Immuno-epidemiological cross sectional surveys were performed to provide snap 
shot information about antibody prevalence for the two vaccine candidates, as 
outlined in the attached manuscript. My role in cross sectional survey sample 
collection included developing and supplying standard operating procedures (SOPs), 
and shipping reagents to the field sites. In each country, team leaders were 
designated who co-ordinated trips to the schools and ensured SOPs were understood 
and sampling performed as required. Following sample collection, I taught a 1 week 
training course at Noguchi Memorial Institute for Medical Research in Accra, Ghana 
for participants from each of the field sites. While the primary objective was capacity 
building to teach participants how to perform ELISA and analyze results, some results 
contributed to the manuscript in this chapter. Following the training session, filter 
paper samples and plasma were transferred to London (at ambient temperature, and 
-20°C respectively) for DNA extraction, sequencing and sexual stage antibody 
quantification using ELISA. 
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Figure 5.7. Map of Ghana indicating the location of the field site in Asutsuare. 
Asutsuare is arked  y ‘ ’  The inset map in the top left hand corner shows the 
location of Ghana within the African continent. Sourced from Google Maps 
(www.google.co.uk/maps), August 2014. 
 
 
Three field sites were selected to represent different levels of endemicity. In Ghana, 
samples were collected from Asutsuare which is in the Dangme district, 
approximately 120km northeast of Accra (Figure 5.7.). This is a rural area, where the 
land is characterized by a network of irrigation canals and the majority of the 
 192 
 
population is subsistence farmers. Asutsuare has a long rainy season from March to 
August and a shorter rainy period from November to December, with dry seasons in 
between. Malaria transmission is low and seasonal and parasite prevalence was  
reported as 2.7% (by microscopy) in 2009  (Kusi, Bosomprah et al. 2014).   
 
 
 
Figure 5.8. Map of Tanzania indicating the location of the field site in Bondo. Bondo is 
 arked  y ‘ ’. The inset map in the bottom right hand corner shows the location of 
Tanzania within the African continent. Sourced from Google Maps 
(www.google.co.uk/maps), August 2014. 
 
 
Bondo was selected as the field site location in Tanzania. It is a village within the 
Handeni district in the coastal region called Tanga located in northeast Tanzania, 
where the population is predominantly subsistence farmers (Figure 5.8.).  Malaria 
transmission is perennial and there are 2 rainy seasons: a long season from March-
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June and a shorter season from October to November (personal communication, Dr. 
Jaffu Chilongola). Parasite prevalence was 23% in 2011, which was determined by 
PCR (unpublished results, Dr. Jaffu Chilongola).  
 
 
Figure 5.9. Map of Burkina Faso indicating the location of the field site in Ouahigouya. 
 uahi ouya is arked  y ‘ ’. The inset map in the bottom right hand corner shows 
the location of Burkina Faso within the African continent. Sourced from Google Maps 
(www.google.co.uk/maps), August 2014. 
 
 
Ouahigouya was chosen as the sample collection site in Burkina Faso (Figure 5.9.). 
The terrain in the northern part of the country is desert, the central region is 
Sudanese savannah and the southern part is characterized by forest. Malaria 
transmission is stable and seasonal with 300-500 infectious bites per person per year 
(Ouedraogo, De Vlas et al. 2008). The dry season runs from November to May and 
the rainy season spans June to October (Ouedraogo, De Vlas et al. 2008).   
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5.54 Methods: Sample size calculation to determine the number of children to 
recruit for the surveys 
  
Without previous information on 10C and 230CMB reactivity in naturally exposed 
populations, sample size was based on school surveys to demonstrate parasite 
prevalence rates with adequate precision. 
Parasite rate estimations taken from school surveys performed in a lower endemic 
site in Ghana and a higher endemic site in Tanzania indicated a difference in parasite 
rate of 55-88% between sites for school aged children (5-14) (Brooker, Kolaczinski et 
al. 2009). Using this data, it was estimated sampling 200 children would enable 
parasite detection by microscopy of 20.2% (95% CI; 15.1-26.5%) in a high endemic 
setting and 10.1% (95% CI; 7.1-14.2%) slide prevalence in a low endemic setting. 
  
5.55 Methods: Ethical permission and field sampling  
 
Ethical permission was obtained from LSHTM (approval number 5946) and local and 
national ethics committees in each country. Sampling was performed as outlined in 
the attached manuscript. Information sheets, consent forms, questionnaires and 
protocols for taking the blood sample and preparing the RNA sample, filter paper, 
microscopy blood slide, and plasma and cell pellet, are included in appendix 2-10.  
RDT was perfor ed accordin  to anufacturer’s instructions  
  
5.56 Methods: Membrane feeding assays 
 
In addition to the membrane feeding referenced in the attached manuscript, SMFA 
was performed by colleagues on a wider range of samples, using protocols described 
elsewhere (Bousema, Sutherland et al. 2011; Boissiere, Gimonneau et al. 2013; 
Tchioffo, Boissiere et al. 2013). 10C and 230CMB antibodies were quantified in these 
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samples to enable assessment of the relationship between naturally acquired 
antibodies and transmission reduction (a reduction in oocyst density).  
 
5.57 Main results: Cross sectional surveys 
 
Please refer to the manuscript for the main results from the cross sectional surveys. 
  
5.58 Results: The sampling population 
 
School children were sampled in this study since they provide an easily accessible 
population that is highly informative to gain knowledge about local epidemiology 
(Stevenson, Stresman et al. 2013). They are likely to reveal patterns of antibody 
acquisition since they may have some level of asexual stage immunity but still carry 
high parasite burdens, and are therefore more exposed to microscopically detectable 
gametocyte densities, compared to adults (Smith, Dushoff et al. 2005; Brooker, 
Kolaczinski et al. 2009).   
 
Although all field sites used the same sampling protocols, there were variations in 
the way field workers visited different classes which resulted in a different age 
distribution for each of the field sites, see Table 5.8. Consequently, the data was 
divided into the following age categories <8.0, 9-11 and >11, to minimize the effect 
of different age skewing per country. Table 5.0. in the attached manuscript indicates 
the median age per each country within these age groups and demonstrates they are 
similar. 
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Table 5.8. Age distribution of study participants for each field site. NB: age data was 
not available for all individuals. 
age Tanzania  Ghana  Burkina Faso  
Median  12  10  8  
IQR  10-14  8-13  7-10  
Range  5-17  3-15  5-16  
Total number  520  180  380  
 
5.59 Results: Effect of season on sexual stage antibody prevalence in cross-
sectional populations in Burkina Faso, Ghana and Tanzania 
 
To try to understand what influences antibody prevalence, the relationship with 
season was explored. Table 5.9. indicates the prevalence of 230CMB antibodies is 
higher during the wet season for all countries when compared to the dry season, but 
this difference is only statistically significant in Burkina Faso, or when analysing the 
dataset as one population. 
Table 5.9. 10C and 230CMB antibody prevalence (%) in school aged children 
according to sampling season in Ghana, Tanzania and Burkina Faso. p-values were 
generated using logistic regression after adjusting for age.  
 Antibody prevalence according to season 
 10C dry  10C wet p-value 230CMB 
dry 
230CMB 
wet 
p-value 
Ghana % 
(n/N) 
3.0% 
(3/100) 
0.9% 
(1/106) 
0.285 4.0% 
(4/100) 
8.5% 
(9/106) 
0.114 
Tanzania % 
(n/N) 
13.0% 
(33/254) 
17.9% 
(33/184) 
0.150 16.6% 
(42/254) 
22.2% 
(41/185) 
0.167 
Burkina 
Faso % 
(n/N) 
20.7% 
(39/188) 
 
15.4% 
(30/195) 
 
0.049 7.9% 
(15/189) 
16.4% 
(32/195) 
0.002 
Overall  
p-value 
  0.785   0.009 
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10C antibody prevalence is higher during the dry season for Ghana and Burkina Faso, 
which is only a statistically significant difference for Burkina Faso. When considering 
the difference in antibody titre by season, there was no statistically significant 
difference for 230CMB (p>0.206), excluding Burkina Faso where titre was 
significantly higher during peak transmission season (p=0.005).  For 10C, while there 
was no statistically significant difference with titre and season in Tanzania (p=0.771) 
titre was lower during the peak transmission season in Burkina Faso and Ghana 
(p<0.001).  To explore how exposure changes with season, the relationship between 
gametocyte prevalence (microscopically detected) and season was explored but 
there was no statistically significant difference in gametocyte carriage between 
seasons for Burkina Faso or Tanzania (p>0.347), (Ghana had no gametocytes). In 
contrast, asexual parasite prevalence was significantly higher during the peak 
transmission season for Tanzania and Burkina Faso (p<0.006), but not for Ghana 
(p=0.343), where parasite prevalence (determined by microscopy) was very low 
overall.  
 
5.6 Linking methods and results: Supportive data sets and further 
exploration of antibody responses and transmission reducing activity 
 
5.61 Methods: Explanation of the supportive sample sets 
 
To expand on the results seen with the cross sectional survey samples (from Burkina 
Faso, Tanzania and Ghana) collected in this chapter, 10C and 230CMB antibodies 
were quantified in 2 additional sample sets. These supportive sample sets were: 
1) The Ugandan cross sectional study: This study sampled individuals from all ages, 
and was used in this chapter to explore antibody response patterns into adulthood 
since the cross sectional surveys focused on school children.  
2) A compilation of samples with known transmission-reducing activity: These 
samples were predominantly taken from gametocyte carriers, from several African 
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countries. TRA was assessed using SMFA (by colleagues at Radboud UMC), and 10C 
and 230CMB antibodies were quantified in this chapter to explore their association 
with TRA. 
To clarify which sample sets are discussed in the following sections they are referred 
to as: the cross sectional survey samples, the Ugandan cross sectional study and the 
SMFA compilation sample set. 
 
5.62 Results: Acquisition of 10C and 230CMB antibodies with age in samples from a 
cross sectional study performed in Uganda 
 
Upon detection of an age dependent antibody acquisition pattern in school aged 
children in a high endemic setting (in Burkina Faso), and meso endemic site in 
Tanzania (for 230CMB only), the next objective was to investigate if this pattern 
continued into adulthood. To answer this question, 10C and 230CMB antibody 
responses were quantified in samples collected in all age groups (6 months to 72 
years) from Kanungu, Uganda. This is a region of low to moderate malaria 
transmission with an estimated EIR of 26.6, which was determined in 2011-2012 
(Kilama, Smith et al. 2014).  Overall, 17.4% (308/1769) of individuals were positive for 
10C antibodies and 13.2% (233/1766) positive for 230CMB antibodies.  
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Figure 5.10. Ugandan cross sectional survey samples: Prevalence of 10C and 230CMB 
antibodies according to study participant age group. The bars indicate the proportion 
antibody positive according to age group (shaded in different colours), and the error 
bars demonstrate the 95% confidence interval.  The asterisks indicates a statistically 
significant positive increasing trend at the <0.001 level (***), which was assessed 
using logistic regression. Results did not change significance boundary when using 
age as either a categorical or continuous variable. 
 
 
Figure 5.10. demonstrates a statistically significant age dependent 10C and 230CMB 
antibody increase in prevalence, and confirms that the pattern previously seen in 
children extends into adults who have the highest antibody prevalence in this 
population. 
 
5.63 Results: SMFA compilation sample set. The association between transmission 
reducing activity and 10C and 230CMB antibodies 
 
Data from a previous study performed in Tanzania was used to confirm the 
association between TRA and 10C and 230CMB antibody responses in the attached 
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manuscript. Since then, antibodies have been quantified in additional samples from a 
SMFA compilation sample set with TRA data. Samples (n=375) were obtained from 
gametocyte carriers (median age 7 years, quartiles 4 and 10 years) from Burkina 
Faso, The Gambia, Cameroon, Gabon and from Dutch Missionaries who had lived in 
malaria endemic regions and were repeatedly infected with malaria.  
To further elucidate the relationship between more effective TRA and antibody 
prevalence, TRA was categorized at >50% (representing 50-89%) and >90% levels 
(representing 90-100%). The % TRA reflects the % reduction of oocyst density when 
comparing control mosquitoes which were fed gametocytes with non-immune sera, 
to test mosquitoes which were fed gametocytes with endemic serum.  
The association between antibody prevalence and TRA was explored using logistic 
regression. Table 5.10. indicates there is a statistically significant association with 10C 
and 230CMB antibody prevalence and TRA at the >90% level.  
Table 5.10. SMFA compilation sample set: Association between transmission 
reducing activity at the >50% and >90% levels and 10C and 230CMB antibody 
prevalence. Transmission reducing activity was categorized at >50% (representing 
50-89%) and >90% (representing 90-100%) levels. p-values are presented along with 
odds ratios with 95% confidence intervals (CI). # indicates there were no 10C positive 
individuals who exhibited >50% TRA.  
Antibody TRA >50%  
(n=31) 
TRA >90% 
(n=16) 
 
 OR (95%CI) p-value OR (95%CI) p-value 
10C # # 5.37 (1.8-16.0) 0.003 
230CMB 0.98(0.35-2.68) 0.962 7.74 (2.44-24.55) 0.001 
 
There were 16 participants who exhibited >90% TRA, 15 of whom had antibody data 
for 10C, and 13 had antibody data for 230CMB.  Six individuals (40.0%) were positive 
for 10C, 8 (61.5%) positive for 230CMB, and 5 of these individuals were positive for 
both antibodies. Five other individuals had >90% TRA, but no detectable antibodies 
against either transmission blocking vaccine candidate, indicating other antibody 
responses may be responsible for TRA. There was no statistically significant 
relationship between TRA at the >50% level and 230CMB antibodies, and none of 
these participants had 10C antibodies, so no calculation was performed, Table 5.10. 
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5.64 Results: SMFA compilation sample set. Antibody acquisition patterns with age  
 
There is age data for 199 participants from the SMFA compilation sample pool. Age 
was once again divided into categories <5 (n=25), 5-14 (n=123) and >15 years (n=51). 
Figure 5.11.(a) indicates the SMFA compilation samples also demonstrate statistically 
significant increasing acquisition of 10C and 230CMB antibodies with age. Figure 
5.11. (b) demonstrates 230CMB titre significantly increases with age, and while 10C 
titre also increases, this was not a statistically significant finding.  
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Figure 5.11. SMFA compilation sample set: Prevalence and density (log antibody titre) 
of 10C and 230CMB antibodies according to study participant age group. (a) The 
proportion of individuals positive for 10C and 230CMB antibodies according to age 
group. The error bars indicate the 95% confidence interval. The asterisk indicates a 
statistically significant positive increasing trend at the <0.001 level (***), determined 
by logistic regression (adjusting for country). Results did not change significance 
boundary when using age as either a categorical or continuous variable. (b) Log 
antibody titre for 10C and 230CMB antibodies according to participant age group. 
Box plots indicate the median (horizontal line), 25th and 75th percentiles (lower and 
upper box limits) and whiskers indicate the 5th and 95th percentiles. The asterisk 
indicates a statistically significant difference at the following levels: >0.05 (not 
statistically significant= NS) and <0.001 (***), which was assessed using linear 
regression. Different colour shading represents the different age categories.  
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5.65 Results: SMFA compilation sample set. The relationship between transmission 
reducing activity and age 
 
When considering functional TRA (categorized at the higher levels) and age (Figure 
5.12.), there was no statistically significant association between age and transmission 
reduction at the >50% level (n=31) (OR 0.98; CI: 0.92-1.03, p=0.437) or the >90% level 
(n=16) (OR 1.02; CI: 0.96-1.10, p=0.423), indicating similar proportions of more 
functional transmission reducers are found within each age category. This suggests 
that while antibody prevalence and titre (for 230CMB) may increase with age, 
antibody functionality does not.   
 
Figure 5.12. SMFA compilation sample set: The proportion of individuals in each age 
group who demonstrate TRA at the >50% and >90% level. >50% TRA represents 50-
89% (n=31) and >90% TRA represents 90-100% (n=16).  The error bars indicate the 
95% confidence interval. The number of participants per age group is:  <5 years 
(n=25), 5-14 years (n=123) and >15 years (n=51). Age groups are represented by 
different colour shading. Age trends were assessed using logistic regression 
(adjusting for country) and were not significant when using age as either a 
categorical or continuous variable (see text). 
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5.66 Results: SMFA compilation sample set. The relationship between transmission 
reducing activity and antibody titre 
 
TRA was categorized according to the following groups 0 (n=208), >0-<50 (n=90), 50-
<90 (n=31) and >90 (n=16) then the relationship was assessed with mean log 
antibody titre between the groups, using ANOVA. Pairwise t-tests were then 
performed between TRA groups to determine which differences were statistically 
significant. Figure 5.13. demonstrates the log antibody titre according to the % TRA. 
Compared to 0% TRA, there was no statistically significant difference between mean 
titre for the different TRA categories and 10C antibodies (p>0.122), apart from 50-
<90% which had a significantly lower titre than 0% (p=0.003). For 230CMB titre, there 
was no statistically significant difference between the TRA groups (p>0.272).  
 
Figure 5.13. SMFA compilation sample set: Log titre for 10C and 230CMB antibodies 
according to the level of transmission reducing activity (TRA). Log antibody titre is 
represented as arbitrary units. Box plots indicate the median (horizontal line), 25th 
and 75th percentiles (lower and upper box limits). Statistically significant differences 
between groups are discussed in the text above. TRA categories are indicated by 
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different colour shaded boxes. The numbers of individuals in each TRA group is as 
follows: TRA 0 (n=208), >0-<50 (n=90), 50-<90 (n=31) and >90 (n=16). 
 
5.7 Linking methods and results: Genetic analysis of cross sectional survey 
field samples from Ghana, Tanzania and Burkina Faso 
 
5.71 Methods: MSP2 genotyping to assess clonal diversity of field sites  
 
MSP2 genotyping by capillary electrophoresis was performed by Dr. Lynn Grignard at 
LSHTM to characterize the field sites in terms of clonal diversity. This was performed 
as referenced in the manuscript.  
 
5.72 Methods: BLAST search to explore previously reported polymorphisms in 
pfs48/45    
 
To investigate the genetic diversity of our vaccine candidate 10C, the pfs48/45 gene 
was sequenced in the cross sectional survey field samples. First, a BLAST search was 
performed to identify which regions are polymorphic; 55 sequences were found 
predominantly from a study by Escalante et al, which compared pfs48/45 diversity in 
samples from Kenya, India, Thailand and Venezuela (Table 5.11.) (Escalante, Grebert 
et al. 2002). The authors identified 42 single nucleotide polymorphisms (SNPs) which 
spanned 39 codon locations, 24 of which resulted in non synonymous changes. 
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Table 5.11. Location and frequency of SNPs and resulting amino acid changes in 
pfs48/45. Evaluated in samples uploaded to BLAST by other researchers 
(www.ncbi.nlm.nih.gov/BLAST/) visited November 2012).* the location is from the 
beginning of pfs48/45.  
Nucleotide Location* 
of SNP  
 Codon 
location 
Amino acid 
change 
SNP frequency 
(in 55 samples) 
42  14 synonymous 1 
60  20 synonymous 1 
69  23 synonymous 1 
95  32 C=Y 2 
99  33 K=N 1 
106  36 S=A 1 
132  44 synonymous 1 
159  53 synonymous 2 
172  58 N=D 1 
215  72 T=N 1 
276  92 synonymous 5 
297  99 synonymous 1 
424  142 I=L 1 
448  150 K=E 1 
454  152 I=L 1 
531  177 synonymous 1 
651  217 synonymous 1 
757 and 759  253 E=K 8 and 4 
762  254 K=N 7 
777  259 synonymous 1 
827  276 K=R 1 
911  304 D=V 25 
937  313 S=G 1 
940  314 I=L 3 
944 and 945  315 D=G 1 
964 and 965  322 S=N 1 and 28 
996  332 synonymous 1 
998  333 E=G 1 
1045  349 I=V 2 
1056  352 synonymous 2 
1064  355 Q=L 1 
1067  356 V=A 3 
1074  358 synonymous 2 
1185  395 synonymous 1 
1211  404 K=R 1 
1240  414 K=E 1 
1265  422 T=I 1 
1272  424 synonymous 1 
1315  439 F=L 1 
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High frequency SNP ‘hotspots’ were observed in nucleotide locations 911 and 965 
where variation was seen in 25 and 28 samples (n=55) respectively (Table 5.11.). 
Twenty-seven SNPs appeared just once and could be singletons since this study used 
cloned isolates. SNPs that were observed more than once, and resulted in non 
synonymous amino acid changes were of most interest. Since non synonymous 
changes were found throughout, the entire gene was sequenced in the field samples 
collected in the cross sectional surveys.  
 
5.73 Methods: DNA extraction from filter papers  
 
DNA was extracted from filter paper samples for pfs48/45 sequencing and MSP2 
genotyping. For Burkina Faso and Tanzania, microscopy positive samples were 
selected at random for sequencing.  As the result of a delay before microscopy 
results were available for Ghana, Ghanaian samples were selected at random, then 
screened for parasite presence using nested PCR (described in section 3.21.) 
(Snounou, Viriyakosol et al. 1993; Snounou, Viriyakosol et al. 1993). Genomic DNA 
was extracted from Whatman 3MM filter papers using the QIAamp DNA Mini kit 
(QiagenTM) following the “isolation of  eno ic DN  fro  dried  lood spots’’ protocol 
as described next. For each sample, three 3mm circles were aseptically punched from 
the centre of the filter blood spot into a sterile 1.5mL microcentrifuge tube using a 
3mm hole punch (Staples, High Wycombe, UK). Forceps and punch were ethanol 
sprayed and flame sterilized between cuts for the different samples, allowing them 
to cool before use. One hundred and eighty µL of buffer ATL (Qiagen TM) was added 
per tube, which was incubated at 85°C for 10 minutes. Samples were pulse 
centrifuged to 14,000 rpm in a benchtop microcentrifuge to gather liquid adhering to 
the microcentrifuge tube lid, then 20µL of Proteinase K (Qiagen TM) was added and 
tubes mixed by vortex. Samples were incubated at 56°C for 1 hour then centrifuged 
briefly. Next, 200µL of Buffer AL was added, tubes mixed by vortex, then incubated 
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at 70°C for 10 minutes. Samples were centrifuged at 14,000 rpm in a benchtop 
microcentrifuge, then 200µL of 100% ethanol was added, mixed by vortex, then 
centrifuged once more. Sample and buffer was added to a QIAamp Mini Spin Column 
inside a 2mL collection tube, then centrifuged at 8000 rpm for 1 minute. The spin 
column was inserted into a new collection tube, 500µL of Buffer AW1 was added, 
then tubes were centrifuged at 8000 rpm for 1 minute. This was repeated with Buffer 
AW2, but centrifugation performed at 14,000 rpm for 3 minutes. The spin column 
was inserted into a new collection tube which was centrifuged at 14,000 rpm for 1 
minute. Then the column was placed in a microcentrifuge tube and 150µL of Buffer 
AE was added, which was incubated at room temperature for 1 minute, then 
centrifuged at 8000 rpm for 1 minute to elute DNA off the membrane. Extracted DNA 
was stored in microcentrifuge tubes at -20°C until use.  
 
5.74 Methods: PCR amplification of pfs48/45 
 
Figure 5.14. (a) indicates the pfs48/45 gene sequence and location of SNPs found in 
samples uploaded to BLAST.  pfs48/45 is a large 1347 base pair single copy gene 
without introns (PlasmoDB 2012). Due to the large size, the primary PCR was 
performed using two primer sets that amplify pfs48/45 in two overlapping segments 
(Kocken, Jansen et al. 1993), using protocols developed elsewhere (Anthony, Polley 
et al. 2007). Figure 5.14.(b) shows the location and coupling of the primer pairs 
which are referred to as set 1 and 2, for the first and second half of the gene, 
respectively, for the nest 1 reaction.  Set 3 and 4 refer to the first and second half of 
the gene (respectively) for the nest 2 reaction.  
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(a) 
 
ATGATGTTATATATTTCTGCGAAAAAGGCTCAAGTTGCTTTTATCTTATATATAGTATTAGTA
TTAAGAATAATAAGTGGAAACAATGATTTTTGTAAGCCTAGCTCTTTGAATAGTGAAATATC
TGGATTCATAGGATATAAGTGTAATTTTTCAAATGAAGGTGTTCATAATTTAAAGCCAGATA
TGCGTGAACGTAGGTCTATTTTTTGCACCATCCATTCGTATTTTATATATGATAAGATAAGAT
TAATAATACCTAAAAAAAGTTCGTCTCCTGAGTTTAAAATATTACCAGAAAAATGTTTTCAAA
AAGTATATACTGATTATGAGAATAGAGTTGAAACTGATATATCGGAATTAGGTTTAATTGAA
TATGAAATAGAAGAAAATGATACAAACCCTAATTATAATGAAAGGACAATAACTATATCTCC
ATTTAGTCCAAAAGACATTGAATTTTTTTGTTTTTGTGATAATACTGAAAAGGTTATATCAAG
TATAGAAGGGAGAAGTGCTATGGTACATGTACGTGTATTAAAATATCCACATAATATTTTAT
TTACTAATTTAACAAATGATCTTTTTACATATTTGCCGAAAACATATAATGAATCTAATTTTGT
AAGTAATGTATTAGAAGTAGAATTGAATGATGGAGAATTATTTGTTTTAGCTTGTGAACTAA
TTAATAAAAAATGTTTTCAAGAAGGAAAAGAAAAAGCCTTATATAAAAGTAATAAAATAATT
TATCATAAAAACTTAACTATCTTTAAAGCTCCATTTTATGTTACATCAAAAGATGTTAATACA
GAATGTACATGCAAATTTAAAAATAATAATTATAAAATAGTTTTAAAACCAAAATATGAAAA
AAAAGTCATACACGGATGTAACTTCTCTTCAAATGTTAGTTCTAAACATACTTTTACAGATAG
TTTAGATATTTCTTTAGTTGATGATAGTGCACATATTTCATGTAACGTACATTTGTCTGAACC
AAAATATAATCATTTGGTAGGTTTAAATTGTCCTGGTGATATTATACCAGATTGCTTTTTTCA
AGTATATCAACCTGAATCAGAAGAACTTGAACCATCCAACATTGTTTATTTAGATTCACAAAT
AAATATAGGAGATATTGAATATTATGAAGATGCTGAAGGAGATGATAAAATTAAATTATTTG
GTATAGTTGGAAGTATACCAAAAACGACATCTTTTACTTGTATATGTAAGAAGGATAAAAAA
AGTGCTTATATGACAGTTACTATAGATTCAGCATATTATGGATTTTTGGCTAAAACATTTATA
TTCCTAATTGTAGCAATATTATTATATATTTAG 
 
(b) 
 
 
 
Figure 5.14. Sequence of pfs48/45 and PCR primer pairing. (a) Sequence of the 
pfs48/45 gene and location of SNPs and 10C vaccine candidate. The underlined 
portion indicates the location of vaccine candidate 10C. The nucleotides highlighted 
in red are SNPs that appear more than once, whereas blue SNPs appear in just in 
1/55 samples. Primer set 1 consists of the turquoise (F21) and pink (R706) primers 
and set 2 is light (F533) and dark green (R1327) primers. Primer set 3 is turquoise 
(F21) and grey (R658) combined, and set 4 is yellow (F600) and dark green (R1327). 
(b) Location of primers used for amplification and sequencing of the pfs48/45 gene. 
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Primers of the same colour represent forward and reverse pairs. Sequencing PCR was 
performing using the same primers as the nest 2 PCR reaction.  
 
The nested PCR reaction used the same external primers, but different overlapping 
internal primers, as indicated in Table 5.12.  
Table 5.12. Primer sequences for amplification and sequencing of the pfs48/45 
gene. NB: the nest 2 primers were also used for the sequencing PCR reactions. b.p. = 
base pairs. 
reaction primer 
pair 
primer 
name  
sequence 5'-3'  product size 
(b.p.) for each 
primer set 
Nest 1 set 1 F21 ATACATGATGTTATATATTTCTGCG 730 
    R706 CAAGAAGGAAAAGAAAAAGCC 
  set 2 F533 AGTGCTATGGTACATGTACG 840 
    R1327 GCAATATTATTATATATTTAGCTCATGA 
          
Nest 2 set 3 F21 ATACATGATGTTATATATTTCTGCG 687 
    R658 GAGAATTATTTGTTTTAGCTTGTGA 
  set 4 F600 CAAATGATCTTTTTACATATTTGCC 780 
    R1327 GCAATATTATTATATATTTAGCTCATGA 
 
DNA extracted from cultured parasites (NF54, NF166 and NF135), was used to 
validate PCR and sequencing protocols, and support another study where the 
transmission-blocking properties of 10C vaccine induced antibodies was determined 
against these gametocyte-producing strains in vitro (Theisen, Roeffen et al. 2014). 
PCR reactions were set up as follows: 1µL of extracted DNA was pipetted into a VWR 
96 well skirted plate (VWR, Bedfordshire, UK), which was kept on ice. Expand High 
Fidelity enzyme mix (Roche, Hertfordshire, UK) was used for amplification with the 
aim of producing high quality sequence traces. Due to the exonuclease activity of the 
enzyme, two separate mastermixes were prepared to prevent primer degradation. 
For each sample, 5.25µL of mastermix 1 (Table 5.13.) was combined with 6.25µL of 
mastermix 2 (Table 5.14.), then added to the 96 well plate, which was sealed with 
StarsSeal film (Starlab, Buckinghamshire, UK).  
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Table 5.13. Mastermix 1 reagents and volumes for primary and nested PCR 
reactions. 
Reagent Final concentration Volume per reaction  
(µL) 
Nuclease free water 
(Ambion) 
N/A 3.75 
dNTP mix (10mM each) 
(Bioline) 
200µM of each 0.25 
PCR primer mix (3µM each) 
(Sigma-Aldrich) 
300nM of each primer  1.25 
 
   
Mastermix total  5.25 
 
Table 5.14. Mastermix 2 reagents and volumes for primary and nested PCR 
reactions. 
Reagent Final 
concentration 
Volume per reaction  
(µL) 
Nuclease free water (Ambion) N/A 3.56 
Expand high fidelity buffer (Roche) 1x 1.25 
Mg2+ (25mM stock) (Roche) 2.5mM 1.25 
Expand High Fidelity enzyme mix  (Roche) 2.6units/reaction 0.19  
   
Mastermix total  6.25 
 
Cycling conditions for nest 1 and 2 PCR reactions were as follows: 94°C for 4 minutes, 
then 45 cycles of (94°C for 1 minute, 50°C for 1 minute, 72°C for 1 minute), followed 
by a final extension step of 72°C for 10 minutes. The nested reaction used the same 
reagents and volumes, but used 1µL of nest 1 product as the template. To confirm 
product amplification, a 0.7% agarose gel was prepared as follows, 0.7g of agarose 
(Sigma-Aldrich, Dorset, UK), was combined with 100mls of 1x TBE (BioRad, 
Hertfordshire, UK), which was heated by microwave until dissolved. When 
sufficiently cool, 5µL of ethidium bromide (Sigma-Aldrich, Dorset, UK), was added, 
the mixture gently swirled to combine, then poured into a gel cast (BioRad, 
Hertfordshire, UK) with combs and allowed to set.  
One µL of PCR product was combined with 2µL of loading dye (Thermo Fisher 
Scientific, Hertfordshire, UK) which was resolved by agarose gel electrophoresis (45 
minutes, 80 volts) and visualized using a transilluminator (BioRad, Hertfordshire, UK).  
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Positive amplification resulted in a band size of 687 base pairs for the first half of the 
gene, and a band size of 780 nucleotides for the second half. Five µL of Hyperladder I 
(Bioline, London, UK) was included on the gel to enable product size estimation.  
 
5.75 Methods: PCR product clean up 
 
PCR products from the nest 2 reaction were cleaned using the QIAquick Spin kit 
(Qiagen), according to the manufacturer instructions, as follows. Forty µL of buffer 
PB was combined with 8µL of PCR product, which was mixed by vortex. Ten µL of 3M 
NaOAc (pH 5.0) was added and mixed by pipetting until a uniform yellow colour was 
observed. Next, sample was added to a spin column inside a 2mL collection tube 
which was centrifuged for 45 seconds at 14,000 rpm to bind the product to the 
membrane. Flow through was discarded and 750µL of Buffer PE was added to the 
column and centrifuged at 14,000 rpm for 45 seconds. Flow through was discarded 
again and the spin column centrifuged once more for 1 minute. Next the column was 
inserted into a new 1.5mL microcentrifuge tube and 50µL of nuclease free water 
added to the membrane and incubated for 1 minute at room temperature. This was 
centrifuged at 14,000 rpm for 1 minute to elute the cleaned product.  
 
5.76 Methods: Estimation of PCR product concentration 
 
For sequencing PCR, the optimal PCR product concentration for amplification of a 
500-1000 base pair fragment is 5-20ng per sequencing reaction. Concentration was 
estimated by analyzing 5µL of cleaned PCR product on a 1.0 % agarose gel alongside 
5µL of Hyperladder I (Bioline, London, UK). The objective was to compare the density 
of the band (demonstrated in Figure 5.15.) to estimate the volume of product 
needed for the sequencing PCR reaction, and if dilution was required. In instances 
where the product was too concentrated, it was diluted in Nuclease-free water 
(Ambion, Renfrewshire, UK). 
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Figure 5.15. Hyperladder I size marker and corresponding estimated protein 
concentration. Hyperladder I was sourced from Bioline, London, UK. Protein 
concentration (ng/band) indicated in this picture is estimated according to the 
strength of the band. Picture was sourced from (www.bioline.com/us/hyperladder-
1kb).   
 
 
5.77 Methods: Sequencing PCR reactions 
 
Sequencing reactions were set up on ice as indicated in Table 5.15. using the BigDye® 
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Renfrewshire, UK).   
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Table 5.15. Mastermix reagents and volumes for sequencing PCR reaction. 
reagent  volume (µL) per 
reaction 
BigDye (Applied Biosystems) 1.0 
Buffer (Applied Biosystems) 1.5 
Primer (10pmole/µL) (F21,F600, R658 or R1327) 3.2  
Nuclease free water (Ambion) 2.3 
  
Mastermix total 8.0 
Purified PCR product (added separately) 2.0 
 
Italicized reagents (Table 5.15.) were added to the PCR plates as follows. Two µL of 
purified PCR product (previously diluted, if needed) was transferred into barcoded 96 
well PCR plates (Thermo Fisher Scientific, Hertfordshire, UK) on ice, then 8µL of 
mastermix was added per reaction. Since each primer amplifies product separately, 4 
reactions were performed per sample.  F21 and R658 primers were combined with 
the purified nest 1 product, and F600 and R1327 were combined with the purified 
nest 2 product. The following thermocycling conditions were used: 25 cycles of (94°C 
for 1 minute, 55°C for 1 minute, 65°C for 1 minute), followed by 65°C for 5 minutes 
for final extension, which was performed using a thermocycler (C1000 Thermal 
Cycler, BioRad, Hertfordshire, UK). 
 
5.78 Methods: Ethanol precipitation of sequencing product 
 
PCR products were ethanol precipitated which was performed as described next. The 
following was added per well, 3.0µL of 3M NaOAc (pH 4.6), 62.5µL of 100% BioUltra 
Ethanol (Sigma-Aldrich, Dorset, UK), and 24.5µL of MQ-H20. Plates were covered with 
PCR Foil (Thermo Fisher Scientific, Hertfordshire, UK), pulse vortexed, then kept on 
ice for 20 minutes. Plates were centrifuged at 3000g for 30 minutes at 4°C, the foil 
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was removed, and plates were inverted onto blue roll to drain. Next, plates were 
centrifuged inverted at 50g for 1 minute, then 150µL of ice cold 70% ethanol was 
added per well. Plates were sealed with PCR foil, inverted 5 times to mix then 
centrifuged for 10 minutes at 3000g at 4°C. The foil was removed and contents 
drained once more. Plates were centrifuged inverted at 50g for 1 minute, then 
10.5µL of HiDi formamide (Applied Biosystems, Renfrewshire, UK) was added to each 
well, and samples sequenced using a ABI3730 sequencer (Applied Biosystems, 
Renfrewshire UK).   
 
5.79 Methods: Sequence trace analysis 
 
Sequence chromatograms were analyzed using Chromas LITE, Version 2.1 
(Technelysium Pty Ltd, Queensland, Australia) and aligned within CLC Sequence 
Viewer 6.7.1. (Massachusetts, USA). To detect SNPs, sample sequences were 
compared to cultured isolate 3D7, gene ID PF13_0247, accessed from PlasmoDB 
(www.plasmodb.org), November 2012. It was not possible to consistently obtain 
nucleotide sequences for the first and last 44 nucleotides. Since these stretches did 
not contain the vaccine candidate, they were excluded from analysis.  
 
5.8 Methods and results: PCR and sequencing protocol optimization 
 
The protocols detailed above are the final protocols used but prior to concluding on 
these, the following PCR and sequencing optimization was performed. Initially, 
sequence traces were short with approximately only 290/687 readable base pairs for 
the first half of the gene and 200/780 for the second half of the gene. Sequences 
were poor quality with undefined sample peaks and high background (identified as 
multiple smaller peaks). To improve sequence quality, the magnesium concentration, 
PCR annealing temperature and primer concentrations were titrated, one at a time. 
The following final magnesium concentrations were attempted in the PCR reaction, 
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1.5mM, 2.0mM, 2.5mM, 3.0mM, 3.5mM  and  4.0mM, and the volume of water was 
adjusted accordingly. Since the final concentration of 2.5mM produced slightly 
longer readable traces, this concentration was used. To try to further improve 
sequence trace quality, a gradient was tried for the PCR annealing temperature, 
44.9°C, 45.4°C, 46.5°C, 48°C, 50°C, 51.6°C, 52.5°C, and 52.9°C. Fifty °C was the 
temperature used in the published protocol, which was also found to deliver optimal 
sequence traces. The primer concentration was titrated from 8-64pmol per reaction, 
but no observable difference in sequence trace quality was found so the 
recommended concentration of 32pmol/reaction was used for subsequent reactions. 
To try to conserve costly reagents, a range of PCR reaction end volumes were 
attempted, 6.25µL, 12.5µL, 25µL and 50µL, and 12.5µL was selected since it 
produced sufficiently strong bands and readable sequences for both primer sets.  
The volume of PCR product in the sequencing PCR reaction was titrated from 4.0-
0.5µL, and 2.0µL was found to be optimal. Similarly, the volume of BigDye used per 
reaction was titrated from 0.5-1.5µL and 1µL per reaction was found to result in 
longer traces. 
 
5.81 Methods and results: Design of new primers for amplification of pfs48/45 
 
It was not possible to amplify the second half of the gene (base pairs 488-1347) for 
20/146 samples (Tanzania=7, Ghana=4 and Burkina Faso=9). Following nested PCR 
there was no visible product on an agarose gel, and while sequencing was 
attempted, these samples did not have readable peaks on the sequencing 
chromatogram. Since the first half of the gene amplified well, poor quality DNA was 
doubted as the cause. While the BLAST search did not reveal previously identified 
SNPs in the primer sequence regions, the majority of uploaded sequences were from 
studies conducted over 10 years ago (Escalante, Grebert et al. 2002; Anthony, Polley 
et al. 2007). It was speculated the presence of a novel SNP(s), or an indel could be 
preventing amplification. PCR was attempted using a gradient across the annealing 
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temperature with the aim of decreasing binding specificity to hope to accommodate 
potential SNPs that could be impacting on melting temperature. No product was 
amplified. 
 
Different primer sets were paired to identify which part of the gene was resulting in 
amplification failure. To assess if there was a mutation in the original forward primer 
(F600), primers F533 and R1327 were combined but produced no amplicon. Next, 
F600 and R706 were combined to exclude SNPs in the forward primer, and this 
produced amplified product, suggesting the problem was in the later part of the 
sequence. Following this, four new primers were designed in the second half of the 
gene (Table 5.16.). Figure 5.16. demonstrates the location of the original, and new 
primer pairs (shaded in orange).   
 
 
Figure 5.16. Sequence of pfs48/45 (nucleotides 488-1347) and location of SNPs and 
primers. The nucleotides highlighted in red are SNPs that appear more than once, 
and SNPs in blue appear in just in 1/55 samples, (from samples uploaded to BLAST). 
SNPs highlighted in pink were identified in endemic samples, from this study. Novel 
primers are shaded in orange, and other colour primers are as previous, light green 
(F533), yellow (F600), grey (R658), pink (R706), and dark green (R1327). 
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Table 5.16. Sequence of new primers for amplification of fragments within 
nucleotides 488-1347 of pfs48/45.  
name  primer sequence 5'-3'  
SJF1  GAATCTAATTTTGTAAGTAATG  
KTrev2  CTGATTCAGGTTGATATAC  
SJR1  TTAGGAATATAAATGTTTTAGCC  
SJR2  TTTAATTTTATCATCTCCTTCAGCA   
 
The following primer pairs were then combined, 1) SJF1 and SJR1 and 2) SJF1 and 
Ktrev2,  attempting an 8 point annealing temperature gradient of 40-55°C. The new 
primers were tested in PCR against a small number of samples (n=4), since gradient 
PCR consumes a large volume of DNA. Both primer sets (SJF1 and KTrev2) and (SJF1 
and SJR1) produced amplification bands for these samples, when using 52.4°C as the 
annealing temperature.  Due to time constraints, the remaining samples were not 
tested, but the results imply there could be SNP/s or indels in the later region of the 
pfs48/45 gene, but this remains to be confirmed.  
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5.9 Extended discussion 
 
The main results and discussion are outlined in the attached manuscript. Additional 
findings discussed here are predominantly concerned with assay optimization, and 
further validation of results from the cross sectional surveys, using supportive sample 
sets.  
 
5.91 MBP-10C vaccine candidate 
 
The primary version of the REDMAL vaccine candidate, MBP-10C suffered 2 
developmental setbacks. Firstly, both endemic and European naive serum 
demonstrated reactivity to fusion partner MBP, and secondly, the level of properly 
folded clinical grade protein (produced by collaborators), was lower than the funding 
body requirement of >95% properly folded product (Will Roeffen, personal 
communication).  
MBP is a protein expression tag that improves yield of overexpressed proteins, and 
enhances their solubility (Sun, Tropea et al. 2011). MBP was not cleaved from 10C, 
since removal can result in protein aggregation, and reactivity of test serum to MBP 
was not anticipated (Fox, Routzahn et al. 2003). There is no obvious explanation for 
the apparent background reactivity to MBP in European controls and endemic sera. A 
BLAST search (www.ncbi.nlm.nih.gov/BLAST) was performed and all close matches 
found to be sugar transporters found among Enterobacteriaceae. Since MBP is a 
bacterial protein, it could be speculated that individuals carry antibodies as a result 
of exposure during immune clearance of natural bacterial infection. However, MBP is 
commonly used as an overexpression fusion partner and there is no evidence in the 
literature to support this hypothesis. Possibly, E.coli contaminants from production 
of 10C may have remained and resulted in ELISA reactivity. The source of the high 
reactivity to MBP remains unconfirmed at present. Since the thesis objectives are 
related to measuring specific antibodies to the sexual stage vaccine candidate and 
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because the product changed to reach higher concentrations of conformational 
protein, the remainder of this work focused on 10C from the R0-10C product. 
 
5.92 Acquisition of 10C and 230CMB antibodies with age 
 
Gaining a more thorough understanding about how antibodies are acquired 
following natural exposure could provide insight into how long vaccine induced 
antibody responses may last for and what is required to boost them. Ideally, from a 
TBV viewpoint, it is desirable for a functional antibody response to be evoked 
following as few exposures (vaccination, or natural) as possible, last a long time and 
be boosted from low parasite densities. Attempts have been made to determine how 
sexual stage antibodies are acquired and what results in TRA. There has been 
conflicting evidence so far regarding an age dependent pattern of sexual stage 
antibody acquisition. As discussed in section 1.36., previous research indicated sexual 
stage antibody prevalence decreased with age, which implies higher density 
gametocytes (typically found in children) are needed to elicit antibody production. 
Furthermore, previous research suggests sexual stage antibodies are reliant on 
recent gametocyte exposure and are short lived rather than forming the cumulative 
immunological memory response, which is commonly seen for asexual stage antigens 
(Bousema, Drakeley et al. 2007; Bousema, Sutherland et al. 2011; Ouedraogo, 
Roeffen et al. 2011). 
 The field sites described in this chapter were selected for sample collection to 
explore differences in antibody prevalence in varying levels of malaria exposure, and 
because these sites are under consideration for future vaccine trials. The schools 
sampled in Burkina Faso were located in a region of hyper endemicity, whereas 
Tanzanian schools were in a site of meso-endemicity, and Ghana in a site of hypo 
endemicity. As indicated in the attached manuscript, participants from Burkina Faso 
demonstrated a statistically significant age dependent increase in antibody 
prevalence for both 10C and 230CMB. In Tanzania there was a significant increasing 
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relationship with age only for 230CMB antibodies. This finding raises questions 
regarding antibody boosting and longevity and contrasts with previous results. 
However, it must be noted that prior studies measured antibodies against native 
proteins Pfs48/45 and Pfs230. Therefore they are not directly comparable since 
previous research has indicated there can be variation in immunogenicity between 
protein epitopes, and 10C contains 3 epitopes out of the 5 found in native protein, 
(Anders, Coppel et al. 1988; Taylor, Egan et al. 1996). Similarly, 230CMB represents a 
portion of 1 of the 7 paired domains of Pfs230 (Farrance, Rhee et al. 2011).  
Consequently, there could be a different pattern of recognition between native and 
recombinant protein. This is discussed more in section 7.2.  
Generally in high endemic settings, the majority of infections with high density, 
microscopically detectable gametocytes are found in children, and the gametocyte 
burden in adults is predominantly submicroscopic gametocytes (Ouedraogo, 
Bousema et al. 2010). Since an age dependent antibody acquisition pattern was 
observed with sexual stage antibodies, and adults have the highest antibody 
prevalence, this implies that sexual stage antibody responses may accumulate on 
exposure and be boosted from submicroscopic gametocytes (Ouedraogo, Bousema 
et al. 2010), although this requires confirmation using molecular gametocyte 
detection. The discrepancies between sites in the age-dependent acquisition of 10C 
and 230CMB antibodies could be explained by infrequent transient infections in 
Ghana which result in limited exposure, insufficient to sustain antibody responses, 
whereas in Burkina Faso, there may be more frequent (or continuous) exposure to 
infections, with accompanying (low densities) of gametocytes. One potential 
modulating factor may be a longer antibody half life in adults compared to children, 
which could contribute to the cumulative response (Bousema, Roeffen et al. 2010).  
There was no consistent pattern with antibody prevalence and season for the 
countries explored. While anticipated antibody prevalence would be higher in the 
transmission season due to more prolonged exposure to potentially higher density 
gametocytes, this was not consistently (or statistically significantly) the case. Once 
more, this implies submicroscopic gametocytes play an important role in eliciting a 
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sexual stage antibody response.  Furthermore, there was no statistically significant 
relationship with microscopically detectable gametocytes and antibody prevalence 
(which is in line with previous research) which again suggests submicroscopic 
densities are sufficient to boost antibody responses (Riley, Bennett et al. 1994; 
Bousema, Roeffen et al. 2006; Drakeley, Bousema et al. 2006; Bousema, Drakeley et 
al. 2007).  
A relationship between parasite carriage and concurrent antibody responses is 
difficult to interpret since there is a time lag between antigen exposure and antibody 
production. For this reason, current antibody responses may reflect long term 
differences in parasite exposure (Ouedraogo, Roeffen et al. 2011). A longitudinal 
study repeatedly sampling participants over time and performing molecular 
gametocyte detection would help to gain a more accurate understanding of this 
relationship.   
To explore antibody prevalence in adults, 10C and 230CMB antibodies were 
quantified in samples from participants aged 6 months to 72 years from Kanungu, 
Uganda. This revealed the previously indicated age acquisition pattern seen in school 
aged children extended into adults who had the highest 10C and 230CMB antibody 
prevalence in the population, once more supporting the hypothesis of a cumulative 
sexual stage antibody response.  
In terms of the vaccine, this data demonstrates all age groups are capable of 
producing antibodies against both vaccine candidates which may translate to 
boosting of a vaccine induced response. However, the functionality of these 
antibodies remains in question since it has been indicated only a relatively small of 
proportion of antibodies demonstrate TRA (Drakeley, Bousema et al. 2006; Bousema, 
Roeffen et al. 2010).  
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5.93 Transmission reducing activity and the relationship with 10C and 230CMB 
antibodies 
 
10C and 230CMB antibodies were quantified in the compilation of samples with 
SMFA data from Burkina Faso, The Gambia, Cameroon, Gabon and missionaries from 
The Netherlands. While these individuals represent different populations in terms of 
previous malaria exposure (and acquired immunity), genetic status and ethnicity, 
data was combined to increase the sample size and strength of the investigated 
associations. All individuals, with the exception of the missionaries, were 
microscopically confirmed gametocyte carriers. Since there was no age data for the 
missionaries and they were first exposed to malaria at an adult age, they were 
excluded from age associated analysis. 
It has previously been revealed estimates of TRA on a continuous scale should be 
interpreted with caution and only TRA >90% can be reproducibly measured (van der 
Kolk, de Vlas et al. 2004). Therefore, TRA was analyzed at the >50% (including 50-89% 
TRA) and >90% (including 90-100% TRA) level. It is important to note within our 
sample population, 31 individuals exhibited TRA at the 50% level and 16 people at 
the 90% level. Since these are low numbers, these results should be interpreted with 
caution. There was no statistically significant relationship between 230CMB 
antibodies and TRA at the >50% level, and none of these individuals had antibodies 
to 10C. When categorized at the >90% level, TRA was significantly associated with 
both 10C and 230CMB antibodies. Forty % of the individuals who demonstrated 
>90% TRA had 10C antibodies (most of whom were also positive for 230CMB), 61.5% 
had 230CMB antibodies, and 5 people had no measurable antibody responses for 
either antigen. It has previously been indicated Pfs230 is more immunogenic 
compared to Pfs48/45, which has been suggested to be a  consequence of the larger 
size of Pfs230 and presence of more epitopes (Williamson 2003). The higher 
immunogenicity may be the reason for the larger proportion positive for 230CMB 
antibodies within the >90% TRA category (Ouedraogo, Roeffen et al. 2011).  
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The SMFA compilation sample set also demonstrated a statistically significant age 
dependent increase in antibody prevalence for both vaccine candidates. Since there 
was no evidence that TRA increases with age. This suggests the functionality of 
antibody responses in this sample set is not well reflected by the ELISA assays.  It is 
unclear what contributes towards functional TRA. 
As discussed in section 1.35. previous studies have provided conflicting evidence 
regarding TRA and native protein, Pfs48/45 and Pfs230, antibody prevalence and 
density. Studies have confirmed a relationship between the 2 (Drakeley, Bousema et 
al. 2006; Ouedraogo, Roeffen et al. 2011), found no relationship (Premawansa, 
Gamage-Mendis et al. 1994), or indicated high antibody titre samples demonstrate 
TRA (Drakeley, Mulder et al. 1998). A study performed in Tanzania suggested the 
proportion of individuals exhibiting  >50% TRA decreased with age, and  just a small 
proportion of individuals from all age categories demonstrated >90% TRA (Drakeley, 
Bousema et al. 2006). While I confirmed there is a relationship with 10C and 230CMB 
antibodies and TRA, no increasing association was found with titre. My findings were 
in broad agreement with the Tanzanian study and showed the proportion of 
individuals demonstrating >50% TRA decreased with age, but this was not a 
significant trend. Furthermore, my findings also agreed that a small proportion of 
each age group exhibited >90% TRA. Potential contributions to functional TRA are 
further discussed in section 7.2. 
 
5.94 pfs48/45 gene sequencing 
 
Mutations were found in field sample pfs48/45 gene sequences. It has previously 
been indicated mutations induced in the cysteine residues resulted in a loss of 
epitope function (Outchkourov, Vermunt et al. 2007). Since none of the non 
synonymous substitutions affected cysteine residues, it seems possible that epitopes 
will remain properly folded in samples with these polymorphisms. Intriguingly, it was 
not possible to amplify the second half of the gene for 20 samples, which could be 
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caused by the presence of an indel or SNP/s in the region of the reverse primer 
thereby preventing primer binding. It would certainly be of relevance to identify the 
source of the problem, since transmission blocking epitopes 1-3 are all within this 
region and a deletion, particularly within epitope 1 which is correlated with higher 
TRA, could reduce vaccine efficacy (Roeffen, Teelen et al. 2001; Outchkourov, 
Vermunt et al. 2007).   
 
5.95 Conclusions 
 
While previous studies indicated malaria endemic populations are antibody positive 
to native proteins Pfs48/45 and Pfs230, it was uncertain if these findings would 
extend to the recombinant proteins which represent just a portion of the native 
proteins. Furthermore, due to the large number of disulphide bonds, overexpressing 
recombinant proteins in the correct conformation in order to achieve good 
functionality is an obstacle. The research discussed within this chapter represents the 
next step in development of 2 novel vaccine candidates.  
The presence of antibodies was demonstrated in participants of all ages from regions 
of hyper, meso and hypo endemicity, and higher antibody prevalence was found in 
the high endemic setting. What appears to be a cumulative antibody memory 
response was identified in the site with high endemicity, and also within the 
additional supportive sample sets. This pattern could reflect antibody boosting from 
submicroscopic gametocyte densities, a longer antibody half life, or improved 
antibody affinity in adults. The observations from this chapter suggest vaccine 
induced antibodies against these specific candidates could be boosted (in all age 
groups) within different endemic settings, which may improve the TRA of vaccine 
induced immunity, although this has not been tested. 
While a statistically significant relationship was demonstrated between 10C and 
230CMB antibodies and TRA, it must be noted what is described falls short of formal 
evidence for a causal association. In order to directly prove this association, 10C and 
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230CMB antibodies in test samples would need to be affinity purified against the 
recombinant antigens then assessed using SMFA. Within the SMFA compilation 
sample set, there is evidence that while 10C and 230CMB antibody prevalence 
increases with age (and titre, for 230CMB), TRA does not, which implies more than 
just antibody prevalence and density is needed to result in functional TRA.  
While antibody responses against 2 transmission blocking candidates were 
investigated in this chapter, it is important to note there are other antigens for which 
antibodies have not been measured, that could be responsible for TRA. HAP2 is an 
example of another known pre-fertilization transmission blocking antigen being 
developed as a vaccine candidate (Miura, Takashima et al. 2013).  Beyond the known 
antigens, proteomics revealed there are approximately 300 genes specific to sexual 
stages, and among these could be other pre-fertilization transmission blocking 
antigens that may contribute to naturally acquired TRA (Florens, Washburn et al. 
2002; Gardner, Hall et al. 2002; Lasonder, Ishihama et al. 2002; Le Roch, Zhou et al. 
2003; Bousema and Drakeley 2011).  
Vaccine research has predominantly focused on pre-erythrocytic and blood stage 
antigens, and there are currently 28 vaccine candidates under development that are 
featured in the clinical trials listed in the WHO Rainbow Table (WHO 2013). 
Comparatively less research has focused on TBV development and as a result, just a 
handful of candidates have been considered for development (Bousema and 
Drakeley 2011). Only 2 are currently undergoing clinical trials, both of which are 
based on Pfs25 (WHO 2013), which has previously been reported to be of low 
immunogenicity (Wu, Ellis et al. 2008).   
The biggest hurdle for the most advanced transmission blocking candidates 
(Pfs48/45, Pfs230 and Pfs25) has been the large number of disulphide bonds which 
has complicated the production of recombinant proteins in the correct conformation 
(Outchkourov, Roeffen et al. 2008; Farrance, Rhee et al. 2011; Gregory, Li et al. 
2012).  These challenges highlight the importance of developing new transmission 
blocking antigens. Exploring some of the uncharacterized sexual stage specific genes 
would form a good starting point in order to identify new candidates.  
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Chapter 6: Determining the transmission reducing activity of IgG purified 
from vaccinated rats against endemic parasites, and assessing the 
suitability of parasite detection methods to detect infectious individuals 
 
6.1 Introduction  
 
Following confirmation of the presence and functionality of naturally acquired 10C 
antibodies in different endemic settings, the next goal was to confirm the ability of 
anti R0-10C IgG from vaccinated rats to reduce transmission of field isolates. 
Previously, plasma from rats vaccinated with R0-10C was confirmed to demonstrate 
functional TRA against a panel of genetically diverse  P. falciparum cultured strains 
(NF54, NF166 and NF135) from different geographical locations, using SMFA 
(Theisen, Roeffen et al. 2014). While results using cultured parasites were 
encouraging, there are differences with natural infection such as parasite genetic 
complexity and varying parasite densities that could affect the success of 
transmission reducing antibodies. To rigorously test the efficacy of any malaria 
vaccine, it needs to be challenged against endemic parasites in a setting in which it is 
intended for use (Bousema, Dinglasan et al. 2012). While touched on briefly in 
section 5.13., a major concern with development of any vaccine is that it may only 
elicit protection against strains that are identical or closely related to the vaccine 
genotype, which could result in vaccine -induced escape mutants. AMA-1 is an 
example of an asexual stage polymorphic candidate where development has been 
hindered as a consequence of the genetic diversity of natural isolates (Dutta, Dlugosz 
et al. 2013).  A clinical trial performed in Mali assessed response to a monovalent 
AMA-1 vaccine candidate and revealed protection was only induced against identical 
or similar strains to the vaccine sequence (Thera, Doumbo et al. 2011). Similarly, 
other researchers determined the genetic variation of MSP-1 19 in a vaccine field site 
in Mali, and discovered the majority of circulating strains were different haplotypes 
to the vaccine candidate. This reiterates the importance of examining endemic 
parasite genetic diversity when developing a vaccine, and exploring the degree of 
cross allele protection that will determine the occurrence of escape mutants (Takala, 
Coulibaly et al. 2007).  
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In this chapter, this was explored by performing membrane feeding combined with 
serum replacement to determine the ability of vaccine derived IgG to reduce 
transmission of endemic parasites. As discussed in section 1.47., there are variations 
of membrane feeding protocols, such as DMFA and SMFA that have been devised to 
address these questions. The techniques have different strengths and while SMFA 
allows control over variables such as parasite density, it has the disadvantage of 
using a small number of parasite isolates (commonly 3D7) for experiments. While 
DMFA performed in the field lacks some control, it has the advantage of using 
naturally infected parasite carriers as the gametocyte source, who  are often carrying 
more genetically diverse gametocytes (Bousema and Drakeley 2011).  Serum 
replacement is a valuable adaptation of the protocol that can be coupled with DMFA 
or SMFA to enable determination of transmission blocking immunity in naturally 
exposed, or vaccinated populations, compared to naive serum.  
Results from the previous chapter indicated pfs48/45 is genetically diverse, especially 
in parasites from Burkina Faso. For this reason, and due to availability of good 
membrane feeding facilities, the study described in this chapter was performed in 
Burkina Faso.  
 
6.2. Study design and objectives 
 
My study was nested within a larger study which randomly selected individuals for 
mosquito feeding experiments in order to assess the human infectious reservoir.  The 
objective of my study was to determine the ability of IgG purified from serum from 
rats that had been vaccinated with R0-10C to reduce or block transmission of 
endemic parasites, using DMFA combined with serum replacement. Six test 
membrane feeding conditions were used in total, whole blood, autologous plasma, 
control plasma, naive rat IgG (0.6mg/mL), positive rat IgG (0.6mg/mL) and positive 
rat IgG (0.2mg/mL). Whole blood was included since it is the most widely used 
approach to determine infectiousness of participants, which was the main outcome 
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of the overarching study. Autologous plasma was included as a quality control 
condition, where blood samples were pelleted then the red blood cell pellet was 
once more mixed with autologous plasma. This sample should give a similar infection 
outcome as the whole blood sample, with the only difference being sample handling. 
This enables identification of a loss in infectiousness as a result of centrifugation, 
which has previously been reported (Bousema, Dinglasan et al. 2012). The European 
naive control plasma was included to allow comparative determination of the TRA of 
naturally acquired antibodies in the participant plasma. For example, if the 
participant serum contained antibodies with functional TRA, the expected outcome 
would be higher prevalence/density of infection in mosquitoes fed with control 
serum, compared to mosquitoes fed with autologous plasma (Bousema and Drakeley 
2011). Similarly, naive rat IgG (Abcam, Cambridgeshire, UK) was used as a control to 
assess the TRA of the vaccinated rat IgG. The vaccinated rat IgG was diluted to 2 
concentrations, 0.6mg/mL and 0.2mg/mL to assess if a dose dependent effect would 
be reflected with TRA.  
Specific chapter objectives were as follows: 
1. To purify IgG from rats vaccinated with R0-10C vaccine candidate and confirm the 
ability of the IgG to prevent the transmission of cultured P. falciparum gametocytes, 
using standard membrane feeding assay.  
2. Determine the sensitivity and specificity of parasite detection techniques to 
identify individuals who infected mosquitoes, which was assessed using direct 
membrane feeding assay. 
3. To test the ability of vaccine-induced IgG in rats to reduce transmission of P. 
falciparum gametocytes from naturally infected gametocyte carriers in Burkina Faso 
using serum-replacement membrane feeding experiments. 
4. Assess the transmission reducing activity of endemic serum using serum 
replacement membrane feeding experiments, and the relationship between 
transmission reducing activity and 10C and 230CMB antibodies. 
 
 230 
 
6.3. Materials and Methods 
 
Work outlined in sections 6.31 and 6.32 was performed by colleagues at Radboud 
UMC. 
 
6.31 Vaccination of rats with R0-10C 
  
Recombinant R0-10C was purified using a Ni-NTA Purification System (Invitrogen, Life 
Technologies, Bleiswijk, The Netherlands) followed by a Sephacryl affinity column (GE 
Healthcare, Eindhoven, The Netherlands), a Size Exclusion Column (GE Healthcare, 
Eindhoven, The Netherlands),  followed by a HiTrap column (GE Healthcare, 
Eindhoven, The Netherlands), containing epitope 45.1. This was performed by 
colleagues at Statens Serum Institut, Denmark as described in more detail elsewhere 
(Theisen, Roeffen et al. 2014). Following this, purified R0-10C was sent to Radboud 
UMC, The Netherlands, where purity and reactivity was confirmed by SDS PAGE, 
Western blot and 2 site ELISA, by colleagues. Next rat vaccination was performed 
using the purified product by Will Roeffen as follows. Three groups of 5 Wistar 
Hanover rats were vaccinated with R0-10C combined with 1 of the following 
adjuvants, SE/GLA, ALUM or AbiSCO.  Rats were administered 3 subcutaneous 
vaccinations with 200µL of 20µg of 100% properly folded R0-10C over an 8 week 
period. Fourteen days following the final vaccination, rats were bled (~2mL per rat) 
and serum separated from the blood pellet by centrifugation at 3000 rpm for 3 
minutes, in preparation for use in SMFA.  
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6.32 Assessing the transmission reducing activity of vaccinated rat serum using 
standard membrane feeding assay (SMFA) 
 
To assess TRA using SMFA, 30µL of rat serum was diluted to an end dilution of 1/9 
with cultured (3D7) gametocytes (150µL) combined with 120µL of naïve human AB 
serum. This was then offered to 20 starved Anopheles stephensi mosquitoes per each 
vaccine/adjuvant combination. Serum taken from rats prior to vaccination was used 
for the control mosquito feeding arm, but was otherwise handled in the same 
manner as described above. Following feeding, fully and partially unfed mosquitoes 
were removed and fed mosquitoes were maintained on glucose soaked pads for 
seven days. Mosquitoes were then dissected and oocyst density was compared 
between test and control serum fed mosquitoes, (Table 6.0.). This was performed by 
colleagues at Radboud UMC. 
Table 6.0. Transmission reducing activity of vaccinated rat serum assessed using 
SMFA. Data provided by Will Roeffen, p-values were determined comparing 
arithmetic means in oocyst density, as routinely done at Radboud UMC (van der Kolk, 
de Vlas et al. 2004). 
Adjuvant 
Group 
Rat # number 
infected  
mosquitoes 
(n=20) 
% TRA p-value 
Alum 1 1 99 <0.001 
 2 0 100 <0.001 
 3 0 100 <0.001 
 4 1 99 <0.001 
  5 0 100 <0.001 
SE/GLA 11 2 99 <0.001 
 12 2 99 <0.001 
 13 1 99 <0.001 
 14 1 99 <0.001 
  15 0 100 <0.001 
AbISCO 16 0 100 <0.001 
 17 0 100 <0.001 
 18 1 100 <0.001 
 19 2 99 <0.001 
 
 232 
 
6.33 Purification of IgG from vaccinated rat serum 
 
The vaccinated serum demonstrated 99-100% TRA for all rats, Table 6.0. Since TRA 
was similar within each of the 3 adjuvant groups, serum from individual rats was 
pooled for each adjuvant group, then purified by affinity chromatography using a 
HiTrap MabSelect Xtra column (GE Healthcare, Eindhoven, The Netherlands).  Prior 
to purification, 200µL of serum from each adjuvant pool was reserved to enable pre 
and post purification comparison of protein concentration and functionality. Serum 
pools were prepared as follows 1.5mL of serum from each rat was pipetted into a 
50mL falcon tube, then 25mls of 10x PBS was added and tubes centrifuged for 15 
minutes at 4000 rpm. IgG purification was performed according to manufacturer 
instructions (Healthcare 2013). To provide a negative control for membrane feeding 
experiments, naïve rat IgG (Abcam, Cambridgeshire, UK) was purified in the same 
manner as the 3 test samples. Following fractionation, protein peaks indicated IgG 
remained in fractions 5-9. These fractions (2mls each) were pooled, neutralized to pH 
7.5 by adding 500µL of 1M Tris pH 8.0, then this volume was adjusted to 20mls with 
1x PBS and added to a Vivaspin 20 column (Sartorius Stedim Biotech GmbH, 
Goettingen, Germany). This centrifugable column concentrated IgG by removing 
lower weight proteins, and removed residual salt from the column purification which 
could interfere with the membrane feeding assay.  The spin column was centrifuged 
at 4000 rpm for 35 minutes to allow low molecular weight material to pass through 
the column, while retaining higher molecular weight proteins in the spin column 
matrix. Flow through was retained until it was later confirmed to be free of IgG. The 
concentrated material (~500µL) within the matrix of the spin column was then 
resuspended in 20mls of 1x PBS, and centrifuged as before, to ensure removal of all 
salt. Following this, the purified protein in the column matrix was resuspended in 
1.5mL of 1x PBS and IgG concentration was determined. IgG concentration was 
assessed in both the concentrated product and flow through using a Nanodrop, Table 
6.1.  
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Table 6.1. Concentration of IgG purified from vaccinated rats from different 
adjuvant groups. Results are shown for the concentrated sample and the column 
flow through.  
Adjuvant group Sample type Concentration mg/mL 
ALUM Concentrated 
sample 
1.36 
 Flow through  0 
AbiSCO Concentrated 
sample 
1.35 
 Flow through  0 
SE/GLA Concentrated 
sample 
1.33 
 Flow through  0 
 
6.34 Reactivity of vaccinated rat IgG against 10C using ELISA 
 
While Table 6.1. indicates there is no IgG in the column flow through material, before 
discarding samples, total IgG was measured reacting to 10C using ELISA for 3 samples 
per each adjuvant group, a) starting material before column purification, b) purified 
IgG and, c) column flow through. The 10C ELISA was performed as previously 
outlined in methods section 3.13., but the human IgG conjugate was substituted for a 
rabbit-anti rat IgG-HRP (Dako, Glostrup, Denmark). Each IgG sample was titrated 
down the plate from row A-H in tripling dilutions from 1/100- 1/218,700.  
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Figure 6.0. Reactivity of titrated rat serum before purification (B.P) and after 
purification (IgG samples) assessed against 10C antigen using ELISA, for each of the 3 
adjuvant groups. Reactivity in ELISA is indicated by optical density. Dotted lines and 
un-filled shapes represent un-purified material and solid shapes and solid lines 
represent purified IgG. Diamonds represent the AbiSCO group, triangles represent 
the alum adjuvant group, and squares represent the SE/GLA group.   
 
 IgG purified from the 3 adjuvant pools shows comparable reactivity on an ELISA 
plate coated with 10C, as shown in Figure 6.0., and demonstrates IgG is specific to 
10C. To increase the volume of material available for membrane feeding experiments 
in the field, IgG was pooled from the 3 adjuvant groups to produce 1 test sample. 
  
6.35 Standard membrane feeding assay (SMFA) and dilution of test IgG dilution 
 
To determine an appropriate IgG test concentration, 2 dilutions were made 
(0.3mg/mL and 0.1mg/mL) which were based on previous titration experiments. This 
was tested using SMFA which was performed by colleagues at Radboud UMC. IgG 
was diluted in European AB serum (Blood Bank, Radboud UMC), which was taken 
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from donors with no travel history to malarious regions. When compared to the 
control group, mosquitoes fed with 0.3mg/mL of IgG from vaccinated rats 
demonstrated a reduction in oocyst density by 99.2% (CI: 97.8-100, p<0.001) which 
was 84.8% (CI:75.3-91.6, p<0.001) for mosquitoes fed with 0.1mg/mL of IgG 
(determined by one sided Mann Whitney, by Will Roeffen). Maintaining an 
approximate ratio of 1:1 of IgG to diluent, purified IgG was diluted in European naïve 
AB serum to 0.6mg/mL and 0.2mg/mL, which was aliquoted into volumes of 300µL in 
the field, ready for serum replacement experiments.   
 
6.4 Fieldwork performed in Burkina Faso to collect endemic parasites 
 
Fieldwork was planned and performed with Dr. Bronner Goncalves, LSHTM. Samples 
were collected together, but used for different purposes. Household selection and 
participant enrolment was performed with a team of demographers, translators and 
drivers. 
 
6.41 Sampling population  
 
Participants were recruited from a village called Laye located 33km North-West from 
Ouagadougou in Burkina Faso. This is a rural region comprised of 3 districts and is 
defined by Sudanese Savannah, where the population are mainly farmers. Malaria 
transmission is high and seasonal, and the transmission season spans July to October 
(Ouedraogo, De Vlas et al. 2008). The EIR has been estimated at 300-500 infectious 
bites per person per year (Cuzin-Ouattara, Van den Broek et al. 1999; Ouedraogo, De 
Vlas et al. 2008).  A survey performed in 2002-2003, demonstrated asexual parasite 
carriage was 60-90% in children under 15 years, and 20-50% in adults (Ouedraogo, 
De Vlas et al. 2008; Ouedraogo, Bousema et al. 2009). The study in this chapter was 
performed at the end of the dry season to complement the main study that was 
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assessing the human infectious reservoir. The target population was healthy 
individuals over the age of 2, with no upper limit.  
The experiment assessing TRA of vaccine induced rat IgG was exploratory in nature 
(no formal sample size calculation was performed) and the first 53 RDT positive 
individuals who were recruited for the larger study were sampled. The larger study 
was descriptive and aimed to obtain estimates of infection prevalence during the dry 
season. Since the insectary was able to provide mosquitoes to allow processing of 6 
individuals per day (each with potentially 6 membrane feeding conditions), 200 
participants were enrolled for the month before the beginning of the dry season, 
which enabled enough time to complete sampling before commencement of the 
rainy season. One hundred children were sampled from age 5-15 were since they 
form the most informative part of the population with the highest parasite carriage 
(Goncalves, in preparation).   
 
6.42 Ethical approval  
 
Ethical approval was acquired from the London School of Hygiene and Tropical 
Medicine (#6271) and the Ethical Review Committee of the Ministry of Health of 
Burkina Faso.  
 
6.43 Participant sensitization and household enrolment  
 
Sensitization was typically performed 1-5 days before participants were brought to 
the centre for sampling. First, houses were selected using the random walk method. 
This involved spinning a pen to select a direction to walk in, then walking from the 
centre of the 1st district in Laye to the outer perimeter of the village counting the 
houses on the way (UNICEF 2010). On the return trip every ‘n’th house was selected 
for enrolment, where ‘n’ is a randomly selected number that results in 10-15 houses 
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being chosen per day. For example, when there were 24 houses, every second house 
(n=2) was selected (12 total), this ensured that while the direction selected was 
random, there was fairly even sampling from the centre outwards. In each week, 
sampling was performed in a different part of the village, so by the end of the study 
all neighbourhoods were represented.    
For each selected house, the sensitization team who spoke the local dialect explained 
the project objectives and procedures, including the purpose of the samples that 
would be taken. From each house 4 individuals: 1 child aged 2-4, 2 children aged 5-14 
and 1 adult >15 years, were randomly selected by drawing numbers from a box. The 
highest numbers were then asked if they would participate in the study. Consent 
forms were read and signed by participants and/or guardians and care was taken to 
ensure participants understood what had been said to them, then questions about 
the study were answered, and household global positioning system (GPS) 
coordinates collected.  
 
6.44 Screening day  
 
Screening was performed in the field several days before sampling with the objective 
of determining if participants were symptomatic before transporting them to Centre 
National de Recherche et de Formation sur le Paludisme (CNRFP). The study nurse 
asked participants about medical history and current symptoms, and then obtained 
axillary temperature. If febrile (> 37.5°C) or suffering from other acute symptomatic 
disease, individuals were treated, referred to their local health facility and excluded 
from the study.   
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6.45 Participant sampling 
 
On the sampling day, participants were brought to the insectary at CNRFP, sampling 
one family at a time where possible and ensuring children were accompanied by an 
adult. At the centre the study nurse asked about medical history once more, 
including development of new symptoms. A physical examination was performed 
and study questionnaire completed on a case report form.  
Finger prick and venous blood samples were taken for RDT, microscopy, serology, 
filter paper collection, parasite detection by PCR and QT-NASBA, gametocyte 
detection by QT-NASBA and membrane feeding assays. A hemocue test (Angelholm, 
Sweden) was performed immediately (according to manufacturer instructions) to 
test and treat for anaemia. Participants were excluded if their haemoglobin level was 
<8g/dL, otherwise they were issued a study ID number and the rest of the sampling 
was performed as follows. Approximately 300µL was taken for the finger prick blood 
sample in a BD Microtainer (Becton Dickinson, Oxford, UK), according to the 
manufacturer guidelines. To store samples for RNA based gametocyte detection, 
100µL of whole blood was immediately transferred into a microcentrifuge tube 
containing 500µL of RNA protect (Qiagen, Surrey, UK) using filter tips. 
Microcentrifuge tubes were inverted 5 times to mix, then samples were maintained 
on ice and transferred to -80°C as soon as possible. On return to the laboratory,  
thick and thin microscopy slides were prepared for each participant along with 3x 
20µL filter paper blood spots which were taken on Whatman 3MM filter paper.  
 
6.46 RDT scoring 
 
The intention was to use gametocyte positive blood for the serum replacement 
experiments with rat IgG. While it would have been preferable to confirm 
gametocyte presence before performing serum replacement, it was not possible to 
hold participants while waiting for microscope slides to be read. Furthermore, many 
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studies have indicated gametocyte carriers often harbour gametocytes at 
submicroscopic densities which are still capable of infecting mosquitoes (Schneider, 
Bousema et al. 2007). Therefore, RDT positivity was used as a proxy for gametocyte 
presence since RDTs offer rapid parasite detection. While RDTs are not gametocyte 
specific, individuals positive for asexual parasites at a density sufficiently high to be 
detected by RDT (sensitivity ~100 parasites/L) were expected to also harbour 
infectious gametocytes (Bell 2002; Bell, Wongsrichanalai et al. 2006). Since studies 
have indicated an increasing relationship between RDT test line colour density and 
parasitaemia (Rodulfo, De Donato et al. 2007), results were scored against the colour 
chart that was provided by the WHO for the RDT product testing project (WHO 
2009). Negative results were scored 0, while positive results were scored from 1-4, 
with 1 corresponding to a faint line, and 4 corresponding to a dark line (see appendix 
11 for the colour chart). RDT results were initially determined as positive or negative 
much sooner than the manufacturer recommended time in order to minimise the 
amount of time between blood draw and feeding mosquitoes. The colour intensity 
scores that were analyzed in this chapter were determined at the manufacturer 
recommended reading time.  
While symptomatic individuals were excluded, in some instances symptoms 
developed after arriving at CNRFP. In this situation, an RDT was performed, and 
following a positive result, the participants were excluded from the study and treated 
with AL (CoArtem, Novartis, Basel, Switzerland). 
 
6.47 Membrane feeding conditions 
 
Six membrane feeding conditions were included for RDT positive individuals: whole 
blood, autologous plasma, control plasma, naive rat IgG (0.6mg/mL), positive rat 
serum (0.6mg/mL) and positive rat serum (0.2mg/mL), using the venous blood 
sample, (see Table 6.2.).  
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Table 6.2. Membrane feeding conditions and sample handling according to 
participant RDT results. 
Condition Purpose RDT results  Sample handling  
Whole blood Assess who is 
infectious 
 
Allow 
determination 
of effects of 
centrifugation 
on 
infectiousness 
All  Directly into the feeder  
Autologous 
plasma 
Determine 
effects of 
centrifugation 
on 
infectiousness 
 
Assess who is 
infectious 
All  Centrifuged, then 
resuspended  
 
European naive 
human serum 
Control to 
assess TRA of 
endemic 
antibodies 
All  Centrifuged, serum 
removed and replaced 
with same volume of 
European naive serum  
 
Naive rat IgG 
(0.6mg/mL) 
Control for rat 
IgG conditions 
Positive 
only 
 Centrifuged, serum 
removed and replaced 
with same volume of 
naive rat IgG 
 
Vaccinated rat 
IgG (0.6mg/mL) 
Determine TRA 
of vaccinated 
rat IgG 
Positive 
only 
 Centrifuged, serum 
removed and replaced 
with same volume of 
vaccinated rat IgG 
(0.6mg/mL) 
 
Vaccinated rat 
IgG (0.2mg/mL) 
Identify 
possible dose 
dependent 
effect of TRA 
Positive 
only 
 Centrifuged, serum 
removed and replaced 
with same volume of 
vaccinated rat IgG 
(0.2mg/mL) 
 
 
6.48 Mosquito husbandry  
 
Mosquito husbandry and dissection was performed by staff at CNRFP. A brief 
overview of processes is described below. Membrane feeding experiments were 
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performed using mosquitoes that had been acquired locally but adapted to colony 9 
years previously (Ouedraogo, Bousema et al. 2009). Four-five day old female 
Anopheles gambiae sensu stricto (s-form) mosquitoes were used for feeding 
experiments. Mosquitoes were starved for a minimum of 5 hours before 
experiments, then shortly before sampling, batches of 60 mosquitoes were aspirated 
into children’s cardboard ice cream cups (500mls) which were covered with mesh 
and secured with an elastic band.  
 
6.49 Equipment preparation 
 
Mini water jacketed glass membrane feeders (Coelen Glastechniek, Weldaad, The 
Netherlands) were connected to each other using plastic tubing attached to an 
Isotemp Immersion Circulator water bath (Thermo Fisher Scientific, Hertfordshire, 
UK) that maintained water at 37-38°C. Water was circulated through the feeders for 
10 minutes before use to acclimatize instruments to temperature. Following this, the 
glass feeders were sealed with 2x2cm pieces of Parafilm (Camlab, Cambridgeshire, 
UK), then were ready for use. To prevent gametocytes from exflagellating due to a 
drop in temperature, plastic wear and serum was also heated to human body 
temperature (37-38°C). An Eppendorf ThermoStat Plus dry incubator (Eppendorf, 
Hertfordshire, UK) was used to heat the following equipment: blunt needles (0.7mm 
x38.1mm, Kendall Monoject, Massachusetts, USA), microcentrifuge tubes, pipette 
tips, and all serum aliquots (European naive control, naive rat IgG, and 2 vaccinated 
rat IgG conditions). A water bath was used to heat: 10 mL syringes (BD Plastipak, 
Becton Dickinson, Oxford, UK), BD heparin vacutainers (Becton Dickinson, Oxford, 
UK) for taking blood, and additional syringes for transferring blood into the glass 
feeders. All centrifugation steps required for serum replacement were performed in 
a heated Eppendorf centrifuge 5702 RH (Eppendorf, Hertfordshire, UK) which was 
also kept at 37°C. Attempts were made to estimate the number of serum aliquots 
that would be needed per session to avoid freeze thawing, and effort was taken to 
ensure serum was heated for just 15 minutes before use. 
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6.50 Membrane feeding and serum replacement sampling  
 
Blood was taken by a trained CNRFP staff member. The volume of venous blood 
taken varied according to the age of the participant, 2 x 2.5mls of blood was taken 
for children <5 years and 2 x 4mls of blood for participants >5 years. Blood was 
collected in a warmed heparin vacutainer (appendix 12) using warmed syringes, and 
was then gently inverted 6 times to mix the blood and heparin.  
The first venous blood tube was maintained in a cold box (ensuring no direct contact 
with the ice packs) and was processed for RNA detection, serology and DNA pellet 
(appendix 10 and 13). The second tube was used for membrane feeding and the 
following steps were performed as quickly as possible to ensure no longer than 10 
minutes passed between taking the blood and feeding it to the mosquitoes. Keeping 
the blood tube warm by holding it, an RDT (First Response Premier Medical, India) 
was performed according to the manufacturer’s instructions. While waiting for the 
RDT to develop, 400µL of blood was pipetted into 6 heated microcentrifuge tubes (1 
for each condition) using a heated pipette tip. The whole blood sample was 
processed first and the entire volume of the first aliquot (~400µL) was pipetted 
directly into a membrane feeding device using a heated syringe and heated blunt 
needle, ensuring no air bubbles were introduced. A labelled mosquito cup was 
placed below the corresponding membrane feeder and was raised to touch the 
Parafilm (covering the bottom of the membrane feeder), by inserting folded paper 
below the cup. A sheet of dark plastic tarpaulin was used to cover the top of the 
feeding chamber to allow the mosquitoes to feed in the dark for 20 minutes. The 
remaining 5 blood aliquots were then centrifuged at 3000 rpm for 3 minutes at 37°C, 
and the next two aliquots were prepared, placing the other 3 in the dry heated 
incubator. The autologous plasma aliquot was processed next, which was inverted 10 
times to mix, then the entire volume was transferred into the membrane feeder 
using a heated blunt needle, and the mosquito cup was positioned below the feeder 
as before. For the European control serum aliquot, all autologous serum was 
removed from the centrifuged blood pellet, noting the volume taken which was on 
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average 200µL (from 400µL of whole blood). Autologous serum was replaced with 
the same volume of heated European control serum, the blood pellet was mixed with 
the replaced serum by inverting 10 times, then the entire volume was loaded into 
the membrane feeder and mosquitoes fed as before. 
RDT results were now decided and if positive, serum replacement was performed 
using the 3 rat IgG conditions: naive rat IgG (0.6mg/mL), vaccinated rat IgG 
(0.6mg/mL) and vaccinated rat IgG (0.2mg/mL), processing the samples one at a time 
as described for the European control serum. Individual timers were set for the 6 
conditions to ensure uniform feeding duration. 
After 20 minutes, the mosquito husbandry team processed the mosquitoes as 
follows. Mosquito cups were placed into holding cages (25x 35x25cm), the mesh 
cover was removed and cups gently tapped to expel the mosquitoes.  After a settling 
period of 10 minutes, unfed and partially unfed mosquitoes (identified by the smaller 
size and lighter abdominal colour) were removed by aspiration. Fully fed mosquitoes 
were maintained at 26-28°C with 80% humidity and care was taken not to disturb 
them for 24 hours post feeding. Mosquitoes were fed with glucose (10%) soaked 
pads that were soaked daily and changed 3 times per week.  
 
6.51 Mosquito dissection and oocyst counting  
 
Mosquito dissection and oocyst counting was performed by staff at CNRFP. 
Mosquitoes were dissected on average 8 days after membrane feeding, then midguts 
were examined for the presence of oocysts as follows. Mosquitoes were removed 
from their holding cage by aspiration into paper cups, then transferred to a Petri dish 
which was stored at -20°C for 10 minutes to sedate mosquitoes in preparation for 
staining and dissection. Using forceps, a mosquito was placed onto the un-frosted 
side of a microscope slide and a droplet of 1.0% mercurochrome was added. Moving 
the slide under a dissection microscope, the midgut was then removed into the 
mercurochrome droplet which was covered with a cover slip. The slide was 
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incubated in a wet chamber for 5 minutes, then examined for the presence of 
oocysts under a microscope. Each slide was read by two individuals, and all positive 
midguts confirmed by a third reader. The number of oocysts was recorded for each 
mosquito dissected.  
 
6.52 Microscopy, molecular and serological laboratory protocols 
 
Microscopy was performed by colleagues at CNRFP to determine presence and 
density of asexual parasites and gametocytes. I performed sexual and asexual 
antibody quantification using ELISA as described in section 3.12 and 3.13., for 10C 
and AMA-1, and GLURP and 230CMB ELISA was performed by Nicolas Ouedraogo, 
from CNRPF.  Nucleic acid extraction and molecular detection of parasites was 
performed by colleagues at Radboud UMC, as follows. The nucleic acid was extracted 
from 100µL of whole blood diluted in 500µL of RNA protect (Qiagen, Surrey, UK) 
using an automated nucleic acid extractor (MagNAPure, Roche, Almere, The 
Netherlands). QT-NASBA for Pfs25mRNA detection was performed as previously 
described (section 4.61.), and QT-NASBA for detection of all parasite stages 
(targeting 18S rRNA) was performed using the same methodology, but different 
primers outlined in Table 6.3. (Mens, Schoone et al. 2006).  
Table 6.3. QT-NASBA primer and molecular beacon sequences for detection of 18S 
rRNA. 
Primer Sequence (5’-3’ orientation) 
Forward  GTCATCTTTCGACGTGACTT 
Reverse  AATTCTAATACGACTCACTATAGGGAGAAGGAACTTTCTCGCTTGCGCGAA 
Molecular 
beacon 
6-carboxyfluorescein CGATCGGAGAAATCAAAGTCTTTGGGCGATCG-
dimethylaminoazosulfonic acid 
 
Along with QT-NASBA detecting 18S rRNA, parasite prevalence was also determined 
by colleagues at Radboud, UMC, using nested PCR developed by Snounou et al., 
which detects DNA for the same target.  This was performed as described in section 
3.22.  
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6.53 Statistical analysis for calculating the reduction of oocyst prevalence and 
density determined using membrane feeding assays 
 
Often transmission reduction is either expressed as a change in oocyst prevalence or 
oocyst density. In this chapter, both are shown. While reduction in oocyst prevalence 
is more important in terms of a vaccine that aims to completely block all infection 
(Stone, Eldering et al. 2013), examining the reduction in density allows identification 
of an effect in absence of complete transmission blocking and is more commonly 
used in systems with artificially high mosquito infection intensities such as SMFA (van 
der Kolk, de Vlas et al. 2004).   
When evaluating natural TRA, the control arm was mosquitoes fed with European 
naive serum and the test arm was mosquitoes fed with autologous plasma. When 
assessing TRA of rat IgG, the control arm was mosquitoes fed with naive rat IgG and 
the test arm was mosquitoes fed with vaccinated rat IgG (0.6mg/mL or 0.2mg/mL). 
For analysis of a reduction in oocyst prevalence or density, a cut off of >2 infected 
mosquitoes was imposed, so conclusions were not derived from very small sample 
numbers. 
Fishers Exact Test was used to determine if differences between oocyst prevalence in 
control and test arms were statistically significant. A one sided Mann-Whitney test 
was used to determine if reduction in oocyst density was statistically significant 
between test and control arms. This was performed in R (version 3.0.2) using code 
supplied by Dr. Michael Bretscher. This test was used since oocyst density is not 
normally distributed. The percentage of transmission reduction (and confidence 
intervals) was determined by bootstrapping.  
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6.6 Results  
 
6.61 Participant population and data collected 
 
Two hundred participants aged 2-74 were recruited from 59 households in Laye, at 
the end of the dry season in May-July 2013 for the overarching study that assessed 
the human infectious reservoir for malaria. The first 53 RDT positive individuals were 
selected for serum replacement with rat IgG and were from the following age groups 
<5 (n=7), 5-14 (n=40) and >15 (n=6). Along with undergoing medical screening and 
completing the medical questionnaire, the following data was collected for each 
participant: RDT result, gametocyte and asexual parasite prevalence and density 
determined by microscopy, parasite prevalence by nested PCR (nPCR), parasite (all 
stages) and gametocyte prevalence by QT-NASBA, antibody prevalence and titre for 
10C, 230CMB, GLURP and AMA-1, and mosquito oocyst prevalence and density for 
each feeding assay. 
 
6.62 Parasite carriage by participant age group 
 
Table 6.4. illustrates participant information and parasite carriage according to age 
group. To assess the differences by age, 3 age categories were adopted <5, 5-14 and 
>15 years. These reflect different populations according to the degree of acquired 
immunity, which impacts on parasite carriage as discussed in 1.31. and 1.32.  
 
 
 
 
 247 
 
Table 6.4. Characteristics of study participants according to age group. p-values 
compare all age groups and were generated using chi square or regression. IQR= 
interquartile range, GM= geometric mean. 
Age group: 
 
characteristics 
<5 5-14 >15 p-
value 
 
Number of participants 
enrolled 
50 100 50  
Median age (IQR) 3(3-4) 9(7-11) 39(27-47)  
Female % (n/N) 57.1(28/49) 56.1(55/98) 30.0(15/50)  
RDT positivity % (n/N) 38.8(19/49) 63.0(63/100) 20.0(10/50) <0.001 
Asexual parasite 
prevalence by microscopy 
% (n/N) 
27.1(13/48) 37.4(37/99) 2.0(1/50) <0.001 
 
Asexual stage density by 
microscopy GM (IQR) 
666(456-1259) 908(409-1727) 39 0.102 
 
Asexual prevalence by 
nPCR% % (n/N) 
44.4(20/45) 62.9(61/97) 32(16/50) 0.001 
 
Asexual parasite 
prevalence by QT-NASBA 
% (n/N) 
44.4(20/45) 65.0(63/97) 42.0(21/50) 0.010 
Proportion (%) (n/N) of 
asexual infections that are 
submicroscopic 
40.9(9/22) 43.9(29/66) 95.7(22/23) <0.001 
 
Gametocyte prevalence 
by microscopy % (n/N) 
4.2(2/48) 8.1(8/99) 2.0(1/50) 0.276 
 
Gametocyte density by 
microscopy GM (IQR) 
25(20-32) 41(15.5-68) 68 (NA) 0.988 
 
Gametocyte prevalence 
by QT-NASBA % (n/N) 
39.6(19/48) 62.2(61/98) 32.0(16/50) 0.001 
Proportion (%) (n/N) of 
gametocytes that are  
submicroscopic 
89.5(17/19) 86.9(53/61) 93.8(15/16) 0.724 
 
 
In total 25.9% (51 /197) of individuals were positive for asexual parasites detected by 
microscopy, which was 46.2% (92/199) detected by RDT, 50.5% (97/192) detected by 
PCR and 54.2% (104/192) detected by QT-NASBA. Gametocyte prevalence was 5.6% 
(11/197) detected by microscopy and 49.0% (96/196) detected by QT-NASBA.  
The age groups were compared to assess if differences in parasite carriage were 
statistically significant (see Table 6.4. for p-values). Children under the age of 15 had 
the highest prevalence of microscopically detectible parasites. The highest 
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submicroscopic asexual parasite prevalence (detected by nPCR or QT-NASBA) was 
seen in children age 5-14 (Table 6.4.). No difference was seen with parasite density 
(determined by microscopy) and age groups. 
While there was no difference in the prevalence of microscopically detectable 
gametocytes between the age groups, submicroscopic gametocyte prevalence 
(determined by QT-NASBA) was significantly higher for age group 5-14. Gametocyte 
density in gametocyte carriers did not vary with age, (Table 6.4.).  
 
6.63 Proportion of submicroscopic and microscopic parasite infections  
 
Along with parasite burden, the proportion of infections harbouring submicroscopic 
and microscopic parasites varies with age. The proportion of asexual stage infections 
that are submicrosopic is similar for <5 and 5-14 years but significantly higher for 
adults, where the majority of infections (95.7%) are submicroscopic, Table 6.4. In 
contrast, the proportion of infections with submicroscopic gametocytes is similarly 
high (86.9-93.8%) for all groups, with no statistically significant difference between 
age groups.  
 
6.64 Parasite detection method comparison 
 
Several detection methods were used to determine parasite prevalence and density, 
and characterize participants according to their infection type, i.e. microscopic or 
submicroscopic (as discussed above) in order to explore which densities are relevant 
for infection in mosquitoes. Here, methodologies are compared in order to 
determine their sensitivity and specificity. RDT antigen detection lines were assessed 
separately since they do not detect exactly the same parasite stages.  
 249 
 
Figure 6.1. graphically represents some of the data shown in Table 6.4, and indicates 
the proportion of individuals parasite positive according to the detection method 
used. 
 
 
Figure 6.1. The proportion of parasite positive individuals according to the detection 
method by age group. Parasite detection methods are represented with different bar 
shading. The error bars indicate the 95% confidence interval. 
 
The pattern seen is in line with previous reports (Bell 2002; Mens, Spieker et al. 
2007), and indicates the following general pattern. Microscopy is least sensitive 
(except in <5 years), (determined by comparatively lower parasite prevalence), 
followed by RDT, with the most sensitive being molecular detection methods. From 
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Figure 6.1., as discussed previously, it can be seen more microscopically detectable 
parasites are found in the younger ages, with a higher proportion of submicroscopic 
infections (detected by nPCR and QT-NASBA but not microscopy) in the older age 
groups. Intriguingly, what can be observed from Figure 6.1.is that RDTs are 
comparatively less sensitive (although not a statistically significant difference) for 
participants 15 years or over, which again is likely to reflect the shift towards 
submicroscopic parasite carriage, which may result in less diagnostic antigen being 
available for detection. For individuals <15 years, parasite prevalence by RDT (any 
line, or HRP2) gave comparable prevalence to that determined by nPCR. 
Using QT-NASBA (18S rRNA detection) as reference, the performance of each 
diagnostic test was expressed in terms of sensitivity, specificity, positive predictive 
value (PPV) and negative predictive value (NPV) (Table 6.5., shows how this was 
calculated, and results are shown in Table 6.6.).   
Table 6.5. Calculation of parasite detection method sensitivity, specificity, positive 
predictive value (PPV), and negative predictive value (NPV). Calculations were 
performed as follows: sensitivity (a/a+c), specificity (d/b+d), positive predictive value 
(a/a+b) and negative predictive value (NPV) (d/c+d). 
Test result Disease is truly present Disease is truly absent  
+ True positive (a) False positive (b) 
- False negative (c) True negative (d) 
 
In this setting with very high parasite prevalence by QT-NASBA, a strikingly lower 
detection sensitivity of microscopy and RDT can be seen. nPCR had the highest 
sensitivity (detected the largest proportion of QT-NASBA confirmed parasite 
carriers), followed by RDT any line, HRP2 line, pLDH line and microscopy. While 
microscopy has the lowest sensitivity, it has the highest specificity and PPV, with all 
other methods being lower, but comparable to each other. NPV broadly followed the 
same pattern as sensitivity, but pLDH RDT line had the lowest NPV.  
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Table 6.6. Sensitivity, specificity, positive predictive value (PPV) and negative 
predictive (NPV) value of parasite detection methods compared to detection by 
18S rRNA QT-NASBA. 95% confidence intervals (CI) are indicated in brackets.  
Detection method Sensitivity  
% (95% CI) 
Specificity  
% (95% CI) 
PPV 
% (95% CI) 
NPV 
% (95% CI) 
Microscopy  45.6(35.8-55.7) 97.7(91.9-99.7) 95.9(86.0-99.4) 60.3(51.7-68.4) 
RDT (pLDH line) 52.3(41.3-63.2) 93.8(84.8-98.2) 91.8(80.4-97.7) 59.4(49.2-69.1) 
RDT (HRP2 line) 77.9(68.7-85.4) 93.1(85.6-97.4) 93.1(85.6-97.4) 77.9(68.7-85.4) 
RDT (any line) 79.8(70.8-87.0) 92.0(84.1-96.7) 92.2(84.6-96.8) 79.2(70.0-86.6) 
nPCR 88.5(80.7-93.9) 94.3(87.2-98.1) 94.8(88.4-98.3) 87.4(79.0-93.3) 
 
6.65 Mosquito feeding and mortality 
 
For 198 participants, the following membrane feeding conditions were assessed, 
whole blood feeding, autologous plasma and European naive control plasma. For 53 
people 3 additional experimental conditions were included, naive rat IgG 
(0.6mg/mL), vaccinated rat IgG (0.6mg/mL) and vaccinated rat IgG (0.2mg/mL). An 
average of 42 mosquitoes was dissected per cup and feeding condition. Initially, the 
proportion of mosquitoes that fed was low at 82.2% (6708/8160) in the first week 
which improved to 90.2% (7086/7860) in the second week, after the number of 
people in the mosquito feeding room was reduced. Similarly mortality was initially 
high at 25.8% (2108/8160) for the first week which decreased to 14.3% (1127/7860) 
in the second week after mosquitoes had been moved from cardboard cups into 
more spacious mesh cages.  
 
6.66 Using parasite detection methods to detect/predict infection in mosquitoes  
 
Twenty four/198 people (12.1%) infected a mosquito in one or more of the feeding 
conditions. Children under the age of 15 were significantly more infectious than 
adults (p=0.011). Twenty-five % (6/24) of infectious people were gametocytaemic by 
microscopy, 62.5% (15/24) positive for asexual parasites by microscopy (which is not 
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directly related to infection in mosquitoes but may be related to higher gametocyte 
densities), 87.5% (21/24) positive for 18S rRNA QT-NASBA, 95.8% (23/24) positive by 
RDT (any line) and 95.8% (23/24) positive for Pfs25mRNA QT-NASBA. While there 
was a statistically significant relationship between gametocyte density and infectious 
participants after adjusting for age (p<0.001), the majority, 70.8% (17/24) of 
mosquito infections were from submicroscopic gametocyte carriers i.e. negative for 
gametocytes by microscopy. The 1 infectious individual that was negative by 
Pfs25mRNA QT-NASBA, was carrying P. malariae parasites, and the 1 infectious 
individual that was negative by RDT was positive by both QT-NASBA methods.   
Since RDTs give the most rapidly available results, they were used to identify 
infected, and therefore potentially infectious, individuals for the serum replacement 
membrane feeding assays. Table 6.7. assesses the discriminative value of different 
diagnostic methods to identify individuals who infected at least one mosquito. While 
the techniques used are diagnostic/detection tools, here they are referred to in 
ter s of their a ility to ‘predict infection’ in osquitoes. Sensitivity, specificity, PPV 
and NPV were calculated as before, comparing each method to the outcome, which 
is infection prevalence in mosquitoes.  
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Table 6.7. Sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV) of detection methods to predict/detect infection in 
mosquitoes. 95% confidence intervals (CI) are indicated in brackets.  
Detection 
method 
Sensitivity 
% (95% CI) 
Specificity 
% (95% CI) 
PPV 
% (95% CI) 
NPV 
% (95% CI) 
Microscopy 
(gametocytes)  
25.0(9.8-46.7) 97.1(93.4-99.0) 54.6(23.5-83.1) 90.3(85.1-94.2) 
Microscopy  
(asexual) 
62.5(40.6-81.2) 79.2(72.4-85.0) 29.4(17.5-43.8) 93.8(88.6-97.1) 
RDT 
 (pLDH line) 
81.8(59.7-94.7) 76.0(67.7-83.1) 36.7(23.4-51.7) 96.1(90.3-98.9) 
RDT  
(HRP2 line) 
87.5(67.6-97.2) 60.9(53.3-68.2) 23.6(15.2-33.8) 97.3(92.2-99.4) 
RDT (any line) 95.8(78.8-99.3) 60.3(52.7-67.7) 25.0(16.6-35.1) 99.1(94.8-99.8) 
nPCR 87.5(67.6-97.2) 54.5(46.6-62.2) 21.7(13.9-31.2) 96.8(90.9-99.3) 
QT-NASBA  
18S rRNA 
87.5 (67.6-
97.2) 
50.3(42.5-58.1) 12.6(8.2-18.1) 20.2(13.0-29.2) 
QT-NASBA  
Pfs25mRNA 
95.8(78.8-99.3) 57.6(49.8-65.1) 24.0(15.8-33.8) 99.0(94.5-99.8) 
 
The data shows RDTs (any line) and QT-NASBA targeting Pfs25mRNA have the 
highest sensitivity for detecting infection that results in infected mosquitoes. In 
terms of specificity, microscopy detecting gametocytes is the most specific predictor 
of infection, followed by microscopy detecting asexual parasites, then RDT detecting 
the Plasmodium lactate dehydrogenase (pLDH) line. Gametocyte detection using 
microscopy and RDTs detecting the pLDH line have the highest PPV indicating if these 
results are positive, they more likely to translate to infection in mosquitoes.  NPVs 
are highest for QT-NASBA (detecting Pfs25mRNA) and RDT (any line). In summary, 
while QT-NASBA (detecting Pfs25mRNA) and RDT (any line) are most sensitive, the 
specificity and PPV indicate they may not necessarily predict infection. Since none of 
the PPVs were very high, this indicates none of these methods can reliably predict 
mosquito infection.  
To further investigate the relationship between RDT positivity and mosquito 
infection, the density of the colour of the RDT lines (scored against the WHO colour 
chart) was examined in relation to mosquito infection. The strength of the 
association is indicated between the density of the positive test line for histidine rich 
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protein 2 (HRP2) (Table 6.8.) and pLDH (Table 6.9.) and infection in mosquitoes. 
While overall, both diagnostic antigens provide similar associations with mosquito 
infection, the effect estimates are larger for pLDH, indicating a stronger association 
compared to HRP2. Use of the pLDH line prevalence therefore seems a slightly more 
reliable predictor of infection in mosquitoes compared to the HRP2 line. 
Table 6.8. The association of HRP2 line colour density with infection in mosquitoes. 
This was performed using logistic regression, after adjusting for age, using RDT score 
0 as the reference category. RDT colour scores 3&4 were combined due to low 
numbers of observations for colour intensity 3 for both the HRP2 and pLDH lines. 
Odds ratios (OR) are presented with the 95% confidence interval (CI), along with the 
associated p-value. Overall trend was assessed using logistic regression, colour score 
0 was compared to colour scores 1-4 (combined).  
RDT score % infectious (n/N) OR (95% CI) p-value 
0 3.7(3/82) 1.00  
1 25.0(2/8) 11.08(1.29-95.31) 0.029 
2 9.09(1/11) 2.26(0.20-25.63) 0.511 
3&4 32.0(16/50) 10.09(2.58-39.44) 0.001 
Overall trend   1.98(1.32-3.00) 0.001 
 
Table 6.9. The association of pLDH line colour density with infection in mosquitoes. 
This was performed using logistic regression, after adjusting for age, using RDT score 
0 as the reference category. RDT colour scores 3&4 were combined due to low 
numbers of observations for colour intensity 3 for both the HRP2 and pLDH lines. 
Odds ratios (OR) are presented with the 95% confidence interval (CI), along with the 
associated p-value. Overall trend was assessed using logistic regression, colour score 
0 was compared to colour scores 1-4 (combined).  
RDT score % infectious (n/N) OR(95% CI) p-value 
0 3.9(4/102) 1.00  
1 26.7(4/15) 12.44(2.19-70.81) 0.004 
2 42.3(11/26) 14.65(3.79-56.73) <0.001 
3&4 37.5(3/8) 11.47(1.87-70.49) 0.008 
Overall trend   2.59(1.61-4.16) <0.001 
 
When only assessing the association between mosquito infection and RDT scores 1-4, 
neither HRP2 (p=0.671), or pLDH (p=0.770) demonstrated a statistically significant 
increasing trend. This indicates that the presence of a positive band, not the band 
intensity, discriminates infectious and non infectious individuals.  
 255 
 
6.67 Infection in mosquitoes fed with autologous plasma compared to whole blood 
 
Infection in mosquitoes fed with autologous plasma and whole blood was compared 
to determine if centrifugation (performed for serum replacement) negatively 
impacted upon gametocyte infectiousness, as suggested by previous research 
(Bousema, Dinglasan et al. 2012). While there was slightly higher infection 
prevalence in mosquitoes fed with autologous plasma, compared to whole blood, 
this was not a statistically significant difference (p=0.084).  
 
6.68 Naturally acquired transmission reducing activity affecting mosquito infection 
prevalence and density 
 
To determine if naturally acquired antibodies demonstrated TRA, oocyst prevalence 
and density was compared in mosquitoes fed with autologous plasma and European 
control serum spiked blood. This was explored in individuals who infected >2 
mosquitoes (n= 6), Table 6.10. One participant demonstrated a statistically significant 
reduction in oocyst prevalence (p=0.013), and 5 demonstrated a statistically 
significant reduction in oocyst density (p<0.048). 
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Table 6.10.  Percent reduction in oocyst prevalence and density comparing mosquitoes fed with European control serum spiked blood to 
mosquitoes fed with autologous plasma. The reduction in oocyst prevalence is shown in the left side of the table and the reduction of oocyst 
density is in the right hand side. 95% confidence interval (CI) is shown in brackets, NB: individuals infecting >2 mosquitoes were included in 
comparisons. 
 Number of infected/no of 
dissected mosquitoes 
  Oocyst density arithmetic mean 
(95% CI) 
 
  
Gametocyte 
carrier ID 
 
European 
control 
Autologous 
plasma 
% reduction in 
prevalence 
p-value  European control Autologous 
plasma 
% reduction in 
density 
p-value  
AF1023 13/39 10/35 16.7(-68.5-62.1) 0.802 1.00(0.44-1.56) 0.94(0.37-1.52) 8.3(-112.2-62.4) 0.426 
AF1028 19/25 12/30 47.4(16.7-70.8) 0.013 6.08(2.51-9.65) 0.90(0.41-1.39) 85.2(68.4-93.3) <0.001 
AF1054 11/47 3/36 64.4(-4.4-100) 0.083 1.49(0.49-2.50) 0.17(-0.04-0.37) 88.8(60.8-100.0) <0.001 
AF1071 21/42 14/43 34.9(-9.2-63.4) 0.125 4.07(1.83-6.31) 1.58(0.36-2.81) 61.2(6.6-86.7) 0.048 
AF1135 15/55 5/36 49.1(-14.6-88.2) 0.195 0.91(0.36-1.46) 0.22(0.01-0.44) 75.6(33.6-95.1) 0.003 
AF1152 14/43 11/44 23.2(-53.6-64.0) 0.484 1.63(0.65-2.61) 0.48(0.16-0.80) 70.7(27.2-88.7) 0.006 
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There was no statistically significant association between age and naturally acquired 
TRA (p=0.251). The relationship between TRA and gametocyte density was assessed, 
but no association was observed (p=0.338). 
 
6.69 Vaccine-induced transmission reducing activity affecting mosquito infection 
prevalence  
 
Next, TRA of IgG purified from immunized rats was assessed by comparing oocyst 
prevalence and density between the two test conditions (0.6mg/mL and 0.2mg/mL), 
and the naive rat IgG condition. Table 6.11. indicates the percent reduction in oocyst 
prevalence. In total, there were 14 individuals who infected at least one mosquito in 
these membrane feeding conditions, 5 of which infected >2 mosquitoes and were 
included in the analysis. Two participants showed a statistically significant reduction 
in oocyst prevalence for mosquitoes fed with 0.2mg/mL of IgG (p<0.029), and 4 
participants showed a significant reduction for 0.6mg/mL of IgG (p<0.015), Table 
6.11. 
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Table 6.11. Percent reduction in oocyst prevalence comparing mosquitoes fed with naive rat IgG to mosquitoes fed with vaccinated rat IgG 
(0.2mg/mL and 0.6mg/mL). 95% confidence interval (CI) is shown in brackets, -∞ refers to inus infinity  for the lower li it of the confidence 
interval, ND= not determined. NB: individuals infecting >2 mosquitoes were included in comparisons.  
 
 
 
Gametocyte 
carrier ID 
No. Of infected/no of dissected 
mosquitoes: 
 
Naive           vaccinated IgG       
 IgG        0.2mg/mL        0.6mg/mL 
 
 
 
 
% reduction in 
prevalence 
0.2mg/mL (CI) 
 
 
 
p-value 
(0.2mg/mL) 
 
 
 
% reduction in 
prevalence 
0.6mg/mL(CI) 
 
 
 
p-value 
(0.6mg/mL) 
 
AF1016 3/33 1/32 1/28 65.6(-∞-100) 0.317 60.7(-∞-100) 0.385  
AF1023 14/40 1/37 2/38 85.0(54.9-100) <0.001 85.0(56.1-100) 0.001  
AF1063 5/38 1/45 0/38 83.1(15.6-100) 0.055 100(ND) 0.021  
AF1071 17/40 2/43 3/37 89.1(69.0-100) <0.001 80.9(52.0-100) 0.001  
AF1089 4/36 1/44 0/35 79.5.0(-∞-100) 0.104 100(ND) 0.042  
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6.70 Vaccine-induced transmission reducing activity affecting mosquito infection 
intensity 
 
Three individuals showed a statistically significant reduction in oocyst density for the 
0.2mg/mL condition (p<0.027), and 4 individuals for the 0.6mg/mL condition 
(p<0.023), Table 6.12.
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Table 6.12. Percent reduction in oocyst density comparing mosquitoes fed with naive rat IgG to mosquitoes fed with vaccinated rat IgG (0.2mg/mL 
and 0.6mg/mL). 95% confidence interval (CI) is shown in brackets,-∞ refers to inus infinity  for the lower li it of the confidence interval  ND= not 
determined. NB: individuals infecting >2 mosquitoes were included in comparisons.  
 
 
 
Gametocyte 
carrier ID 
Oocyst density arithmetic mean (CI) 
 
 
Naive rat IgG                    vaccinated IgG    
                                 0.2mg/mL          0.6mg/mL 
 
 
 
% reduction 
0.2mg/mL (CI) 
 
 
 
 
p-value 
0.2mg/mL 
 
 
 
% reduction 
0.6mg/mL (CI) 
 
 
 
 
p-value 
0.6mg/mL 
 
AF1016 0.09(-0.01-0.19) 0.03(-0.03-0.09) 0.07(-0.08-0.22) 65.6(-∞-100) 0.164 21.4(-∞-100) 0.214  
AF1023 1.56(0.51-2.61) 0.03(-0.03-0.08) 0.24(-0.15-0.64) 85.2(41.9-100) <0.001 85.2(43.7-100) <0.001  
AF1063 0.29(0.03-0.55) 0.02(-0.02-0.07) 0 92.3(51.7-100) 0.027 100(ND) 0.011  
AF1071 3.63(1.62-5.63) 0.07(-0.03-0.17) 0.41(-0.06-0.87) 98.1(93.7-100) <0.001 88.8(68.3-100) <0.001  
AF1089 0.14(-0.0-0.28) 0.02(-0.02-0.07) 0 83.6(-∞-100) 0.053 100(ND) 0.023  
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No difference was observed with oocyst prevalence (p=0.954) or density (p=0.450) 
between 0.6mg/mL and 0.2mg/mL conditions.  
 
6.71 Antibody responses to sexual and asexual antigens 
 
Antibody responses were quantified against asexual stage antigens AMA-1 and GLURP 
and sexual stage antigens 10C and 230CMB. Figure 6.2. demonstrates antibody profiles 
and titre by age group.  
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Figure 6.2. Antibody profiles for 230CMB, 10C, GLURP and AMA-1 in relation to age 
group. (a) The proportion of individuals antibody positive by age group. The error bars 
indicate the 95% confidence interval, (b) Log antibody titre (arbitrary units) by age group. 
Box plots indicate the median (horizontal line), 25th and 75th percentiles (lower and 
upper box limits) and whiskers indicate the 5th and 95th percentiles. The asterisk 
indicates a statistically significant positive increasing trend with age at the following 
levels: 0.05 – 0.01 (*), 0.01- 0.001 (**), and <0.001 (***), after adjusting for parasite 
carriage and density. Age groups are shaded in different colours. 
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Combining all age categories, the proportion of people positive for GLURP antibodies 
was 26.5% (52/196) and 66.2% (129/195) for AMA-1. Responses to sexual stage 
antigens were lower, with 14.7% (29/197) positive for 230CMB and 15.3% (30/196) 
positive for 10C. Both antibody prevalence and titre significantly increased with age for 
all antigens, after adjusting for parasite prevalence and density, Figure 6.2. (a) and (b). 
 
6.72 Relationship between antibody prevalence to 10C and 230 and naturally 
acquired TRA and infectiousness to mosquitoes  
 
Having confirmed the presence of naturally acquired 10C and 230CMB antibodies, the 
next objective was to assess if the reduction in oocyst prevalence or density 
demonstrated in autologous plasma (in section 6.68.) was associated with 10C or 
230CMB antibodies.  
TRA was classified as a binary variable to distinguish individuals with or without 
statistically significant TRA who had infected >2 mosquitoes (those shown in Table 
6.10.). The relationship with antibody prevalence and density was assessed using 
logistic regression, after adjusting for age. Out of the infectious individuals (n=6) listed 
in Table 6.10., just 1 (age 3) had sexual stage antibodies, but demonstrated no 
statistically significant relationship with TRA and, 10C or 230CMB antibody prevalence 
(p=0.923, for both) or titre (p>0.394).  
Next, the relationship between the presence of 10C or 230CMB antibodies and 
mosquito infection was explored for gametocyte positive individuals for the 
autologous plasma feeding conditions. The hypothesis was that gametocytaemic 
individuals with 10C or 230CMB antibodies were less likely to infect mosquitoes 
compared to gametocyte carriers without 10C or 230CMB antibodies. There was no 
statistically significant relationship between the prevalence of mosquito infection and 
antibody prevalence for 10C antibodies (p=0.370) or 230CMB antibodies (p=0.409), 
after adjusting for gametocyte density and age, for gametocyte positive individuals, 
using logistic regression.  
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Neither was there a statistically significant association between the prevalence of 
mosquito infection and antibody titre for 10C (p<0.376) and 230CMB (p<0.992) in 
individuals gametocyte positive by QT-NASBA, or just by microscopy (Figure 6.3.). 
There also was no statistically significant relationship with oocyst density and antibody 
titre for 10C (p=0.640) and 230CMB (p=0.110).  
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Figure 6.3. 10C and 230CMB log antibody titre in relation to participant infection status. 
(a)  Log antibody titre (arbitrary units) for infectious and non infectious individuals for 
all gametocyte carriers. (b) Log antibody titre for infectious and non infectious 
individuals with microscopically detectable gametocytes only. Infectious participants 
are represented with triangles and not infectious with dots.  The median titre is 
demonstrated by the horizontal line. NS= no statistically significant difference. 
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6.8 Discussion 
 
6.81 General findings  
 
The objective of the overarching project was to identify who within the population was 
the largest contributor to the infectious reservoir. These questions are being 
addressed by a colleague and my activities focused on exploring different diagnostic 
methods for detecting malaria infections, and infectious individuals, and assessing the 
transmission reducing activity of vaccine-induced or naturally acquired sexual stage 
antibodies. 
In the study area, during the dry season, children <15 years harboured the highest 
asexual parasite prevalence determined by microscopy, with 5-14 year olds carrying 
significantly more submicroscopic asexual infections, compared to the other ages.  
Children aged 5-14 formed the majority of the gametocytaemic reservoir, harbouring 
the highest overall gametocyte burden (microscopically and submicroscopically 
detected combined), and also the highest prevalence of submicroscopic gametocytes. 
This finding is in agreement with other studies that also concluded gametocyte 
carriage was highest in children, which is likely a consequence of the higher asexual 
parasite burden found in this age group, leading to the generation of more 
gametocytes (Bousema, Gouagna et al. 2004; Ouedraogo, Bousema et al. 2010). This 
information is highly relevant for application of control measures and targeting 
children 5-14 years old could be an appropriate approach to reducing the infectious 
gametocytaemic reservoir, within the dry season. 
While microscopy suggested low gametocyte prevalence, QT-NASBA revealed many 
infections harboured gametocytes, therefore indicating the gametocytaemic reservoir, 
was mostly comprised of submicroscopic gametocytes. This emphasises the need for 
sensitive gametocyte detection methods, when determining the infectious reservoir. 
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6.82 Sensitivity of different diagnostic methods to detect the parasitaemic reservoir 
 
Several parasite detection tools were used in this study and were compared to assess 
their relative sensitivity.  Compared to RDTs and molecular detection, microscopy is 
least sensitive for asexual parasite detection (excluding those <5 years), especially in 
older age groups where the majority of infections are submicroscopic. The lower 
sensitivity of microscopy has been extensively reported, and while it is in part 
attributed the labour intensiveness of preparing and reading slides, sequestered 
parasites will also go undetected. This gives some techniques, such as RDTs an 
advantage since they detect antigen that may be present in absence of detectable 
parasites in the circulation (Kattenberg, Tahita et al. 2012). 
The sensitivity of the RDT HRP2 line is consistently higher than the pLDH line ((WHO) 
2012), which is likely to be because more HRP2 is produced by parasites, compared to 
pLDH (Cunningham, in preparation). In addition, HRP2 lingers post clearance (Makler 
and Piper 2009), and allows infections that have already been cleared from the 
circulation to be detected, resulting in a higher proportion of HRP2 positive individuals. 
The relative sensitivity of RDTs is highest in age group 5-14 (who have highest density 
infections), and lowest in adults who mostly have submicroscopic infections and 
therefore less antigen.  
Molecular detection methods QT-NASBA and nPCR were the most sensitive parasite 
detection tools. While both methods detect 18S rRNA, the targets for amplification are 
different. QT-NASBA amplifies transcripts of 18S rRNA which are found in high 
abundance in all parasite stages (hundreds of copies per parasite) whereas nPCR 
amplifies DNA copies of 18S rRNA which are present in lower abundance (~5 per 
parasite) (Wampfler, Mwingira et al. 2013). QT-NASBA therefore offers more sensitive 
detection, when compared to nPCR (and all other techniques), an effect which is 
especially pronounced within the older age groups. While RDTs and microscopy fall 
short for detection of all malaria infections across the different age groups, molecular 
methods offer more sensitive detection. 
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6.83 Sensitivity of different diagnostic techniques to detect the infectious reservoir  
 
Serum replacement with rat IgG was performed in this study and the idea was to 
conduct this for confirmed gametocyte positive individuals only. While screening 
participants for microscopically detectable gametocytes would have been preferable, it 
was not logistically feasible to ask participants to wait until microscopy slides were 
read, or visit CNRFP twice, which is a considerable distance from Laye, to be pre-
screened. At the time of performing the field work, RDT positivity (HRP2 line) was used 
as a proxy to detect the infectious reservoir since it is reasonable to assume if asexual 
parasites are present, gametocytes may also be present. The ability of RDTs and other 
diagnostic methods to detect the infectious reservoir was considered. 
There was a statistically significant increasing relationship between the presence of 
microscopically detectable gametocytes and mosquito infection (oocyst prevalence), 
which is in line with findings from other studies (Boudin, van der Kolk et al. 2004; 
Schneider, Bousema et al. 2007; Ouedraogo, Bousema et al. 2009). Despite this finding, 
the majority (70.8%) of mosquito infections were from submicroscopic gametocyte 
carriers, which reiterates their importance and reemphasises the need for sensitive 
methods to accurately detect the infectious reservoir. Detection methods were 
compared to assess their ability to detect/predict infection in mosquitoes. QT-NASBA 
(Pfs25mRNA) and RDT (any line) had the highest sensitivity, but microscopy and the 
pLDH line had the highest specificity and PPV.  
RDTs were assessed in further detail looking at the association between mosquito 
infection and colour density of the RDT test lines, to reveal if this provides additional 
information about participant infectiousness. While colour intensity for both HRP2 and 
pLDH (compared to 0) were significantly associated with infection in mosquitoes, the 
strength of the association was slightly stronger for pLDH. However, when assessing 
infectiousness and the relationship between the degree of positivity (line scores 1-4) 
there was no statistically significant increasing relationship, indicating while prevalence 
of RDT positivity is related to infectiousness, the colour density is not. 
Premier Medical First Response Combo RDT was used in this study. For this RDT, pLDH 
seems a slightly better choice for detection of gametocytes and detection/prediction 
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of infection, but does suffer from lower sensitivity compared to the HRP2 line. It is 
possible there may be another pLDH detecting RDT on the market that offers higher 
sensitivity and specificity, and could form a useful tool for gametocyte detection. It is 
important to note, in this project RDTs were scored against the WHO colour chart 
using procedures developed by the Centers for Disease Control and Prevention (CDC), 
but colour scores were recorded for 1 person only. This was performed within this 
study in an exploratory manner, but to make this protocol more robust, ideally results 
would be recorded for two readers (to allow inter person validation) who had 
undergone training to ensure streamlining of interpretation of results. 
 RDT lines were assessed separately since the targets differ in several ways. Firstly 
HRP2 is a residual parasite metabolite and can linger for several weeks post clearance 
of parasites, and therefore could suggest recent, rather than active parasite infection 
(Kattenberg, Tahita et al. 2012).  Secondly, HRP2 is produced by young gametocytes, 
but not mature gametocytes (which have the potential to infect mosquitoes), whereas 
pLDH is produced by mature gametocytes (Bell, Wongsrichanalai et al. 2006; Nyunt, 
Kyaw et al. 2013). A previous study monitoring the gametocidal effects of drug 
compounds, found gametocytaemia determined by microscopy to correlate well with 
pLDH and the authors suggested pLDH as a suitable proxy for gametocytaemia. 
Furthermore, they reported low levels of pLDH to correlate with lower densities of 
oocysts in the mosquito (D'Alessandro, Silvestrini et al. 2013).  While this supports the 
findings linking pLDH prevalence and infectiousness in my study, it must be noted the 
study described above was performed using higher density gametocytes than seen in 
my participants. 
Pre-screening with QT-NASBA (Pfs25mRNA detection) or microscopy would 
theoretically be the favourable approach to detect potentially infectious gametocyte 
carriers in this study. However, QT-NASBA is time consuming and has so far not been 
widely adapted for use in the field and since gametocytes often circulate at low 
densities and may dip below microscopic detection from a day to day basis, 
microscopy may misrepresent the gametocytaemic reservoir. Therefore, screening 
against a sensitive pLDH RDT could offer a more stable indicator for mature 
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gametocyte presence and infection potential, although an HRP2 RDT was also found 
suitable in this study.  
 
6.84 The occurrence of naturally acquired transmission reducing activity 
 
Previously performed meta-analysis revealed centrifugation of blood conducted during 
serum replacement can result in lower gametocyte infectiousness compared to whole 
blood samples (Bousema, Dinglasan et al. 2012). There was slightly higher mosquito 
infection from autologous plasma feeds, but this was not a statistically significant 
difference. Since infection was not lower in mosquitoes fed with autologous plasma, I 
feel confident that methods used for serum replacement did not negatively affect 
infectiousness of gametocytes.  
To assess if there was naturally occurring TRA, oocyst prevalence and density was 
compared between mosquitoes fed with European control serum and autologous 
plasma samples. This revealed that 16.7% (1/6) of infectious participants infecting >2 
mosquitoes exhibited a statistically significant reduction in oocyst prevalence, and 
83.3% (5/6) participants showed a significant reduction in oocyst density in the 
autologous plasma fed mosquitoes. This finding (although derived from few data 
points) is in general agreement with data from a publication that compared studies 
performed across 8 studies in 3 countries. Here, the authors demonstrated in 68.2% of 
experiments there was a significantly lower proportion of infected mosquitoes fed 
with autologous plasma compared to control serum (Bousema, Sutherland et al. 2011).  
 
6.85 Transmission reduction of vaccine-induced IgG 
 
Generally there was low mosquito infection in this experiment which restricted the 
number of robust comparisons. Regardless, the vaccinated rat IgG (0.6m/mL) 
demonstrated a statistically significant reduction in oocyst prevalence of 80.9-100%, 
which was an 85.2-100% reduction in oocyst density, for 4/5 people who infected >2 
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mosquitoes. For the 0.2mg/mL condition, there was a statistically significant reduction 
in oocyst prevalence of 85.0 and 89.1% (in 2/5 people) which was a reduction in oocyst 
density of 85.2-98.1% in 3/5 people. Within this study, 2 IgG concentrations were 
tested but no dose dependent effect was seen. 
This study builds upon our previous research where TRA of vaccinated rat IgG was 
assessed against 3 cultured isolates (Theisen, Roeffen et al. 2014). While pfs48/45 has 
not been sequenced in the endemic samples collected in this chapter, it is very 
encouraging I now have evidence that vaccine induced IgG blocks transmission within 
an endemic setting. While it is certainly relevant to test TBV efficacy against all 
infection levels including submicroscopic infections, which represent a large portion of 
the gametocytaemic reservoir (Schneider, Bousema et al. 2007), higher oocyst 
prevalence and density would provide a larger number of comparisons to derive 
robust conclusions about the TRA of vaccine induced rat IgG.  
There have been few other studies that tested TRA of vaccine induced serum against 
endemic parasites.  One study assessed the TRA of serum from humans vaccinated 
with Pfs25 in a different region of Burkina Faso and achieved an average reduction in 
oocyst density of 80.3% and a reduction in oocyst prevalence of 31.0% (Da, Dixit et al. 
2013). There are differences between the study methodologies, firstly, they screened 
participants using microscopy to ensure gametocytes were present which resulted in a 
higher mean oocyst density (Da, Dixit et al. 2013).  Secondly, the authors fed larger 
numbers of mosquitoes (150) across 3 feeders for a longer time of 30 minutes. 
Increasing the number of mosquitoes fed, and using multiple feeders helps to 
eli inate ‘feeder effect’ and also increases the sample size and power of the study. 
Another study confirmed the TRA of serum from mice vaccinated with Pfs25, but once 
more they firstly selected for gametocyte positive individuals and also fed mosquitoes 
for a longer duration of 30 minutes (Arakawa, Komesu et al. 2005).  
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6.86 The functional importance of naturally acquired antibody responses to 10C and 
230CMB   
 
10C and 230CMB antibodies were quantified to confirm recognition to the vaccine 
candidates in this population, and enable assessment of TRA attributed to sexual stage 
antibody prevalence. 10C and 230CMB antibody prevalence demonstrated a 
statistically significant increasing acquisition pattern with age, which is not the 
commonly seen pattern for sexual stage antigens (covered in section 1.36.), but is in 
line with findings from Chapter 5.  
After confirming the presence of 10C and 230CMB antibodies, next TRA was assessed 
by comparing oocyst prevalence and density in the autologous plasma and European 
control plasma conditions. One person (age 11) demonstrated a statistically significant 
reduction in oocyst prevalence of 47.4%, and 5 people (aged 4-15)  showed a 
significant reduction in oocyst density of 61.2-88.8%. Only 1 of these individuals had 
antibodies for 10C and 230CMB and there was no statistically significant association 
with TRA and antibody prevalence or titre.  To determine if 10C or 230CMB antibodies 
were protecting from infection in mosquitoes (irrespective of the % of TRA), the 
association was assessed between infection prevalence and density in mosquitoes and 
antibody prevalence and density (for 10C or 230CMB), but no statistically significant 
relationship was found.  
In this study it was not possible to link together 10C or 230CMB antibody prevalence or 
density with a reduction of infection in mosquitoes. Since antibody prevalence and 
density was measured for just two sexual stage targets, 10C and 230CMB, it must be 
noted there may be other pre-fertilization antigens such as HAP2 that may result in 
TRA but have not been measured (Miura, Takashima et al. 2013).  
There are varying ideas regarding what induces functional TRA. A previous study 
assessing TRA in The Gambia, Kenya and Cameroon reported higher levels of TRA were 
associated with recent gametocyte carriage the week before membrane feeding 
(Bousema, Sutherland et al. 2011). Data from another study in Cameroon suggested 
that intensity of TRA was associated with current gametocyte density. The authors 
reported a high level of functional TRA in individuals harbouring gametocyte densities 
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over 150/µL (Boudin, van der Kolk et al. 2004). While the relationship between TRA 
and gametocyte density was assessed in my samples, there was no association. Since 
sampling was performed in the dry season, gametocyte densities were low and just 1 
participant harboured a density over 150/µL, and they did not exhibit statistically 
significant TRA.  It has been suggested sampling later in the transmission season has 
been associated with higher TRA which implies recent gametocyte exposure may play 
a role in functionality (Bousema, Sutherland et al. 2011). This hypothesis supports the 
low levels of TRA found in our samples that were taken during the dry season. 
 Previous studies in Tanzania have indicated TRA is more common in children and 
decreases with age. This decrease has been hypothesized to a consequence of asexual 
immunity controlling asexual parasite density and subsequent gametocyte production 
(Drakeley, Bousema et al. 2006). My data indicates sexual stage antibodies accumulate 
with age, which suggests sufficient antibody boosting still occurs in adults, or 10C and 
230CMB antibodies have substantial longevity. Since adults are predominantly carrying 
submicroscopic gametocytes, it is tempting to conclude this low density is sufficient to 
boost antibody responses. However, longitudinal studies are needed to confirm this 
and determine whether antigen exposure from submicroscopic gametocytes is 
sufficient to induce or sustain functional TRA.   
While results in Chapter 5 indicated a statistically significant association between 10C 
and 230CMB antibodies and TRA using SMFA, it was not possible to extend that finding 
to this chapter using DMFA. It is important to note, SMFA performed in Chapter 5 used 
purified IgG, while membrane feeding performed in this chapter used endemic whole 
blood. SMFA is easier to standardize and the ability to grow high gametocyte densities 
in culture makes it easier to reach statistical power when comparing oocysts from 
mosquitoes fed with control and test blood (Bousema and Drakeley 2011). DMFA 
suffers more individual variation e.g. participants have variable and generally lower 
gametocyte densities and could have residual antimalarial drugs in their blood stream, 
all of which make assessment of TRA more difficult. Regardless, the data in this chapter 
suggests naturally acquired antibodies to 10C and 230CMB may not have a key role in 
influencing the human infectious reservoir during the dry season in Burkina Faso. This 
needs to be explored in other settings and during the peak transmission season. 
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The main limitation of this study is that low mosquito infection resulted in few robust 
analyses to compare the TRA of vaccine induced IgG. To increase chance of infection, 
the study could be repeated during the peak transmission season, when gametocyte 
prevalence and density have been indicated to be significantly higher, and more 
people will be infectious (Ouedraogo, De Vlas et al. 2008). To screen for potential 
gametocyte carriers, a sensitive pLDH RDT could be used with the hope of more 
specific gametocyte detection. To further boost the power of the study a larger 
number of mosquitoes could be fed (~100 per feeder), and to account for the 
membrane feeder effect, multiple membrane feeders could be used per condition. If 
the study were to be repeated, it would certainly also be of value to sequence 
pfs48/45 in the individuals who exhibited TRA to explore which strains vaccine derived 
immunity protects against.  
 
6.87 Conclusions 
 
This study indicates children comprise the majority of the gametocyte reservoir and 
are responsible for the most mosquito infections, during the dry season in Laye in 
Burkina Faso. This information could be used for targeted control to reduce the 
infectious reservoir within the dry season and in particular, this group could be ideal to 
vaccinate with a TBV to prevent seeding of transmission to the surrounding 
population. Since the majority of mosquito infections were from submicroscopic 
gametocyte carriers, this reiterates the need for more sensitive and rapid detection 
tools to enable detection of all relevant gametocyte densities. Until such tools are 
available, guided by data from this study I speculate use of a sensitive pLDH RDT could 
provide slightly more specific gametocyte detection, compared to an HRP2 RDT.  
An age dependent antibody acquisition pattern for 10C and 230CMB antibodies was 
observed in this sample population which reinforces findings from Chapter 5. While 
infection prevalence and density was low in samples from this chapter, some 
participants had high enough infectivity to enable demonstration that vaccinated rat 
IgG significantly reduced or blocked transmission. Since transmission reduction was 
not 100% in all participants evaluated this indicates a higher concentration than 
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0.6mg/mL of IgG is needed to achieve more complete transmission blocking. These 
encouraging findings provide a valuable starting point towards bridging the gap 
between transmission reduction confirmed using SMFA and transmission reduction in 
an endemic setting, against more genetically diverse parasite strains.  
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Chapter 7: Final discussion 
 
7.1 Diagnostics for malaria elimination and malaria transmission trials 
 
Following recognition of the value of transmission blocking vaccines, new challenges 
have arisen, such as identifying tools to facilitate their development (Vogel 2010). One 
aspect of this, is accurately detecting gametocytes to understand who is capable of 
transmitting their infection to mosquitoes. The first chapter of this thesis explored 
methods for mRNA collection for detection of low density gametocytes stored on filter 
papers kept at different temperatures and humidity conditions. This chapter 
demonstrated Pfs25mRNA can be detected from both the FTA Classic Card and 
Whatman 903 Protein Saver Card, but RNA was detected more often from the 903 
Protein Saver Card when stored under more challenging warmer temperatures, or 
humid conditions. What may be of more importance is that this chapter revealed the 
cheapest and most commonly used filter paper, Whatman 3MM, appears to be 
appropriate for gametocyte mRNA collection and storage. These findings have to be 
interpreted with caution since Whatman 3MM was evaluated under just 3 conditions 
not including humidity which was revealed to have the largest impact on diminishing 
RNA stability. Nevertheless, my findings demonstrated that the most widely used filter 
paper may allow the detection of submicroscopic gametocyte densities.  An important 
part in sensitive parasite detection is optimal sample collection, storage and 
extraction. Hopefully the results in the publication in Chapter 4 could help towards 
forming an SOP to recommend optimal sampling methods for detection of 
gametocytes and move towards standardizing methodology to aid inter-lab 
comparability of results.  
The information revealed by Chapter 4 is valuable since use of filter papers reduces the 
cost of field sampling in several ways. Firstly, filter papers themselves are cheap 
compared to nuclease-free microcentrifuge tubes that are commonly used for whole 
blood sampling, secondly the study performed in my thesis (along with others) (Jones, 
Sutherland et al. 2012; Pritsch, Wieser et al. 2012; Kast, Berens-Riha et al. 2013) have 
indicated costly freezers may not be necessary for filter paper sample storage 
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(although this may depend on the storage duration), and finally since filter paper 
samples are not categorized as biohazardous they can be transported at room 
temperature without specialist shipping permits or dry ice. This expands the feasibility 
of sampling gametocytes to remote field sites in resource poor settings, and to 
projects with smaller budgets. Furthermore, filter paper sampling is advantageous 
since only small blood volumes are needed, finger prick samples can be used which 
obviates the need for performing venipuncture (which requires more safety 
precautions, specialised personnel and results in more discomfort to the participant) 
(Kast, Berens-Riha et al. 2013).   
An important next step to advance this research would be to confirm if RNA can be 
detected from routinely collected finger prick samples directly applied to filter paper, 
in contrast to finger prick samples collected in a microtainer then pipetted onto filter 
paper. While I made a start at addressing this, by indicating gametocytes were 
detected from routinely collected filter paper samples in Uganda, this was using a 
small number of samples. Ideally, this finding should be confirmed with larger sample 
sets that preferably have gametocyte density data (determined by microscopy) to aid 
comparison, at least for the higher density samples. Additionally, it would then be 
useful to assess the effect of long term filter paper storage on mRNA sample stability 
and detection success. 
If RNA filter paper sampling was to be introduced into a field study, staff would need 
specific training on sample collection and handling, since RNA is less robust compared 
to DNA or antibodies, which are routinely collected on filter paper. Sample collection 
precautions include wearing gloves for filter paper preparation and handling, ensuring 
filter papers are dried in a dust free sterile environment out of direct sunlight and only 
storing papers once thoroughly dry. Furthermore, filter papers must be stored in 
sealable plastic bags along with colour changing desiccant. Although these precautions 
should be commonly exercised for DNA and antibody collection on filter papers, they 
may be more important for RNA collection to prevent introduction of ubiquitous 
RNases and consequent degradation. Humidity indicator Cards (Adsorbents & 
Desiccants Corporation of America, California, USA) may prove a useful tool to monitor 
the presence of moisture.  
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There is considerable debate about the circumstances in which it is important to 
detect gametocytes. In many situations, the specific detection of gametocytes may not 
be essential. Previous research indicated the majority of malaria infections carry 
gametocytes, and even if not gametocytaemic at one time point, they are likely to 
become gametocytaemic (Bousema and Drakeley 2011). Therefore detecting 
infections (any parasite stages) is sufficient for most purposes since every infection is 
plausibly contributing to the gametocytaemic reservoir, and to transmission potential. 
The development of sensitive molecular parasite detection tools has led to an 
unveiling of unexpected parasite carriage patterns. For example, recent research 
revealed the majority of infections (70-80%) in regions of low transmission intensity 
are submicroscopic and asymptomatic. It was previously thought that limited exposure 
(and therefore limited immunity) would result in higher density infections in low 
transmission settings (Bousema, in press). It is currently unknown how parasite 
densities are seemingly controlled so efficiently despite limited cumulative exposure to 
malaria (Bousema, in press). This finding is in agreement with a previous study (Okell, 
Bousema et al. 2012), that also indicated the high prevalence of submicroscopic 
infections in low endemic areas. This has implications for epidemiological studies and 
malaria control and elimination programmes (WHO 2014), and emphasises that rapid 
field friendly malaria detection methods are needed that detect submicroscopic 
parasites.  
In general, these findings suggest that the specific detection of gametocytes may be 
less important for routine surveillance, and certainly for public health purposes, the 
sensitive detection of all infections (with or without concurrent gametocytes) is most 
relevant. However, there are several circumstances where gametocyte detection is 
desirable. One example is for population studies to assess the infectious reservoir to 
gain an understanding of who is responsible for malaria transmission (Wampfler, 
Mwingira et al. 2013). With this information, it could be possible to perform targeted 
interventions toward responsible groups, which the aim of a more efficient cost 
effective approach to control. For example, in the village sampled in Burkina Faso in 
Chapter 6, it was revealed that children aged 5-14 comprised the majority of the 
infectious reservoir within the dry season. It could be speculated targeting this age 
group with transmission reducing interventions e.g. bednet coverage (or use of a TBV 
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when available), could have a larger impact on overall reduction of parasite 
prevalence.  
Another circumstance where gametocytes need to be detected is to evaluate 
gametocidal drugs e.g. primaquine. For this purpose, mean gametocyte circulation 
time post treatment is commonly used to determine drug efficacy (Eziefula, Bousema 
et al. 2014). Alternatively, gametocyte detection is required when performing 
mosquito infectivity studies to gain an understanding of which gametocyte densities 
are relevant for mosquito infection (André Lin Ouédraogo, Jetsumon Sattabongkot et 
al. 2013).  
 
7.2 Naturally acquired and vaccine induced transmission reducing immune responses 
 
An anticipated advantage of a TBV is that natural gametocyte exposure may boost a 
vaccine derived response which perhaps could improve antibody functionality by 
resulting in an enhanced antibody response with better antibody avidity. In Chapter 5 
(and 6) evidence indicated exposed populations have antibodies to 10C and 230CMB 
vaccine candidates. Furthermore, these antibodies appeared to accumulate with 
repeated exposure, as reflected by the age-dependent antibody acquisition pattern 
and the higher antibody prevalence in the high endemic sites.  In the sample sets 
assessed, 10C and 230CMB antibody presence (but not increased titre) was 
demonstrated to be associated with TRA at the >90% level. Since antibody titre was 
not found to impact upon TRA, it could be speculated functional antibodies (with >90% 
TRA) are the result of improved antibody affinity. Possibly, this could occur when B 
cells are stimulated by an antigen for a second time therefore resulting in the 
production of new daughter B cells. During this process, single point mutations may 
occur within both the heavy and light immunoglobulin chains, which have the potential 
to result in affinity maturation e.g. the production of antibodies with improved 
cytophilic activity. It has been theorized that over time, mature antibodies would out 
compete others (Honjo and Habu 1985; Or-Guil, Wittenbrink et al. 2007).  
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While it could be hypothesized that TRA should increase with age since 10C and 
230CMB antibody prevalence increases with age, no significant age relationship was 
found. Just a small proportion of individuals from all age groups exhibited >90% TRA, 
and this proportion displayed no age dependent pattern. This indicates antibody 
presence alone does not accurately predict TRA.  
Alternatively, the discordance between antibody presence and TRA could be attributed 
to sequence polymorphisms in pfs48/45. In Chapter 5 I indicated pfs48/45 has 5 non-
synonymous amino acid substitutions in the functional epitopes (I-III). I also 
demonstrated the proportion of isolates identical to 3D7 varies by country, with 17.9% 
in Burkina Faso ranging to 69.2% in Ghana. The compilation sample sets assessed for 
TRA in Chapter 5 are from a range of countries, Burkina Faso, The Gambia, Cameroon, 
Gabon (and Dutch missionaries) and were assessed for their ability to block or reduce 
transmission of 3D7 using SMFA. Possibly, individuals exhibiting >90% TRA are those 
who have been exposed the most to 3D7 and mounted antibodies predominately 
against this allele. The majority of individuals demonstrating >90% TRA are from 
Cameroon, for which I have no information regarding pfs48/45 allele types. In a 
separate study, we provided evidence that R0-10C vaccine induced immunity blocks 
transmission against 3D7, NF135 and NF165 (Theisen, Roeffen et al. 2014). Since the 
vaccine allele is 3D7, this indicates a degree of cross allele protection, but there are 
non-synonymous amino acid substitutions not represented by these cultured isolates, 
that appear in endemic parasites and their relevance needs to be confirmed.  
Asides from this, there are several possible explanations for the lack of an age-
dependent acquisition of TRA, despite the age dependent increase in 10C and 230CMB 
antibody prevalence. These include 1) differential acquisition of antibodies to the 
different epitopes (which induce antibodies of varying functionality), 2) variation in 
antibody avidity, or 3) production of different antibody isotypes/subclasses, which may 
also exhibit different functionality (Tongren, Drakeley et al. 2006).  
Epitopes I, II and III of Pfs48/45 are present in vaccine candidate 10C. It has previously 
been indicated epitopes II and III stimulate production of transmission reducing 
antibodies but epitope I induces the most effective antibodies (Outchkourov, Roeffen 
et al. 2008). However, epitope III is immunodominant and it could be speculated the 
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increasing age dependent antibody acquisition pattern predominantly reflects 
antibodies produced against epitope III. A previous study performed in Cameroon 
supports this hypothesis. Here, endemic antibodies reacting to native protein Pfs48/45 
were found to be predominantly specific to epitope III (Mulder, Lensen et al. 1999).  
This could explain the lack of increasing relationship with individuals exhibiting >90% 
TRA and age (which is linked to cumulative antibody acquisition) (Roeffen, Raats et al. 
2001; Outchkourov, Vermunt et al. 2007). If this is the case, this suggests detection of 
antibodies directed against epitope I, while only reflecting 1/3 of the vaccine candidate 
functional epitopes, might reveal a stronger correlation with TRA.   
Recognition to malaria antigens has been demonstrated to be selective with some 
individuals producing antibodies to some epitopes, but not other epitopes in the same 
protein, which has been suggested to be attributed to clonal imprinting (Taylor, Egan 
et al. 1996). Since epitope III of 10C may be immunodominant, it could be speculated 
the primary immune response is more commonly mounted against this epitope. If this 
is the case, subsequent immune responses may continue to be produced against 
epitope III (as a result of clonal imprinting). To investigate this, the reactivity to 
different 10C epitopes could be determined for sera with a known TRA phenotype. 
There are several other features that could impact on antibody-antigen binding (and 
therefore affect TRA), such as antibody avidity and the functionality of the antibody 
isotype (e.g. IgG, IgA, IgM, IgD, IgE) or subclass (e.g. IgG1-4) against the different 
epitopes. Since previous research indicated TRA below 90% is not reliably replicated 
between experiments, it would be logical to assess avidity and identify isotypes or 
subclasses only in serum demonstrating >90% TRA (van der Kolk, de Vlas et al. 2004). 
Antibody avidity could be explored using dissociation ELISA, or BiaCore technology to 
test the strength of the antibody-antigen binding. While antibody avidity could be 
hypothesized to mature and improve upon increasing cumulative exposure (and 
therefore age), this has not been explored for 10C and the different epitopes. 
Possibly, specific antibody isotypes or subclasses could be responsible for the most 
effective TRA (which again could be related to their avidity). Generally, for antibodies 
produced against asexual/pre erythrocytic malaria antigens, IgG has been suggested to 
be the most important (most cytophilic) antibody isotype for malaria protection, which 
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was demonstrated using passive transfer experiments (Cohen, Mc et al. 1961; 
Sabchareon, Burnouf et al. 1991; Dobano, Quelhas et al. 2012). Furthermore, 
subclasses IgG1 and IgG3 have been suggested to be most important for clearance of 
parasites, and are more commonly produced against malaria antigens (Tongren, 
Drakeley et al. 2006; Eisenhut 2007; Mewono, Matondo Maya et al. 2008; Stanisic, 
Richards et al. 2009; McCarra, Ayodo et al. 2011; Dobano, Quelhas et al. 2012). 
Antibody subclass switching has been observed for MSP (Tongren, Drakeley et al. 
2006). In this thesis, total IgG was measured for all ELISA assays; if the functional 
antibody isotype or subclass was not dominant in the serum samples, it is possible 
these responses could be shrouded and not sufficiently captured by a total IgG 
measurement. To explore antibody isotypes in the serum (and their relationship with 
TRA), ELISA could be performed but detecting with different secondary antibodies 
specific to the range of isotypes or subclasses (e.g. using IgG1-HRP, IgG3-HRP etc). 
With this knowledge, if an isotype/subclass was found to be particularly important for 
functional TRA, efforts could be made for the vaccine to specifically elicit a response to 
that isotype/subclass. For example, in the instance of MSP2, IgG3 was suggested to be 
the most functional subclass for reducing parasite densities. It was therefore proposed 
that future vaccines based on MSP2 could include a T-cell epitope that specifically 
induces IgG3 production (Tongren, Drakeley et al. 2006).   
Research performed in Papua New Guinea assessed antibody subclass produced 
against RESA and discovered only IgG3 demonstrated an age dependent pattern (Beck, 
Felger et al. 1995).  This could form another potential hypothesis for the difference in 
age dependent patterns observed with native Pfs48/45 and Pfs230 (some studies did 
not show an age dependent acquisition pattern (Ouedraogo, Roeffen et al. 2011)) and 
the recombinant proteins 10C and 230CMB (which did display an age dependent 
increase).  
Antibodies can develop against (and bind to) a wide array of Plasmodium antigens; for 
this reason they are most important for transmission reduction (Bousema and 
Drakeley 2011). However, it has been suggested that white blood cells (WBCs) and 
cytokines may have a small effect on transmission reduction. For example, leucocytes 
have been suggested to phagocytose gametes that have been opsonised (which is 
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dependent on antibody presence) (Lensen, Bolmer-Van de Vegte et al. 1997; Lensen, 
Mulder et al. 1998; Bousema and Drakeley 2011). Alternatively, cytokines (e.g. tumour 
necrosis factor alpha (TNF-α)) in co  ination with  Cs have  een su  ested to play 
a role in transmission reduction (Naotunne, Karunaweera et al. 1993; Bousema and 
Drakeley 2011).  Neither of these ideas have been explored in this project, which was 
concerned with vaccine candidate antibody responses and functionality, but, 
peripheral blood mononuclear cells (PBMCs) were collected in Burkina Faso which will 
be assessed for their activity in another project.  
While results from Chapter 5 indicated a strong association with 10C and 230CMB 
antibodies and TRA using SMFA, this association was not observed in the field in 
Chapter 6 where DMFA was performed. In Chapter 6, naturally acquired antibodies to 
10C and 230CMB did not appear to play an important role in defining the human 
infectious reservoir or predicting which gametocyte carriers showed evidence of TRA. 
However, it appears antibodies to both candidates do block transmission when using 
SMFA. It must be noted the lack of an association (with TRA and antibodies) in Chapter 
6 was based on data from a low number of infectious individuals, during the dry 
season. Low gametocyte density infections (while typical of natural infection), 
introduce complications when aiming to use membrane feeding in the field and reach 
adequate statistical power. This is something that needs further development and 
standardization before membrane feeding can be considered a robust tool for use in 
clinical trials. Repeating DMFA in larger studies, during the peak transmission season, 
and within different endemic settings, would be a useful next step to inform how 
naturally acquired TRA varies when exposure to gametocytes may be more prolonged 
and gametocyte densities may be higher.  Asides from this, it must be reiterated there 
are methodological differences between SMFA and DMFA. SMFA is much more 
standardized and forms the current gold standard method for assessing TRA (Bousema 
and Drakeley 2011).   
In Chapter 6, I confirmed the functional TRA of vaccine induced antibody responses in 
rats. This represents an important step in development of the vaccine candidate by 
extending the statistically significant TRA demonstrated using SMFA and cultured 
isolates (Theisen, Roeffen et al. 2014) to the field where the vaccine will be deployed.  
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My finding that the highest tested concentration of pooled rat IgG did not completely 
prevent transmission of all isolates may indicate the assay needs to be optimised with 
a higher starting IgG concentration to achieve more complete blocking. While 
performing this experiment during the dry season where gametocyte densities were 
low was relevant and reflected the low densities seen in the majority of infections 
(Bousema and Drakeley 2011), to improve the statistical power, the study should be 
repeated with patent gametocyte carriers who may infect larger numbers of 
mosquitoes and form a more sensitive starting point to measure TRA (Ouedraogo, 
Bousema et al. 2009; Bousema, Dinglasan et al. 2012).   
However, recent experiments using an animal model system suggested a transmission 
blocking intervention that resulted in transmission reduction of 32% was sufficient to 
eliminate transmission in a low endemic site (Blagborough, Churcher et al. 2013). As 
part of the target product profile for a TBV, it was stated the vaccine should reduce 
transmission by >85% (Penny, Maire et al. 2008). The TRA seen in the field with our 
candidate (in a small number of participants) is close to this goal of >85%, but needs 
confirming in a larger population. In light of the data derived from modelling, perhaps 
improvements may not be necessary, depending on the transmission intensity of the 
intended site of vaccine roll out. The >85% transmission reduction benchmark could be 
excluding potentially useful vaccine candidates and perhaps the target product profiles 
should be re-evaluated according to transmission intensity in the location of use.  
 
7.3 A toolbox for community trials with transmission blocking vaccines 
 
Research on TBV has been prioritized in light of global malaria eradication initiatives.  A 
recent publication that summarized the Malaria Vaccine Technology Roadmap strategy 
(Nunes, Woods et al. 2014) reflects these changes by including TBV in the goals. The 
authors highlighted important gaps in current knowledge that need to be filled to 
enable evaluation of TBV (Nunes, Woods et al. 2014). Along with tools to assess the 
human infectious reservoir, the need for standardized membrane feeding assays was 
discussed. Another specific potential problem that was mentioned was that pre-
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fertilization TBV candidates may suffer immune escape mutants since vaccine 
candidates are exposed to host immunity (Nunes, Woods et al. 2014).  
In my thesis I have made progress towards addressing several of the concerns 
expressed by the Malaria Vaccine Initiative (MVI) (Nunes, Woods et al. 2014). I have 
demonstrated transmission stage parasites can be detected from filter papers, and 
proposed a robust combination of sampling methods which play a role in identifying 
the human infectious reservoir. I have shown naturally acquired antibodies to 10C and 
230CMB vaccine candidates are detectable in all age groups in several sample sets 
from different endemic settings. This has implications for future transmission blocking 
vaccine trials which need to consider malaria endemic populations may have 
antibodies prior to vaccination. Furthermore, within these populations, it is possible 
the vaccine derived immune response could elicit an enhanced reaction since immune 
memory cells may already be present from natural exposure (Siegrist 2014).   
I provided evidence of functionality of naturally acquired antibodies and showed that 
antibodies produced against our vaccine candidate (10C) significantly blocked 
transmission of endemic parasites. I have demonstrated pfs48/45 contains 
polymorphisms with strong geographical variation, which forms a starting point to 
determine their relevance for 10C vaccination. These findings have all contributed 
towards filling in these knowledge gaps to aid further TBV development. A hurdle for 
TBV development that was highlighted by MVI, was the variability in how membrane 
feeding assays are performed and assessed (Nunes, Woods et al. 2014). The serum 
replacement method I performed, along with other membrane feeding protocols 
performed by colleagues were published in a methodological paper with the aim of 
encouraging standardization of protocols to aid inter laboratory comparability (André 
Lin Ouédraogo, Jetsumon Sattabongkot et al. 2013). 
Our vaccine candidate is still in the early stages of development and the next step is 
toxicity studies of a batch of GMP produced R0-10C. An important consideration for all 
groups developing TBV candidates is trying to reduce the cost per vaccination. Since it 
is likely the vaccine will be deployed to all age groups, this significantly increases the 
cost and there are concerns the vaccine may exceed malaria elimination budgets 
(Nunes, Woods et al. 2014).  Furthermore, attempts need to be made to improve 
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acceptance of a community based vaccine that provides delayed benefit on an 
individual level. Efforts have been made by MVI, WHO and the Gates Foundation to 
encourage collaboration between research groups, and there is optimism that 
progress may now advance more rapidly (Nunes, Woods et al. 2014).  
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Appendix 
 
Please note: These protocols were all supplied by colleagues, as detailed below.  
 
 
Appendix 1: Preparation of L6 buffer, L2 buffer, and silica, for guanidine based 
nucleic acid extraction 
 
Protocol provided by Medical Microbiology Department, Radboud University Medical 
Centre, Nijmegen, The Netherlands.  
 
Reagents and catalogue numbers: 
SiO2, Sigma 5631 (80% 1-5 micron)   EDTA, Tritriplex, Merck, 8418 
Tris, Trizma base Sigma T6066 (T12), Mw 121.1 NaOH, Merck 6498 
GuSCN, Fluka 50990, Mw 118.16 (Sigma –Aldrich) Triton-X-100, Packard 6008084 
 
The Tris-HCl is a component of L2 and L6 buffers, make this first as shown below. 
0.1M Tris-HCl, pH 6.4 (1 litre) 
 Dissolve 12.1g Tris in 800 ml of ddH2O 
 In a fume cupboard, slowly add 8.1ml of HCl (37%)  
 Adjust  the pH to 6.4 
 Then top up to 1 litre with ddH20   
  
L2 buffer 
 
 Dissolve 120g GuSCN in 100 ml of 0.1M Tris-HCl, pH 6.4  
 Gently shake in a 60°C water bath until dissolved, then aliquot into 50ml falcon 
tubes.  
 
0.2M EDTA pH8 (500mls): 
 Dissolve 37.2g of  EDTA and 4.4g NaOH in 400 ml of autoclaved MQH2O, pH  
and top up to 500mls 
 
 
 309 
 
L6 buffer (keep dark) 
    
 Gently dissolve 1200g of GuSCN in 1 litre of pre-made 0.1M Tris-HCl, pH 6.4, at 
60°C in a water bath 
 Add 220 ml of 0.2M EDTA pH8 
 Add 26ml of Triton-X-100 
 Mix and aliquot into 50ml falcon tubes.  
 
Silica 
In a cylinder (diameter 5cm, height 27.5cm), do the following: 
 Suspend 60 g of silica in 500 ml of ddH2O 
 Leave to sediment for 24 hours at room temperature  
 Remove 430 ml of supernatant by aspiration 
 Add ddH2O up to 500 ml and resuspend by shaking 
 Leave to sediment for 5 hours  
 Remove 440 ml of supernatant 
 Add 600 l of HCl 37% and resuspend by vortex 
 Aliquot into small bottles (1 mL) and autoclave wet for  20 min at 121°C, in 
tightly closed bottles 
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Appendix 2: Cross sectional survey information sheets 
 
Supplied by Teun Bousema 
 
Overview 
A cross-sectional school survey to determine the recognition of antibody responses to 
Pfs48/45- 10C malaria transmission blocking vaccine candidate 
 
Introduction 
Dr. [Chilongola/Dodoo/Nebie] of [Kilimanjaro Christian Medical Centre/Noguchi 
Memorial Institute for Medical Research/ Centre National de Recherche et de 
Formation sur le Paludisme] is leading a team that will be conducting studies on 
immunity against malaria in the area of [Bondo/Asutsuare/Ouahigouya]. In the current 
study, we want to determine how common immune responses are that influence the 
spread of malaria. This information is very valuable for the future testing of a malaria 
vaccine. In the current study, we will not give anybody a vaccine. We will determine 
natural immunity to malaria. 
 
Why is this study being done? 
Malaria is one of the most important health problems in [Tanzania/Ghana/Burkina 
Faso]. The vaccine that we are trying to develop could play an important role in 
fighting malaria. For this, we need to study natural immune responses to malaria. We 
also want to determine how many children are infected with malaria parasites and 
how this is related to mosquito exposure. 
 
What will happen if I agree to let my child take part in this study? 
If you agree to let your child take part in this study, we will ask them some questions 
about age, residence and other general information. In addition, we will ask him/her to 
provide a small blood sample by finger prick. This will be used to check for malaria and 
to determine their level of immunity. 
We may also contact you later to catch mosquitoes in your house.  
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How long will my child be in the study? 
Your child will be sampled twice: once in the rainy season and once in the dry season. 
Sampling will not normally take more than 15 minutes. 
 
What risks can I expect if my child takes part in the study? 
The risks of drawing blood from a finger prick include temporary discomfort and 
bruising. The amount of blood removed per time-point is less than a quarter of a 
teaspoon so it is too s all to affect your child’s health   
 
Are there benefits if my child takes part in the study?   
Your child will receive free clinical care from the study staff medical officers and nurses 
if a clinical malaria attack is detected. In addition, the knowledge gained from this 
study will help the country of [Tanzania/Ghana/Burkina Faso] in determining the best 
way to treat and prevent malaria in children.   
 
What other choices do I have if I do not allow my child to participate in this study? 
Whether you allow your child to participate or not is completely your choice. If you 
decide not to take part in this study, there will be no penalty to you.   
 
Will information about my child be kept private? 
The study personnel will treat all information gathered as private, and records will be 
kept securely in locked filing cabinets and offices. No personal identification 
information such as names will be used in any reports arising out of this research. The 
findings of this study will be presented in a village meeting but individual findings will 
not be reported. 
 
Who pays for this study?  
The European Union has funded this study. 
 
What are the costs of taking part in this study?   
There are no costs to you for taking part in this study.  
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Will I be paid for taking part in this study? 
You will not be paid for taking part in this study. 
 
What are my rights if my child takes part in this study? 
Taking part in this study is your choice. You may choose for your child to either take 
part or not take part. If you decide your child will participate in this study, you may 
change your mind at any time.  No matter what decision you take, there will be no 
penalty to you in any way.  
 
Who can answer my questions about the study? 
You can talk to the researchers at the study clinic or on telephone nu  er […]  a out 
any questions or concerns you have.  You may also contact [Chilongola/Dodoo/Nebie] 
or other  e  ers of the tea  on telephone nu  er […]   f you have any questions  
comments or concerns about taking part in this study, please talk to the researchers 
first.  If for any reason you do not wish to do so, or you still have concerns, you may 
contact the chair an of the ethical co  ittee on […]    
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Appendix 3: Cross-sectional survey consent form 
 
Supplied by Teun Bousema 
A cross-sectional study to determine antibody responses to the Pfs48/45-10C malaria 
transmission blocking vaccine candidate 
INSTITUTIONS: Kilimanjaro Christian Medical Centre (Moshi, Tanzania), Noguchi 
Memorial Institute for Medical Research (Kintampo, Ghana), Centre National de 
Recherche et de Formation sur le Paludisme (Ouagadougou, Burkina Faso), AMANET 
(Dar es Salaam, Tanzania), London School of Hygiene & Tropical Medicine (London, 
UK), Radboud University Nijmegen Medical Centre (Nijmegen, the Netherlands) 
PRINCIPAL INVESTIGATOR: Chilongola/Dodoo/Nebie  
 
PARTICIPATION INFORMATION: We would like your child to participate in a medical 
study. It is very important that you understand the following general principles, which 
apply to all participants within our studies  
i) Participation is entirely voluntary.  
ii) Persons may withdraw from participation in this study or any part of the 
study at any time.  
iii)      After you read the explanation, please feel free to ask any questions that will       
allow you to clearly understand the nature of the study. 
 
INTRODUCTION:  
Malaria is common in [Tanzania/Ghana/Burkina Faso]. A vaccine would be a very 
valuable tool to protect people from malaria. One of the possible vaccines is a vaccine 
that blocks the spread of malaria. The current study wants to determine this type of 
immunity in people who are naturally exposed to malaria. 
 
PROCEDURES TO BE FOLLOWED: 
A single 0.25-0.35mL blood sample, approximately a quarter of a teaspoon, will be 
taken from the finger. This blood will be used to determine parasite carriage and 
detect  antibodies against malaria parasites. It will be stored in the laboratory in 
[Moshi, Accra, Ouagadougou] and will only be used for the mentioned purposes. Some 
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of the samples may be transported to Europe for additional analyses. A short 
questionnaire will be administered. 
 
RISKS AND DISCOMFORTS:  
Mild discomfort and bruising is possible at the site where the finger prick blood sample 
is obtained. 
The volume of blood is approximately a quarter of a teaspoon and is too small to affect 
your child’s health   
 
DURATION OF VOLUNTEER'S PARTICIPATION: 1 day, to be repeated twice during the 
year 
NUMBER OF VOLUNTEERS IN THE STUDY: 100 per school, a total of five schools are 
included in three countries.  
 
ASSURANCE OF CONFIDENTIALITY OF VOLUNTEER'S IDENTITY: Records relating to 
your/your child's participation in the research will remain confidential. Identifying 
information will not be used in any report resulting from this study. You will receive a 
copy of this consent form. 
 
BENEFITS/MEDICAL CARE FOR ILLNESS: You/your child will be entitled to free malaria 
treatment if this is considered beneficial by the study physician.  
 
FOR INFORMATION OR ANSWERS TO QUESTIONS CONCERNING YOUR RIGHTS AS A 
RESEARCH SUBJECT YOU MAY CONTACT: Dr. [Chilongola/Dodoo/Nebie]; Mobile 
phone: […] 
 
IF THERE IS ANY PORTION OF THIS CONSENT EXPLANATION SHEET THAT YOU DO 
NOT UNDERSTAND, ASK THE INVESTIGATOR BEFORE SIGNING. 
 
I have read the information sheet concerning this study [or have understood the verbal 
explanation] and I understand what will be required of me and what will happen to me 
if I take part in it. Questions have been answered by Dr. [Chilongola/Dodoo/Nebie ]. I 
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agree to take part in this study and understand that at any time I may withdraw from 
this study without giving a reason and without affecting my normal care and 
management. 
I approve/disapprove (delete one) that part of my sample may be shipped abroad for 
analysis  
 
Name   
 ______________________________________________________ 
 
Child's name (if applicable)
 ______________________________________________________ 
 
Signature / finger print:    ______________________ 
Date_______________ 
 
Signature/fingerprint child (if applicable) ______________________ 
Date_______________ 
 
Witness's Signature:     ______________________ 
Date_______________ 
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Appendix 4: Child Questionnaire 
Supplied by Teun Bousema. 
Parasitological survey –  2011 Stool Urine 
 
Blood exam 
Pupil Study ID no:    |___|___|___|___| 
 
School: ________________________                            Date  survey: |___|___| / |___| / 2011   
Class:  |___| Age:  |___|___| Sex:       Male  Female   
Complete the following with each child recruited into the survey 
A.Residence Response  Codes 
A1. Since Primary one, where have 
you lived?/umeishi wapi tangu 
uanze shule ya msingi? 
 
A2. What is the name of the village 
you reside in now? /Kijiji chako 
chaitwaje? 
 
Within District/ Katika wilaya 
 Outside district/Nje ya wilaya 
 
 
 _______________________________ 
 
 
   [__] 
 
                                                 
[__] 
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A3. In minutes, how long does it 
take you to walk to schools? / 
Unachukua dakika  ngapi 
kutembea hadi shuleni? 
 
[__|__] 
 
B.Socio-economic status Response  Codes 
B1. In your house, are there any of 
the following? / Kwa nyumba yenu 
kuna vitu vifuatavyo?  
 
READ OUT & FILL IN WITH Y/N 
(More than one option maybe 
selected) 
Electricity/ Stima/umeme 
Solar power/ Umeme kutoka kwa jua 
 
Flush toilet/ Choo cha maji 
Owns a pit latrine/  Choo chenu binafsi cha shimo  
Uses someone elses pit latrine/ Mnatumia choo cha 
shimo na wengine 
 
Telephone; landline/  Simu ya meza 
Telephone; mobile phone/ Simu ya mkononi  
[__] 
[__] 
 
[__] 
[__] 
[__] 
 
[__] 
[__] 
B2.What type of wall does your 
house have? / Je kuta za  
nyumba yenu ni za aina 
gani? 
1=Stone or bricks or cement/ Mawe, Matofali au 
simiti 
2=Clay/mud/ Udongo 
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READ OUT OPTIONS 
(Select only one answer) 
3=Wood/ Mbao 
4=Other (specify)/ Zinginezo (eleza) 
 
[____________________________________] 
 
 [____] 
B3. What type of flooring does your 
house have?/  Je sakafu ya 
nyumba yenu ni ya aina 
gani? 
 
READ OUT OPTIONS 
(Select only one answer) 
1=Cement or tiles or linoleum / Simiti au  
     vigae 
2=Wooden planks /Sakafu ya mbao 
3=Earth or sand/ Udongo au mchanga 
4=Other (specify)/ Zinginezo (eleza) 
[____________________________________] 
 
 
 
 
 
 
[___] 
B4. What type of roof does your 
house have? / Je paa la  
Nyumba lenu ni la aina 
gani? 
 
READ OUT OPTIONS 
(Select only one answer) 
1=Tiles/ Vigae  
2=Iron sheets/ Mabati 
3=Grass or thatch/ Nyasi 
4=Makuti/ Makuti 
5=Other (specify)/ Zinginezo (eleza) 
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[____________________________________] 
 
[__] 
B5. What is the main type of fuel 
used 
 by your family for  cooking?/Kwa 
kawaida, mnatumia nini kwa 
kupika? 
 
READ OUT OPTIONS 
(Select only one answer) 
1=Electricity or gas/ Stima au gesi? 
2=Kerosene/ Mafuta ya taa 
3=Charcoal/ Makaa 
4=Firewood/ Kuni 
5=Dung/ Samadi 
6=Others (specify)/ Zinginezo (eleza) 
 
[____________________________________] 
 
 
 
 
 
 
 
[__] 
B6.What is the main source of 
water for drinking or cooking in 
your home? / Kwa Kawaida, maji 
ya kunywa au kupika yatoka 
wapi? 
 
       READ OUT OPTIONS 
         (Select only one answer) 
1=Piped/tap water/ Maji ya bomba 
2=Borehole or well/ Kisimani/chemichemi 
3=Rain water/ Maji ya mvua 
4=Stream or river/ Maji ya mtoni 
5=Bought/ Mnanunua 
6=Bottled water/ Maji ya chupa 
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7=Others (specify)/ Zinginezo (eleza) 
 
[____________________________________] 
 
 
[__]  
 
C.Bed net use  Response  Code 
C1. Do you normally sleep under a 
bednet?/Je kwa kawaida unalala 
ndani ya neti? 
 
C2. Did you sleep under a bed net 
last night?/Je ulilala ndani ya neti 
jana usiku? 
 
C3. What is the colour of your bed 
net?/ Neti yako ni ya rangi gani? 
 
C4. When do you receive your bed 
net? / Ulipata neti yako lini? 
 
Yes/ndio 
No/La 
Don’t know/Sijui 
 
Yes/ndio 
No/La 
Don’t know/Sijui 
 
[_______________________________] 
 
This school term/Muhula huu  
 
 
[__] 
 
 
[__] 
 
[__] 
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Last school term/Muhula  uliopita  
Last school year/Mwaka jana 
 
D: Animals  Response Code 
What animals are found in your 
compound? / Je mna wanyama 
wagani kwa boma yenu? 
 
D1.Cattle /Ng’ombe 
D2. Sheep/kondoo 
D3. Goats/Mbuzi 
 
READ OUT OPTIONS 
 
 
CIRCLE CORRECT RESPONSE 
Yes/No Ndio/La 
Yes/No Ndio/La 
Yes/No Ndio/La 
 
 
 
 
 
[__] 
[__] 
[__] 
 
F.Fever Response Code 
F1. Do you have fever or hot body 
at the moment ? Je, una joto jingi 
au mwili moto hivi sasa? 
 
Yes/No/Don’t know 
Ndio/La/Sijui 
 
[__] 
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F2.  In the last 2 weeks have you 
had fever or hot body? / Wiki mbili 
zilizopita ulikuwa na joto jingi au 
mwili moto? 
 
F3.  In the last 2 weeks have you 
had blood in urine/ Wiki mbili 
zilizopita ulikuwa na damu au 
kichocho katika mkojo wako? 
 
Yes/No/Don’t know 
Ndio/La/Sijui 
 
 
Yes/No/Don’t know 
Ndio/La/Sijui 
 
 
[__] 
 
 
[__] 
 
G. Family and siblings Response Code 
G1.How many people live in your 
household? / watu wangapi 
wanaishi kwa nyumba yenu? 
 
G2. How many siblings do you 
have? /  
Je watoto wa mama yako ni 
wangapi? 
[_______] 
 
 
[_______] 
[_______
] 
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 Name of sibling 
(Jina la ndungu) 
Sex 
Kike/ 
Mume 
Age 
Miaka  
In same 
school? 
/Anasoma 
hapa?) (N/Y) 
Name of 
school if ‘N’ 
(Kama la, 
anasoma 
shule gani?) 
Class 
number 
(Darasa) 
Does he/she 
normally sleep 
under a bednet? 
/ 
Je hula ndani ya 
chandarua? 
Did he/she 
sleep under a 
bed net last 
night? / Alilala 
ndani ya 
chandarua jana 
usiku? 
What is the 
colour of their 
bed net? / 
Chandarua 
yenu ni rangi 
gain? 
1          
2          
3          
4          
5          
6          
7          
8          
9          
10          
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Appendix 5: School Questionnaire  
 
  Supplied by Teun Bousema 
SCHOOL SURVEY QUESTIONNAIRE: ____________________District 
Date: ______/______/2011 
School name: 
_____________________________________________________________ 
Year school established: 
_____________________________________________________ 
Person interviewed: 
_________________________________________________________ 
Head-teacher (yes ,no) if No, describe: 
__________________________________________ 
Longitude: [__]__] . [__]__]__]__]__]__]     Latitude: - [__] . [__]__]__]__]__]__] 
A. General demographics Response Code 
A1. Total number of children in school  [____]   
A2 Total number of teachers in school   [____]  
A3.Village nearest to school 
A4.Village furthest from school  
____________________] 
[____________________] 
 [____] 
 [____] 
B. Health programmes Response Code 
B1.Does the school have a feeding 
program?  
Y/N 
 
 [____] 
B2.Did pupils receive free bednets in 
school campaigns? 
 
Y/N 
 
[____] 
B3.Is the school involved in a 
deworming programme? 
 
Y/N 
 
[____] 
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Appendix 6: Blood sampling procedure 
 
Protocol supplied by Teun Bousema 
Definition 
This SOP describes how to collect blood for thick and thin film, DNA sampling, RNA 
sampling, plasma, RDT and filter paper. 
Staff  
All trained study staff 
Materials 
- Dry cotton wool 
- Gauze 
- Cotton wool swabs soaked in 70% Ethanol (provided with Premier Medical 
First Response RDT). 
- Swab containers 
- Disposable sterile puncture device (provided with Premier Medical First 
Response RDT). 
- EDTA microtainer  
- Screw cap tubes for plasma 
- Glass microscope slides 
- Slide box 
- Pre-labelled stickers 
- Permanent marker pen or pencil 
- Sharps bin 
- Clean plastic disposable gloves 
- Whatman 3 filter papers, previously arranged into their protective card 
jackets 
- RDTs (Premier Medical First Response) 
- L6 buffer (guanidine isothiocyanate buffer) (Severn Biotech) pre-measured in 
eppendorfs 
- Extraction Matrix (Severn Biotech) 
- Silica gel  
- Sealable bags 
- Barrier tips for 40µL, 50µL and 900µL volu es (i e  200 and 1000μ  tips) 
- Pipettes to measure above mentioned volumes  
- Cryoboxes for sample storage 
- Cool boxes 
- Ice 
- Blue roll 
- 70% ethanol 
-  
Procedure for collecting blood slide from finger/heel prick:  
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1. Before going out to the field, please confirm that the following are correctly 
labelled according to the pre-agreed labelling protocol (see India Meeting 
minutes), slides, EDTA microtainers, filter papers, L6 eppendorfs, and screw 
cap tubes for plasma. Take the following tubes out to the field with you, 
EDTA microtainers, filter papers L6 eppendorfs and slides. The plasma 
samples can be dealt with on return to the lab as described in protocol 5. 
2. When in the field, prepare the equipment and consumables making sure 
sharps are safely placed out of reach of children.  
3. Explain to the participant/parent/carer the procedure you are about to do 
and the reason why.  
4. Wear a clean pair of disposable gloves  
5. Squeeze the finger from the base towards the top, stimulating the blood flow.  
6. Make sure the finger is pointing downwards, to aid the flow of blood  
7. Make sure the site of pricking is clean  
8. Disinfect finger with a swab moistened with methylated spirit or 70% ethanol 
(or use the swab provided with the RDT). 
9. Allow the finger to air-dry  
10. Apply a thin layer of Vaseline on the place where you want to prick  
11. Using a sterile blood lancet, prick the finger deeply on the side of the tip of 
the finger.  
12. Discard used lancets directly into the sharps disposal container  
13. Wipe away the first droplet of blood with gauze  
14. Hold the microtainer tube in an angle of ~45° angle from surface of finger.  
15. Squeeze gently from the base of the finger towards the tip, allowing the 
blood to flow. The blood should flow easily and without interruption, only 
the first droplets take some effort.  f the squeezin  (‘ ilkin ’) is done with 
too much force, haemolysis can occur which can affect the results.  
16. Take approximately 300µL of blood in the microtainer. Lines are indicated, 
make sure to take not more than 500µL, not less than 200µL.  
17. Gently invert the tube 10 times. This is done to mix the blood with the EDTA 
which will prevent the blood from clotting. 
18. Remove 50µL of blood for the RNA sample. This is to be immediately put into 
an eppendorf with 900µL of previously aliquoted L6 buffer. Vortex the L6 
aliquot straight away if possible, or invert 10 times. If tubes can be processed 
within 1 hour, leave at room temperature. If it will take >1 (up to 5 hours, not 
longer), store in cool box or fridge.  
19. The remaining volume of blood in the microtainer tube will be used for 
plasma and DNA extraction. For this, the microtainer should be kept in a cool 
box or fridge until further processing. It should not be frozen before it has 
been processed. 
20. Collect three drops of blood on the Whatman 3 filter paper (see appendix 8 
for further details). Make sure that the drops wet the full thickness of the 
paper (i.e. the blood is also visible at the back of the paper) 
21.  Perform RDT (First Response Combo, Premier Medical, India) according to 
the anufacturer’s instructions. 
22. Take the slide as described in appendix 9. 
23. On return to the lab, prepare the plasma sample, as outlined in appendix 10. 
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Appendix 7: Procedure for RNA collection in L6 buffer 
 
Protocol supplied by Teun Bousema 
 
Definition 
This protocol is for taking the RNA sample from the EDTA microtainer tube. This 
sample will later be used to determine gametocytaemia. As the target is RNA, these 
samples need to be handled as carefully and as aseptically as possible to avoid 
introduction of RNAses. 
Material 
- L6 buffer (Severn Biotech) 
- Extraction matrix (Severn Biotech) 
- gloves 
- Eppendorfs 
- 70% ethanol 
- RNA sample log book 
- Cryoboxes 
- Barrier tips for 900µL 
- Pipette that measures 900µL 
- Barrier tips for 40µL 
- Pipette that measures 40µL 
- Vortex 
- centrifuge 
 
1. When handling all RNA equipment, ensure that all surfaces, pipettes, tube 
racks and any other equipment is wiped down first with 70% ethanol prior to 
use to avoid introduction of RNases into the eppendorfs. 
2. Label the eppendorfs according to the naming protocol.  
3. Within the lab in the most sterile environment possible, aliquot out 900µl of 
L6 buffer into the eppendorf using a barrier tip, but before aliquotting the 
buffer, change your gloves to reduce the possibility of introduction of 
RNAses.  
4. Next transport the eppendorfs out to the field site.  
5. These tubes should be kept in the dark at room temperature and should not 
be prepared >7 days before the actual sample collection to prevent 
evaporation. 
6. When taking the microtainer EDTA sample in the field, after inverting the 
blood in the EDTA tube (10 times), using a barrier tip, pipette off 50µL and 
aliquot this into the 900µL of the L6 buffer.  
7. If possible, mix immediately by vortex. 
8. If not, immediately invert the tube 10 times. 
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9. Samples can be stored at room temperature for 1 hour or in a cool box or 
fridge for 5 hours. 
10. Following return to the lab, vortex the sample thoroughly. In the most 
aseptic environment possible, do the following. Change your gloves, then 
add 40µL of extraction matrix to the eppendorf.  
11. Vortex this for 5 seconds then shake gently at room temperature for 10 
minutes. 
12. Then vortex again for 5 seconds, spin for 25 seconds at full speed in a 
microfuge. Change your gloves, then open the tube and remove the 
supernatant. The remaining pellet is now ready to be shipped for RNA 
extraction. It can be shipped with icepacks that have been stored overnight 
at -80°C after consultation of the LSHTM coordinator. 
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Appendix 8: Whole blood collection on filter paper  
 
Protocol supplied by Teun Bousema 
 
Definition 
This SOP is to be used when processing DNA blood spots collected on filter paper. For 
best results the blood spot should be dried as soon as possible. This usually occurs in 
the field and at the health facility. The drying process is crucial and takes place in two 
steps. This sample will be used for species determination via PCR, and for ELISA. 
Staff  
Laboratory technicians and fieldworkers 
Material 
- Whatman 3MM filter paper  
- manila or cardboard paper 
- clean forceps 
- gloves 
- plastic medicine dispensing bags 
- colour indicating silica either as individual grains or as small bags  
- Filter paper log book 
- Filter paper storage container 
 
Prepare filter paper: 
1. Wear gloves during all steps. 
2. Cut Whatman number 3MM filter paper in pieces of ~5x2cm. 
3. Cut manila/cardboard paper or paper card in pieces of ~14x2.5cm. Each piece 
of card should make 11 protective jackets. 
4. Place a strip of filter paper and a strip of cardboard end-to-end and 
overlapping by 0.5 cm and staple together. 
5. Fold down the stapled part so that the filter strip lies down the cardboard 
strip. 
6. Fold up the bottom of the cardboard strip over the filter paper to form a 
protective cover. 
7. The filter paper is now ready for use. 
 
Filter paper blood collection and processing: 
1. Wear clean gloves during all steps 
2. Do not directly touch the filter paper, only touch the protective cover 
3. Label the filter paper with correct sticker label 
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4. Collect three large drops of blood on the filter paper (approximately 20µL 
each) and make sure the droplets are in the middle of the filter paper (see 
figure below). 
 
 
 
 
 
5. Make sure that the drops wet the full thickness of the paper (i.e. the 
blood is also visible at the back of the paper) 
6. Place the filter papers in a drying container to allow it to dry but protect it 
from the wind and sand 
7. After a minimum of one hour, fold the filter paper and place the filter 
paper in a plastic bag, combining up to 5 filter papers per plastic bag. Do 
not close the bag. Realize that this is only the first step of the drying 
process. After collection of all samples (i.e. samples from all individuals) 
upon returning in the laboratory/clinic or project house, commence with 
step 8. 
8. Remove the filter papers from the plastic bags with clean forceps and 
gloves and place them on top of the plastic bags 
9. Ensure that the filter papers are on a surface that cannot be disturbed by 
the wind, insects, animals or individuals. 
10. Allow them to dry overnight at room temperature 
11. Put five filter papers into each plastic bag 
12. Add one bag of silica into each plastic bag with the filter papers.  
13. Push the air out of the bags and close the bags tightly ensuring the seal 
has completely closed. 
14. Combine plastic bags in a larger sealable plastic bag with another quantity 
of silica gel inside.  
15. Place the plastic bag in an airtight container. 
16. Place at -20°C and check silica gel every two weeks for changes in colour. 
17. If the colour changes from orange to green, replace the silica gel sachet 
18. Keep at -20°C until processed for PCR or ELISA. When samples are taken 
from the freezer, allow them to come to room temperature for at least 2 
hours before you open the bag to prevent condensation. 
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Appendix 9: Preparation of a thick and thin blood slide 
 
Protocol supplied by Teun Bousema 
Definition 
This protocol describes how to collect a thick and thin film. The follows the protocol 
where it is described how blood is collected from a finger prick sample. 
Staff  
All trained study staff 
Materials required: 
- Glass slides that are clean and grease-free (this may require cleaning with 
ethanol prior to going to the field). 
- Slide box 
- Permanent marker pen 
- Sticker label  
- Alcohol pads 
- Lancets 
- Sharps bin 
 
Procedure for preparing a blood slide from finger/heel prick sample (following from 
protocol describing how to take a finger prick): 
1. Wipe away the first droplet of blood. 
2. Squeeze gently to obtain drop of blood. 
3. Discard used lancets directly into the sharps disposal container 
4. Using two completely clean grease-free microscope slides collect blood 
directly onto labelled slides: a small drop of blood to the centre of the slide 
for thin smear and a large drop about 1-2 cm away from the frosted end of 
microscope slide. 
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Making thick and thin blood films  
Thick and thin blood films should be made on the same slide as shown below. The 
picture on the right indicates the required quantity of blood. 
 
 
Thin smear  Thick smear  Sticker 
 
5. Immediately spread the thin film using a smooth edged slide spreader 
(Clean slide) inclined at 450 to horizontal line (a well made blood film 
should have a smooth tail end not ragged and be free of vertical lines and 
holes (a poorly spread film is extremely difficult to report because the red 
cells, parasites, and white cells will appear distorted) 
6. Allow the blood film to air-dry with the slide in a horizontal position and 
placed in a slide boxes or any other safe place (where there is no risk of the 
blood coming into contact with dust or flies) for transport and staining. 
7. Use the hairdryer to speed up the process of drying but keep it at least 30 
cm away from the slide. 
8. Be aware of flies and insect that might disturb the slide when drying in the 
open air. Try to find a place without flies or if not possible keep disturbing 
them. 
9. Do not stain the slide until back in the laboratory. 
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Appendix 10: Plasma and cell pellet separation procedure 
 
Protocol supplied by Teun Bousema 
 
Definition 
This protocol is for the separation of plasma from the finger prick samples that are 
collected in the cross-sectional surveys. This plasma will later be used in the ELISA, 
the cell pellet can be used for DNA extraction and parasite molecular detection. 
 
Material 
- Previously taken EDTA blood samples 
- Screw cap tubes 
- Centrifuge 
- gloves 
- Ice 
- Pipette that measures 100µL 
- Tips for 100µL 
- Plasma sample log book 
 
Procedure: to be done from previously taken blood samples in EDTA tubes. 
 
1. Label the screw cap tubes with the patient ID. 
2. Blood should be transported to the lab in the original EDTA microtainer tubes  
in which the sample was collected, packed in cool boxes pre-packed with ice 
packs or ice cubes.  
3. Avoid direct contact of the microtainer tubes with ice packs as this can cause 
haemolysis of the red blood cells. Also make sure that tubes are not frozen. 
4. Remove tubes from cool boxes and put them into a tube rack.  
5. If you are unable to process the samples on same day store blood tubes in the 
fridge (+4°C, not in the freezer) overnight. 
6. Use the centrifuge to spin the blood down at a low speed for 3 minutes. The 
exact speed depends on the centrifuge; for a centrifuge with a maximum speed 
of 13000 rpm, the speed used is 3000 rpm. In general, the lowest speed at 
which there is a clear plasma separation in 3 minutes should be used; higher 
speeds can cause haemolysis. 
7. Remove tubes carefully from centrifuge and put in tube rack in an upright 
position. Do this slowly to make sure that the plasma and blood cells do not 
mix. (If you make a mistake and the cells mix, just centrifuge again) 
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8. Label one empty clean tube with screw cap. You need to pre print stickers with 
the labelled patient ID for this purpose. 
9. Transfer all of the  plasma to the screw cap tube 
10. Keep the cell pellet in the original tube. Close this tube and place it in -20°C (or -
80°C) for future DNA extraction. 
11. Carefully close the lid of the tubes. 
12. Place the plasma tubes in -20°C (or -80°C) 
13. Write in PLASMA log book that samples have been separated with the date and 
sign that you have stored them. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 336 
 
Appendix 11: WHO RDT scoring colour chart 
(Provided by Dr. Jane Cunningham, WHO). 
 
 
 337 
 
Appendix 12: Vacutainer blood collection 
 
Protocol supplied by Teun Bousema 
Collecting a venous bleed sample. 
NOTE: Two venous bleed samples will be taken per person. 2x 4mls for individuals 
over the age of 5 and 2x 2.5ml for children under the age of 5. The first venous bleed 
is for the membrane feeding and serum replacement experiments. It is essential that 
the membrane feeders are prepared and ready before the venous blood samples are 
taken- please check!  
MATERIALS 
- Clean plastic disposable gloves 
- Dry and wet swabs soaked in methylated spirit (70% ethanol) 
- Swab containers 
- Disposable venipuncture sampling set  
- Sharps disposal container 
- Heparinized tubes for venous blood collection 
- Labels for Venous bleed 1 and 2. 
 
VENOUS BLOOD SAMPLING 
1. Write the unique patient number (3 digits) on the venous bleed sample labels 
(one la el called venous1  the second called venous2) after ‘ F1’  alon  with 
the date of sampling. Attach the labels to the heparin tubes. 
2. Support the forearm from which blood will be taken by a pillow or arm of 
chair. 
3. Apply the tourniquet, place a finger behind the tourniquet clip to prevent the 
skin or hairs being pinched.  
4. Place the tourniquet approximately 5-15 cm above planned puncture site. 
5. Assess subject for a suitable vein.  
6. Assemble equipment. Holding the coloured end of the needle sheath/luer 
adaptor in one hand, twist and remove the clear translucent end. Thread 
rubber covered needle into holder. For Luer adaptor attach winged infusion 
set. 
7. Clean the skin with an alcohol swab and allow to dry. 
8. Position the needle and holder in the direction of the vein. Do not connect 
the tube before the needle has pierced the skin.  
9. Inform the subject that he/she may feel a sharp sting when the skin is 
pierced. 
10. Pierce the skin directly over the vein and enter with a smooth and quick 
entry. The needle should enter the vein at a 10-15° angle. 
11. Use the Heparin tube to collect blood. 
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12. With one hand secure the needle and holder. With the other hand press the 
tube onto the needle with the thumb. Once the blood is running, give a sign 
to the person in the insectary that he/she can prepare the feeders. 
13. Remove tube when filled with the required amount of blood and mix by 
inverting 5-6 times gently. 
14. Make sure 2 venous samples are taken per person (as mentioned in the 
notes). 
15. Withdraw needle from vein in a quick movement. (Always remove the tube 
from holder before withdrawing the needle from the vein). 
16. Discard needle and holder immediately into an approved sharps container. 
Needles should never be recapped. 
17. Place cotton balls over the puncture site immediately after the needle has 
been withdrawn and apply direct pressure to the site. 
18. The donor may apply pressure to the puncture site. 
19. Remove gloves. 
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Appendix 13: Procedure for RNA collection in RNAProtect 
 
Protocol supplied by Teun Bousema 
 
 
Collecting, processing and storing RNA samples from venipuncture. 
 
MATERIALS 
- Clean plastic disposable gloves 
- Disposal container for pipette tips 
- 200µl pipette 
- Disposable 200µL filter/barrier tips 
- Eppendorf tubes with 500µL of RNAProtect (Qiagen) stabilizing buffer 
- Labels for venous bleed RNAProtect samples 
- Boxes for sample storage 
 
 
RNA SAMPLE PROCESSING AND STORAGE  
1. As soon as possible after blood has been taken in the heparin tube, do the 
following steps in a sterile environment. 
2. Write the unique patient number (3 digits) on the venous bleed RNAProtect 
sa ple la els after ‘ F1’  alon  with the date of sa plin    ttach the la els to 
the 3 RNAProtect aliquots.  
3. Transfer 100µL of blood with a filter/barrier tip in the first pre-aliquoted and 
labeled tube with 500µL of RNAProtect stabilizing buffer, mix well by 
inverting the tube 5 times.  
4. Repeat this for the second and third RNA samples. 
5. Store all three at -80C in separate boxes for different locations. 
 
 
